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Abstract 
Proteolysis targeting chimeras (PROTACs) are an emerging field of therapeutics and promising 
potential drug candidates. PROTACs consist of a target protein binder connected via a linker to an E3 
ligase binder. PROTACs hijack the ubiquitin proteasome system to degrade the target protein in a 
cellular environment. This work focuses on the androgen receptor (AR) protein, a key nuclear receptor 
for healthy prostate development. Hence, AR inhibition and degradation are well-established 
strategies for treatment of prostate cancer. First, in this work stapled peptide PROTACs recruiting E3 
ligase MDM2 for AR degradation were investigated. MDM2 has been underexploited as an E3 ligase 
for PROTACs, despite a beneficial ability to modulate the p53 protein, a vital tumour suppressor, in 
additional to inducing protein degradation. Using a two-component peptide stapling strategy, stapled 
peptide PROTACs were developed for AR degradation via recruitment of MDM2. Stapled peptides are 
commonly used to target challenging protein-protein interactions, such as MDM2-p53. Peptides are 
capable of emulating elements of protein structure, offering significant advantages over small 
molecule alternatives. Second, a series of small molecule MDM2 recruiting PROTACs were synthesised 
to establish a novel ligand capable of expanding the PROTAC toolbox. Finally, photoswitchable AR-
degrading PROTACs were synthesised. The photophysics and biological activity of the PROTACs were 
analysed. These PROTACs integrated ortho-fluoroazobenzene for light-induced conformational 
change. Incorporating photoswitchable moieties in pharmaceutical entities has been demonstrated 
to mitigate off-target toxicity, a promising strategy to reduce attrition rates in drug discovery. 
Improved selectivity, efficacy, and overall safety profiles could be delivered by dosing an inactive drug 
and using light to modulate its biological activity at the site of action. 
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Figure 1: Summary of novel PROTAC technologies development 
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1. Chaper 1: Introduction 
1.1 Proteolysis Targeting Chimeras (PROTACs) 
1.1.1 Ubiquitin Proteasome System (UPS) 
Selective cellular degradation of proteins is mediated by the ubiquitin proteasome system (UPS), and 
is a vital process for cell survival.1 Early studies of protein degradation were published by Hershko et. 
al. in 1971, who found that the process was ATP-dependent.2 Following this, Hershko went on to 
discover an ATP-dependent proteolysis factor (APF-1) found to be vital for protein degradation.3 APF-
1 was later identified as ubiquitin, a polypeptide universally observed in nature.4 Subsequent 
experimentation gave an understanding of the role ubiquitin played in proteolysis. Initially, ubiquitin 
molecules are enzymatically linked to a protein, leading to the attachment of a polyubiquitin tag which 
is then recognised by the proteasome resulting in protein degradation.5   
Three key enzymes involved in the UPS were elucidated in subsequent years (figure 2). Firstly, the 
ubiquitin activating enzyme E16 activates the ubiquitin molecule by adenylating the C-terminus7 and 
forming a thioester bond at a surface cysteine residue. The activated ubiquitin is then transferred to 
a second key enzyme E2, known as the ubiquitin carrier protein8 before finally being transferred to a 
surface lysine residue of the target protein mediated by the E3 ligase.8 This enzyme is responsible for 
recruiting the target protein, thus is vital for the high specificity of the UPS.9,10 This process is then 
repeated to form a polyubiquitin chain. Ubiquitin can also be removed from the protein by various 
deubiquitylating enzymes (DUBs).11 A protein is targeted for degradation by the 26S proteasome when 
it acquires a chain of at least four ubiquitin molecules. The 26S proteasome removes and recycles the 
ubiquitin units and degrades the target protein into short peptide fragments. The UPS process has 
been comprehensively reviewed by Hershko and Ciechanover.12  
  
Figure 2: Diagram of the UPS mediated degradation of target proteins 
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1.1.2 Principles of PROTACs 
PROTACs (PROteolysis TArgeting Chimeras) are an interesting new area of medicinal chemistry. These 
molecules were designed to recruit the UPS for the degradation of therapeutically relevant proteins.11 
PROTACs are heterobifunctional molecules containing a ligand for an E3 ligase, a linker motif, and a 
second ligand to bind a target protein.11 The E3 ligase and the target protein bind to the PROTAC, 
forming a ternary complex (figure 3). The proximity of the E3 ligase to the target protein facilitates its 
polyubiquitination, labelling the protein for degradation within the cell.11 PROTACs have great 
potential due to their ability to theoretically target any protein within the cell, providing a binding 
molecule is available.11 
 
Figure 3: Diagram of PROTAC mechanism of action 
There are many benefits associated with the use of PROTACs. Theoretically, PROTACs are catalytic in 
nature, hence they can be dosed at a very low level and still achieve a high therapeutic effect.13 This 
low dose potential should reduce side effects, improving quality of life. Another key benefit for the 
use of PROTACs is their alternative mechanism of action to standard drugs, which generally inhibit or 
activate target proteins. In diseases where drug resistance can occur this is particularly useful, 
provided the PROTAC is still capable of binding the protein partners, key proteins may still be degraded 
using the UPS completely knocking out their activity.11  
PROTACs also have immense potential in protein research and genomic elucidation. To understand a 
proteins function, generally it is deactivated in the cell and phenotypical changes are observed.14 
There are many ways to achieve this result, such as genetic knockout methods, post-transcriptional 
inactivation, and post-translational modification interference.14 PROTACs could be very useful for the 
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simplification of these knockout methods, as any protein could be targeted for complete degradation 
using cheap and easily synthesised chemicals.14 
 
1.1.3 History of PROTAC development 
This method of ‘hijacking’ the UPS was first carried out by Sakamoto et. al. in 2001,15 with the synthesis 
of PROTAC-A (figure 4). PROTAC-A contained a phosphopeptide to bind to E3 ligase Skp, Cullin, F-box 
(SCF) and a small molecule binder of protein MetAP2; ubiquitination was observed in vitro. To 
establish binding affinity and specificity at intracellular concentrations, PROTAC-A was applied to egg 
extracts where degradation was observed. Although this discovery was a highly significant proof of 
concept, it was known PROTAC-A would be unable to penetrate the cell due to the impermeable 
peptide sequence.15 
 
Figure 4: PROTAC-A developed by Sakamoto et al.15 
Further work targeted the estrogen receptor and the androgen receptor with PROTAC-B (figure 5).16 
These peptidic PROTACs did not solve the permeability issues, as microinjection into the cells was 
required for activity.  
 
Figure 5: Structure of androgen receptor targeting PROTAC-B 
To address the issue of cell permeability, an FKBP12 targeting PROTAC was developed, incorporating 
an eight-amino acid poly-D-arginine chain to the peptide-based von Hippel-Lindau (VHL) binder (figure 
6).17 Sufficient degradation was observed at 25 µM concentration in cells.17 
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Figure 6: First developed cell permeable PROTAC-C 
Initial results for peptide based PROTACs were promising, with proof of concept studies showing 
successful target protein degradation; however, the inherent limitations of peptides including poor 
permeability and pharmacokinetic properties limited their efficacy. To address these issues, PROTAC 
development was shifted toward the field of small molecules. The first new generation PROTAC was 
developed by Schneekloth et al. in 2008 (figure 7).18 PROTAC-D targeted AR using E3 ligase MDM2, 
and although cell permeability was improved, potency was poorer compared to previous peptidic 
results.18 
 
Figure 7: First small molecule PROTAC-D 
Following this discovery, new small molecule binders for alternative E3 ligases have been identified, 
leading to significant advances in the potency and permeability of PROTACs.11,13,19,20 
HaloTag fusion proteins were targeted by Buckley et al. utilising the E3 ligase VHL (figure 8).21 
HaloPROTAC3 was found to be particularly potent with a DC50 of 19 nM. HaloTag fusion proteins are 
non-endogenous but are commonly used in chemical genetic studies. This study demonstrated the 
importance of optimal linker length, as PROTAC activity was vastly reduced at short length likely due 
to negative steric interactions.21 
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Figure 8: PROTAC targeting the HaloTag fusion protein developed by Buckley et al. 21 
Studies targeting bromodomain BRD4 using E3 ligase cereblon were published simultaneously by both 
Winter et al.22 and Lu et. al 23 (figure 9). Winter’s dBET1 showed rapid BRD4 cellular degradation at 
100 nM concentration with complete degradation after 2 h. Unfortunately, stability of these 
phthalimide-based compounds was found to be limiting, and partial BRD4 recovery was observed 24 
h post treatment. Consequences of dBET1 on cellular protein abundance were also assessed. Of the 
7429 proteins screened, 3 were markedly depleted: BRD2, BRD3, and BRD4, highlighting selectivity 
limitations. dBET1 attenuated tumour progression, and reduced BRD4 levels in tumour-bearing mice. 
Lu’s ARV-825 also showed BRD4 protein degradation, with a sub-nM DC50. The efficacy of the PROTAC 
was shown to be more extensive and longer lasting than the BRD4 binder alone. Interestingly, a bell-
shaped dose dependence curve was observed known as the hook effect, rationalised by the formation 
of dimer protein-PROTAC complexes at higher concentration which compete with the active trimer 
complex formation. Selectivity issues were also observed for ARV-825.23 
 
Figure 9: A) dBET1 developed by Winter et al.22 B) ARV-825 developed by Lu et al.23 
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Bondeson et al. used PROTACs to target the RIPK2 protein, a serine-threonine kinase which mediates 
immune signalling (figure 10).24 The PROTAC designed gave a DC50 of 1.4 nM in cellular studies.  In this 
study, the sub-stoichiometric catalytic nature of the PROTAC was evaluated by comparing the absolute 
quantity of PROTAC to that of ubiquitinated RIPK2 in vitro. Depending on molarity, stoichiometry 
values of 2.0 – 3.4 were observed as evidence for catalysis. These numbers are thought to be a 
significant underestimation due to experimental limitations. In addition, at high concentrations of 
PROTAC efficacy was considerably reduced due to the hook effect. 
 
Figure 10: PROTAC targeting RIPK2 developed by Bondeson et al.24 
Recently, a small molecule BRD degrader has been developed by Zhou et al. (figure 11A).25 This 
PROTAC was highly potent, with an IC50 of 51 pM in leukaemia cells, and showed rapid tumour 
regression in vivo. The PROTAC linker was extensively optimised, establishing the substantial and 
unpredictable effects linker type and length have on the degradation efficiency (figure 11B).25 They 
found that even minor changes in linker nature (e.g. ester to amide bond) resulted in major shifts in 
potency. They also reported that an optimal linker length (in their case a five-carbon linker) exists. 
 
Figure 11: A) PROTAC targeting BET proteins found to have pM activity; B) Different linkers synthesised with IC50 values of 
resultant PROTACs 
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Since these developments, there has been a surge in publication of PROTACs targeting a huge range 
of different proteins, including covalent PROTACs,26,27 macrocyclic PROTACs,28 homo-PROTACs for self-
degradation29 and dual VHL cereblon targeting PROTACs.30 Many extensive reviews on these exist,31–
33 hence only a few significant cases will be discussed further. 
 
1.1.4 Recent PROTAC developments 
An interesting model was recently reported describing how the cooperative recruitment of a protein 
target into a ternary complex by a PROTAC can effect both selectivity and efficacy.34 Isothermal 
calorimetry (ITC) and x-ray crystallography were used to better understand the complex interactions 
dictating ternary complex formation. A crystal structure of PROTAC MZ1 bound to BRD4 and VHL was 
reported, which showed the ligand folding promoted additional intermolecular interactions between 
the two proteins resulting in cooperative binding (figure 12). The concept of ligand-induced protein-
protein interactions was validated and quantified through ITC studies, surface mutagenesis and 
proximity assays. In addition, Gadd et al. were then able to use this understanding for the structure-
based-design of a new PROTAC which showed highly selective BRD4 degradation in cells.  
 
Figure 12: Crystal structure of BRD4 (blue) and VHL (purple) bound to PROTAC MZ1 generated from PDB: 5T35 34 
An interesting approach was taken by Bondeson et al. who generated a PROTAC using a promiscuous 
kinase warhead.35 By synthesising highly promiscuous cereblon and VHL-recruiting PROTACs capable 
of binding >50 kinases, they showed only a subset of the bound targets were degraded. PROTAC-E was 
derived from kinase inhibitor Foretinib (figure 13) which binds to 133 kinases with little control. The 
VHL-recruiting PROTAC degraded 9 of these proteins compared to the cereblon-recruiting PROTAC 
which degraded 14. This is significantly lower than the 133 possible kinases which could have been 
targeted and highlights the high levels of specificity which can be attained using the PROTAC 
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technology. Interestingly, the affinity of the kinase to the PROTAC was not a robust predictor of 
activity. Instead, ability to induce a stable ternary protein complex was more predictive with highly 
effective degradation observed when protein-protein interactions stabilised the ternary complex. 
 
Figure 13: Structure of kinase inhibitor Foretinib derived PROTAC  
Interesting comparisons between protein inhibition and degradation have recently been published on 
CDK9 using cereblon-recruiting PROTACs36 and RTK using VHL-recruiting PROTACs37. Both studies 
found the PROTAC approach to have superior activity over inhibition alone. The PROTAC activity 
observed was longer-lasting than the inhibition approach. Activity was dependent on rate of protein 
re-synthesis instead of clearance rates.  
Despite the many benefits of PROTACs described above, there are also considerable challenges which 
accompany the future development of PROTACs. It is well-known that efficacy can now be achieved 
at low nM and pM concentrations.22–25 However, delivery and bioavailability remains a challenge due 
to the high molecular weight of the molecules (700 – 1000 Da)20 which can limit their scope. There has 
recently been a surge in interest in ‘beyond rule of 5’ compounds and many of these exhibit reasonable 
oral bioavailability and drug-like properties.38 Indeed, oral delivery of PROTACs has already been 
validated as an effective administration method.39 For clinical applications, there are additional 
complications of dosing brought on by the hook effect where at high concentrations, formation of 
dimer complexes dominates rather than the therapeutically active ternary complexes. Achieving the 
appropriate therapeutic index for maximum effect is difficult in these cases as systemic drug 
concentrations often fluctuate in vivo. This requires further data to overcome.40 PROTAC metabolism 
can also complicate further developments due to potential losses in binding to either protein partner. 
This may result in inactive metabolites which compete with the PROTAC for protein binding. Another 
aspect of PROTACs which is not well-understood is their off-target toxicity, which could damage 
healthy cells alongside the disease. Finally, although numerous PROTACs have shown exceptional 
activity against many targets, this doesn’t mean that resistance to PROTACs won’t ultimately emerge 
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following extended PROTAC usage. A recent study on BET-targeting PROTACs found chronic exposure 
to these PROTACs led to drug resistance in cancer cell lines, and further treatment of these cell lines 
with BET-PROTACs failed to induce degradation. The cause of this resistance was not loss of binding 
to the target proteins, but instead determined to be genomic alterations in core components of E3 
ligase complexes.41  
 
1.2. Prostate Cancer 
Prostate cancer (CaP) is the second most prevalent cancer in men worldwide, and in developed regions 
such as the UK, it is the most prevalent.42 In 2012 alone, ca. 1.1 million cases were diagnosed globally 
with ca. 307,000 deaths.42  
The androgen receptor (AR) is a nuclear receptor which controls gene expression, depending on ligand 
binding.43 The normal development and function of the prostate is moderated by the interactions 
between the AR and binding androgens, most notably testosterone and the more potent metabolite 
5α-dihydrotestosterone (DHT) (figure 14).43 These hormones bind to the AR ligand binding domain 
(LBD), and induce transcriptional activity through a conformational change in the protein, which allows 
it to recruit cofactor proteins and transcriptional machinery.43  
 
Figure 14: Structures of endogenous androgens, testosterone and 5α-dihydrotestosterone 
Prostate cancer is intrinsically dependent on androgen signalling, as these interactions are responsible 
for stimulating proliferation and inhibiting apoptosis. Due to its significance, androgen deprivation 
therapy (ADT) is commonly the first line treatment for advanced hormone-sensitive prostate cancer.44  
Antiandrogens antagonise the endogenous androgens by competitive inhibition of the LBD,43 and are 
therapeutically useful in the treatment of prostate cancer. By blocking the endogenous androgens and 
possessing no intrinsic AR activity when bound, cell proliferation is terminated, leading to apoptosis.43 
One prevalent class of antiandrogens are the substituted toluidides (figure 15). Bicalutamide is the 
most frequently prescribed due to its reduced hepatotoxicity and 6 day half-life.45 
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Figure 15: Non-steroidal antiandrogens used for treatment of prostate cancer 
Although most prostate cancer diagnoses are androgen-dependent, this often progresses to 
castration resistant prostate cancer (CRPC) after 2-3 years of ADT. CRPC has little to no response to 
anti-androgen inhibition, however, AR expression remains crucial for tumour progression.46 There are 
multiple mechanisms leading to CRPC, including AR amplification/hypersensitivity, mutations in the 
AR, and androgen-independent AR activation.47 A key pathway is AR amplification/hypersensitivity 
where cells become sensitive to the low androgen concentrations following ADT. This can occur either 
from AR overexpression or mutations allowing promiscuous AR activation from molecules other than 
androgens, and lead to the progression of prostate cancer.48 Ligand-independent AR activation is also 
a vital mechanism, where various growth factors and proteins increase AR signalling pathways.49  
When antiandrogens such as bicalutamide are present in CRPC, they can still bind to the AR, however 
typically there is a switch in their activity from antagonist to agonist, associated with differences in 
coactivator and corepressor recruitment to AR target genes.50 
Although understanding of CRPC has substantially developed in the past decade, it is still not 
comprehensive. Due to the high mortality rates of this late-stage cancer, more effective treatments 
for the disease are urgently required. 
Second-generation antiandrogens have been developed to show activity in CRPC. A key new drug, 
enzalutamide (figure 16) was approved in the US in 2012 for the treatment of CRPC.44 Enzalutamide 
was identified following a screen for compounds that retain AR activity in cells with increased AR 
expression. This orally available drug was developed by Medivation and in Phase I/II clinical trials 43% 
of the 30 patients showed >50% decline in prostate-specific antigen (PSA), a key prostate cancer 
biomarker.51  
 
Figure 16: Chemical structure of enzalutamide 
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Enzalutamide is an AR signalling inhibitor able to target the AR by inhibiting endogenous androgen 
binding, inhibiting nuclear translocation of activated AR, and through reduced binding of AR to DNA 
(figure 17).52,53 The binding affinity of enzalutamide to the AR in CRPC cell lines was found to be five- 
to eight- fold greater than bicalutamide,51 and when gene-expression was studied it was found not to 
have agonist activity in most resistant cells, unlike bicalutamide.51 
 
Figure 17: Diagram showing the different AR signalling pathways that enzalutamide inhibits, adapted from Schalken et al.52 
Unfortunately, resistance to enzalutamide can still occur, thought to be due to a mutation in the AR 
ligand binding domain. Similarly to the first-generation antiandrogens, activity can be switched from 
antagonist to agonist.54 Research has been done to simulate the antiandrogen-AR complex to provide 
rationale for future third-generation antiandrogens able to bypass the agonist mechanism.55 Finding 
new drugs to target CRPC is hugely important, since drug resistance is developing rapidly in prostate 
cancer.  
 
1.3. Strategies for degradation of the androgen receptor 
1.3.1. Selective Androgen Receptor Degraders (SARDs) 
Degradation of hormone receptors has been a valid therapeutic strategy prior to the development of 
PROTACs. Selective estrogen receptor degraders (SERDs) downregulate ER and have been highly 
effective treatments for breast cancer, for example approved drug Fulvestrant (figure 18).56 Upon 
binding, SERDs induce a conformational change to ER which exposes hydrophobic residues 
synonymous to misfolded ER, which is recognised by the cell leading to degradation. There are a 
limited number of known scaffolds for generation of SERDs. Fulvestrant is currently the only clinically 
approved example and only one other scaffold is in clinical trials.57 Recently, a novel class of SERDs 
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was discovered with a modular design strategy to expand the degradation toolbox.58 This strategy 
involves attachment of a linker with a synthetic handle to an ER binder which can then be conjugated 
with a variety of different degrons to rapidly screen numerous candidates.  
 
Figure 18: Examples of reported SERDs from clinically approved Fulvestrant to newly developed scaffolds 
This hydrophobic tagging approach to protein degradation has also been applied to AR. However, 
development of selective androgen receptor degraders (SARDs) has been considerably slower than 
SERDs, and currently no SARDs have been clinically approved.59 The first reported SARD was published 
in 2011 (figure 19). This compound was able to down-regulate AR in AR-dependent cell-lines, however 
adverse cardiovascular effects were predicted due to hERG ion channel potentiation.60 Further 
developments were able to bypass this hERG activity, leading to first-in-class SARD AZD3514.61 This 
compound showed significant disease stabilisation and PSA reduction in clinical trials, despite notable 
side effects including nausea and vomiting.62 Niclosamide is an FDA-approved treatment for anti-
helminthic therapy also able to reduce AR levels. Despite its strong activity in preclinical models, the 
drug exhibited unacceptably high toxicity for clinical studies.63 Recently, SARD279 demonstrated the 
potential to overcome some resistance mechanisms, despite showing a modest DC50 of 2 µM.64 More 
effective SARDs have also been reported, including UT-6965,66 and next-generation candidate UT-34, 
which had improved properties and was more efficacious in vivo.67 
 
Figure 19: Examples of recently reported SARDs 
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Compared with PROTACs, one advantage of the new generation of SARDs is their smaller molecular 
weights which translates to improved pharmacological characteristics and oral bioavailability which 
are vital factors in drug development.68 Currently, SARD development is at an early stage and potential 
side effects are unknown. Fundamentally, PROTAC technology is considerably more generalisable than 
SERDs/SARDs demonstrated by the single clinically approved example of this technology compared to 
numerous proteins targeted by PROTACs. 
 
1.3.2. Specific and Non-genetic Inhibitor-of-Apoptosis proteins-dependent Protein Erasers 
(SNIPERs) 
Another way to degrade AR is using a SNIPER approach. SNIPERs are a specific type of PROTAC which 
use inhibitor-of-apoptosis proteins (IAPs) as the ubiquitin ligase.69 The first SNIPER targeting AR was 
AR SNIPER 1, reported by Itoh et al. (figure 20A). This SNIPER was demonstrated to reduce AR levels 
in cells at 30 µM concentration through Western blot analysis.70 
A further example of a SNIPER approach to AR degradation was reported in 2017 by Shibata et al. 
(figure 20B).71 AR SNIPER 2 incorporated higher binding affinity ligands and was shown to potently 
degrade AR in AR-dependent prostate cancer cell lines via a proteasome-dependent pathway, 
resulting in inhibited AR-mediated gene expression, and reduced cell proliferation.  
 
Figure 20: SNIPER structures for degradation of AR via IAPs; A: AR SNIPER 1, B: AR SNIPER 2 
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In contrast to PROTACs, SNIPERs induce degradation of both the target protein as well as the cIAP1 
ubiquitin ligase. This may limit the use of this technology for target protein knockdown, as lowering 
levels of ligase would in turn lower the rate of target protein degradation.72 Further research on how 
this additional degradation pathway will affect SNIPER activity is needed, in particular a 
comprehensive study on IAP cellular concentrations and re-synthesis rates. For effective SNIPER use, 
E3 ligase levels would need to be equal or greater than target protein levels. However, it is worth 
noting that cIAP1 is frequently overexpressed in tumour cells and related to drug resistance. Inhibition 
of the IAP protein family has been established as a valid treatment for cancer, and several examples 
are currently under clinical development.73 Hence, the dual activity of SNIPERs for target protein and 
cIAP1 degradation may offer additional benefits for treatment of various cancers. 
 
1.3.3. PROTACs targeting AR 
Over the past 10 years, there has been a surge of interest in PROTACs targeting AR since the first AR-
targeting peptidic PROTAC (figure 5) and the first small molecule AR targeting PROTAC (figure 7). 
A head-to-head biological comparison between enzalutamide and a PROTAC derivative of 
enzalutamide, ARCC-4 (figure 21) was recently reported. This PROTAC was found to degrade ~95% of 
cellular AR at low nanomolar potencies.74 ARCC-4 was also found to inhibit prostate tumour cell 
proliferation and exhibited activity on AR point mutant variants. Enzalutamide loses its anti-
proliferative effects in high androgen environments, whilst ARCC-4 overcomes this major limitation 
and offers significant benefits as an alternative prostate cancer treatment. In addition, ARCC-4 was 
found to be ca. 10-fold more potent than enzalutamide despite its lower intracellular concentrations 
which stem from poorer permeability. 
 
Figure 21: Structure of AR targeting PROTAC ARCC-4 
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Another AR-targeting PROTAC was reported in 2019 (figure 22). ARD-69 uses an AR antagonist 
connected via a rigid linker to a VHL ligand.75 This PROTAC was found to be highly potent, with a sub-
nanomolar DC50 and over 95% AR degradation in prostate cancer cell lines. This high potency was 
achieved following an extensive screen of different AR and VHL binders, in addition to linker types and 
lengths. This highlights a significant challenge in PROTAC development, with huge numbers of 
compounds required to establish activity and little predictability in design. Typical linker types used in 
PROTACs are highly flexible, and generally consist of ether connections or alkyl chains. The linker for 
ARD-69 is very different, it is made up of piperidine rings and an alkyne linkage which imparts rigidity 
to the drug. Increasing the rigidity through the linker is a potential strategy to improve the 
pharmacological properties of a PROTAC, and in this case high efficacy was observed in mouse models. 
Further studies from the same group also showed that highly potent AR PROTACs could be prepared 
using a weak binding VHL ligand with a Ki of 2.8 µM.76 This once again highlights the importance of the 
ternary structure of a PROTAC over the individual binding affinities of its substituents.  
 
Figure 22: Structure of AR degrader ARD-69 
Recently, ARV-110 an oral PROTAC developed by Arvinas, has been reported for the degradation of 
AR for prostate cancer treatment. The preclinical data on this compound was extremely promising, 
with in vivo efficacy demonstrated in CRPC and enzalutamide resistant tumour models.77 ARV-110 was 
progressed into phase 1 clinical trials in March 2019, followed by an ER degrader ARV-471, which 
entered clinical studies in August 2019 with initial read-outs looking encouraging.78 It is still too early 
to judge the pharmacokinetic and safety profiles of these PROTACs from these initial trials, however 
the rapid development of these PROTACs is indicative of their promise as therapeutic candidates. 
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2. Chapter 2 
2.1. Chapter 2: Introduction 
2.1.1. Protein-Protein Interactions (PPIs) 
Protein-protein interactions (PPIs) are responsible for regulating numerous cellular processes such as 
replication, signal regulation, and protein synthesis.79 Despite the integral role PPIs play in cellular 
function, they are underexploited in therapeutics due to the difficulties involved in targeting them.80  
Historically, there has been a large focus on developing small molecules to treat diseases due to their 
general ease of synthesis and good pharmacokinetic properties.80 With recent developments leading 
to FDA approvals of numerous biologic therapeutics, designing Lipinski’s ‘ideal’ drugs is no longer 
crucial.81,82 Despite these developments, targeting PPIs is still a formidable challenge. The surface area 
of the PPI interface typically varies between 600 and 6000 Å for heterocomplexes,83 hence, to 
selectively and potently disrupt the PPI an inhibitor must have many binding contacts (figure 23A). 
Achieving this using small, ‘drug-like’ molecules is challenging. Protein binding sites are often non-
contiguous, which presents additional targeting challenges and selectivity is difficult to achieve due to 
the often featureless interfaces.80 This is in direct contrast to typical ‘druggable’ targets such as 
receptors or enzyme active sites which generally have well-defined binding pockets (figure 23B).84 
 
Figure 23: Adapted from Tsomaia85 with permission from Elsevier; A) shows the PPI interface between BCL-2/BID proteins; 
B) shows a small molecule kinase inhibitor  
Designing small molecule PPI inhibitors can be daunting. One strategy used to design inhibitors is to 
elaborate the structure-activity relationship of the natural ligand to increase potency and selectivity.80 
It is challenging to directly apply this method to protein-based ligands due to their size, complexity, 
and generally poorly characterised interface. Conventional high throughput screening often leads to 
few, weakly potent hits, which can be difficult to develop into potent lead compounds.86  
The development of PPI inhibitors has garnered great interest in recent decades, thus the field has 
experienced rapid growth. One reason being the greater understanding of interfaces and key binding 
interactions.87 Methods to study binding have been developed which enhance understanding of PPIs, 
A B 
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particularly where no crystal structure can be obtained. One well-established method relies on 
identifying key binding hot spots through alanine scanning, where amino acid residues are substituted 
with alanine and the change in binding energy recorded.88  This identifies key binding residues, known 
as hot spots. Following this, screening libraries can be designed for identification of potent drugs.89  
Another relevant technique for rational drug design is computational docking, where a ligand and 
binding site are conformationally modelled to establish binding modes and key interactions.90 This 
technique enables virtual screening, which indicates scaffolds likely to bind to a target protein.90 The 
utility of docking is debated due to difficulties predicting accurate 3D protein structures; however, 
techniques have been refined, and de novo design has successfully predicted binding modes.91 
The discovery of small molecule PPI inhibitors has progressed greatly in recent years. Despite the 
challenges discussed, there are examples of inhibitors able to potently bind at the PPI interface.92 The 
cytokine interleukin-2 (IL-2) is a protein responsible for T cell activation and rejection of tissue grafts.93 
The potent small molecule binder SP4206 (figure 24), was developed using fragment-based 
approaches.94 The PPI interface bound to an initial fragment was characterised, and tethering 
experiments were conducted to elucidate key binding positions. Following this, compound assembly 
combined key fragments and indicated valuable combinations to synthesise and test. Compound 
SP4206 was shown to be highly potent, with an IC50 of 60 nM and a Kd of 100 nM.93–95  
 
Figure 24: IL-2 small molecule inhibitor SP4206 developed by Sunesis Pharmaceuticals 
 
2.1.2. p53-MDM2 PPI 
One relevant PPI commonly targeted is p53-MDM2.96,97 The tumour suppressor p53 protein is thought 
to be the ‘guardian of the genome’, as its key functions involve inducing cell cycle arrest, senescence, 
and apoptosis in response to various stress signals.98 The levels of functioning p53 in tumours is low, 
due to either inactivation of the gene encoding p53 (TP53) through mutation, or direct p53 
inactivation through binding to cellular proteins.99 One such protein, MDM2 (murine double minute 
2) was discovered to form a tight complex with p53, regulating its function.100 The autoregulatory 
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feedback loop of these two proteins is vital for their function, with p53 inducing MDM2 expression 
which in turn promotes p53 inhibition and degradation.101 The level of p53 in healthy cells is 
minimised, then, in response to stress, high p53 levels are rapidly achieved resulting in cell cycle arrest 
and apoptosis. A key aspect of MDM2 functionality is its ability as an E3 ligase to cause ubiquitination 
of bound p53, which targets p53 for cellular degradation.102 Many tumours overexpress MDM2 
causing p53 functionality to be lost and continued tumour cell proliferation.103 Hence, reactivating p53 
is a method for treatment of cancer and there are many approaches which can achieve this. 
A key strategy to reactivate the p53 pathway is through MDM2 inhibition.104 A significant study 
showed p53 activation through MDM2 inhibition supressed tumour formation in mice.105 However, 
side effects of targeting this pathway, such as lymphopenia and intestinal apoptosis, were observed 
by Mendrysa et. al.106 Dosing ca. 80% of MDM2 levels gave positive tumour suppressing results, whilst 
maintaining the integrity of the intestine. Lymphopenia was a more significant issue and ca. 20-50% 
reduction in MDM2 activity was required to prevent this condition.105  
An early success story in small molecule PPI inhibitors are the nutlin family of compounds (figure 25), 
which are inhibitors of the p53-MDM2 PPI. Interestingly, these cis-imidazoline analogues were 
identified through library screening methods and gave high IC50 values in the range of 100 – 300 nM.107 
From crystal structure analysis of bound nutlin-3, it is thought that the rigid imidazoline scaffold directs 
three of the attached groups into pockets where vital p53 amino acid residues normally bind.107  
 
Figure 25: Small molecule p53-MDM2 inhibitors 
Nutlin-3 was found to be the most potent MDM2 inhibitor. Further optimisation of its binding, cellular 
potency, and pharmacokinetics yielded RG7112 (figure 26). This molecule is the first MDM2 inhibitor 
to reach the clinic,108 and recently published Phase I data was promising.109  
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Figure 26: RG7112 (Roche) Drug Candidate 
Degradation of MDM2 through PROTAC mechanisms has also been validated as an effective strategy 
for cancer treatment.110 Li et al. have recently reported a first-in-class MDM2 degrader, MD-224 which 
employed E3 ligase cereblon for MDM2 degradation (figure 27).111 This PROTAC rapidly degraded 
MDM2 at sub-nanomolar concentrations and cell proliferation assays gave an IC50 of 1.5 nM. This 
PROTAC was 10 – 100 times more potent than MDM2 inhibition alone, and in vivo studies showed 
long-lasting tumour regression at well-tolerated doses. 
 
Figure 27: Structure of MD-224, a degrader of MDM2 via E3 ligase cereblon 
 
2.1.3. Introduction to peptides 
Peptides are another class of therapeutics commonly used to target PPIs. Peptides consist of a short 
sequence of amino acids, generally fewer than 50 residues.112 There are many peptide drugs on the 
market, examples include 26 amino acid, chronic pain drug ziconotide,113 and 39 amino acid type 2 
diabetes drug exenatide.114 
The intermediate size and molecular weight of peptides gives them many useful properties. Peptides 
can be applied to a wide range of PPI targets, due to their ability to mimic elements of a proteins 
structure, and inherent similarity to the natural binding proteins.115 Physiologically, peptides also have 
low tissue accumulation due to their size, and can have lower toxicity than small molecules, as a result 
of their higher biocompatibility, specificity, and fewer off-target effects.116 Peptides can also be 
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synthesised relatively easily compared to numerous biologics. Compared to small molecules however, 
peptide synthesis entails high production costs due to long synthetic routes and purification 
challenges.112 
The secondary structure of a peptide is vital to its function, as the shape largely determines binding 
specificity. One prevailing element of this is the α-helix (figure 28). The number of amino acids per 
turn is 3.6, optimal for stabilisation through hydrogen bonding between backbone residues on 
adjacent coils (i,i+4).117,118 Unfavourable steric clashes between side chains are minimised through the 
torsion angles of the backbone, contributing to the stabilisation of  the α-helix.119 Additional stability 
can also be imparted through salt bridges between oppositely charged side chains, such as lysine and 
glutamate residues.120 The combination of these favourable interactions promotes formation of 
α-helices in peptides; however, without the structural rigidity of high molecular weight proteins, the 
conformational flexibility results in poor helicity in water.121 
 
Figure 28: Peptide α-helix, reproduced from Ref. 44 with permission from The Royal Society of Chemistry.122 
The major drawbacks of peptide-based therapeutics are the poor proteomic stability and lack of 
conformational rigidity.115 Another challenge facing peptides is their poor membrane permeability – 
making it difficult to target intracellular PPIs.85 These issues can be linked to the lack of defined 
secondary structure, hence improving peptide helicity can improve peptide properties.123 These 
problems have been addressed in two major ways: backbone modifications, and peptide cyclisation.115 
Backbone modification involves changing atoms on the amino acid backbone to impart greater 
stability to physiological conditions, these compounds are generally referred to as peptidomimetics.124 
One example of this is β-peptides, where the altered amino acid backbone (figure 29) favours 
hydrogen bonding with more distal neighbouring groups, for example the 10-helix hydrogen bond.125 
This induces a secondary structure with improved helicity and pharmacological properties.126 
 
Figure 29: Peptidomimetics with altered backbone giving β-peptides 
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2.1.4. Peptide cyclisation 
Peptide cyclisation is a well-developed area of research. Macrocyclisation rigidifies the peptide 
conformation which generally enhances stability to proteolysis,85 and cell permeability.127 Cyclosporin 
A is a head-to-tail cyclic peptide and a potent immunosuppressive drug isolated from fungi in 1984 
(figure 30).128 The cyclic and N-methylated backbone of this orally administered peptide was thought 
to impart better pharmacokinetic properties and improved stability over the unmodified peptide.85 
 
Figure 30: Structure of immunosuppressant cyclosporin A  
Stapled peptides are an emerging class of macrocyclised peptides, where covalent linkage of two 
amino acid residues positioned in i,i+3, i,i+4, i,i+7, or i,i+11 positions forms a ‘staple’ between helical 
coils.115 Peptide stapling can be categorised as either one-component, where the two modified amino 
acid residues directly react with each other, or as two-component, where the two amino acid residues 
react with a bridging molecule (figure 31).122 
 
Figure 31: One-component vs two-component i,i+7 peptide stapling122 reproduced with permission from the RSC 
Early examples of cyclisation of amino acid side chains involved lactam formation between 
proteogenic Lys and Glu/Asp residues.129 One of the major benefits of lactamisation is its use of natural 
amino acids, which are cheap and commercially available. However, the requirement of additional 
orthogonal protecting group strategies for solid phase peptide synthesis (SPPS) can be complex.130 
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Cyclisation through disulfide bridges has promoted helicity and improved stability at elevated 
temperatures.131 This also benefits from use of natural amino acids, however poor stability of disulfide 
bonds in reducing environments limits their therapeutic potential.122 
One of the most established stapling methods is hydrocarbon stapling, initially developed in the 
Grubbs group.132–134 Their early work incorporated olefinic amino acids into a peptide sequence, which 
were then cyclised using ring-closing metathesis (RCM). 52,53 This work was extended to longer 
peptides where RCM of i,i+4 unnatural residues was performed (figure 32A).134 Following this, 
Schafmeister et. al. first introduced the term ‘stapled peptides’ applied to hydrocarbon stapling using 
RCM of α,α-disubstituted amino acids (figure 32B).135 The optimal i,i+7 stapled peptide had increased 
helicity and stability to proteolysis by trypsin compared to native and unstapled alternatives.  
 
Figure 32: A) RCM hydrocarbon stapling by Grubbs,134 B) Verdine’s all-hydrocarbon RCM stapling135; 
These initial successes allowed further development by Walensky et. al., applying the concept of 
stapled peptides to PPI targets including BCL-2.136 BCL-2 is a protein critical for regulation of apoptosis, 
and an appealing target for therapeutics.136 Using stabilised α-helix of BCL-2 domains (SAHBs), which 
are stapled peptides able to mimic a vital part of the binding domain, the apoptosis pathway could be 
activated.136  These stapled peptides had high specificity and improved stability to proteolysis, and 
were shown to kill leukaemia cells. The study showed SAHBs were also effective in vivo, with growth 
of leukaemia inhibited in mice.136  
There have been many other examples of using hydrocarbon stapled peptides to target challenging 
proteins, such as the inhibition of the NOTCH transcription factor,137 and β-catenin.138 An interesting 
recent development in this field extends methodology to the synthesis of bicyclic peptides, using 
orthogonal ring-closing alkyne and olefin metathesis.139 
Copper catalysed azide-alkyne cycloaddition (CuAAC) click chemistry was first used to staple peptides 
by Cantel et. al. (figure 33).140,141 There are many benefits to using CuAAC approaches to staple 
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peptides, such as the high yields, biocompatibility, and low cost reagents.142 Following this work, click 
chemistry peptide stapling was applied to the BCL-9/β-catenin PPI, generating a helical peptide with 
improved binding affinity and stability compared to linear and wild-type peptides.143 
 
Figure 33: Copper catalysed azide-alkyne cycloaddition synthesis of stapled peptides140,141 
The second category of peptide stapling is known as two-component peptide stapling, where a 
bifunctional linker able to react with the complementary amino acids is used as a ‘staple’. Two-
component stapling enables introduction of complex and diverse staples, which can be used to 
improve the properties of the peptide or introduce new functionality. Synthesis of these stapled 
peptides is theoretically more challenging than the one-component equivalent due to the side 
reactions possible, for example the double coupling by-product (figure 34).122 Oligomerisation may 
also be a problem, hence solution phase reactions at low concentrations are generally required.122  
 
Figure 34: Potential side reactivity found in two-component stapling;122 Reproduced from Ref. 44 with permission from The 
Royal Society of Chemistry 
There have been many examples of two-component peptide stapling strategies which have been 
comprehensively reviewed elsewhere.144 
 
2.1.5. p53-MDM2 binding stapled peptides 
Previous work in the Spring group has applied two-component CuAAC peptide stapling to the 
development of p53-MDM2 PPI inhibitors.123,145 The peptide sequence used (SP), was developed 
through point mutations of the wild-type p53 sequence to establish a potent MDM2 binder. This 
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peptide sequence was then stapled with different diyne linkers in an attempt to improve cell 
permeability (figure 35).123 
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Figure 35: Two-component stapled peptides with varied R-groups 
Stability of the peptides was improved upon stapling. The IC50 values varied between 90 and 149 nM 
and Ki varied between 3.7 – 11.7 nM. The cell permeability was assessed using a cellular reporter 
assay. Activity of each peptide was measured at 25, 50, and 100 µM concentrations (figure 36). Dose-
dependent p53 activation was observed for SP5, with little activation observed for the remaining 
peptides, likely due to poor cell permeability.123 This study highlighted the benefits of two-component 
peptide stapling, as optimised stapling gave significantly improved properties. 
 
Figure 36: where SP0 is the unstapled peptide residue, SP1: R = H, SP2: R = -NH-TAMRA, RRR-SP0: linear peptide with three 
arginine residues at N-terminus; taken from Lau et al. with permission from the Royal Society of Chemistry 123 
Further studies were undertaken extending the two-component stapling methodology to the copper-
free synthesis of stapled peptides.145 This strategy used the Sondheimer diyne, which reacted with the 
peptide via a double strain-promoted azide alkyne cycloaddition (SPAAC) reaction. The biocompatible 
stapling was carried out in the presence of cells in 96-well plates before evaluating in a p53 reporter 
assay (table 1).145  
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Peptide Sequence 
In vitro binding affinity 
for MDM2 (Kd, nM)  
Fold p53 activation 
of stapled peptide 
(50 µM) Unstapled Stapled 
A Ac-ETFXDLWRLLXEN-NH2 16 ± 1 3.1 ± 0.4 1.03 ± 0.03 
B Ac-LTFXHYWAQLXS-NH2 36 ± 3 14 ± 1 1.5 ± 0.3 
C Ac-TSFXEYWALLX-NH2 9 ± 1 7.6 ± 0.7 1.5 ± 0.2 
D Ac-LTFXEYWAQLXSAA-NH2 6.0 ± 0.6 2.5 ± 0.3 2.3 ± 0.2 
E Ac-LTFXEYWAQLXS-NH2 6.5 ± 0.6 7.5 ± 0.7 2.9 ± 0.2 
Table 1: Stapled peptide sequences with measured binding affinities for MDM2 and cellular p53 activation 
Peptide A is based on the SP sequence used previously and gave poor cellular activity. Peptides B – E 
are based on phage-derived peptides PMI,146,147 and PDI,148 and exhibited improved cellular activity. A 
crystal structure of peptide E complexed with MDM2 shows the α-helical conformation of the stapled 
peptide interacting with MDM2 (figure 37), with defined hotspot binding triad (F3, W7, L10).145 The 
staple motif interacts with the protein,145 however due to the open face of the MDM2 surface and the 
staple orientation, structural elaborations of the staple should not significantly affect MDM2 binding.  
 
 
Figure 37: Stapled peptide E bound to MDM2, 1.9Å resolution; taken from Lau et al.145 permission from John Wiley and Sons 
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2.1.6. Advantages of the recruitment of MDM2 as an E3 ligase in PROTACs 
Overall, exploitation of MDM2 as an E3 ligase for PROTAC generation has many potential benefits over 
the other commonly used E3 ligases, cereblon and VHL. Importantly, MDM2 is upregulated in many 
cancers hence could be more selective in degrading target proteins in these cancer phenotypes.149 This 
additional selectivity could also lead to a more targeted therapy with reduced side effects, since 
protein degradation would be more pronounced in the MDM2-overexpressing cancerous cells.  
Moreover, MDM2 recruiting PROTACs may unlock the potential to harness a dual mechanism of 
action.150 Indeed, MDM2 inhibition is a valid strategy for the treatment of cancers, due to its 
autoregulatory feedback loop with p53. As a result, MDM2 recruiting PROTACs would not only 
degrade AR through the PROTAC mechanism, but also inhibit MDM2 to promote p53 levels.151 This 
dual effect may lead to improved potency and selectivity for cancer, whilst potentially providing 
additional protection against resistance. 
There are over 600 identified E3 ubiquitin ligases,152 however, investigation into alternative E3 
components remains an underexplored area within the PROTAC field. Accordingly, the development 
of additional ligands to enable the recruitment of different E3 ligases is an important line of research 
that would further expand the PROTAC toolbox. Currently, it is very challenging to design highly potent 
PROTACs without substantial optimisation and as such, increasing the number of available E3 ligases 
for degradation may simplify this procedure, enabling exploitation of the inherent biases of a given E3 
ligase to a subset of proteins. Accordingly, the validation of a novel ligand for MDM2-mediated 
degradation could instigate degradation of additional protein targets.  
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2.2. Chapter 2: Aims and Objectives 
The objective of this project was to develop a novel PROTAC, which incorporated a stapled peptide 
using two-component CuAAC click methodology. The key benefit of using 2-component stapling was 
the ability to introduce additional functionality through the staple and improve the peptide’s 
properties, including cell permeability and solubility. As MDM2 is an E3 ligase able to polyubiquitinate 
p53, it follows that stapled peptide PROTACs could be developed through staple elaboration.  
The generation of ‘drug-like’ PROTACs is a major challenge in this field due to difficulties in achieving 
high permeability and bioavailability resulting from their high molecular weight. Stapled peptides are 
known to have the advantage of high cellular stability, permeability and good biocompatibility over 
their linear counterparts. Due to the catalytic nature of PROTACs, high cellular stability is vital for a 
long-lasting therapeutic effect without requiring high or frequent dosing. The stapled peptides 
developed in the Spring group targeting the p53-MDM2 PPI were demonstrated to achieve low nM 
binding affinities and good cellular activity. This stapled peptide approach was hypothesised to extend 
the PROTAC toolbox and further investigate the utility of E3 ligase MDM2 for UPS-mediated protein 
degradation. Additionally, the two-component stapling strategy was envisaged to be applicable to the 
degradation of a wide range of proteins through simple staple modification, enabling rapid and 
efficient PROTAC investigation.   
Targeting AR with PROTACs has enormous potential for the development of more effective CRPC 
therapeutics. Rather than inhibiting AR, like first generation antiandrogens, PROTACs induce 
degradation which is vital for their applicability to CRPC. Using an alternative mechanism of action to 
directly deplete AR levels, causing reduced proliferation and enhanced apoptosis, is thought to be a 
promising strategy for the development of next generation CRPC treatment.11  
Novel stapled peptide PROTACs were designed, which used a peptide sequence to recruit MDM2 as 
an E3 ligase and an enzalutamide-based binder to recruit AR (figure 38). Enzalutamide does not display 
agonist behaviour in cell lines with overexpressed AR and has high affinity for AR making it an ideal 
PROTAC component (Section 1.2.2). The peptide could be macrocyclised with a staple which is 
conjugated to enzalutamide using CuAAC approaches. With an initial PROTAC in hand, biological 
assays could be performed to establish activity in AR-positive cell lines.  
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Figure 38: Synthesis of stapled peptide PROTAC 
Research in the field of PROTACs has established huge activity differences based on varying linker type 
and lengths, hence further studies will be done to optimise the properties and activity of the PROTAC. 
The investigation will initially employ a six-unit poly-ethylene glycol (PEG) linker, due to its high 
flexibility allowing the ternary complex to adopt favourable conformations, and solubility. From 
literature precedent,21 the strategy for linker length optimisation will involve using a long, six-unit PEG 
chain for initial studies then reducing the length in further work to improve efficacy. 
Ideally the target protein would be varied in future studies, as a major benefit of PROTACs is their 
applicability to multiple targets with just minor alterations of linkers and target protein binders. A 
proof of concept experiment would involve swapping the enzalutamide-based fragment for an 
alternative binder, for example using an estrogen receptor binder for the application to breast cancer. 
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2.3. Chapter 2: Results and Discussion  
2.3.1. Synthesis of 1st generation PROTAC staples 
The synthesis of staple 1 was designed based upon the retrosynthesis outlined in figure 39. Initially, 
the complex staple was disconnected into the carboxylic acid 2, and PEG linker 3 which could be joined 
through an amide coupling. PEG linker 3 could be synthesised through esterification of benzoic acid 6 
with 7. Carboxylic acid 2 could be synthesised using an isothiocyanate-amine cyclisation of 4 and 5 to 
form the thiohydantoin core. Molecules 4 and 5 can be synthesised from the respective commercially 
available compounds, 8, 9, and 10. The route is highly modular, which is preferable for efficiency and 
yield; it also allows for easy installation of alternative linkers and AR binders. The final steps in the 
synthetic route are simple esterification and amide coupling chemistry which are typically high 
yielding.  
 
Figure 39: Retrosynthesis of staple 1 to commercially available starting materials 
The general synthesis of enzalutamide is a patented procedure involving a key isothiocyanate-amine 
cyclisation to form the thiohydantoin core.153 The synthesis proposed was a shorter, potentially more 
efficient route to reach the carboxylic acid rather than the N-methyl amide of enzalutamide. 
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Isothiocyanate 5 was initially synthesised from commercially available 4-amino-2-
(trifluoromethyl)benzonitrile 10. Literature procedures used thiophosgene,153 however this is a 
particularly toxic, hazardous reagent and its use was undesirable. Alternative routes to this functional 
group were studied (scheme 1). Reacting the amine with carbon disulfide and triethylamine followed 
by p-toluenesulfonyl chloride is a standard route to isothiocyanates,154 however, in this case no 
reaction was observed. A second attempt used carbon disulfide and triethylamine followed by Boc2O 
and 4-(dimethylamino)pyridine (DMAP),155  this was also unsuccessful and resulted in recovery of 
starting material. This was thought to be due to the electron deficiency of the arene due to strongly 
electron withdrawing nitrile and trifluoromethane groups, resulting in a less nucleophilic aniline. 
 
Scheme 1: Initial attempted synthesis of isothiocyanate 5 
Next, the reaction was attempted using thiocarbonyl-diimidazole (TCI), and the desired product was 
observed (scheme 2). TCI is regarded as a non-hazardous alternative to thiophosgene, typically used 
to synthesise thioureas via isothiocyanates.156 A quick solvent screen identified dichloromethane 
(DCM) as the optimal solvent for this reaction, which was likely to be due to the high solubility of both 
starting materials. 
 
Scheme 2: Synthesis of isothiocyanate 5 using TCI 
With the first building block in hand, work began towards the synthesis of the enzalutamide fragment 
(scheme 3). The first step involved an Ullman coupling between 2-fluoro-4-bromobenzoic acid 8 and 
2-aminoisobutyric acid 9 to form diacid 11. Purification of 11 was challenging due to its high polarity, 
resulting in poor yields. Diesterification of acid 11 using thionyl chloride gave 4 in 67% yield.  
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Scheme 3: Attempted synthesis of 12 
This was followed by the cyclisation in DMSO. Unfortunately, no desired product was observed by LC-
MS or TLC analysis of the reaction mixture, with substantial quantities of starting material 10 detected, 
indicating hydrolysis of 5 despite the anhydrous conditions. Attempts to optimise the reaction by 
varying solvents and equivalents of 5 resulted in complex mixtures of unidentified products. The 
mechanism for the cyclisation step is thought to begin with the nucleophilic attack of the amine onto 
the isothiocyanate, followed by intramolecular cyclisation through attack onto the adjacent ester. It 
was initially thought that the ring constraints meant that only the proximal ester would be subject to 
this intramolecular reaction, forming a favourable 5-membered ring (Baldwin’s Rules). However, the 
intermolecular reaction with starting material 4 or a reaction intermediate would form a variety of 
products. This was not conclusively proven by LC-MS analysis of the reaction mixture nor 1HNMR 
studies. It was thus decided to explore an alternative route to attain 2. 
The alternative approach to the synthesis of enzalutamide followed a patented procedure (scheme 
4).153 The initial step involves protecting 8 as an amide, prior to the Ullmann coupling. Product 14 was 
challenging to purify due to difficulties removing DMF and eluting the highly polar carboxylic acid.  The 
carboxylic acid 14 was then converted to the methyl ester 15 using iodomethane. When purification 
of 14 was omitted, and the crude compound was directly methylated the yield was much improved 
and purification of ester 15 was simple.  
32 
 
 
Scheme 4: Alternative synthesis to carboxylic acid 2 
To form the thiohydratoin core, 15 was cyclised with isothiocyanate 5. This reaction resulted in greater 
success than previous attempts. A solvent screen of DMSO and DMF both resulted in successful 
product formation, with DMF giving the higher yield. The yield was improved by increasing the 
quantity of isothiocyanate to 2 equivalents to give 63% yield. It is unknown exactly why this cyclisation 
procedure was successful with 15 but not with 4, however was hypothesised to be a result of side 
reactivity of the aryl-ester present in 4, masked as a less reactive amide in 15. 
Finally, amide 16 was hydrolysed by heating in concentrated hydrochloric acid (conc. HCl) in a sealed 
tube for two days, to successfully generate desired carboxylic acid 2.  
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2.3.2. Initial synthesis of linker 3 
Diyne-benzoic acid 6 was synthesised according to literature procedures,157 through a three step route 
(scheme 5). Initial esterification of 3,5-dibromobenzoic acid gave 18, followed by a Sonogashira 
coupling to form 19. Hydrolysis of 19 formed 6 in an excellent 87% overall yield.  
 
Scheme 5: Synthesis of diyne benzoic acid 6 from commercially available 17 
Next, the mono-functionalised PEG chain was synthesised, according to a published route (scheme 
6).158 This involved mono-tosylation of six-unit PEG, using Ag2O and KI to enhance selectivity for the 
monotosylated product 21. This mono-tosylation is highly selective for symmetrical diols, proposed to 
be due to internal hydrogen bonding, which causes a difference in acidity between the two hydroxyl 
protons (figure 40).159  
 
Figure 40: Internal hydrogen bonding of PEG chain chelate, where Hb is rendered more acidic 
Nucleophilic substitution of 21 with sodium azide gave 22 in quantitative yield, which was followed by 
a reduction to produce amine 23. Initial attempts subjected 22 to hydrogenation conditions, using 
palladium on carbon catalyst and H2 gas at atmospheric pressure; however, after 24 h only starting 
material was isolated. This was likely to be due to H2 pressure, since literature procedures employed 
10 bars of H2, instead of atmospheric pressure.160 For ease of operation, alternative conditions were 
identified. The Staudinger reaction generated the desired amine 23 in quantitative yield,158 which was 
then N-Boc-protected to give linker 7 in quantitative yield. 
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Scheme 6: Mono-functionalisation of six-unit PEG chain to form 7 
It was decided to initially connect the linker to the diyne 6, which was synthesised in fewer steps with 
a greater yield than AR-binder 2. It was more efficient to introduce 2 in the penultimate step of the 
PROTAC synthesis. Diyne 6 was connected using an esterification reaction with 
N,N'-dicyclohexylcarbodiimide (DCC) and catalytic 4-dimethylaminopyridine (DMAP). This gave 
product 24 in relatively low yield of 48% due to difficulties purifying this highly polar compound 
through column chromatography (scheme 7). Initial attempts to remove the Boc group used 4 M HCl 
in dioxane, however this resulted in poor yields potentially due to stability issues. TFA was 
subsequently used to give amine 3 in quantitative yield. 
 
Scheme 7: Synthesis of diyne PEG linker 3 
The next step was the amide coupling of linker 3 with carboxylic acid 2. This proved to be challenging, 
requiring various conditions to be screened (table 2). 
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Entry Conditions Results 
1 HATU (1.5 eq), DIPEA (3.0 eq) Complex Mixture, by-product 25 observed  
2 HATU (2.0 eq), DIPEA (2.0 eq) Complex Mixture, trace product, unable to purify 
3 DCC (1.2 eq), DMF Complex Mixture 
4 (COCl)2 (3.0 eq), DMF, DCM Complex Mixture 
Table 2: Conditions attempted for the amide coupling of 2 and 3 
The initial two attempts at this reaction used HATU/DIPEA conditions. Entry 1 gave significant levels 
of a by-product with 533 Da molecular weight observed through LCMS, proposed to be structure 25 
(figure 41). The direct reaction of amine with HATU leading to compound 25 was thought to consume 
3, reducing the equivalents left to react with the activated ester. The order and timing of the reagent 
additions is known to be important for optimum reactivity.161 For entry 2, equimolar quantities of 
HATU and DIPEA were used, and 2 was initially combined with HATU and DIPEA and stirred for ca. 30 
mins to form the active ester prior to the addition of 3. LCMS analysis of the reaction mixture showed 
a potential peak with the correct product mass; however, no product was isolated post-purification. 
Using DCC to form the active ester prior to reaction with 3 was also unsuccessful. The final conditions 
relied on forming the more reactive acyl chloride in situ using oxalyl chloride and catalytic DMF. This 
was also unsuccessful and gave complex mixtures of products by LC-MS analysis of the reaction 
mixture. 
 
Figure 41: Proposed guanidinium by-product 25 of HATU DIPEA based coupling 
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Although there were a substantial amount of alternative coupling reagents which could be screened, 
after further consideration it was decided that the di-amide linker 26 (figure 42), would be synthesised 
rather than the ester alternative which was identified as unstable in these reactions.  
 
Figure 42: Amide based linker 26 
Esters are generally not as robust to hydrolysis as amide bonds, due to their greater reactivity towards 
nucleophilic attack at the carbon centre. This biological instability may affect the PROTACs activity, 
hence avoiding esters where possible would be preferable for future PROTAC development. 
 
2.3.3. Synthesis of linker 26 
The initial route to mono-Boc protected diamine 30, involved a four step procedure (scheme 8).162 The 
initial di-tosylation and nucleophilic substitution to form di-azide 28 were successful in high yields. The 
Staudinger reaction, which was effective in the previous route, failed to yield any diamine 29 in this 
instance. Even though literature precedent for the transformation of this substrate exists,163 
competing inter- and intra-molecular processes at the iminophosphorane intermediate stage could 
be responsible for the observed lack of desired product formation. 
 
Scheme 8: Attempted synthesis of mono-Boc protected diamine 30 
Known literature procedures to access 30 rely on a seven step synthesis, starting from 20 and installing 
the two amino groups separately (scheme 9).158,164 Despite being fairly lengthy and inelegant, this 
route was found to be robust and reproducible, thus 30 was synthesised rapidly and in 73% yield over 
seven steps. 
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Scheme 9: 7-step route to the mono-Boc protected diamine 30 
The subsequent coupling reaction between linker 30 and acid 6 using HATU and DIPEA was successful 
on a 10 mg scale to give 33. Following this, 33 was deprotected using TFA before attempts were made 
to connect 2 to give staple 34 (scheme 10). However, the HATU/DIPEA coupling was unsuccessful, 
yielding a complex mixture of materials, including a guanidinium by-product analogous to 25.  
 
Scheme 10: Attempted synthesis of staple motif 34 
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To identify improved conditions for the amide coupling, a model system was developed. A shorter PEG 
chain was chosen, using commercially available 2,2'-(ethane-1,2-diylbis(oxy))bis(ethan-1-amine) 35. 
The system would also serve as a shorter PEG linker for future PROTAC development.  
The initial mono-Boc protection step was undertaken according to literature procedures (scheme 
11).165,166 Despite many attempts, varying the equivalents of Boc2O used, concentration, temperature, 
and speed of addition, the optimal yield was only 27%. This was much lower than reported literature 
procedures and was thought to be due to purification difficulties commonly associated with amines 
due to column chromatography streaking. Due to the availability and low cost of the starting material, 
27% yield was deemed acceptable for the purpose. 
 
Scheme 11: Synthesis of mono-Boc protected 3-PEG chain 36 
A screen of amide coupling conditions was then undertaken (table 3). Standard conditions using 
DCC/HOAt, PyAOP, HATU/DIPEA, and oxalyl chloride were attempted. Both DCC with HOAt additive 
and PyAOP were successful, giving 37 as the major product. Conditions using HATU/DIPEA and oxalyl 
chloride were unsuccessful and gave complex mixtures of products. 
 
Entry Conditions Results 
1 DCC, HOAt Product observed 
2 PyAOP Product observed 
3 HATU, DIPEA Complex Mixture 
4 (COCl)2, DMF, DCM Complex Mixture 
Table 3: Screen of amide coupling reagents for the synthesis of 37 
Following this, the N-Boc protecting group was removed using TFA to give 38 in good yield and purity 
(scheme 12). 
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Scheme 12: Deprotection of 37 to give amine 36 
To form staple 39, the two sets of conditions found to be successful in the previous screen (table 3, 
entries 1 and 2), were attempted on milligram scales. Both reactions were successful, however 
DCC/HOAt conditions gave a higher yield of 36% (scheme 13). 
 
After these more effective amide coupling conditions were found, they were applied to the desired 
six-unit PEG linker. Initially the amide coupling to give 33 was repeated using PyAOP, which gave an 
improved 65% yield compared to 14% for the HATU-mediated process. Following this, amide coupling 
of 26 with 2 was performed and staple 34 was isolated in 20% yield (scheme 14). The low yield was 
thought to be due to unoptimised conditions for the six-PEG linker, as well as the fact that 34 was 
found to be unstable to silica following 2D TLC analysis. The longer PEG chain results in a more polar 
compound, which elutes slower on silica compared to the three-PEG model system. Despite the low 
yield, additional optimisation of the reaction conditions and purification process was not attempted 
due to sufficient material for the subsequent stapling procedures. 
 
Scheme 14: Synthesis of six-unit PEG based staple 34 
Scheme 13: Synthesis of three-unit PEG staple 39 
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2.3.4. Synthesis of MDM2-binding peptide sequences 
With the staple in hand, attention was turned to the synthesis of the peptidic part of the PROTAC. To 
synthesise the most cell permeable MDM2 binding peptide sequences, unnatural amino acid 43 was 
initially synthesised, containing the azide required for click stapling. The ornithine based azide was 
chosen as the three-carbon distance between the peptide backbone and the staple was found to be 
optimal in previous work.167,168 Synthesis of the modified amino acid had already been reported by the 
Spring group,168 and necessitates the synthesis of a diazo-transfer reagent. Reaction of sodium azide, 
sulfuryl chloride, and imidazole resulted in the isolation of 40 in 61% yield (scheme 15). The sulfuric 
acid salt was previously found to be safer and more stable than the HCl salt which can also be used.169  
 
Scheme 15: Synthesis of diazo-transfer reagent 40 
Boc-protected ornithine was then deprotected and acidified to give 42 in quantitative yield, which was 
then subjected to a copper-catalysed diazo-transfer reaction to give Fmoc-Orn(N3)-OH 43 in 59% yield 
(scheme 16). This amino acid could then be directly coupled in solid phase peptide synthesis (SPPS). 
 
Scheme 16: Synthesis of Fmoc-Orn(N3)-OH 
Two peptide sequences were chosen for initial PROTAC formation, P1, and P2 (table 4). These 
sequences gave high in vitro binding to MDM2, and both showed cell activity, although P1 had greater 
cell penetration (section 2.2.3).145  
Name Sequence 
P1  Ac-LTFXEYWAQLXS-NH2 
P2  Ac-TSFXEYWALLX-NH2 
Table 4: Chosen peptide sequences, where X = Orn(N3) unnatural amino acid 
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Manual SPPS was used to synthesise peptide sequence P1, and automated SPPS was used to 
synthesise P2 for the subsequent stapling experiments. Peptides were purified using semi-preparative 
HPLC prior to CuAAC click stapling reactions. 
 
2.3.5. CuAAC peptide stapling 
The peptide stapling reactions developed in the group use CuAAC click reactions to form 1,4-triazoles 
from azide and alkyne functional groups. A 1:1 ratio of tBuOH and water was found to be the best 
solvent system in previous studies. For optimal results, it was found that using CuSO4●5H2O, THPTA 
ligand, and sodium ascorbate gave the most effective double click stapling.167 
The CuAAC reaction of peptide sequence P1 with 34 gave PROTAC-1 (scheme 17), which was then 
purified using preparative HPLC. The isolated yield of PROTAC-1 was just 27%, despite full conversion 
of P1 to a single product by analytical HPLC analysis of the reaction mixture. This was thought to be 
due to the small scale and loss of product during HPLC purification.  
 
Scheme 17: CuAAc stapling reaction to synthesise PROTAC-1 
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The stapling of P2 with 34, using synonymous reaction conditions, rapidly gave PROTAC-2 in 30% yield 
(figure 43). Biological testing required under 1 mg of each PROTAC, hence the yields were deemed 
acceptable for purpose. 
 
Figure 43: Structure of PROTAC-2 
 
2.3.6. Biological testing of PROTAC-1 and PROTAC-2 
With the two PROTACs in hand, assessment of their biological activity commenced. Cell proliferation 
assays were run with Dr Daniel O’Neill (AstraZeneca). Androgen receptor positive cells, (LNCaP, lymph 
node carcinoma of the prostate) and AR negative cells (PC3, prostate cell line) were cultivated and 
treated with the two PROTACs at varying concentrations. The two cell lines were chosen to allow 
assessment of the activity of the compounds. The synthesised PROTACs should only degrade the AR, 
thus leading to reduced LNCaP cell proliferation, and should be inactive towards PC3. If PC3 cells were 
affected, then it would indicate cytotoxicity problems with the PROTACs. Cell confluency was 
measured over a five-day period (figure 44). 
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Results showed that for LNCaP cells, PROTAC-1 had slight efficacy at the two highest concentrations: 
30 µM and 10 µM. At the top concentration, PROTAC-1 caused 30% reduction in cell proliferation. 
PROTAC-2 showed no activity in either cell line. These results are in line with previous work carried 
out on the P2 peptide,145 which showed poorer cell activity, possibly due to reduced cell permeability. 
Importantly, these results showed that at these concentrations, no cell toxicity was observed, as AR-
negative PC3 cells were not affected by either PROTAC. 
 
2.3.7. Synthesis and biological testing of PROTAC-3 
It has been shown in many previous PROTAC studies that the length and nature of the linker motif can 
have a significant effect on PROTAC activity (section 1.1). The first step in optimising the linker was to 
reduce the length, as this would result in a lower molecular weight and less polar PROTAC, potentially 
improving cell permeability. It was decided that the shorter, three-unit PEG linker synthesised 
previously 39, would be used for the next PROTACs. The shorter length may also improve efficacy by 
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Figure 44: Graphs showing the change in confluency of treated LNCaP and PC3 cell lines after 5 days at varying 
concentrations of PROTAC-1 and PROTAC-2; assays performed by Dr Daniel O’Neill 
LNCaP: PROTAC-1 
LNCaP: ROTAC-2 
PC3: PROTAC-1 
PC3: PROTAC-2 
44 
 
reducing the conformational flexibility and making the distance between the two protein complexes 
closer for optimal poly-ubiquitination. 
It was decided that only the more active P1 peptide sequence would be used for future PROTAC 
studies, as the P2 sequence showed no activity in preliminary results. Using the three-unit PEG based 
staple, CuAAC click chemistry was carried out to form PROTAC-3 (scheme 18). 
 
Scheme 18: Synthesis of PROTAC-3 
The LNCaP and PC3 cell assays used for the initial PROTAC studies were then used to assess the 
biological activity of PROTAC-3 by Dr Daniel O’Neill (figure 45). 
45 
 
 
Figure 45: Graphs showing the change in confluency of treated LNCaP and PC3 cell lines after 5 days at varying 
concentrations of PROTAC-3; assays performed by Dr Daniel O’Neill 
The graphs showed a limited effect on proliferation of the AR-positive cell line at the two highest 
concentrations. No effect on proliferation of PC3 cells was observed, showing the compounds do not 
have cytotoxicity issues. Unfortunately, the results showed no pronounced improvement on 
PROTAC-1.  
PROTAC-3 was predicted to be an enhancement on PROTAC-1, as shortening the linker length could 
provide a more favourable distance between the E3 ligase and target protein. In addition, three PEG-
units would ideally be more permeable than six, due to its reduced size and hydrophilicity. However, 
as proliferation was comparable to PROTAC-1, it was thought that the low activity could be related to 
the intrinsic properties of the PROTACs, most likely their limited cell permeability. Hence, the use of a 
PEG-chain linker was unlikely to be a viable option for developing highly efficacious PROTACs. 
 
2.3.8. Synthesis of PROTAC-4 and PROTAC-5 
For the 2nd generation PROTACs, it was decided that exploration of more permeable linkers would be 
attempted. One such linker was devised using six-carbon alkyl chains connected with amide bonds. 
The PEG-based linkers were thought to be too polar for optimal permeability. It was thought that this 
alkyl-based linker would be more effective at improving cell permeability due to its lipophilic nature. 
Short chain (eight linking atoms) and long chain (14 linking atoms) variants were synthesised for 
stapling with the P1 peptide sequence, for a crude study of linker length effects. 
The synthesis of the eight-atom linker 46 was performed using amide coupling and deprotection 
chemistry (scheme 19). Diyne 6 was reacted with N-Boc-1,6-hexanediamine to form 44 in 62% yield. 
PC3: PROTAC-3 LNCaP: PROTAC-3 
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Deprotection using TFA/dichloromethane gave 45 in 87% yield. Finally, staple 46 was synthesised from 
the amide coupling of 45 with 2, giving 60% yield. 
 
Scheme 19: Synthesis of short alkyl linker staple 46 
To synthesise the longer linker staple 50, amine 45 was coupled with 47, which gave 48 in 74% yield 
(scheme 20). Deprotection using TFA formed 49, which was coupled with 2. The yield for this step was 
low, thought to be due to purification issues, as signs of enzalutamide decomposition were observed. 
 
Scheme 20: Synthesis of longer alkyl linker staple 
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After synthesising the new alkyl-based staples, CuAAC click chemistry was utilised to form PROTAC-4 
(scheme 21).  
 
Scheme 21: CuAAC stapling to form PROTAC-4 
In an analogous reaction, P1 reacted with staple 50 to form PROTAC-5 (figure 46). 
 
Figure 46: Structure of PROTAC-5 
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2.3.9. Biological assessment: Cell proliferation assays of PROTAC-4 and PROTAC-5 
The two 2nd generation PROTACs were then tested in AR-positive (LNCaP) and AR-negative (PC3) cells 
by Dr Daniel O’Neill, as previously (figure 47). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low levels of activity were observed with PROTAC-4, similarly to PROTAC-1 there was slight reduction 
in proliferation at the highest concentration. Interestingly, PROTAC-5 exhibited promising activity at 
the top concentration of 30 µM with a confluency reduction of ca. 70%, corresponding to a pIC50 of 
4.8. This was in great contrast to PROTAC-4 which showed minimal effects on cell proliferation, 
highlighting the importance of optimal linker length. The linker in PROTAC-4 is very short compared 
to literature PROTACs (section 1.1.3). This may result in steric repulsion between the E3 ligase protein 
and AR, which limits formation of the active ternary complex, resulting in low activity. PROTAC-5 
appeared to have a slight effect on the control PC3 cells at the highest concentration. This low level of 
activity is classed as inactive hence does not flag cytotoxicity concerns. 
Images of the control LNCaP cells and those treated with 30 µM of PROTAC-5 showed a substantial 
reduction in confluency after 5 days (figure 48). 
Figure 47: Graphs showing the change in confluency of treated LNCaP and PC3 cell lines after 5 days at varying 
concentrations of PROTAC-4 and PROTAC-5 performed by Dr Daniel O’Neill 
LNCaP: PROTAC-4 PC3: PROTAC-4 
LNCaP: PROTAC-5 PC3: PROTAC-5 
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A plot of confluence over five days showed a small reduction in cell confluency when treated with 10 
µM of PROTAC-5 compared to the DMSO control (figure 49). The maximum concentration of 30 µM 
gave a substantial reduction in confluency. It was noted that there were some solubility issues with 
PROTAC-5, with crystallisation occurring on addition to the assay. This was not unexpected, since the 
alkyl linker further reduces solubility of the already poorly soluble stapled peptide. It is possible that 
this crystallisation is causing the anti-proliferative effect, although if this was the case then the PC3 
cells should also be affected. Results may be further improved if the solubility of the PROTAC could be 
increased without affecting the permeability. 
 
Figure 49: LNCaP after 200 hours of growth (light blue trace: DMSO control; dark blue trace: 10 µM PROTAC-5; pink trace: 
30 µM PROTAC-5); assays performed by Dr Daniel O’Neill 
Overall, the biological activity of PROTAC-5 observed in the cell proliferation assays is a slight 
improvement on the cell permeable peptide-based PROTACs discussed previously (section 1.1.2). This 
data provides a vital indication of the viability of using stapled peptides to improve PROTAC properties. 
Figure 48: A) Image of highly confluent control LNCaP cells after 5 days; B) Image of LNCaP cells dosed with 30 µM of PROTAC-5 
after 5 days; ; assays performed by Dr Daniel O’Neill 
A B 
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2.3.10. Synthesis of dihydrotestosterone based PROTAC 
The biological results obtained for PROTAC-5 were very promising, however further work was required 
to increase the efficacy and produce a more active hit. The higher activity observed for the less polar 
alkyl linker compared to the PEG linker indicated that permeability may be a limiting factor. One way 
to improve the permeability of the PROTACs is to substitute the enzalutamide AR binder with the 
highly cell permeable, endogenous AR binder DHT, 51.170 DHT has been used in AR targeting PROTACs 
previously (section 1.1.2), and is known to have a very high binding affinity for AR. Due to the 
difference in functionality of DHT compared to enzalutamide, the previously synthesised diyne linkers 
were not suitable for directly attaching to DHT, hence a new synthesis was designed. Attachment of 
DHT to the linker via the hydroxyl was the most straightforward option, and unlikely to affect AR 
binding. The 14-atom linker was chosen due to its greater cellular activity. 
DHT may be incorporated through esterification with N-Boc-protected aminocaproic acid, followed by 
a deprotection to give 53 (scheme 22). The ester 52 was attained in quantitative yield, however, 
following TFA deprotection, purification of 53 proved to be challenging. Although TLC analysis of 53 
showed a single product, 1H NMR showed impurities. It was decided that amine 53 would be used 
directly in the subsequent step without further purification.  
 
Scheme 22: Synthesis of DHT linker 53 through esterification and deprotection 
To achieve a convergent synthesis, which would be more efficient for future elaboration of different 
linkers, it was envisaged that the second half of the linker could be synthesised independently through 
a selective intermolecular amide coupling (scheme 23). Unfortunately, no desired product was 
observed, likely due to intramolecular cyclisation of 6-aminocaproic acid to caprolactone. It had been 
thought that by activating 6 with DCC and DMAP to form the active ester, prior to the addition of the 
6-aminocaproic acid, the intramolecular by-product could be avoided, however the reaction was 
unsuccessful.  
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Scheme 23: Desired synthesis of second linker fragment 
To overcome this problem, 6-aminocaproic acid was initially protected as tert-butyl ester 56 in 53% 
yield (scheme 24). Amine 56 was then treated with acid 6 with PyAOP to form 57 in high yield. The 
tert-butyl ester group was then removed using TFA to form acid 58 in quantitative yield. 
 
Scheme 24: Synthesis of acid 58 
With 58 in hand, attempts were made to connect it to amine 53, through an amide coupling to form 
staple 59 (scheme 25). This was found to be challenging and no product was detected by LC-MS or 1H 
NMR despite numerous attempts. It was thought that the complication of potential imine formation 
between the free amine and ketone of the DHT fragment 53 was hindering the reaction, in addition 
to impurities associated with using crude and likely unstable amine 53. 
 
Scheme 25: Attempted convergent synthesis of DHT staple 59 
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An alternative stepwise approach from 58 was devised, where each intermediate could be purified 
(scheme 26). A simple procedure of amide coupling and deprotection gave acid 60 which could then 
be esterified using the DHT to give staple 59. The final step in this sequence gave a fairly poor yield, 
thought to be due to the small scale of the reaction which resulted in more significant losses in the 
work up and purification procedure, in addition to steric issues resulting from the very hindered DHT 
alcohol. Adequate material was obtained for stapling purposes, hence the reaction was not optimised. 
 
Scheme 26: Successful synthesis of staple 59 
The final step to form PROTAC-6 is the ‘click’ stapling to peptide P1, which was performed under the 
previous conditions and was successful in forming this PROTAC (scheme 27). 
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Scheme 27: Synthesis of PROTAC-6 
 
2.3.11. Biological assessment: High Throughput CETSA Evaluation 
PROTACs 1-5 were previously analysed through cell proliferation assays to establish cellular activity, 
however these assays were unable to identify the cause for the antiproliferative effect, which could 
be complex in a cellular environment. Therefore, the most promising candidates PROTAC-5 and 
PROTAC-6 were tested in an assay which could specifically evaluate AR levels to confirm the PROTAC 
mechanism of action.  
In recent years there has been greater focus on developing assays to establish target engagement in 
a cellular environment, which can provide a direct measurement of the cellular activity of different 
drugs. These assays provide more information than typical enzymatic assays as fundamental 
properties such as permeability and cellular stability will impact the results, making it more predictive 
of clinical efficacy. Cellular thermal shift assays (CETSA) have been developed for this purpose. CETSA 
provides an understanding of in-cell target engagement through the thermal stabilisation of a target 
protein when bound to a ligand.171  
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Protein thermal melting curves of purified proteins have been used to establish target binding through 
thermal shift assays (TSAs). A protein is treated with a compound and the melt curve is then measured, 
a positive shift in the melt temperature (ΔTm) is indicative of a compound interacting with and 
stabilising the protein.171,172  
CETSA takes the principles of TSA and applies it within a cellular environment. General cellular assays 
monitor drug efficacy through downstream responses rather than direct binding affinity, for example 
a cell proliferation assay, and this can lead to a poor understanding of a drugs action.171 CETSA directly 
measures target engagement within a cell, which is necessary to conclusively validate the biological 
activity of a drug. Label-free and physiologically relevant methods of measuring target engagement 
are extremely useful for high throughput screening in early drug discovery. However, this technology 
has only been reported for a handful of cellular targets.173   
A high-throughput CETSA protocol has recently been developed in a prostate cancer cell line 
endogenously expressing AR.174 Differentiating between AR binders and AR co-regulator binders has 
been a significant challenge for the identification of new AR antagonists. This assay can differentiate 
between AR and related targets. The assay involves heat shocking the compound-treated cells over a 
range of temperatures causing AR to unfold and aggregate. Then the remaining levels of soluble AR is 
measured against the thermally denatured and precipitated proteins. The ΔTm of AR depends on the 
protein’s thermal stability and stabilisation occurs in the presence of a bound inhibitor. To increase 
the throughput of this assay, the soluble AR levels were quantified using AlphaScreen® FRET 
technology which measures an output fluorescence signal using an AR binding antibody pair. In the 
absence of a heat shock, this technology enables quantification of cellular AR levels in response to 
treatment with a PROTAC to determine whether AR degradation is occurring.  
These CETSA assays were expected to indicate whether the antiproliferative effect of PROTAC-5 
observed previously in cell proliferation assays (section 2.8.2) was a direct result of AR degradation. 
This assay was conducted with the help of Dr Joseph Shaw (AstraZeneca), for PROTAC-5 and 6 along 
with an assortment of controls (figure 50).  
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Figure 50: CETSA determined IC50 values for PROTACs and control compounds, performed with Dr Joseph Shaw 
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Unfortunately, no AR degradation was observed for PROTAC-5, and a slight increase in AR levels was 
observed for PROTAC-6 indicating agonistic activity. Positive controls NVP-AUY-922, tanespimycin 
(both AR chaperone heat shock protein 90 inhibitors), and AR downregulator niclosamide all showed 
the expected lowering of AR levels. Negative controls ailanthone (p23 inhibitor) and enzalutamide 
showed no significant effect on AR levels, validating the assay. The assay was repeated over two 
timepoints 1 h and 4.5 h; AR degradation by the PROTAC mechanism is rapid and should be observed 
within this timeframe. The endpoint AR signal was lower after 4.5 h across all compounds due to the 
general instability of the cells observed over longer periods.  
There were many potential reasons for the failure of these PROTACs to degrade AR. The PROTACs 
could have been unable to bind MDM2 or AR, unable to form the correct ternary structure 
conformation for efficient ubiquitination, suffer from instability or have poor cell permeability. The 
binding of the PROTACs to MDM2 and AR could be tested using either enzymatic or cellular assays 
with the respective proteins. The ternary structure conformation was much more difficult to 
understand without generating a crystal structure of the PROTAC bound to the two proteins, which is 
highly challenging. The permeability of stapled peptides was known to be a major challenge, due to 
their large size and polarity. Attaching the linker and enzalutamide staple to the peptide almost 
doubles its molecular weight, which may further reduce its cell permeability. 
Further biological testing was required to understand why these PROTACs are inactive. However, the 
general complexity of PROTACs makes it very challenging to fully understand and resolve these issues. 
Testing the binding of the PROTACs to each protein partner was hypothesised to be a simple way to 
better understand these PROTACs. 
  
2.3.12. Biological assessment: MDM2 expression, purification and competitive FP 
In order to further investigate why the synthesised PROTACs were unable to degrade AR, the PROTACs 
binding affinity toward MDM2 was measured. Recruitment of MDM2 by the PROTAC is vital for the 
proteasomal mediated degradation of a target protein, thus if the peptide staple hindered its ability 
to bind MDM2, no AR degradation would be observed. 
The MDM2 protein was expressed and purified with the assistance of Rohan Eapen in the lab of Dr 
Laura Itzhaki in the Department of Pharmacology. Firstly, the gene encoding for the region of MDM2 
residues 6-125, which form the p53/MDM2 PPI interaction site, was cloned into a pRSETa vector from 
a plasmid provided by the Itzhaki group, which contained the gankyrin gene in addition to the MDM2 
sequence (figure 51).  
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Figure 51: A: Composition of initial plasmid encoding gankyrin; B: Composition of generated plasmid encoding for MDM2  
Next, the generated plasmid was amplified, the transformants sub-cultured and the DNA extracted 
prior to purification and analysis (figure 52A). The plasmid was then transformed in the E. coli 
expression cell line, C41(DE3), induced with IPTG, and the protein extracted. The protein was purified 
by His-tag trap, before treatment with thrombin to remove the tag. Finally, purification of the protein 
by high-performance ion exchange chromatography yielded MDM2 (6-125) protein, which was 
analysed by SDS-PAGE analysis (figure 52B). In this instance, it was found that the His-tag cleavage was 
unsuccessful, thus the protein generated was 6-His-tag MDM2 (6-125). This was not expected to affect 
the subsequent competitive FP experiments, as this tag was distal from the MDM2 binding site. 
 
Figure 52: A: Amplified plasmid gel showing purity; B: SDS-PAGE of recombinant MDM2 protein following purification 
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With the recombinant MDM2 protein in hand, binding affinity of the stapled peptide PROTACs to 
MDM2 was assessed through competitive fluorescence polarisation (FP) as previously described.147,175 
Generally, in a competitive FP experiment a compound of interest is titrated against a fluorescently 
labelled protein binder of known binding affinity, known as the tracer, and the protein. This allows 
quantification of the strength of binding of a compound to the protein, assessed by the compound’s 
ability to outcompete the tracer. The tracer used for these experiments was a 5-TAMRA-labelled 
peptide sequence (TAMRA-RFMDYWEGL-NH2) based upon the native p53 MDM2 binding sequence 
and reported to bind MDM2 with a Kd value of 17.6 ± 1.7 nM.175 Additionally, positive controls of P1 
and nutlin 3a were used to validate the generated six-His-tagged MDM2 protein. 
PROTACs 3, 4, and 5 were established to be potent MDM2 binders in this assay, with calculated Kd 
values of 68, 53, and 38 nM respectively (figure 53). Although the potencies calculated are slightly 
lower than the stapled peptides prepared in previous studies,123 they are of the same order of 
magnitude indicating that the staple motif does not significantly hinder MDM2 binding.  
 
Figure 53: Competitive FP curves for PROTAC 3-5 establishing potency against MDM2 
Although PROTAC-6 was not tested in this assay due to its limited supply, it was envisaged that the 
extent of MDM2 binding would be similar to PROTACs 3-5 as a result of similarities between the 
PROTACs structure and size. 
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2.3.13. Biological Assessment: AR recruitment 
With activity against MDM2 confirmed, AR recruitment was investigated. This was performed by Dr 
Joseph Shaw using the CETSA target engagement protocol to determine intracellular AR binding in 
LNCaP cells in both the antagonist (figure 54A) and agonist binding modes (figure 54B). For the 
antagonist mode, competition of 1 nM DHT added causes a reversal of DHT-induced thermal 
stabilisation after the 46 °C heat shock, which causes a decrease in AlphaScreen® signal. The agonist 
mode results in an increased AlphaScreen® signal after heat shock. 
  
Figure 54: CETSA to show AR target engagement with both antagonist (A) and agonist (B) binding modes, performed by Dr 
Joseph Shaw 
A 
B 
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The ability of these enzalutamide derived PROTACs connected using the acid handle to bind AR is well-
known in literature and patents,64,74,176–178 hence this cellular assay was predominantly chosen to 
assess cell permeability and cellular stability. 
PROTAC-5 was unable to bind AR in the antagonist binding mode cellular assay, compared to the 
positive control enzalutamide which bound with a pIC50 of 7.16. Although this implies that PROTAC-5 
is fundamentally unable to bind AR, the enzalutamide motif used is prominent in the literature and 
patents and AR binding is well-known. Hence, assuming this motif is capable of binding AR, the most 
likely reason for this negative result is the poor cellular permeability of PROTAC-5. It is likely that 
PROTAC-5 is completely unable to cross the cell membrane to engage with AR. 
PROTAC-5 and PROTAC-6 were then examined in the agonist binding mode assay. As expected 
PROTAC-5 showed insignificant levels of activity, as enzalutamide is an AR antagonist. PROTAC-6 was 
found to bind AR with a pIC50 of 7.69, slightly lower than that of testosterone (pIC50 = 8.21). DHT is 
known to be a stronger AR binder than testosterone.170 It is unknown from this assay whether 
PROTAC-6 can cross the cell membrane or whether the cell stability of this PROTAC is low and the 
ester bond connecting the linker to DHT is hydrolysed to release the permeable and potent free DHT.  
These results were extremely useful in answering some of the previously mentioned questions. Both 
PROTACs were unable to cause degradation of the AR. There may be several contributing factors 
causing this, however it is most likely to be the stapled peptides poor cellular permeability. Results for 
PROTAC-6 have implied either a lack of intrinsic stability resulting in release of free DHT, which was 
anticipated due to the ester connection used, or again poor cellular permeability.  
Despite the inconclusive nature of these results, further biological testing was not pursued. This was 
because regardless of the exact reason for their lack of activity, these issues with permeability or 
ternary complex formation would be extremely difficult to overcome. AR binding could be directly 
assessed using enzymatic assays, such as competitive FP and permeability assays such as PAMPA or 
Caco-2 could be used to quantify the exact level of cell permeability. However, there was no straight-
forward access to these assays, hence this data was not pursued. In addition, the results would not be 
particularly useful for development of stapled peptide PROTACs, as imparting permeability to stapled 
peptides is not trivial.179 
PROTACs recruiting MDM2 as an E3 ligase are not well known in literature compared to other E3 
ligases such as VHL and cereblon. An alternative approach to developing MDM2-recruiting AR 
degrading PROTACs is to move to a small molecule approach. Small molecules are more inherently 
permeable than stapled peptides hence the resulting PROTACs are more likely to degrade AR. 
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2.4. Chapter 2: Conclusions 
To conclude, novel stapled peptides have been synthesised aiming to degrade AR using MDM2 as an 
E3 ligase. The peptide sequence used is a p53 derived sequence previously shown to have a high 
affinity for MDM2. Through two-component peptide stapling it was possible to simultaneously 
stabilise the resulting stapled peptide and attach a linker and AR binding motif to generate the desired 
PROTAC. With this design, six stapled peptide PROTACs were generated, exploring different peptide 
sequences, linker lengths and types, and AR binding motifs. 
Initially, the PROTACs were tested using AR cell proliferation assays of AR positive LNCaP cells and AR 
negative PC3 control cells. Little activity was observed for PROTACs 1-4; however, PROTAC-5 showed 
a significant reduction in proliferation of the LNCaP cell-line at top concentration of 30 µM and limited 
activity at a lower concentration of 10 µM, with a pIC50 of 4.8. No antiproliferative effect was observed 
with AR negative PC3 cells indicating an AR dependent effect.  
In addition, PROTAC-6 was generated which used cell permeable endogenous steroid DHT to bind AR. 
However, when tested in direct AR degradation CETSA assays, no degradation was observed for 
PROTAC-5 or PROTAC-6. PROTAC-6 increased levels of AR, indicating that the DHT motif was working 
as an agonist. This was likely a result of the unstable ester linkage which was used to connect the DHT 
motif to the linker, which could be rapidly hydrolysed in a cellular setting to release agonist DHT. Ester 
bonds are well known to be fairly unstable in a cellular environment, a property often exploited for 
use in pro-drugs.180 
Further studies of the stapled peptide PROTAC series showed that the PROTACs were able to bind 
MDM2 in competitive FP assays, with high potency. Unfortunately, PROTAC-5 did not exhibit AR 
binding in a cellular assay indicating limited permeability which is known to be a problem for stapled 
peptides. PROTAC-6 did show AR binding in the cellular agonist assay mode; however, this was 
thought to once again indicate the poor stability of this PROTAC. 
Overall, after promising initial results, these PROTACs were found to be incapable of degrading AR in 
a cellular setting. Although the specific reasons behind this lack of activity were not conclusively 
shown, it was decided that the limitation of poor cellular permeability was too significant of an issue 
to overcome. 
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2.5. Chapter 2: Future Work 
Synthesis of PROTACs with greater cell permeability is required to drive the cellular activity of stapled 
peptide PROTACs. One way to improve permeability is to append a cell penetrating tag to the PROTAC, 
which uses properties of known cell-penetrating peptides to promote cellular-uptake.181 Examples 
include incorporation of a poly-arginine tail. It has been observed that polycationic peptides with chain 
lengths varying between 7 – 20 residues are able to enter cells more easily than neutral peptides.182 
The uptake of these peptides is commonly through endocytosis, however passive mechanisms have 
also been reported.183 Poly-arginine chains could be incorporated into the PROTAC either as an 
alternative to the alkyl linker (figure 55A), or, if this additional bulk was found to disrupt poly-
ubiquitination, it could be incorporated directly into the MDM2 peptide sequence, providing it doesn’t 
affect intrinsic binding properties (figure 55B). A limitation of this approach is the potential for 
lysosomal entrapment, where the stapled peptide enters the cell through endosomes and is unable 
to escape.184 
 
Figure 55: Methods of incorporating cell penetrating tag, A: as a PROTAC linker; B: directly into the peptide sequence 
Another method of improving the permeability of stapled peptide PROTACs is through an in situ 
stapling strategy. This would require attachment of the AR binder and linker to a double SPAAC linker 
such as the Sondheimer diyne linker described previously (section 2.2.3). This means the peptide and 
linker could be introduced to cells separately to significantly reduce the molecular weight, increasing 
the likelihood of good permeability (figure 56A). Once in the cell, the components could react through 
a biorthogonal click to generate the full PROTAC structure. This strategy was previously shown to 
improve the cellular activity of these stapled peptides.145 This approach was applied to PROTACs by 
Lebraud et al. and termed CLIPTACs.185 CLIPTACs were prepared by splitting cereblon-recruiting small 
molecule PROTACs into two components and attaching a click precursor on each side. These CLIPTACs 
were shown to degrade two oncology target proteins BRD4 and ERK1/2 in a cellular environment. The 
challenge of using this method to generate stapled peptide PROTACs is the limitations in biorthogonal 
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double click reagents, which are typically challenging to synthetically modify.186 An alternative 
approach would be to generate a stapled peptide with a click component attached and treat it with a 
click modified linker and AR binder in the cell (figure 56B). This approach would be synthetically 
simpler, however the permeability of this type of stapled peptide is unknown. PROTACs constructed 
using similar copper-catalysed click methodology to conjugate the two protein binders together have 
been shown to be highly effective and the modularity of the toolbox increases overall efficiency.187 
 
Figure 56: Approaches to in situ click to generate PROTAC, A: using double SPAAC for stapling and AR binder attachment; B: 
using single click reagents 
Overall, strategies exist to generate stapled peptide PROTACs capable of overcoming the intrinsic 
permeability limitations. However, since the surge in activity of small molecule PROTACs, the use of 
peptide components has become considerably less popular. There is still some interest in this area, 
with a recent publication using stabilised peptides to degrade the ER α.188 This paper reported the 
attachment of a peptide sequence targeting ERα via a short carbon linker to a peptide sequence 
targeting VHL. The ERα targeting peptide sequence was cyclised through one-component peptide 
stapling methods to stabilise the PROTACs. These PROTACs degraded ERα in a cellular environment 
with a DC50 < 20 µM, this is considerably less potent than small molecule alternatives. Further attempts 
to improve the activity of these PROTACs led to a slight improvement in potency IC50 ~ 9.7 µM.189 
These results highlight the significant challenges of achieving high potency with peptide based 
PROTACs, small molecule variants have greatly surpassed peptidic PROTACs and have achieved over 4 
orders of magnitude greater activity. 
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3. Chapter 3 
3.1. Chapter 3: Introduction 
3.1.1. Overview of small molecule MDM2 inhibitors 
As described within the previous chapter, many challenges were faced during the development of 
stapled peptide PROTACs, particularly the poor cell permeability and stability. As such, subsequent 
efforts focussed on identifying alternative strategies to construct potent PROTACs with more 
favourable properties. Aside from peptide-based warheads, small molecules offer many advantageous 
properties that could alleviate these issues. Indeed, within recent years several small molecule 
PROTACs featuring high potency and adequate bioavailability have been reported in the literature 
against a range of different proteins (section 1.1.4).31,190 
The first reported small molecule PROTAC was published by Schneekloth et al. in 2008 (figure 57A) 
which used a nutlin derivative to recruit MDM2 for AR degradation.18 This PROTAC was demonstrated 
to degrade AR through Western blotting at 10 µM concentration in HeLa cells (figure 57B). The nutlin 
derivative incorporated within this PROTAC is a racemic compound with a high molecular weight of 
638 Da, resulting in a PROTAC with ca. 1200 Da molecular weight. This large size could be a 
contributing factor to the weak potency observed due to low cell permeability.191  
 
Figure 57: A: structure of small molecule PROTAC which used nutlin as an MDM2 binder for AR degradation; B: Western 
blotting analysis of PROTAC activity in HeLa cells,18 reproduced with permission from Elsevier 
Despite the promise of harnessing MDM2 as an E3 ligase for targeted protein degradation (section 
2.2.4), no further examples of MDM2 recruiting PROTACs were present in the literature at the outset 
of this project. This highlighted the importance of identifying novel small molecule motifs capable of 
hijacking MDM2 for PROTAC mediated degradation. 
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There have been a large number of small molecule MDM2 inhibitors identified in the past decade, 
many of which are currently undergoing clinical trials with promising initial data (figure 58).192  
 
Figure 58: Structures and molecular weight of clinical candidates for the inhibition of MDM2 
The nutlin series were the first reported small molecule MDM2 antagonists.107 Further optimisation 
of this scaffold led to the discovery of RG7112,193 the first clinical MDM2 inhibitor that was found to 
reactivate the p53 pathway and generate clinical responses in phase I trials.109  The second generation 
clinical candidate RG7388 is based on a pyrrolidine core and was found to have higher potency and 
selectivity toward MDM2.194 Another clinical candidate, AMG 232, was reported as a potent and 
selective piperidinone based MDM2 inhibitor with a binding affinity of 0.045 nM.195,196 This drug 
proved efficacious and was well-tolerated in phase I studies.197 Another MDM2 inhibitor to recently 
enter the clinic was NVP-CGM097,198,199  a substituted 1,2-dihydroisoquinolinone derivative with an 
IC50 of 1.7 nM, which has been reported to demonstrate promising clinical activity.200 SAR405838 has 
a binding affinity of 0.88 nM to MDM2, good pharmacokinetic properties, and has been shown to 
potently activate the p53 pathway in vivo.201 Phase I studies of this inhibitor in patients with advanced 
solid tumours showed a good safety profile with limited activity.202 Finally, SAR405838 is also being 
clinically evaluated as a combination therapy, where preliminary anti-tumour activity has been 
observed.203 
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Despite the potent nature of these clinical candidates, several factors limited their incorporation into 
PROTACs. Namely, this related to the fact all five candidates described had high molecular weights of 
>550 Da and required complex syntheses due to the presence of multiple stereocentres. In contrast, 
the features sought for this purpose were low molecular weight, simple chemical synthesis (or 
commercial availability), and an obvious and validated exit vector for PROTAC growth which would 
not significantly hamper MDM2 protein binding. E3 ligase recruiting motifs used in PROTACs do not 
need to have nanomolar binding affinities to generate extremely potent PROTACs,76 hence, 
identification of less complex and more readily synthesisable MDM2 binders was investigated through 
in silico methods.   
 
3.1.2. Computational methods to generate novel PPI inhibitors 
Identification of novel small molecule inhibitor scaffolds for PPIs is highly challenging. A well-validated 
approach to rapidly and cost-effectively generate new hits against targets of interest is through 
computational methods.204,205 One such strategy to identify novel hits is through in silico screening of 
virtual compound libraries against the target protein binding site.206  
Two commonly adopted methods for computationally screening databases are via ligand-based and 
structure-based searching. Ligand-based screening methods harness structure-activity data from 
known binders. There are different methods for generating this data, whereby either the individual 
chemical functionalities responsible for binding towards specific residues for a given target are 
identified and matched or whole molecule shape similarity comparisons are drawn between known 
and new ligands. Often, this generated data is utilised to form a 3D pharmacophore describing the 
shape and functionality of a small molecule, which can then be compared to the known ligand to 
predict binding potential.207,208 This approach has many advantageous features, such as the speed of 
hit identification and the rapid elimination of obvious non-binders. However, this methodology still 
suffers from a few limitations, such as its qualitative nature and often the production of very weakly 
binding hits due to difficulties in ranking quality.209 In contrast, structure-based database searching 
uses docking techniques to assess the binding affinity of a virtual compound to the 3D protein 
structure. This has the advantage of providing docking scores which can roughly indicate hit binding 
affinity.210 The limitations of this approach, however, are that the computing time required to 
generate the data is high and the accuracy of predictions correlates to the flexibility of compounds, 
with those featuring many conformations proving more challenging to accurately predict.211 
Nevertheless, there are significant advantages in efficiency associated with the use of virtual over 
physical compound collections for screening. 
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In a similar vein to high throughput screening approaches, hit generation through virtual screening 
methods relies on large databases of compounds that cover a broad area of chemical space.212 There 
are many databases of compounds available for virtual screening with different properties and 
availabilities, such as the ZINC database that features over 120 million compounds.213,214 The overall 
chemical space of small carbon-based molecules is predicted to encompass over 1060 compounds.215 
Similarly to the deficiencies of physical library coverage, it has been noted that only a minimal fraction 
of this space has also been explored using virtual methods.216 Virtual libraries have many benefits 
associated with their use, including their ease of curation compared to physical collections; hence 
chemical space coverage is considerably easier to manipulate. It is now well known that the probability 
of identifying hits against a given target is highly dependent on the composition of a screening 
library.217 Thus, it is vital to ensure a given virtual library is of sufficient diversity to increase this 
likelihood; this is even more essential when pursuing challenging targets such as PPIs. 
The two computational approaches for hit identification have previously been applied in a synergistic 
fashion to identify small molecule binders at the MDM2-p53 interface.218 These efforts resulted in the 
identification of nanomolar MDM2 inhibitor NSC 66811 through screening a virtual database (figure 
59).219 Lu et al. initially used pharmacophore screening to identify a series of hits from the National 
Cancer Institute (NCI) 3D database. These initial hits were then docked to the MDM2 surface and the 
predictive binding affinity of each compound ranked. Next, the compounds identified to be the most 
potent were obtained and biologically screened to confirm binding affinity to MDM2. These efforts 
proved successful, since NSC 66811 was identified to bind MDM2 with a Ki of 120 nM and was found 
to be active in a cell-based assay. 
 
Figure 59: Structure of racemic MDM2 binder NSC 66811, discovered through virtual screening of NCI’s database 
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3.2. Chapter 3: Aims and Objectives 
In order to identify novel MDM2 binding scaffolds, it was hypothesised that utilising the two previously 
described computational approaches in tandem could prove a powerful approach to identify potential 
small molecule binders that may be suitable for PROTAC construction. However, as noted within the 
previous section, the identification of a suitable virtual screening library is an essential factor that 
contributes to the viability of this process. Thus, it was envisaged that due to the challenging nature 
of PPI disruption, a structurally diverse and 3D library would be required for this strategy. Novel small 
molecule MDM2 binders identified through in silico screening methods could then be synthesised and 
validated before applying to the PROTAC field. 
Over the past two decades, among others, the Spring group have pioneered the development of 
diversity-oriented synthesis (DOS).220,221 DOS is a divergent approach for generating diverse compound 
libraries that cover large areas of chemical space in an efficient manner through common 
intermediates.220,221 Importantly, DOS libraries have many advantages, including the low inherent bias 
towards a specific biological target since they are often constructed in a target-agnostic fashion. 
Inspired by these features, a virtual compound collection of novel, diverse and 3D structures had 
previously been generated using a DOS-inspired strategy. Importantly, due to the inherently modular 
approach of this chemistry, it would be assumed that resulting scaffolds would be readily synthetically 
tractable and thus, hits could be quickly validated. Moreover, the 50,000-member library had also 
been assessed in terms of biological space coverage and compound promiscuity, which highlighted 
the favourable properties of this library compared to other commercial collections. Following these 
studies, this DOS-derived compound collection was applied towards the identification of novel MDM2 
binders.222 The computational work described was performed by Dr Lewis H. Mervin.  
The computational workflow involved initial mining of the library using ligand-based screening, 
comparing the library compounds with a set of known active and inactive small molecules to shortlist 
the 25,000 top compounds. These high scoring compounds were then docked against MDM2 protein 
using Glide223 to generate docking scores which assess the degree of binding predicted. Four of these 
compounds, 62 - 65 were then chosen for further study because they featured within the top 30 
ranked compounds and contained novel MDM2-binding scaffolds dissimilar from active compounds 
(figure 60).222 It was important for the proposed MDM2 binders to encompass areas of chemical space 
which had not previously been explored. Similarity evaluation of these structures compared with 
known MDM2 binders found them to have little similarity with their nearest neighbours. Importantly, 
these identified compounds all contained a triazole core and could be easily prepared for testing using 
simple and robust chemistry. Compound 65 was prepared by Dr Sarah Kidd. 
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Figure 60: Structures of computationally predicted MDM2 inhibitors, relative docking scores are shown in blue222 
The binding poses predicted for these compounds with MDM2 in the p53 protein binding interface 
are shown in figure 61A and B. Hydrogen bonding interactions were predicted between the amine 
functionality in all four compounds towards both GLN72 and TYR67 (figure 61C). Additionally, the 
triazole ring of each compound was predicted to bind in the same region of the interface with high 
overlap.  
 
Figure 61: A) Superposition of MDM2 ligands identified visualised with a solid molecular surface; B) a cartoon and stick 
representation; C) Structure of ligand 64 bound to MDM2 highlighting interactions made with surrounding amino acids222 
With these results in hand, the synthesis and biological evaluation of the potential MDM2 binders was 
proposed. In turn, if successful, it was hypothesised to incorporate these compounds into a series of 
novel PROTACs, which would recruit MDM2 as the E3 ligase for degradation of AR. In contrast to 
Chapter 2, where stapled peptides were used for this purpose these small molecule PROTACs were 
expected to have considerably improved permeability, which was anticipated to translate to improved 
activity and pharmacological properties.  
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3.3. Chapter 3: Results and Discussion 
3.3.1. Synthesis of computationally derived small molecule MDM2 binders 62 - 64 
A retrosynthetic analysis of the three proposed small molecule MDM2 binders highlighted a simple 
click chemistry-based route could be utilised to access the compounds (figure 62). Since the three 
compounds shared a central triazole ring, it was hypothesised this could be split into the respective 
alkyne and a common azide constituents. In the forward route, it was hoped these components could 
be reacted using a ruthenium catalysed azide-alkyne cycloaddition to give the 1,5-regioisomer. 
Moreover, the three proposed alkynes could all be synthesised using simple chemistry from 
commercially available building blocks 70 - 72. 
 
Figure 62: Retrosynthetic analysis of the proposed MDM2 binders 62 – 64 from commercially available starting materials 
In line with this proposal, azide 66 was prepared from commercially available 4-chlorobenzoylmethyl 
bromide (scheme 28). This was achieved via a nucleophilic substitution with sodium azide, directly 
followed by ketone reduction using sodium borohydride to form the azido-alcohol 66 in good yield.  
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Scheme 28: Synthesis of azide 66 
With the desired azide component in hand, next the synthesis of the three alkynes and related final 
products was pursued. Firstly, alkyne 67 was easily prepared through N-Boc protection of amine 70 
(scheme 29). Here, the low yield of 42% was attributed to the compound’s high volatility. Next, the 
core triazole ring of compound 74 was assembled through ruthenium-catalysed click chemistry of 
alkyne 67 and azide 66, which proceeded in excellent 94% yield to generate a 1:1 mixture of 
diastereoisomers (calculated by 1H NMR). Finally, N-Boc deprotection of 74 with TFA in 
dichloromethane gave final compound 62 in good yield. 
 
Scheme 29: Synthesis of compound 62 
Following the success in the formation of 62, the synthesis of the second potential binder 63 was 
investigated (scheme 30). Commercially available cyclohexanecarbaldehyde was treated with p-
anisidine in the presence of dehydrating agent to form the PMP-imine, which was immediately reacted 
with propargyl bromide in a Barbier-type coupling in the presence of activated zinc (prepared through 
washing zinc metal with HCl) to produce a mixture of alkyne 75 and allene 76 products (ca. 1:0.56, 
determined by 1H NMR). Purification of these two products by column chromatography proved to be 
extremely challenging, instead yielding an inseparable mixture of the two entities. Thus, the crude 
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mixture was telescoped into the next reaction since it was envisaged that the allene impurity would 
have no effect on the subsequent reaction. The PMP group was then removed with cerium (IV) 
ammonium nitrate (CAN) to yield the mixture of alkyne and allene amines 77 and 78, which were then 
immediately re-protected with a Boc group to give 68 in 29% yield over two steps. The low yield is 
rationalised by the purging of allene impurity during the purification of 68. Next, the triazole core was 
then constructed through a ruthenium-catalysed cycloaddition to give 79 as a 1:1 mixture of 
diastereoisomers, which was finally deprotected with TFA to afford 63 in high yield. 
 
Scheme 30: Synthesis of proposed binder 63 
The final molecule to be prepared was 64. In this instance, commercially available cyclohexanone was 
reacted with 2-methyl-2-propanesulfinamide, in the presence of titanium (IV) ethoxide to give N-
sulfinyl imine 80 in good 62% yield (scheme 31). Initially, the Barbier-type reaction previously used to 
generate 75 was attempted to form the quaternary carbon centre of 81. Unfortunately, this was 
unsuccessful and only starting material was isolated upon purification. Next, a Grignard approach was 
proposed for the addition of a propargyl group to imine 80. Propargylmagnesium bromide224 has been 
prepared previously from propargyl bromide and magnesium turnings using mercury chloride,225,226 
however, due to the toxicity of HgCl2 alternative approaches were sought. Initial attempts at forming 
this Grignard reagent using iodine as initiator were unsuccessful. After switching to a zinc bromide-
catalysed procedure,227 the Grignard reagent was successfully formed, however the molarity was 
considerably lower than expected (0.1 M, compared to literature 0.5 – 0.6 M227) after titrating against 
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menthol with 1,10-phenanthroline, indicating incomplete formation.228 As a result, sulfinyl imine 80 
was reacted with an excess of Grignard reagent to yield sulfinamide 81 in almost quantitative yield. 
The tert-butanesulfinyl auxiliary was subsequently removed under acidic conditions at 90 °C for 2 
hours. Next, the nitrogen was re-protected with a Boc group, to avoid catalyst poisoning via 
coordination but enabling milder downstream deprotection. Pleasingly, this sequence afforded 69 in 
excellent yield over two steps. Finally, the central triazole ring was once more constructed using 
ruthenium catalysed click chemistry to give 82 in 84% yield, and the N-Boc group removed with TFA 
in dichloromethane to give compound 64 in high yield.  
 
Scheme 31: Synthesis of compound 64 
With these compounds and the fourth compound 65 (figure 63, synthesised and characterised by Dr 
Sarah Kidd) in hand, subsequent efforts focussed on assessing the biological activity of the four 
compounds. 
 
Figure 63: Additional compound 65 synthesised by Dr Sarah Kidd 
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3.3.2. Biological evaluation of MDM2 binders 62 - 65 
Initially, the biological activity of the compounds towards MDM2 was assessed through competitive 
fluorescence polarisation (FP) with recombinant MDM2 protein as previously described in Chapter 
2.147,175 In this instance, the FP assay for compounds 62 - 65 was conducted in triplicate at a maximum 
concentration of 3 mM, which was found to be the highest concentration possible with respect to the 
solubility and upper limit of DMSO toleration within the assay. 
In these experiments, the competitive FP showed no MDM2 activity of the small molecules at 
concentrations under 1 mM, with limited activity observed at > 1 mM concentrations. At these higher 
concentrations, the greatest inhibition of tracer binding was observed for 63 and 65, whilst very little 
activity was observed for 62 (figure 64). No complete dose response curve was attained as the 
compounds were unable to saturate the protein, even at maximum concentration. Thus, without a 
complete curve the binding affinity of the molecules could not be established quantitively. As a result, 
only very weak binding could be identified. 
 
Figure 64: Competitive FP curves attained for MDM2 ligands 62 - 65222 
The lack of observed activity in this competitive FP assay could be attributed to the extremely high 
binding affinity of the tracer molecule to the protein (17.6 ± 1.7 nM175). As such, due to the small 
fragment-sized nature of the molecules in question, it was hypothesised that these molecules were 
unable to fully outcompete the tracer as a result of mismatched affinities. However, assay 
development was beyond the scope of this project, and as such an alternative strategy for compound 
evaluation was sought. 
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To better establish the biological activity for these fragment-sized molecules, differential scanning 
fluorimetry (DSF) was employed. DSF is a biophysical assay that can assess the binding of a compound 
to a protein through determination of the shift in protein melting temperature (Tm). This shift in melt 
temperature is proportional to the binding affinity of the compound due to protein stabilisation. 
Although it is more difficult to quantify the exact binding affinity of the compounds using this method, 
it was anticipated that the binding could be conclusively confirmed, and the binding potential of each 
compound could be compared. 
DSF was conducted alongside the positive control nutlin, a known high affinity MDM2 binder and the 
negative control DMSO. The DSF data revealed all compounds shifted the melt temperature of MDM2 
in a concentration dependent manner (figure 65). The most promising compound was 63, which 
shifted the melt temperature by 2.4 °C at the maximum concentration of 2.5 mM. This result 
confirmed the ranking assigned by using FP data and provided additional confidence of MDM2 binding 
across the series.  
 
Figure 65: DSF of MDM2 ligands 62 - 65 at 2.5 mM, 500 µM, and 100 µM concentrations222 
Whilst both the competitive FP and DSF were able to validate the binding of these fragment-like 
molecules toward MDM2, the binding affinity was concluded to be extremely low. This was highlighted 
when these compounds were compared to the known MDM2 binder nutlin 3a in both assays (figure 
66). Nutlin 3a was shown to have ca. 90 nM binding affinity with a maximum shift in MDM2 melt 
temperature of over 20 °C. 
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Figure 66: Competitive FP graph and DSF melt temperature shifts of small molecules 62 - 65 compared to known MDM2 
binder nutlin 3a 
Due to the hypothesised weak binding of these fragments and the challenges associated with 
establishing the binding affinities, it was decided that further compounds would not be synthesised. 
Although the binding affinity for each protein in a PROTAC can be considerably lower than for standard 
inhibition drugs due to their catalytic activity,76 it was deemed that as a result of the extremely weak 
binding nature of these fragments that developing PROTACs would be challenging. 
 
3.3.3. Overview of published MDM2 binder 
Due to the lack of success in generating novel MDM2 binders for PROTAC generation using in silico 
methods, an alternative strategy to identify suitable small molecule components was sought. In this 
manner, it was envisaged that known literature MDM2 binders could be modified to enable 
incorporation into a novel PROTAC to validate this hypothesis. 
Many clinical candidates which inhibit MDM2 are unsuitable for PROTAC incorporation due to their 
challenging syntheses, high molecular weights and lack of synthetically viable positions for PROTAC 
growth (growth vectors), as previously described (section 3.1.1). Therefore, known MDM2 binders 
were analysed against these criteria to identify more suitable PROTAC components. 
SP-141 was developed by Wang et al.229 and was shown to exhibit in vitro and in vivo activity against 
breast cancer cell-lines (figure 67). This compound was developed through a combination of HTS and 
computer-aided rational drug design and was hypothesised to occupy the p53 binding site of MDM2. 
It was also found to have an affinity of 28 ± 6 nM by FP and 43 nM in a Biacore assay, which was of a 
comparative magnitude to nutlin-3 (45 ± 4 nM and 90 nM, respectively). In addition, due to a 
molecular weight of just 324 Da, this molecule proved an ideal candidate for further PROTAC 
exploration. This feature was vital, since lower molecular weight and intrinsically linked properties 
such as rotatable bonds and number of hydrogen bond donors/acceptors could result in improved cell 
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permeability and pharmacokinetic properties of the overall PROTAC.230 Significantly, to examine the 
specificity of the MDM2 binding, the researchers also conjugated a biotin tag to the indole nitrogen 
and conducted a pull-down assay to confirm MDM2 binding.229 As such, this provided an ideal vector 
to attach the remainder of the PROTAC, since it had been previously demonstrated that conjugation 
of a linker and biotin molecule did not affect MDM2 recruitment. Moreover, the synthetic tractability 
was also a significant advantage of SP-141, since it was synthesised in just two steps from 
commercially available 5-methoxytryptamine and naphaldehyde. 
 
Figure 67: MDM2 inhibitor SP-141 prepared through two-step process from 5-methoxytryptamine and naphaldehyde 
In addition to SP-141, the tyrosine-based compounds 85 and 86 had been reported by Giustiniano et 
al. as MDM2 inhibitors (figure 68).231 Thus, it was hypothesised to also be a fruitful source for small 
molecules for PROTAC development. In these studies, 85 and 86 had been identified utilising 
computer-aided methods involving the virtual screening of compound libraries. In this case, the 
compounds were docked against the key hydrophobic hot spots between protein p53 and MDM2, 
Phe19, Trp23, and Leu26. The best ligands were assessed in vitro and found to bind MDM2 at low 
nanomolar potencies. Once more, this series of compounds proved attractive due to their relatively 
low molecular weights, rendering them appealing for PROTAC development. Importantly, this 
compound also offered two potential PROTAC growth vectors, which theoretically could be achieved 
using simple chemistry. An additional advantage was the ease of synthesis, whereby it was envisaged 
that the core could be constructed in one step from commercially available materials following the 
described procedure. In a similar fashion to SP-141, compound growth through the phenol exit vector 
had also been previously studied through connection of a propyl-aminopyridine group, with the 
resultant compound retaining activity and found to bind to MDM2 with 142 nM potency.231 This 
further evidenced this position as a potentially viable region for PROTAC growth, without significantly 
hindering the MDM2 binding abilities. 
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Figure 68: Tyrosine based MDM2 binders 85 and 86 showing MDM2 inhibition 
The final MDM2 inhibitor chosen for PROTAC investigations was imidazole-based compound 87, 
reported by Popowicz et al. (figure 69).232 Initial studies by the researchers indicated that these 
compounds were low nanomolar binders of MDM2. This series of inhibitors contained a central 
imidazole scaffold and once again were designed to capitalise upon the key hydrophobic hot spots 
Phe19, Trp23, and Leu26 confirmed through crystal structure analysis. Further work from the same 
group expanded the study to optimise potency against MDM2 in cell-based assays.233 This study found 
the optimised candidate had increased cytotoxicity in p53 positive cells and induced cell-cycle arrest. 
Importantly, within this paper a variety of analogues had been readily prepared, including an aliphatic 
chain attached through the carboxylate position, providing a well-scoped out potential exit vector. 
These analogues were also found to bind MDM2 with high affinity, validating this position as suitable 
for PROTAC growth without hindering MDM2 recruitment. In this instance, the higher molecular 
weight of this series was a concern, however, the higher potency towards MDM2 and ease of synthesis 
were deemed to be redeeming factors warranting their investigation. 
 
Figure 69: Imidazole-based MDM2 binder 87 chosen for PROTAC development 
With the three MDM2 binders in mind, the synthesis of the corresponding PROTACs was next 
investigated. The strategy envisaged for PROTAC construction utilised installation of a linker moiety 
within the predefined exit vectors and connection to the AR binders previously used for the stapled 
peptide PROTAC development described in Chapter 2. Accordingly, these proposed small molecule 
PROTAC-variants combined elements of the previous stapled peptide PROTAC. In this case, it was 
decided that only enzalutamide would be used as the AR binding motif due its ‘drug-like’ properties 
and antagonistic binding mode. As such, efforts were first focussed on the optimisation of these 
components given the challenges described during the synthesis of these moieties in Chapter 2. 
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3.3.4. Synthetic procedure to access enzalutamide based AR binder 
The route to the carboxylic acid 2 described in Chapter 2 involved a five step longest linear sequence, 
which proved to be time-consuming and inefficient. As such, a new one-step procedure from 
commercially available enzalutamide firstly was developed to provide faster access to this key PROTAC 
building block (table 5). Primary amide 16 was previously hydrolysed by heating with conc. HCl at 120 
°C in a sealed tube. However, in an attempt to increase the safety of this reaction on larger scales, an 
alternative procedure was sought. Initially, hydrolysis of the N-methylamide was attempted through 
refluxing with concentrated HCl. This was found to be extremely ineffective giving 6% conversion by 
LCMS after 2 days and an overall isolated yield of 31% after 6 days.  
 
Entry Scale  (mg/mL) Conditions Time LCMS Conversion  
1 40 110 °C reflux 2 days 6% 2, 94% SM 
2 33 130 °C, 8-9 Bar, µwave 1.5 h 29% 2, 29% SM, 26% 88, 11% 89 
3 10 110 °C, 4-5 bar, µwave 1 h 14% 2, 67% SM, 4% 88, 6% 89 
4 10 100 °C, 3-4 bar, µwave 1 h 8% 2, 92% SM 
5 30 100 °C, 4-5 bar, µwave 12.5 h 22% 2, 33% SM, 25% 88, 12% 89 
6 10 100 °C, 4 bar, µwave 14 h 37% 2, 4% SM, 27% 88, 4% 89 
7 10 80 °C, 2-3 bar, µwave 3 h 7% 2, 93% SM 
8 10 80 °C, 2-3 bar, µwave 19 h 21% 2, 79% SM 
Table 5: Conditions screened for the hydrolysis of enzalutamide 
In an attempt to increase the rate of hydrolysis, it was decided to 
investigate microwave conditions where additional pressure could be generated to improve the 
conversion. Initially, the reaction was heated to 130 °C, generating 8-9 bar pressure for 1.5 h. LCMS 
analysis of the crude mixture revealed 29% of both SM and 2. However, this also resulted in the 
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identification of two prominent new impurities, hypothesised to be 88 and 89 where the 
central thiohydantoin ring amide had been hydrolysed. It was hoped that lowering the temperature 
and thus the pressure could achieve effective hydrolysis without disrupting the core ring. The 
following reaction at 110 °C, 4 – 5 bar for 1 h gave 14% 2, 67% SM and cumulative 10% of impurities. 
Overall, it was found that high temperature and pressure led to greater conversion, however, 
considerable levels of impurities were also generated. At lower temperatures of 80 °C, conversion was 
reduced, however, the reaction was considerably cleaner. In addition, reaction concentration was 
found to be crucial despite the reaction being a heterogeneous slurry. More concentrated reactions 
led to lower conversion and greater overall impurity profiles.  
The optimal temperature identified was 80 °C (2-3 bar), which led to 21% 2 after 19 h. Low conversion 
was observed; however, it was comparable to the reflux conditions, but enabled a significantly 
reduced reaction time. Moreover, due to the one-step nature, this enabled more efficient access to 
the key starting material.  
 
3.3.5. Synthesis of SP-141-based MDM2 PROTACs 
To incorporate SP-141 into a PROTAC, it was decided to functionalise at a carboxylic acid through N-
alkylation with tert-butyl 2-bromoacetate (scheme 32). It was hypothesised that this would enable a 
facile amide coupling to generate the final PROTAC. Importantly, SP-141 was incorporated in the final 
step, owing to its limited supply from commercial sources, which is a result of the restricted nature of 
its starting materials. SP-141 was treated with a dilute solution of tert-butyl 2-bromoacetate in the 
presence of Cs2CO3 at ambient temperature, which yielded quantitative 90. Administration of tert-
butyl 2-bromoacetate as a dilute solution was discovered to be crucial to avoid over-alkylation. The 
final step to the SP-141-PROTAC precursor involved deprotection of the tert-butyl ester. This was 
achieved using a 1:1 mixture of TFA/DCM, which proceeded rapidly and gave full conversion to 91 
without further purification. 
 
Scheme 32: Synthesis of acid-tagged MDM2 binder 91 through N-alkylation and subsequent ester deprotection 
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With 91 in hand, synthesis of the SP-141-based PROTAC could begin. For initial tests of the activity of 
this PROTAC, a linker length of four PEG units was chosen. This was designed to balance PROTAC 
solubility with spatial distribution between the two binding components. 
The synthesis of the four-PEG linked SP-141 PROTAC-7 first involved preparing the linker conjugated 
enzalutamide derivative 94 (scheme 33). Acid 2 was coupled with N-Boc protected amine 92 to yield 
93 in good yield. The N-Boc-protecting group was then removed with TFA in DCM to form amine 94 in 
high yield. 
 
Scheme 33: Preparation of linker-enzalutamide conjugate 94 through amide coupling and deprotection chemistry 
Next, the PEG-enzalutamide amine was reacted with the SP-141 derivative 91 in the presence of HATU 
and DIPEA to yield PROTAC-7 in 34% yield (scheme 34). 
 
Scheme 34: Synthesis of PROTAC-7 through HATU-mediated amide coupling 
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Due to the limited supply of SP-141, only the four-PEG linked PROTAC-7 was prepared for initial testing 
to validate the feasibility of this MDM2 core before further optimisation. This linker length was 
expected to impart solubility whilst maintaining a reasonable distance between the two proteins in 
the PROTAC ternary complex. 
 
3.3.6. Synthetic procedure for tyrosine based MDM2 PROTACs 
The next MDM2 inhibitor to be synthesised was 86.231 This simple tyrosine derivative had two 
potential exit vectors which could be very easily harnessed for PROTAC growth (figure 70). Exit vector 
1 grows from the ester group, which can be hydrolysed to the acid and coupled to the linker through 
amide couplings. In addition, exit vector 2 can be used, which would grow the PROTAC from the 
opposite end of the molecule through the phenol functionality. An O-alkylation strategy can be used 
to connect the linkers to this phenol in a simple fashion. As the exact binding conformation of this 
MDM2 series was unknown, it was hypothesised that exploring PROTAC incorporation through the 
two different exit vectors would maximise the possibility of generating an active PROTAC. 
 
Figure 70: MDM2 inhibitor 86 with exit vectors to be exploited 
MDM2 inhibitor 86 could be prepared in high yield via a simple amide coupling between commercially 
available tyrosine-methyl ester 95 and 3,3-diphenylpropionic acid 96 (scheme 35). It was decided that 
the PROTAC would be synthesised by attaching linkers to this central core, with the enzalutamide 
motif incorporated in the final step. This would be an efficient way to synthesise these PROTACs 
considering the lower availability of acid 2 compared to the easily synthesised MDM2 binder 86. 
 
Scheme 35: Synthesis of MDM2 inhibitor 86 through amide coupling chemistry 
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The synthesis of PROTACs derivatised through growth vector 1 involved initial hydrolysis of the methyl 
ester with lithium hydroxide to produce acid 97 (scheme 36). Next, two commercially available N-Boc 
protected PEG amines containing three or four PEG units were coupled to 97 under EDCl.HCl, HOBt 
coupling conditions, proceeding with high yields. The N-Boc protecting groups were then removed 
with TFA to yield the free amines 100 and 101, which were finally coupled with the enzalutamide acid 
2 in the presence of HATU and DIPEA to form PROTAC-8 and 9 in good respective yields. 
 
Scheme 36: Preparation of PROTACs 8-9 through exit vector 1 via deprotection and amide coupling chemistry 
Derivatisation through growth vector 2 was more complex as this required O-alkylation rather than 
simple amide coupling chemistry. Firstly, 86 was treated with alcohol 102 under Mitsunobu conditions 
(scheme 37). Unfortunately, this was unsuccessful, leading to a complex mixture of products. 
 
Scheme 37: Attempted Mitsunobu reaction to form linker conjugate 103 
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Preparation of reactive PEG linkers was next attempted to enable O-alkylation via direct nucleophilic 
substitution with the phenol. The mesylate and iodide derivatives of two- and three-unit PEG linkers 
were prepared for this purpose. Mesylation of N-Boc protected alcohol derivative 102 was achieved 
through treatment with methanesulfonyl chloride and triethylamine, providing 104 in high yield 
(scheme 38A). Additionally, N-Boc protected PEG alcohol 105 was iodinated using Appel conditions 
generating iodide 106 in a moderate 64% yield (scheme 38B).  
 
Scheme 38: A: Mesylation strategy to prepare reactive linker 104; B: Appel reaction used to prepare iodide derivative 106 
Next, O-alkylation of phenol 86 was carried out in the presence of K2CO3 at elevated temperature, 
generating 103 and 107 in good yields (scheme 39). Next, the N-Boc protecting groups were removed 
with TFA and resulting compounds 108 and 109 were coupled with 2 to yield PROTAC-10 and -11. 
 
Scheme 39: Synthesis of PROTAC-10 and 11 through exit vector 2 via alkylation and subsequent amide coupling 
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3.3.7. Synthetic procedure for imidazole based PROTACs 
The final set of MDM2 binders to be incorporated into PROTACs were the imidazole scaffolds.233 Two 
principle scaffolds were chosen for the PROTAC design, both of which contained useful carboxylic acid 
handles which could be harnessed as suitable PROTAC growth vectors (figure 71). 
 
Figure 71: Structures of chosen MDM2 binding motifs with exit vector for PROTAC growth highlighted 
These imidazole cores could be synthesised through a Van Leusen three-component reaction by 
combining an aldehyde, amine and tosyl-methyl isocyanate (TosMIC). This enabled construction of a 
significant level of complexity in a one-pot reaction (figure 72). 
 
Figure 72: Retrosynthesis of the core imidazole scaffold to three components 
The synthesis of these scaffolds involved reaction of common aldehydes and TosMICs with different 
amine derivatives. Aldehyde 112 was synthesised from commercially available substituted-indole 111 
via a Vilsmeier-Haack formylation with POCl3 and DMF (scheme 40). 
 
Scheme 40: Vilsmeier-Haack formylation of indole 111 to prepare aldehyde 112 
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Next, TosMIC 116 was prepared using a two-step literature process234 from commercially available 4-
fluorobenzaldehyde 113 (scheme 41). This procedure involved one-pot formation of formamide 115 
via the intermediate bis-amide 114. Next, formamide 115 was dehydrated using POCl3 to generate 
TosMIC 116 in high yield. 
 
Scheme 41: Synthesis of TosMIC 116 via two-step procedure from aldehyde 113 
With these components in hand, imidazole 118 was prepared via a Van Leusen imidazole formation 
with aldehyde 112, TosMIC 116, and commercially available amine 117 (scheme 42). Finally, 118 was 
hydrolysed under basic conditions which generated acid 87 in high yield. 
 
Scheme 42: Three-component Van Leusen imidazole formation to produce inhibitor 87 
The final MDM2 binder required a more complex amine component, which was prepared through 
nucleophilic substitution between phenol 119 with bromide 120, generating 121 in almost 
quantitative yield (scheme 43). Next, 121 was reduced to the desired amine 122 in high yield following 
treatment with LiAlH4. 
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Scheme 43: Synthesis of amine 122 through O-alkylation and subsequent reduction 
Finally, the three-component Van Leusen reaction enabled formation of the imidazole 123 in good 
yield (scheme 44). The ester was then hydrolysed to acid 110 in high yield.  
 
Scheme 44: Three-component Van Leusen imidazole formation to form inhibitor 110 
With the MDM2 binders in hand, PROTAC formation was investigated through attachment of 87 and 
110 to enzalutamide four-PEG linker 94, and newly formed three-PEG derivative 125 (scheme 45).  
 
Scheme 45: Synthesis of enzalutamide conjugated three-PEG linker 125 for direct MDM2 binder attachment 
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Finally, the MDM2 recruiting PROTACs 12-15 were generated through a series of amide coupling 
reactions between MDM2 binders 87 and 110 and enzalutamide PEG linkers 94 and 125 (scheme 46). 
 
Scheme 46: Synthesis of PROTACs 12-15 through HATU-mediated amide coupling of MDM2 inhibitors with enzalutamide-
linker derivatives 94 and 125 
 
3.3.8. Synthesis of small molecule VHL recruiting PROTAC 
In order to enable comparison of the MDM2 PROTACs 7 – 15 in the downstream biological 
assessments, a VHL recruiting PROTAC targeting AR for degradation was also prepared. A VHL PROTAC 
would enable quantitative assessment of the activity of the MDM2 recruiting PROTACs compared to 
alternative E3 ligase recruiting PROTACs. Importantly, a VHL-recruiting PROTAC would be a positive 
control useful for future assay validation. In this case, a specific VHL binding motif was chosen based 
on literature examples that demonstrated high potency in the PROTAC form.235 
The proposed PROTAC-16 incorporated an alkyl-based linker (figure 73), in line with derivatives 
prepared in Chapter 2. It was hypothesised that this linker would generate a PROTAC with a 
comparable protein spacing to the MDM2 PROTACs, whilst avoiding the hydrophilic PEG linker, which 
could negatively impact the cell permeability when combined with the peptidic VHL binding moiety. 
The synthesis of this PROTAC was envisaged to proceed via simple amide coupling connections 
between the three PROTAC constituents VHL binder, linker and AR binder. 
89 
 
 
Figure 73: Structure of VHL-recruiting PROTAC-16 with key amide bond connections highlighted 
Synthesis of the VHL binder was carried out in line with literature procedures.235 Firstly, commercially 
available amine 126 was N-Boc protected, followed by a palladium-catalysed C-H activation to connect 
4-methyl thiazole affording 128, which was deprotected to yield HCl salt 129 (scheme 47). 
 
Scheme 47: Synthesis of 129 as the HCl salt from commercially available amine 126 
Next, synthesis of the core dipeptide moiety began from commercially available amino acid 130. This 
was initially protected as methyl ester 131 in good yield, then reacted with 132 to form 133. Hydrolysis 
of 133 gave 134 in 70% yield. Subsequently, 134 was coupled with 129, which afforded 135 in high 
yield, before a final TFA deprotection generated VHL binder 136. 
 
Scheme 48: Synthesis of VHL binder 136 through a series of amide coupling and deprotection steps 
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With the VHL binder in hand, the next step in the synthesis of PROTAC-16 was to conjugate the linker. 
The alkyl-based linker was installed through sequential amide coupling reactions of six-carbon units 
47, followed by N-Boc deprotections to generate amines 138 and 140 in high respective yields (scheme 
49). Finally, the AR binding derivative 2 was attached through an amide coupling, generating desired 
PROTAC-16 in moderate yield. 
 
Scheme 49: Synthesis of VHL-enzalutamide PROTAC-16, through amide coupling and deprotection chemistry 
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Additionally, DHT-recruiting PROTAC-17 was prepared via a similar route. Final conjugation of the DHT 
moiety was hypothesised through an esterification approach, following several unsuccessful attempts 
at alkylating DHT. Amine 138 was treated with succinic anhydride, which generated acid 141 in high 
yield. This compound was then reacted with DHT in the presence of DCC and catalytic DMAP to 
generate desired PROTAC-17 (scheme 50). This final esterification proceeded in very low yield, likely 
due to the high steric hindrance of the DHT neo-pentyl alcohol. Additionally, PROTAC-17 was 
discovered to be unstable with ester hydrolysis observed by NMR after one-week storage at room 
temperature. The instability of this PROTAC limited its utility in further biological studies, as the 
degradation product DHT behaves as an agonist, increasing AR levels and masking potential PROTAC 
degradation. Thus, incorporation of DHT into the AR degrading PROTACs was abandoned. 
 
Scheme 50: Synthesis of VHL-DHT PROTAC-17 found to be unstable, DHT was connected through esterification 
With this series of PROTACs in hand, biological testing was conducted to establish activity of both the 
novel MDM2-recruiting PROTACs and the VHL-recruiting control PROTAC-16. 
 
3.3.9. Biological analysis of small molecule MDM2 PROTACs 
The synthesised MDM2-recruiting PROTACs were then biologically assessed using a high-throughput 
AlphaScreen® assay. This assay is based upon the CETSA AlphaScreen® AR degradation protocol used 
in Chapter 2 with slight modifications. Initially, each PROTAC was incubated for 16 h with AR-positive 
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LNCaP cells, followed by cell fixing, treatment with an AR antibody pair, and subsequent plate analysis. 
The endpoint of the assay is detection of endogenous AR by AlphaScreen®, hence cellular AR levels 
are measured following PROTAC treatment. This simple, high-throughput assay was used to narrow 
down the MDM2 inhibitors used for this series of PROTACs to the most promising ones. This efficient 
strategy allows for further synthetic efforts to be more focussed. The graphs were analysed and qAC50 
values were reported corresponding to the concentration required to induce 50% activity. These 
assays were run by Dr Andreas Hock at AstraZeneca. 
Firstly, a series of controls were analysed (figure 74). The positive control used for this assay was 
known degrader niclosamide. This gave a good dose-response curve correlating to 228 nM potency, 
within the accepted range expected for this AR degrader. The negative controls used were DMSO, 
which showed no response in this assay as well as enzalutamide. Enzalutamide is an AR antagonist, 
which is unable to degrade AR hence no obvious dose-response curve was observed. There was a 
slight downward correlation for the enzalutamide control which most likely corresponds to its anti-
proliferative effect on AR-positive cell-lines, such as these LNCaPs, due to its strong antagonistic 
activity. 
 
Figure 74: Dose-response curves for controls, positive control niclosamide and negative controls enzalutamide and DMSO, 
run by Dr Andreas Hock 
The MDM2 binders were also run as controls, to understand whether they had any effect on AR levels 
independent to the PROTAC activity. Binders 85, 86 and 110 were found to have no effect on AR levels 
in this assay (figure 75). However, the remaining two MDM2 binders had a positive concentration 
dependent effect on the cells, calculated to be around 6.0 µM for 87 and 1.2 µM for SP-141. There are 
a few different factors which may have caused this response. It could be a result of various limitations 
of the assay, which does not account for the toxicity or antiproliferative effects that these compounds 
may invoke. This is particularly relevant for known MDM2 inhibitors, which are able to invoke cell 
cycle arrest therefore limiting cell proliferation due to inhibition of the p53-MDM2 interaction.236 This 
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effect has also been observed in LNCaP cells treated with MDM2 inhibitor nutlin 3a,237 which further 
complicates the validation of these compounds. In addition, the assay also does not measure 
compound precipitation which can give false positives in the data. If the compound has poor solubility 
it will precipitate on addition to the cells on the plate, the precipitate may cause cell death which 
would be difficult to distinguish from a positive result. Solubility is unlikely to be an issue at these 
concentrations due to their low molecular weight and the presence of hydrophilic handles. However, 
solubility of the full PROTAC structures is expected to be lower due to the high molecular weight. 
 
Figure 75: Dose-response curves for MDM2 inhibitor control compounds, run by Dr Andreas Hock 
The SP-141-derived PROTAC-7 also displayed reasonable activity in this assay (figure 76). However, 
the qAC50 calculated was 885 nM, which was of a similar magnitude to the inhibitor alone. This was 
not a promising result, as connecting the PROTAC had no obvious benefit.  
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Figure 76: Dose-response curve of SP-141-based PROTAC-7, run by Dr Andreas Hock 
Next, the tyrosine based PROTACs were investigated. Both MDM2 binders 85 and 86 exhibited no 
activity in the assay, thus any activity observed would be promising. PROTAC elaboration through exit 
vector 1 enabled degradation activity for PROTAC-8 and -9 with low µM qAC50 observed (figure 77). 
 
Figure 77: Dose-response curves for tyrosine-based PROTACs connected through exit vector 1, run by Dr Andreas Hock 
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Results attained from the phenol exit vector 2 looked generally more promising (figure 78). PROTAC-
10 and -11 had reasonable activity in the low µM, with the longer PEG linker exhibiting higher potency 
and degrading AR to a greater extent compared to PROTAC-8 and -9. Accordingly, this exit vector was 
hypothesised to be more promising for further PROTAC development.  
 
Figure 78: Dose-response curves for tyrosine-based PROTACs connected through exit vector 2, run by Dr Andreas Hock 
Following these promising results, PROTACs 12-15 which incorporated the imidazole based MDM2 
binders 87 and 110 were examined (figure 79). The most potent compound was PROTAC-13, which 
gave a qAC50 of 348 nM. The shorter PEG chain length variant PROTAC-12 showed no obvious activity. 
The potency of this compound was 20-fold higher than the control MDM2 inhibitor 87 alone, 
indicating potential PROTAC activity. The difluoroaryl substituted PROTACs 14-15 gave slight activity 
at the highest concentrations, corresponding to qAC50 of 10.2 and 23.5 µM for the respective PEG 
chain lengths. Although the corresponding control inhibitor 110 exhibited no activity, these PROTACs 
had very weak effects in the assay. Overall, this indicated that 87 was the most promising of the two 
scaffolds, with good activity observed at the longer linker length.  
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Figure 79: Dose-response curves for imidazole based MDM2 PROTACs, run by Dr Andreas Hock 
Finally, the control VHL-recruiting PROTAC-16 was screened (figure 80). Interestingly, PROTAC-16 did 
not appear to be more active than the MDM2-recruiting PROTAC series despite recruiting VHL, a well-
validated E3-ligase. This may result from the unoptimised linker, as many more variants would be 
required to optimise AR degradation levels and PROTAC potency.  
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Figure 80: Dose-response curves for VHL-recruiting PROTAC-16 run by Dr Andreas Hock 
These initial findings were promising, as activity was observed for a large proportion of the synthesised 
PROTACs across almost all the MDM2 binding scaffolds. Notably, none of the tested PROTACs achieved 
100% AR degradation, the reduction for all PROTACs was ca. 50% or under. This is not particularly 
unusual for unoptimized PROTACs, as it is well known that linker length and properties have a major 
effect on not only potency but extent of protein degradation. The activity observed in this assay for 
the MDM2 inhibitors alone additionally complicates PROTAC analysis, hence a more informative assay 
was required to elucidate this further. Ideally, future assays would be capable of differentiating 
between toxicity, precipitation and AR degradation activity. 
 
3.3.10. Synthesis of additional PROTACs using alternative linkers 
It was hypothesised that through additional linker variation the activity and extent of AR degradation 
could be optimised. Synthetic efforts were focussed on the scaffolds identified by the AlphaScreen® 
assay to be most promising, 87 and 86 connected through the phenol exit vector.  
A longer linker was chosen for PROTAC-17, incorporating chloro-substituted MDM2 binder 87. A PEG 
linker with a length of 19 atoms was hypothesised to be a good comparison to PROTAC-12 and -13, 
containing 13 and 16 atoms respectively. Due to a low supply of enzalutamide acid 2, the synthesis 
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was carried out in the direction of MDM2 binder 87 to AR binder 2 (scheme 51). Initially, acid 87 was 
coupled with amine 30 in the presence of HATU and DIPEA to form 142 in moderate yield. This was 
then N-Boc deprotected using TFA and the amine immediately coupled with enzalutamide acid 2 to 
generate PROTAC-17 in 51% yield over two steps. 
 
Scheme 51: Synthesis of six-PEG linker imidazole based PROTAC-17 
In addition, longer linkers were chosen for MDM2 binder 86, a four-unit PEG linker gave an overall 
distance of 12 atoms. The required mesylate linker 144 was prepared through mesylation of 
commercially available alcohol 143 through the previously used procedure (scheme 52).  
 
Scheme 52: Mesylaton of alcohol 143 to form mesylate 144  
The mesylate 144 was then subjected to O-alkylation conditions with phenol 86 to form 145 (scheme 
53). The N-Boc protecting group was then removed with TFA and the enzalutamide acid 2 was 
conjugated through an amide coupling reaction, generating PROTAC-18 in good yield. Both the methyl 
ester PROTAC-18 and the hydrolysed acid PROTAC-19 were prepared for further biological testing. It 
was hypothesised that the acid moiety would improve the PROTACs overall solubility profile, whilst 
maintaining MDM2 binding affinity. 
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Scheme 53: Synthesis of PROTAC-18 and -19 connected via a four-PEG linker 
Furthermore, an increased linker length was investigated to fully probe linker distance for this MDM2-
recruiting PROTAC series. It was proposed that attachment of a two-carbon appendage to the phenol 
86 could extend the linker length to 15 atoms (scheme 54). With this strategy in mind, phenol 86 was 
treated with tert-butyl bromoacetate in the presence of K2CO3 forming 147 in high yield. Next, the 
tert-butyl ester was deprotected using TFA to selectively hydrolyse this ester in the presence of the 
methyl ester giving acid 148 in almost quantitative yield. Acid 148 was then treated with four-PEG 
amine 92 to generate 149 in moderate yield. The N-Boc group was then removed in TFA in quantitative 
yield and the resulting amine 160 was subject to amide coupling conditions with enzalutamide acid 2 
in the presence of HATU and DIPEA to generate desired PROTAC-20. 
100 
 
 
Scheme 54: Synthesis of PROTAC-20 with extended linker length 
 
3.3.11. Further biological testing considering AR levels 
Due to the limitations with the high-throughput AlphaScreen® assay previously discussed, an 
alternative assay was investigated to further analyse this PROTAC series. An imaging assay developed 
by AstraZeneca was hypothesised to be a good alternative. This assay measured AR levels in addition 
to imaging the cells, which gave an indication of cell viability. Importantly, the assay was also able to 
calculate the number of live cells at the assay endpoint, hence could identify toxicity related effects. 
In addition, the assay could observe any compound solubility issues which could lead to unreliable 
results. This assay was performed by Dr Andreas Hock at AstraZeneca.  
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LNCaP cells were plated and compounds dosed in a 11-point, one in two dilution with a top 
concentration of 30 µM. The plates were incubated for 16 h before being fixed and stained for AR. The 
PROTACs were not run in replicate, as this enabled screening of all PROTACs on one plate to identify 
interesting hits. A subsequent assay run in the future would provide the duplicate data for validation. 
Niclosamide and DMSO were used as the respective positive and negative controls in this assay (figure 
81). Niclosamide exhibited a strong dose-response curve, comparable to previous runs. However, the 
reduction in nuclear count at top concentrations indicated some toxicity. DMSO treatment showed no 
overall trend in AR levels or reduction in nuclear count. 
 
Figure 81: Dose response curves for positive control (niclosamide) and negative control (DMSO) run by Dr Andreas Hock 
Next, the MDM2 inhibitor controls 85, 86, 87 and 110 were analysed. As three of the five MDM2 
binders exhibited a positive dose response curve in the previously used AlphaScreen® assay, these 
results would enable further validation of this imaging assay.  These MDM2 binders indicated no 
change in AR levels or toxicity (figure 82). Enzalutamide acid 2 also exhibited no degradation. 
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Figure 82: MDM2 inhibitor controls 85, 86, 87 and 110 and enzalutamide acid 2; performed by Dr Andreas Hock 
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The final MDM2 binder considered, SP-141, conclusively indicated its high toxicity (figure 83). 
Considering only AR levels generates a strong dose response curve, indicating high potency. However, 
when nuclear count was considered, the toxicity of this compound was obvious, at high dose a 
substantial level of cell death was observed. 
 
Figure 83: SP-141 and PROTAC-7 effects on LNCaP cells considering AR nuclear levels and cell count, performed by Dr 
Andreas Hock 
Next, the MDM2 PROTACs incorporating imidazole based binders were investigated. Independently, 
these MDM2 inhibitors exhibited no activity against the cells, with the nuclear count indicating no 
obvious toxicity effects. PROTAC-14 and -15, based on MDM2 binder 110, did not show clear dose-
response curves (figure 84A). PROTAC-14 showed a general downward trend in AR but with no 
plateauing at high or low concentration. PROTAC-15 looked slightly more promising with stable AR 
levels until almost the top concentration (30 µM) where levels drop, however the potency of this 
PROTAC is far too weak to follow up. The PROTACs based on the chloro-substituted imidazole 
derivative looked more interesting (figure 84B). PROTACs 12, 13 and 17 all showed more typical dose-
response curves, PROTACs 12 and 17 both did not plateau despite AR levels being reduced by ca. 33%. 
PROTAC-13 displayed a good sigmoidal curve, indicating approximately low micromolar potency. 
However, the extent of AR degradation following incubation with this PROTAC was fairly low, ca. 20% 
AR reduction. Despite this incomplete AR degradation and low µM potency, PROTAC-13, which 
incorporated a four-PEG unit linker was the most promising of this imidazole PROTACs series. It was 
hypothesised that additional optimisation of linker length and characteristics would improve both 
activity indicators.  
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Figure 84: Dose-response curves of imidazole-based MDM2 PROTACs A) 110 based MDM2 binder; B) 87 based MDM2 
binder; performed by Dr Andreas Hock 
Additionally, the MDM2 PROTACs incorporating binders 85 and 86 also showed some promising 
results. PROTAC-8 and -9, derived from the acid exit vector on the MDM2 inhibitor were less 
interesting (figure 85A). Despite a reasonable level of AR degradation observed, the curves did not 
plateau in the concentration ranges used, indicating extremely low potency. The phenol exit vector 
derived PROTACs had improved dose-response curves (figure 85B). PROTAC-10 was the most potent 
with a DC50 of ca. 600 nM, and 33% AR degradation. PROTAC-18, which contained an additional PEG 
unit in the linker region, had a similar potency and degradation extent. PROTAC-11 and -20 exhibited 
AR degradation however the shape of their dose-response curves was less appealing as showed a 
downward trend rather than a typical sigmoidal shape. Finally, PROTAC-19 looked even less promising 
for similar reasons. 
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Figure 85: Dose-response curves of tyrosine based MDM2 PROTACs A) through acid exit vector; B) through phenol vector; 
performed by Dr Andreas Hock 
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Overall, some promising results were identified through this round of MDM2 PROTAC testing. 
Compared to the positive control niclosamide, PROTAC-10 exhibited greater potency. Additionally, 
PROTAC-13 generated a dose response curve with reasonable potency. Although AR degradation was 
displayed by most of these PROTACs, full AR degradation was not identified in any case. However, this 
is not unusual for a small set of unoptimized PROTACs, as considerable linker variation is a well-
established strategy for improvement in potency and extent of degradation. 
To gain further insight into the mode of action of these novel PROTACs, more biological testing was 
proposed. Firstly, the binding of the MDM2 PROTACs to MDM2 was investigated in enzymatic assays. 
This was an important control measure to ensure the degradation observed was via E3 ligase MDM2. 
It was theorised to be less important to validate AR binding, as these enzalutamide-based binders have 
been used commonly in literature and patents, hence their ability to bind and degrade AR was well-
established as discussed in Chapter 2.  
In addition, validation of the proteasome mediated AR degradation was postulated to be an important 
control. One way to investigate this would be to dose an excess of the E3 ligase binder with the 
PROTAC. This ligand would outcompete the PROTAC and prevent formation of the active ternary 
complex, thus eliminating AR degradation. This supports the theory that the PROTAC acts via 
recruitment of the E3 ligase and therefore the UPS. This control has been used predominantly for VHL 
and cereblon PROTACs, however, MDM2 PROTACs would be more difficult to investigate with this 
approach due to the biologically relevant MDM2-p53 PPI. MDM2 inhibitors are well-known to prevent 
cell proliferation and initiate cell death, hence dosing this inhibitor would not clearly show the 
correlation between AR degradation and MDM2 PROTAC, due to the convoluted data.  
An alternative method of confirming the UPS degradation pathway, would be to block the proteasome 
using an inhibitor known as epoxomicin.238 Dosing this inhibitor alongside the PROTAC is hypothesised 
to knockout degradation activity, as the proteasome would be unable to function. For MDM2 
recruiting PROTACs, this could be the most conclusive strategy for UPS validation. 
 
3.3.12. Assessment of MDM2 Binding through FP and DSF 
In order to measure the binding of the PROTACs to MDM2, competitive FP was performed as described 
in Chapter 2. The assay was carried out in triplicate and the top concentration achieved was dictated 
by compound solubility, in most cases limited to 0.3 mM. A 23-point, two in three titration curve was 
obtained for each PROTAC following incubation with recombinant MDM2. Controls of nutlin 3a and 
the known MDM2 binding peptide sequence, P1, were used for assay validation. 
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SP-141 based PROTAC-7 was first investigated, at top concentration of 0.3 mM (figure 86). PROTAC-7 
showed extremely limited activity against MDM2 under these conditions. Further studies were 
undertaken to measure the binding affinity of MDM2 binder SP-141 to MDM2. Unfortunately, no 
obvious activity was observed even at top concentration of 50 µM. This was a surprising result as Wang 
et al. had reported the SP-141 motif to bind to MDM2 with ca. 28 nM affinity.229 In this publication, it 
was proposed that SP-141 binds in the same pocket as p53, hence it would be expected to be active 
in this assay. In accordance with these results, further studies using DSF were proposed for validation. 
 
Figure 86: FP curves for PROTAC-7, top concentration of 0.3 mM and SP-141, top concentration of 50 µM 
Following these disappointing results, the tyrosine based MDM2 PROTACs were analysed. PROTAC-8 
and -9, which incorporate the linker through the carboxylic acid exit vector, also showed extremely 
limited binding affinity even at top concentration of 0.3 mM (figure 87). These results indicated that 
PROTAC growth from this vector may have hindered inhibitor binding to MDM2. 
 
Figure 87: FP curves for PROTAC-8 and -9, top concentration of 0.3 mM 
Next, the tyrosine derived PROTACs which incorporated the linker through the phenol vector were 
studied (figure 88). Interestingly, PROTAC-10, -11 and -18 all showed very limited binding to MDM2, 
potentially due to steric hindrance from the linker. 
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Figure 88: FP curves for PROTAC-10, -11, and -18, top concentrations of 300, 300, and 376 µM respectively 
The tyrosine derived MDM2 inhibitors 85 and 86 were then screened to investigate whether the 
PROTAC appendage was preventing MDM2 binding or whether there was an intrinsic issue with the 
MDM2 binders (figure 89). Unfortunately, no binding was observed, indicating that these inhibitors 
may be unable to recruit MDM2. The literature reported MDM2 binding affinity of 86 was 19 nM, 
which was not observed in this assay. The compounds reported in the paper were also designed to 
bind the p53/MDM2 binding pocket using the three key hot spots commonly exploited.231 
 
Figure 89: FP curves for MDM2 inhibitors 85 and 86 at top concentration of 50 µM 
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Finally, the imidazole based MDM2 PROTACs were studied. PROTAC-14 and -15 incorporated MDM2 
inhibitor 110 and showed very low binding affinity at top concentrations of 300 µM (figure 90). 
Derivative 110 was a novel design; hence the binding affinity is unknown. 
 
Figure 90: FP curves for PROTAC-14 and -15, top concentration of 0.3 mM 
Finally, the PROTAC that incorporated imidazole binder 87 looked considerably more promising. Two 
of the prepared PROTACs, PROTAC-12 and -17 were analysed through competitive FP (figure 91). The 
solubility of these PROTACs was considerably lower than the other PROTAC series previously reported, 
hence the top concentrations which could be screened were much lower. PROTAC-12 exhibited 
inhibition at the top concentration of 10 µM, which was a substantial improvement on all previous 
results. PROTAC-17 incorporated a six-PEG unit linker, which improved the overall solubility, enabling 
a top concentration of 75 µM. Almost complete inhibition was observed with this PROTAC at these 
concentrations, indicating binding affinity to be in the order of 50 µM. Despite the validation of the 
PROTACs binding to MDM2, this binding affinity is still lower than expected for this inhibitor.   
 
Figure 91: FP curves for PROTAC-12 and -17, top concentrations of 10 µM and 75 µM respectively 
Next, imidazole based MDM2 inhibitors, 87 and 110 were analysed for comparison with the literature 
reported value (figure 92). Inhibitor 87 bound MDM2 with a Kd of 110 ± 10 nM, and inhibitor 110 had 
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a Kd of 2.3 ± 0.3 µM. Compared to the literature value of 6 nM, binder 87 was almost 20 times less 
potent. This was hypothesised to be a considerable difference, potentially causing the low activity of 
this series of PROTACs.  
 
Figure 92: FP curves for MDM2 inhibitors 87 and 110 at top concentration of 33 and 22 µM respectively 
Further validation of the binding of these published small molecule MDM2 inhibitors was acquired 
using DSF, as described in section 3.3.2. DSF can detect binding at a much weaker potency than the 
competitive FP assay, and theoretically could indicate whether weak MDM2 binding is occurring. DSF 
was performed with Rohan Eapen in the department of Pharmacology. MDM2 inhibitors were 
analysed in triplicate at three concentrations, 400, 200 and 100 µM. The melt temperature of MDM2 
protein was determined in the presence of compound, enabling analysis of the protein stability.   
The results of the DSF corresponded well with the competitive FP run previously (figure 93). SP-141, 
85, and 86 exhibited little effect on the melt temperature of MDM2, less than 1 °C difference at all 
concentrations. This validated that these three compounds were unable to bind MDM2. The imidazole 
based MDM2 binders, 87 and 110 exhibited a melting temperature shift across all concentrations. 
MDM2 binder 110 demonstrated a small temperature shift of ca. 2 °C at 400 µM. Analysis of 87 found 
the 400 µM top concentration to be insoluble, hence no data was collected. However, the remaining 
concentrations showed a significant temperature shift of ca. 14 °C. 
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Figure 93: A: Plot of ΔTm of MDM2 inhibitors at different concentrations; B: Observed shift in absorption minima at different 
concentrations of imidazole based inhibitors compared to MDM2 alone 
The poor binding of MDM2 inhibitors SP-141, 85 and 86 to MDM2 was confirmed in two enzymatic 
assays, one of which was designed to detect very weak binding. The PROTACs developed based on 
these motifs are unable to recruit MDM2 for the degradation of AR, hence their development was 
subsequently abandoned. The remaining imidazole series of PROTACs were confirmed to bind MDM2 
by competitive FP and DSF. Unfortunately, these PROTACs were less active compared to the tyrosine 
based series in the AR degradation assays. Although, PROTAC-13 exhibited a promising dose-response 
curve despite relatively low potency, which warranted further study. 
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3.4. Chapter 3: Conclusions 
Overall, a series of novel MDM2-recruiting small molecule PROTACs were prepared for degradation of 
AR. Following analysis of these PROTACs through a series of AR degradation assays, PROTAC binding 
to MDM2 was assessed. Unfortunately, two of the three MDM2 inhibitors incorporated into PROTAC 
designs showed no binding affinity to MDM2 in both competitive FP and DSF, making it challenging to 
understand the AR degradation observed in previous assays. It was postulated that the inhibitors could 
bind MDM2 in a region other than the p53 interface. If this was the case, then these enzymatic assays 
would be unable to detect this due to the MDM2 protein construct used. However, this was thought 
to be unlikely as the compounds were all reported to bind at the p53/MDM2 interface.  
The degradation dose-response curve observed for PROTAC-7 corresponded well with the general 
toxicity observed. Hence, the lack of MDM2 binding, although surprising, did not alter the assessment 
of this series, which was intrinsically limited by high toxicity. 
The tyrosine based PROTACs were found to be incapable of binding MDM2 in competitive FP and DSF. 
However, promising dose response curves were observed through the AR degradation imaging assay 
for multiple compounds of the series. PROTAC-10 had a DC50 of ca. 600 nM and exhibited ca. 33% AR 
degradation. It is hypothesised that these compounds could be acting as SARDs, where the compounds 
bind AR, inducing conformational changes, which ultimately cause proteasomal mediated AR 
degradation (figure 94). Further investigation is required to validate this mechanism of action. 
 
Figure 94: Structure of PROTAC-10 compared to SARD279 
The imidazole based PROTACs were the most promising series. Both MDM2 binders 87 and 110 
displayed affinity for MDM2 in enzymatic assays, although there was ca. 20-fold difference in the 
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reported Kd compared to the measured value for inhibitor 87. It has been observed in the literature 
that weakly potent VHL binders can still achieve extremely potent degradation,76 which indicated that 
these MDM2 binders would still be suitable for PROTAC use. Additionally, PROTAC-13 exhibited a good 
dose response curve in the AR degradation assay, hence further validation of this activity is warranted. 
Whilst the biological characteristics of these PROTACs was under investigation, an additional MDM2 
recruiting PROTAC was reported by Hines et al.239 The developed PROTAC comprised of a BRD4 binder 
connected to a nutlin derived MDM2 recruiter via a four-unit PEG linker. BRD4 was degraded by 98% 
with nanomolar potency. The additional p53 stabilisation induced by MDM2 inhibition caused a 
significant anti-proliferative effect on many cancer cell lines containing wild type p53, resulting in 
greater activity compared to VHL recruiting PROTAC alternatives. This study further highlights the 
utility of MDM2 as an E3 ligase, as the synergistic nature of p53 stabilisation and protein degradation 
led to enhanced biological activity. Although this study proved the hypothesis that MDM2 PROTACs 
have great potential, the MDM2 binders used were still of high molecular weight and synthetically 
complex. Development of PROTACs incorporating simple MDM2 binders would be a valuable addition 
to the PROTAC toolbox. 
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3.5. Chapter 3: Future Work 
Further controls to validate the AR degradation study are required before additional synthetic work is 
initiated. The proteasomal mediated degradation of the imidazole series of PROTACs must be proven 
through inhibition of the proteasome. This is an important control which reduces the possibility of the 
observed dose-response curves being an artefact. It will also be important to run this control with 
potential SARD PROTAC-10. 
Further validation of the SARD mechanism of action for PROTAC-10 would be useful, as SARD 
degradation is also proteasome mediated. One method to validate the SARD mechanism would 
involve studying the effect of heat shock protein 90 (HSP90) on AR degradation in the presence of the 
compound.64 HSPs play a key role by either stabilising misfolded proteins, or enabling UPS-mediated 
degradation.240 A recent study found that incubation of cells with SARD and HSP90 inhibitor 
geldanamycin resulted in enhanced degradation activity. Inhibition of HSP90 causes upregulation of 
HSP70,241 a key protein for targeting misfolded proteins for proteasomal degradation. Analysing the 
interactions of HSP inhibitors with PROTAC-10 would provide a useful insight into the mechanism for 
degradation.  
Additionally, the mechanism of action could also be probed by co-dosing PROTAC-10 with a protein 
synthesis inhibitor.66 This is hypothesised to significantly reduce protein levels to a greater extent than 
the molecule alone, due to prevention of protein synthesis, which would indicate that the compound 
is interacting with cellular AR protein rather than decreasing the rate of protein synthesis or mRNA 
levels. 
Following the validation of the UPS-mediated mechanism of action of the imidazole PROTAC series, 
further linker design is necessary for optimisation of the extent of AR degradation and potency. 
Currently, only three different PEG linkers have been explored with three, four, and six PEG units, 
however, a comprehensive screen of linker lengths and properties would be required to fully optimise 
the biological response (figure 95). Insertion of methylene units into PEG linkers has been 
demonstrated to be effective for improving PROTAC activity, hence this would be incorporated into 
various linker lengths to compare activity. 
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Figure 95: Potential linkers to be studied to optimise AR degradation and potency of imidazole based PROTAC series 
Overall, there is promise in these novel small molecule MDM2 recruiting PROTACs, however, further 
biological validation in addition to optimisation studies would be required to maximise biological 
activity. 
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4. Chapter 4: Development of photoswitchable PROTACs 
4.1. Chapter 4: Introduction 
4.1.1. Introduction to photopharmacology 
High attrition rates in the drug development process are a key problem which limits the approval of 
new medicines.242 A recent study on causes of drug attrition noted that although failure due to 
pharmacokinetic limitations have reduced, overall attrition rates remain high due to an increase in 
efficacy and safety related failures.243 Methods to predict safety problems in early development are 
lacking, despite recent developments in this area.244  Toxicity is a major cause of drug attrition, which 
either stems from the drug’s chemical structure, on-target effects or off-target effects.245 On-target 
toxicity results from the drugs activity on the target of interest, which may be related to the general 
effects on both healthy and diseased cells. Off-target toxicity typically refers to a drug’s affinity for 
multiple targets, which could be unrelated to the target of interest.246 In addition, poor selectivity of 
a drug also lowers the toxicity threshold which narrows the therapeutic window, leading to suboptimal 
dosage. One approach to circumvent toxicity is through photopharmacology.247 
Photopharmacology uses light to control biological systems. Light can influence the biological activity 
of a molecule by altering its pharmacokinetic or pharmacodynamic properties. There are many 
benefits of using light for this purpose, such as its non-invasive nature, speed of action and high spatial 
and temporal control.248 Light’s action on molecules can either be reversible or irreversible, and many 
successful therapeutic applications have been published.248,249 Light-controlled drugs offer an 
opportunity to impart additional selectivity. Ideally, a safe and inactive drug can be dosed to a patient, 
and the drug can then be switched into its biologically active form at its site of action, limiting any 
toxicity and increasing the therapeutic index of a drug (figure 96). 
 
Figure 96: Photopharmacology summary 
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Photopharmacology has been successfully applied to a variety of targets both in vitro and in vivo, for 
example enzymes,250 ion channels251 and G protein coupled receptors (GPCRs).252 
 
4.1.2. Chemical approaches to photopharmacology 
There are many strategies which use light to control biological effects. Chemical methods include 
photodynamic therapy (PDT),253 photocleavable protecting groups (photocages), photoaffinity labels 
(PAL), and photoswitchable moieties. 
PDT uses light to activate a photosensitiser which then generates a highly reactive oxygen species 
which reacts with cellular biomolecules leading to cell death. PDT is well-established and has been 
applied to various cancers over the past two decades, highlighting the immense potential of light-
controlled therapies.254  
Another type of photopharmacology uses photocages to mask functionality, which can then be 
removed using light. Photocages can be used to eliminate biological activity in the caged form and 
then release the active drug following irradiation. There have been a variety of groups used as 
photoremovable protecting groups, classic examples include nitrobenzyl derivatives, arylcarbonyl 
methyls, and coumarin groups (figure 97).255 A major limitation of many photocages is the 
requirement of high energy light sources to cleave the protecting group due to the high energy of 
standard organic bonds (350 – 400 kJ/mol). Cleavage of these strong bonds requires ca. 340 nm UV 
light which has poor tissue penetration and can be biologically damaging leading to toxic effects.256 
New photocleavable groups have been recently developed focusing on weaker bonds which can be 
cleaved using longer wavelengths, but these are still in early stages of development.257,258 An 
additional limitation of this technology is its irreversibility. Once the photocage is removed the active 
drug is revealed and this can still be transferred around the body causing off-target toxicity. 
 
Figure 97: Examples of groups using for photocaging of drug molecules 
PAL uses chemical probes to covalently bind a target molecule. These chemical probes bind to their 
cellular targets through competitive inhibition. Activation with light forms a reactive species which 
rapidly reacts with the nearest molecule, forming a covalently bound species. This technology has 
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been used to elucidate the cellular binding partners of numerous hit molecules and is a vital tool for 
chemical biology.259 Many photoaffinity groups exist and commonly used groups include phenylazides, 
phenyldiazirines, and benzophenones which respectively form nitrenes, carbenes and diradicals as the 
reactive species (figure 98). PAL is typically used for molecular target identification rather than as a 
therapeutic strategy. 
 
Figure 98: Examples of light-responsive functionalities for use in PAL 
Photoswitches exist as different isomers which can be interconverted using light. The biological 
activity of a compound can be greatly changed by altering its structure due to the specific shape 
required to occupy distinct binding pockets or biological interfaces. Hence, a drug can either be 
inactive or active following incorporation of a photoswitch, depending on its environment. This is an 
ideal application of photopharmacology. The inactive, safe drug can be dosed, and light can then be 
used to switch the drug to the active conformation specifically at its site of action. This method greatly 
reduces toxicity by only exposing a localised area to the active drug. Photoswitches also benefit from 
their reversibility, which offers further advantages for their safety profiles.248 
Photopharmacology is well-suited for diseases which are highly localised, particularly those located 
on skin and eyes where light can easily reach. One limitation of the light commonly used in 
photopharmacology is its short UV wavelengths, which poorly penetrates biological tissue.260 This 
makes it highly challenging to apply these approaches to internal diseases non-invasively. Red or 
ideally near-IR wavelengths are much better suited for these biological applications due to its 
improved penetration, however most classes of photoswitches require higher energy light sources to 
induce isomerisation. 
 
4.1.3. Introduction to photoswitches and their biological applications 
There have been numerous examples of photoswitches designed for photopharmacology 
applications, the most prevalent of which are azobenzenes and diarylethenes (figure 99). 
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Figure 99: Prevalent photoswitches used in photopharmacology, azobenzenes and diarylethenes 
Diarylethenes undergo a photochromic reaction which converts between the open-ring and closed-
ring isomers. This reaction is thermally irreversible and typically requires UV light (280 – 400 nm) to 
form the closed-isomer and visible light (>400 nm) to re-open the ring. These photoswitches have 
been utilised for a broad range of applications, including fluorescence, electrical conductivity as well 
as biological applications such as photoswitchable DNA.261,262  
Azobenzene converts into the cis isomer upon radiation with UV light.263 The two isomers of 
azobenzene have distinctly different geometries and dipole moments. They are interconverted using 
380 nm light to switch from the trans to the higher energy cis state and are switched back to the 
thermostable state using visible light or thermal energy. This photoisomerization is reversible and the 
resulting conformational change can affect a tethered protein’s structure or a ligand’s position within 
a protein’s binding site.264 Azobenzene has been used for biological modulation for over half a century, 
after first being applied to the photocontrol of chymotrypsin in 1968 by Erlanger et al. using its unique 
light sensitive nature to regulate the enzymes inactivation.265 
Azobenzenes have also been applied to two-component peptide stapling to produce 
photoisomerisable stapled peptides (figure 100). These photoswitchable staples can change the 
helical nature of the peptide in response to light. They were initially used by Kumita et al.266 and 
effectively increased helical content upon isomerisation from trans to cis. Substituted versions of 
these linkers were then applied to the BCL-xL PPI, and substantial differences in binding were observed 
depending on light irradiation.267 Azobenzene based stapled peptides have since been applied to 
numerous biological applications, highlighting their potential as optochemical tools and theraputics.268 
 
Figure 100: Photoswitchable linker for two-component peptide stapling used by Kumita et al.266 
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Ion channels are key for fast synaptic transmissions in the nervous system and are important 
therapeutic targets. There have been many examples of photoswitches designed to target these 
channels. One early example is the nicotinic acetylcholine receptors (nAChRs), a specific type of 
pentameric ligand-gated ion channel, targeted using azobenzene derived inhibitors AzoCharCh and 
Azo-PTA in 1969 (figure 101).269 These azobenzenes were switched between the cis and trans isomers 
using 320 and 420 nm light. The more active trans-isomer inhibited this channel to a greater extent 
compared to the cis isomer, validating the concept that this channel could be regulated using light. 
More recently, further agonists of this channel have been developed to generate structure activity 
relationships leading to greater activity, including AzoCholine.270 AzoCholine was photoswitched using 
440 and 360 nm light and exhibited greater potency over earlier compounds. 
 
Figure 101: nAChR ion channel inhibitors developed based on azobenzene photoswitches 
Another well-validated therapeutic target are GPCRs, which are transmembrane proteins vital for 
cellular signalling. One study combined the structure of known protein ligand VUO415374 with an 
azobenzene photoswitch to create the first photoswitchable allosteric modulator of a GPCR (figure 
102).271 This photoswitch was highly selective for one type of GPCR and found to have nanomolar 
potency, although a poor thermal half-life of 80 s. This photoswitch was then tested in vivo and light-
dependent activity was exhibited. Further studies within the same group comprehensively optimised 
the structure of this scaffold, considering its photophysical characteristics in combination with 
biological effects and extended the in vivo studies to rodents.272 
 
Figure 102: Structure of a novel photoswitchable allosteric modulator of a GPCR 
An interesting recent study by Wegener et al. found that red light (630 – 700 nm) could be used to 
activate antibacterial agents for treatment of infections.273 This photoresponsive antibacterial was 
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based on clinically approved antibiotic trimethoprim, which targets the biosynthesis of folate in a both 
Gram-positive and Gram-negative bacteria through inhibition of dihydrofolate reductase. Resistance 
to trimethoprim usage is a common occurrence, making it an important candidate for 
photopharmacology. The photoswitchable antibiotic developed showed an 8-fold difference in activity 
following its irradiation with red light (figure 103). This is an important application of photoswitches, 
as these photopharmacology strategies could limit the excessive exposure of active antibiotic to 
bacteria and therefore reduce the occurrence of resistance, a growing concern for global health.274 
 
Figure 103: Azobenzene photoswitch antibacterial which becomes 8-fold more potent in response to red light 
There are numerous further examples of photoswitch applications to biological targets, with new 
targets frequently reported. Multiple comprehensive reviews exist on new photoswitchable 
compounds developed for a range of biological applications.248,250,275 
 
4.1.4. Recent developments in photoswitch design 
The ideal photoswitch for use in biological systems would be non-toxic, undergo complete 
photoswitching to its active isomer with near-IR wavelengths of light and be completely stable to 
cellular molecules such as glutathione.  
UV light is well-known to cause damage to biological tissue, either by direct biomolecule absorption 
of short genotoxic UV wavelengths (220 – 280 nm), or through the formation of reactive species 
following absorption of longer UV wavelengths (280 – 400 nm) which can damage biomolecules 
including DNA and cell membranes.276 This damaging nature of UV light severely limits its utility in 
photopharmacology, in addition to its poor tissue penetration. Tissue penetration is affected by the 
extent of light scattering and biological chromophore absorption. Thus penetration is highly 
wavelength dependent, with UV wavelengths only penetrating up to 1 mm of tissue.277 The optimal 
wavelength window is between 600 and 1200 nm, with penetration of ca. 2 cm achieved by 800 nm 
light. Despite this extent of penetration not being sufficient for many applications, light may be 
delivered deeper into the body through insertion of optical fibres.249  
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Azobenzenes have been shown to undergo reduction of the azo-core in the presence of glutathione 
and other thiols, inactivating the photoswitch.278 This instability has great implications for the in vivo 
use of the azobenzene switching core. However, in a zebrafish study, switching was reliably observed 
over 2 days indicating this instability may not be a substantial problem, although the thermal 
relaxation of these compounds was rapid with a half-life of 7.5 mins.279 
There have been many recent developments toward ‘next-generation’ photoswitches to address the 
wavelength limitations which hinder the clinical use of photoswitching drugs. Many new chemical 
systems have been developed alongside modifications made to known cores to improve the 
photoswitch properties, particularly stability and photoconversion.280,281  
The highest wavelength transition of an unsubstituted azobenzene is ca. 400 nm, which is an overlap 
of n-π* and π-π* transitions. Through ortho-modification of the core azobenzene structure with either 
methoxy groups,282 thiols,283 chlorines,284 or fluorines,285 the n-π* transition is red-shifted with greater 
separation between the cis and trans forms (figure 104). This results in improved photostationary 
states (PSS, the steady state isomeric ratio generated following irradiation), higher stability, and more 
desirable red-shifted wavelengths for switching. Similar observations have been made with bridged 
azobenzenes known as diazocines,286,287 as well as arylazo-heterocycles, which also have very 
promising switching wavelengths as well as good intrinsic properties.288 
 
Figure 104: Azobenzene photophysical characteristics, effect of ortho-substitutions on switching wavelengths and stability 
Ortho-fluoroazobenzenes have greatly improved photophysical properties compared to the 
unsubstituted azobenzenes.289 Through introduction of highly electron withdrawing fluorine atoms, 
the electron density in the N=N bond is reduced. This lowers the n-orbital energy and unusually 
renders the cis form more thermodynamically stable than the trans. This results in green light (520 – 
560 nm) inducing trans to cis, and blue light (450 – 490 nm) inducing cis to trans isomerisation with 
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high photoconversions through n-π* excitation. This ortho-substitution does not cause significant 
distortion to the planar trans geometry of the azobenzene core due to the small size of the fluorine 
atoms. In addition, the half-life of the cis-isomers is remarkedly long, ca. 30 h at 60 °C.290 Due to these 
highly desirable properties these photoswitches have been applied to a range of applications in 
addition to biological,291,292 including liquid crystal polymers,293,294 metal-organic frameworks,295,296 
molecular machines,297 and crystal engineering.298,299 
Another promising class of photoswitches are the indigoids (figure 105), which contains indigo, 
thioindigo and hemiindigo. These photoswitches switch in both directions using >400 nm light, and 
have been shown to be extremely stable, with high photoconversions.300 In particular, the hemiindigos 
have been recently reported to be easily synthesised and have excellent photophysical 
characteristics.301,302 Upon irradiation with 470 – 530 nm light, the trans isomer was formed with > 
90% PSS, this could be switched back with 590 – 680 nm light yielding 99% of the cis isomer. In 
addition, the thermal stability was found to be extremely high, with a reported half-life of up to 83 
years at 25 °C. Due to their favourable photophysical properties, these photoswitches are well-suited 
for photopharmacology applications demonstrated by their recent application to fluorescence 
switching in RNA binders. These derivatives were found to reversibly switch on or off using visible light 
without affecting their RNA association.303 
 
Figure 105: General structures of indigoid photoswitches and switching wavelengths of hemiindigo core 
There are many alternative classes of recently developed photoswitch which switch using a variety of 
different conditions, including chiral imines,304 acylhydrazones,305 and donor-acceptor Stenhouse 
adducts.306,307 These new photoswitches have a variety of uses and expand the photoswitch toolbox 
beyond therapeutic applications to a range of interdisciplinary fields.280,281 
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4.2. Chapter 4: Aims and Objectives 
PROTACs are ideal candidates for application to photopharmacology. Firstly, the conformation of a 
PROTAC is key to its activity, hence the introduction of a photoswitch leads to two very different 
isomers hypothesised to have significantly distinct biological activity. In addition, a photoswitch can 
easily be incorporated into the structure due to the modularity of a PROTAC. PROTACs consist of two 
protein binders connected through a linker, this linker can be modified to contain a photoswitch with 
little synthetic effort.  
Two photoswitches were chosen for incorporation into the novel photoswitchable PROTACs: ortho-
fluoroazobenzene and hemiindigo. Initial designs for the two classes of photoswitchable PROTAC 
incorporated the VHL binding ligand and the enzalutamide-based AR binding ligand connected to the 
photoswitching units (figure 106). 
 
Figure 106: Structures of designed photoswitchable PROTACs based on azobenzene and hemiindigo core 
123 
 
These photoswitches were chosen due to their ease of synthesis, strong photophysical properties and 
high stability. The structural difference of the two azobenzene conformations is significantly larger 
than that of the hemiindigo conformers. This was hypothesised to optimise the likelihood of 
developing a successful AR degrading PROTAC with highly differentiated biological activity. 
Following the preparation of the photoswitchable PROTACs, the photophysical characteristics were 
investigated to quantify switching wavelengths and efficiency. The biological activity of the PROTACs 
would then be studied and further optimisation of the structures would be carried out to improve the 
differential activity of the series. Finally, the technology was applied to alternative proteins of interest 
to provide a proof-of-concept study of the generality of photoswitchable PROTACs. 
Whilst this PROTAC series was under biological analysis, alternative photoswitchable PROTACs have 
been reported providing validation of this photopharmacology strategy. Trauner et al. reported 
photoswitchable PROTACs which recruited cereblon for the degradation of both BET bromodomain 
proteins and FKBP12.308 These PROTACs incorporated an azobenzene photoswitch unit into the linker 
and were demonstrated to switch with 390 nm light. Good differential biological activity was observed 
for the optimised linker lengths, and the more active PROTAC in this work was found to be the cis 
isomer. Unfortunately, the kinetic stability of the PROTACs necessitated continuous light pulsing 
throughout the experiment.  
In addition, Pfaff et al. recently published ortho-fluoroazobenzene photoswitchable PROTACs also 
targeting the bromodomain proteins using E3 ligase VHL.309 These PROTACs were found to be active 
in the trans form and offer further evidence of the utility of photoswitchable PROTACs. 
Although these recent publications reduce the novelty of the photoswitchable PROTACs described in 
this chapter, they do validate the potential of this idea for achieving selective and potent degradation 
of a range of proteins. At the point of writing, no photoswitchable PROTAC targeting AR or ER have 
been reported, hence applying photoswitches to the light-enabled degradation of these clinically 
relevant proteins is a useful advance. 
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4.3. Chapter 4: Results and Discussion 
4.3.1. Synthesis of Hemiindigo Core 
Hemiindigo PROTAC 151 could be accessed through a convergent route which connected the three 
key components: VHL binder 154, photoswitch 152 and bromo-enzalutamide derivative 153 (figure 
107). The VHL binder was thought to be amenable for an N-arylation strategy to the aryl-bromide of 
the photoswitch via Buchwald or Ullmann coupling chemistry. The AR binding motif 153 was envisaged 
to connect through N-alkylation of the central hemiindigo nitrogen. This strategy was expected to 
provide a rapid and convergent route to the hemiindigo photoswitchable PROTACs, where the 
methodology could be extended to alternative protein binders at a late stage with few complications. 
 
Figure 107: Retrosynthesis of hemiindigo photoswitchable PROTAC to three key components connectable by N-alkylation 
and N-arylation 
Synthesis of the core hemiindigo scaffold was reported by Petermayer et al. from commercially 
available indoxyl acetate 156 and 4-bromobenzaldehyde.301 Due to its high cost and low availability, a 
route to indoxyl acetate 156 was identified to provide a reliable and cost-effective source. A one-step 
procedure from indole was reported by Liu et al. which used mild conditions combining PhI(OAc)2 with 
DBU to attain the desired product (scheme 55).310 Although this procedure was reported to yield 76% 
product, after multiple attempts a maximum yield of 7% was isolated, which was not feasible to supply 
an early stage starting material. The reason for the great discrepancy between the published yield and 
this result was unknown, the product appeared to be quite unstable to the column conditions and it 
is possible that moving from the reported 0.3 mmol scale to the scale-up 4 mmol conditions could 
have resulted in discrepancies. 
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Scheme 55: Synthesis of indoxyl acetate 156 
Next, a one-pot route to hemiindigo 159 through palladium-catalysed carbonylation of substituted 
alkynes and iodoanilines was attempted, reported by Li et al.311 This route used formic acid as the CO 
source and acetic anhydride as the activator to give a variety of hemiindigos in good yields with high 
functional group tolerance. Initially, the procedure was attempted with 4-ethynylanisole as a readily 
available alkyne to test the feasibility of this reaction (scheme 56). The reaction was successful and 
generated 44% yield of methoxy-substituted hemiindigo 159.  
 
Scheme 56: One-pot palladium-catalysed carbonylation to produce methoxy-substituted hemiindigo 159 
The one-pot route was then applied to the desired substrate, 1-bromo-4-ethynylbenzene 160 (scheme 
57). This was found to be unsuccessful, giving multiple spots by TLC. The hypothesised direct 
Sonogashira product 161 was observed in a high quantity via LCMS. This was proposed to result from 
direct reaction between alkyne 160 and iodo-aniline 158. The carbonylation product 152 was not 
observed. Despite the reported 58% yield of bromo-derivative 152 in the publication, no product was 
identified. It was hypothesised that complications arising from general cross-reactivity and the 
unsuccessful carbonylation gave a multitude of difficult to separate products. Hence, this route to the 
desired hemiindigo 152 was abandoned. 
 
Scheme 57: Attempted one-pot palladium-catalysed carbonylaion for the synthesis of bromo-substituted hemiindigo 152 
126 
 
Due to the difficulties faced with the one-step protocols, an alternative approach to indoxyl acetate 
156 was adapted from the Pitayatanakul et al. procedure.312 This strategy attained hemiindigo 152 in 
a two-step procedure via the iodo-indole intermediate 162 which was immediately treated with 
AgOAc due to its low stability (scheme 58). This route was found to be more effective, with higher 
yields and shorter reaction times. Indoxyl acetate 156 was then hydrolysed with 1.5 M NaOH and 
treated with 4-bromobenzaldehyde to yield hemiindigo 152 in excellent yield.  
 
Scheme 58: Synthesis of bromo-substituted hemiindigo 152 
 
4.3.2. N-Alkylation attempts of hemiindigo core 
With a stock of the hemiindigo in hand, attempts were then made to alkylate the nitrogen with N-Boc-
protected two-carbon linkers which would enable easy amide coupling connection of the AR binder. 
N-Boc-ethanolamine was first activated using MsCl and DIPEA to form the mesylate 164, which was 
then treated with hemiindigo 159 with NaH (scheme 59). Hemiindigo derivative 159 was used as a test 
substrate for the initial alkylation attempts, due to its ease of synthesis via a one-step reaction. This 
reaction was found to yield an inseparable 1:1 mixture of starting material and product 165 and 
despite increasing equivalents of alkylating agent 164 and NaH, greater conversion was not observed.  
 
Scheme 59: N-alkylation of hemiindigo with mesylate 164 to generate a mixture of 1:1 SM and product 165  
Alkylation of the desired bromo-substituted hemiindigo 152 was then attempted (scheme 60). Initial 
attempts with mesylate 164 did not yield any product, despite obvious deprotonation of the 
hemiindigo 152 observed through a distinct colour change from brown to turquoise. The equivalents 
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of NaH were lowered from 1.5 to 1 eq. however no change was observed. It was proposed that the 
mesylate 164 may not be reactive enough for this highly electron deficient aromatic system, hence 
the iodide derivative 167 was used in further attempts.  
 
Scheme 60: Attempted N-alkylation of bromo-substituted hemiindigo 152 with mesylate 164 
Alkylation of hemiindigo 152 with commercially available iodide 167 was attempted using NaH over 
24 h, however only SM was recovered (scheme 61). Additionally, alkylation attempts using K2CO3 and 
18-crown-6 ether at 120 °C for 24 h led to 152 decomposition. 
 
Scheme 61: Conditions attempted for alkylation of bromo-substituted hemiindigo 152 
After little alkylation success using these two-carbon alkylating units, efforts were made to avoid the 
use of the N-Boc protecting group. Thus, the desired enzalutamide tagged substrate 168 was prepared 
in good yield from reaction of acid 2 with 2-bromoethylamine hydrobromide salt (scheme 62). This 
substrate was then immediately reacted with hemiindigo 152 in the presence of NaH. No product was 
detected, and the major LCMS product had a molecular weight corresponding to proposed structure 
170. This structure corresponds to an intramolecular reaction of the two-carbon tag with the 
neighbouring amide to form the five-membered ring cyclised product. 
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Scheme 62: Attempted N-alkylation of bromo-substituted hemiindigo 152 with bromo-derived enzalutamide 168 and 
hypothesised cyclised enzalutamide derivative 170  
To circumvent the problem with the reactive amide nitrogen, a di-N-Boc derivative of the alkylating 
agent 172 was prepared by treating dibromoethane with HN(Boc)2 in the presence of NaH (scheme 
63). Unfortunately, attempts to attach this motif to hemiindigo core 152 were unsuccessful, with only 
starting material recovered. 
 
Scheme 63: Synthesis of double N-Boc-protected bromo-substituent 172 for attempted N-alkylation of hemiindigo 152 
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4.3.3. N-Alkylation attempts of indole 
Due to the major difficulties encountered during alkylation attempts on the core hemiindigo scaffold, 
an alternative approach was sought where indole could be directly alkylated prior to formation of the 
hemiindigo core. Initial attempts at this alkylation used the mesylate 164 and NaH, however a low 
yield of 21% was isolated (table 6). When repeated with the iodide derivative 167, the yield was 
improved to 27%. However, the conversion was still low with a significant quantity of starting material 
recovered. Further alkylation attempts were made using Cs2CO3 at reflux which also yielded little 
conversion, and upon increasing the equivalence of alkylating agent, no improvement was observed. 
 
With the alkylated indole 174, attempts were made to construct the hemiindigo core through a mild 
and direct palladium-catalysed oxidative acetoxylation of the indole, reported by Choy et al. (scheme 
64).313 This procedure was found to be relatively simple to conduct, however for this substrate system 
a low yield of 33% was obtained. Compound 175 was used immediately in the next step due to its 
poor stability. Unfortunately, attempts at the subsequent hemiindigo core formation using 4-
bromobenzaldehyde were unsuccessful. Although product 166 was detected by LCMS and crude 1H 
NMR, purification from significant levels of unknown by-products was challenging. Due to the low 
reaction scale, resulting from the previous poor yielding steps, isolation of 166 was unsuccessful. 
Run X Conditions Results 
1 OMs 1.25 eq. NaH, DMF, r.t. 21%  
2 I 1.1 eq. NaH, DMF, r.t 18 h then 80 °C 27%  
3 I 2 eq. Cs
2
CO
3
, MeCN, reflux 18 h 17% 
4 I 1.5 eq. NaH, DMF, r.t. 24 h Complex mix 
Table 6: Conditions attempted for the alkylation of indole 155 with N-Boc protected alkylating agents 
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Scheme 64: Attempted synthesis of N-alkylated hemiindigo 166 from substituted indole 174 
Due to the difficulties faced throughout the attempted alkylation of the highly unreactive hemiindigo 
nitrogen, it was decided to turn to an alternative photoswitch. Azobenzene scaffolds have many 
advantageous features, such as their high stability and distinctly different conformations. Hence, 
azobenzene-based photoswitchable PROTACs were developed for the proof of concept studies. 
 
4.3.4. Synthesis of ortho-fluoroazobenzenes PROTAC series targeting AR 
Retrosynthetic analysis of ortho-fluoroazobenzene based PROTAC 176 led to identification of four key 
fragments which can be combined in a convergent fashion (figure 108). It was proposed to build the 
azobenzene core through a Mills reaction between nitroso derivative 178 and aniline 179. This core 
could then be combined with the VHL binder 154 through an N-arylation Buchwald/Ullman coupling 
approach and the AR binding motif 177 could be connected through an amide coupling. A two-carbon 
linker between the AR binder and the core photoswitch was introduced to increase the flexibility of 
the PROTAC, known to be important for ternary structure formation.31 In addition, this enabled 
introduction of the amine functionality, important for connection to the core azobenzene. 
 
Figure 108: Retrosynthesis of azobenzene photoswitchable PROTACs into four simple components 
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To synthesise the azobenzene core 182, firstly 2,6-dibromoaniline was treated with NBS to brominate 
the para-position to generate 181 in good yield (scheme 65). This compound was then oxidised using 
OxoneTM to the nitroso-derivative 178 in high yield, which was then reacted with commercially 
available aminobenzoic acid 179 in a mixture of toluene, acetic acid and TFA in the dark. After 
monitoring over 3 days, no product was observed, and only starting materials were isolated following 
purification. This was thought to be due to interference of the carboxylic acid in the reaction. 
 
Scheme 65: Attempted synthesis of bromo-carboxylic acid substituted azobenzene 182 through a Mills reaction from 2,6-
dibromoaniline via NBS bromination and OxoneTM mediated oxidation to nitroso-substituent 178 
To circumvent this issue, aminobenzoic acid 179 was protected as ethyl ester 183 in high yield, prior 
to repeating the Mills reaction with 178 (scheme 66). After monitoring for 5 days, the reaction yielded 
a mixture of starting materials and product, upon purification, 27% 182 was isolated, alongside both 
starting materials, giving full mass balance. Despite the slow and low yielding nature of this reaction, 
it was acceptable due to easy recovery of the starting materials alongside product during purification. 
 
Scheme 66: Alternative Mills reaction to synthesise bromo-carboxylic acid substituted azobenzene 182 from derivative 179 
With the core azobenzene building block 182 in hand, attempts were made to connect the VHL binder 
154. Initial attempts used Ullmann coupling conditions (scheme 67). After 4 h, all starting material was 
consumed, however LCMS analysis of the crude material showed very low amounts of product, and 
high levels of proposed SNAr product 185 where the VHL amine 154 reacted directly with an ortho-
fluoro substituent. It was hypothesised that due to the high temperatures required, the Ullman 
coupling conditions did not differentiate well between the bromo- and the fluoro- substituents in this 
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highly electron deficient aromatic system, leading to significant cross reactivity. To address this 
problem, palladium-catalysed N-arylation approaches were sought. 
 
Scheme 67: Attempted Ullmann coupling of 154 with bromoazobenzene 182, SNAr product 185 highlighted 
Buchwald Hartwig cross coupling conditions were attempted next, it was proposed that the oxidative 
addition into the bromo-aryl bond would be favourable compared to the aryl-fluoro substituents. 
Initial attempts used Pd(PPh3)4 and NaOtBu at 100 °C for 22 h, which yielded a complex mixture of 185 
and decomposed products (table 7). A change in the catalyst system to Pd2(dba)3 and BINAP at 110 °C 
for 18 h also gave a complex mixture with no desired product observed. It was thought that these 
temperatures were too high for this highly electron deficient system, hence a final attempt used 
XantPhos at 90 °C. This gave a mixture of SNAr product 185 and desired product 184 in 1:1 ratio. 
Although product was identified by LCMS, the yield and poor conversion required high quantities of 
the VHL-binding ligand, the limiting reagent. Although there are a considerable number of different 
catalyst and ligand systems which could be attempted,314,315 both starting materials for this reaction 
were too precious to undergo extensive screening. Hence, due to these inefficiencies, the direct 
conjugation of the VHL-binder strategy was abandoned, and alternative approaches were sought. 
133 
 
 
Run Conditions LCMS analysis 
1 Pd(PPh3)4, NaOtBu, K2CO3, Toluene, 100 °C, 22 h Complex mix containing 185 
2 Pd2(dba)3, BINAP, NaOtBu, Toluene, 110 °C, 18 h Complex mix 
3 Pd2(dba)3, XantPhos, Cs2CO3, Dioxane, 90 °C, 18 h 1:1 Mix 185:184 
The high nucleophilicity of the aliphatic amine in 154 was identified to be a significant problem for its 
direct reaction with the electron deficient azobenzene 182. One method to circumvent this, is through 
using a less nucleophilic amine source such as the benzophenone imine, which could then be 
unmasked in acidic conditions yielding aniline 187 (scheme 68). This strategy would form a core 
azobenzene substituted with both an acid and an amine on opposite sides of the core. The differential 
functionality could then be used for respective amide couplings with the two protein binding motifs. 
Unfortunately, this approach was also unsuccessful, and a complex mixture containing no identifiable 
product was obtained.  
 
Scheme 68: Attempted Buchwald-Hartwig of benzophenone imine 
A final attempt was made to directly attach a nitrogen to the aromatic azobenzene system through 
Buchwald-Hartwig reaction of less reactive acetamide with the aryl-bromide (scheme 69). The 
reaction proceeded extremely well, with quantitative yield of 188 attained after 1 h. Attempts were 
Table 7: Attempted conditions for the N-arylation of bromoazobenzene 182 using Buchwald-Hartwig conditions 
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then made to hydrolyse the amide (as well as the ester present) under acidic conditions. Although no 
starting material remained after 4 h at 100 °C, no product was identified through LCMS and the crude 
1H NMR showed a complex mixture of products. It was hypothesised that either the core azobenzene 
degraded in these extreme conditions, or the exposed acid and amine participated in side reactions 
after deprotection, which led to a complex mixture of polymeric species. 
 
Scheme 69: Buchwald-Hartwig conditions for acetamide reaction with 182 before attempted acidic amide hydrolysis 
Final attempts at this connection strategy proposed a Chan-Lam coupling between the VHL amine and 
a boronic acid derivative of the azobenzene core (scheme 70). Chan-Lam conditions are milder than 
Buchwald-Hartwig alternatives, which could discourage SNAr reactivity. Unfortunately, formation of 
the boronic ester 190 from aryl bromide 182 proved unsuccessful, resulting in a complex mixture. 
 
Scheme 70: Attempted generation of boronic ester azobenzene derivative 190 
Due to the complications faced in this strategy, an alternative approach was identified using a simpler 
azobenzene core, which would theoretically yield a simpler and more robust route to this azobenzene 
series of photoswitchable PROTACs. 
 
4.3.5. Alternative azobenzene conjugation strategy 
To avoid the challenging N-arylation reaction, an alternative linkage was sought for connection of the 
VHL binder 154. An amide coupling strategy was chosen due to its robust nature, high expected yields, 
and broad functional group tolerance (figure 109). Hence, azobenzene 191 was chosen as an ideal 
photoswitch for easy modulation and preparation. This photoswitch is functionalised with an ester on 
one end and an acid on the other, which enables a simple strategy of amide coupling one protein 
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binder, then ester deprotection to the acid, followed by amide couple of the second protein binder to 
form the full PROTAC structure. 
 
Figure 109: Amide coupling strategy for conjugation of protein binders to core azobenzene 191 
The synthesis of azobenzene 191 followed the same oxidation then Mills reaction strategy of the 
previous azobenzene. Aniline 179 was oxidised via treatment with OxoneTM to form nitroso-
intermediate 192, which was then treated with aniline 183 through a Mills reaction to build the azo-
core 191 (scheme 71). This final reaction was challenging, very low yields were consistently attained 
even with extended reaction times of over 7 days. Purification by column chromatography was also 
extremely challenging due to the polar nature of the product and starting materials which all were 
found to streak on the column, hindering pure product isolation. In addition, the nitroso-intermediate 
192 was found to degrade on the column, introducing further impurities of a similar polarity to the 
desired product 191. The best yield attained was 16% after 3 days, mainly due to the poor reaction 
conversion combined with purification difficulties. Despite these issues, enough product was isolated 
to continue the synthesis and due to the robust nature of the subsequent amide coupling reaction, 
some starting material impurities were tolerated. 
 
Scheme 71: New route to alternative azobenzene core 191 via Mills reaction of nitroso-acid 192 and aniline 183 
Next, the AR-binding motif 177 was prepared (scheme 72). Enzalutamide acid 2 was reacted with two-
carbon bis-amine 193, obtaining 194 in high yield. The N-Boc protecting group was subsequently 
removed with TFA and desired the amine 177 was isolated in almost quantitative yield. 
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Scheme 72: Preparation of amine-tagged enzalutamide derivative 177 via amide coupling and N-Boc deprotection 
With both AR-binder and VHL-binder amines in hand, azoPROTAC1 could then be prepared through 
further simple amide couplings (scheme 73). Azobenzene 191 was treated with VHL binder 154 with 
HATU and DIPEA to form ester 195 in high yield, which was deprotected to unveil the acid 196 with 
LiOH. In order to avoid another challenging acid purification, this intermediate was immediately 
reacted with enzalutamide amine 177 to avoid unnecessary product loss through column 
chromatography. The final amide coupling also proceeded with high yield to generate the desired 
product, azoPROTAC1. 
 
Scheme 73: Preparation of azoPROTAC1 through sequential amide couplings 
 
4.3.6. Photoswitching of azoPROTAC1 
With azoPROTAC1 in hand, the next challenge was to investigate the switching capabilities of the 
ortho-fluoroazobenzene core to ensure the large protein binding substituents on both ends of the 
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azobenzene did not hinder the efficiency and ease of switching. To analyse this, collaborators were 
sought in the Cavendish Laboratory in the Department of Physics. With the help of Jeffrey Gorman 
from the Optoelectronics group, switching of azoPROTAC1 in both directions was demonstrated using 
a 405 nm and 520 nm continuous diode laser set-up.  
It was important to consider solvent when assessing photophysical properties, as the solvent polarity 
can change the absorption spectra, known as solvatochromism.316 The solvent absorption cutoff must 
also be accounted for, as below this the solvent absorbs all light. Ideally, the solvent used for the 
photoswitching study would be either aqueous or cell media, as this would be most applicable for 
biological applications, however, the solubility of the PROTACs was too poor to generate UV-vis 
spectra with a high signal-to-noise ratio. Therefore, acetonitrile was chosen to emulate the literature 
examples and provide a direct comparison to the reported photoswitches. In addition, the cutoff 
wavelength of acetonitrile is 190 nm, hence above this wavelength there would be no solvent effects 
interfering with the spectra. This enabled observation of the π-π* and n-π* characteristic absorptions.  
Firstly, a UV-vis spectrum of azoPROTAC1 was taken in its initial state, which was a mixture of the cis 
and trans isomers due to exposure to ambient light throughout the synthesis (figure 110). This UV-vis 
trace showed the two expected absorptions characteristic of these ortho-fluoroazobenzenes. At 250 
- 350 nm in the UV region, a very strong π-π* absorption is observed, and a considerably weaker n-π* 
absorption was observed in the visible region between 375 - 500 nm. 
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Figure 110: UV-vis spectra of azoPROTAC1, inset displaying zoomed n-π* transition 
It is the presence of this red-shifted n-π* transition which is key for the visible light promoted switching 
of these azobenzenes, hence the sample was concentrated to magnify this region of interest, resulting 
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in complete saturation of the less interesting UV absorption. With improved absorption in this region, 
the switching was analysed through a cycle of cuvette irradiation and UV-vis spectroscopy, to observe 
a red-shift in the absorption over a series of timepoints (figure 111). The PSS for this cis to trans 
transition was observed after 17 minutes of irradiation with 405 nm light. 
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Figure 111: UV-vis spectra following irradiation with 405 nm light, inset displaying zoomed n-π* transition 
The diluted, 405 nm irradiated azoPROTAC1 was analysed by UV-vis spectroscopy to generate the full 
spectra without saturation (figure 112). The 300 – 350 nm region showed the characteristic red-shift 
in π-π* absorption expected for this azobenzene following irradiation.  
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Figure 112: UV-vis spectra for diluted 405 nm irradiated azoPROTAC1. inset displaying zoomed n-π* transition 
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The next step was to test whether azoPROTAC1 was able to switch back using a 520 nm light source. 
The same cuvette was then irradiated with 520 nm light for a series of timepoints and monitored by 
UV-vis spectroscopy (figure 113). The spectral shift was minimal after 32 minutes, however once the 
laser power was increased, the shift was rapid and substantial after 5 minutes of higher intensity 
irradiation. This highlights the importance of the light source intensity, as the absorption at this 
wavelength is considerably lower than at 405 nm, reflecting the longer switching time.  
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Figure 113: UV-vis spectra showing photoswitching following irradiation with 520 nm light for various times 
Following these switching experiments, the UV-vis spectra of the PSS of switching in both directions 
were overlaid (figure 114). This enabled observation of the overlap in absorption between the two 
isomers, an indication of how effective the switching is. In addition, it was used to establish the 
wavelength where there was the greatest differential between the absorption of the two isomers. 
This preliminary data could then be used to identify the ideal wavelengths for further switching 
experimentation, 415 nm and 530 nm. 
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Figure 114: Overlapped visible region of UV-vis spectra for both isomers of azoPROTAC1 at their PSS with 405 and 520 nm 
Following the proof-of-concept switching experiments, a new set of LEDs were purchased from 
ThorLabs, at 415 nm and 530 nm wavelengths, which were used for all further experiments. These 
LEDs have a bandwidth of 14 nm for the 415 nm LED and 35 nm for the 530 nm LED. Although the 
switching observed at 405 nm was pleasing, moving to 415 nm was hypothesised to limit the level of 
< 400 nm light exposed to cells, which may be biologically harmful (section 4.1.4).  
The switching experiments were then repeated with the 415 and 530 nm LEDs. The PSS overlay of the 
n-π* of the UV-vis spectra between the two isomers showed greatly improved differential overlap 
(figure 115). This highlighted the importance of wavelength in achieving optimal photoswitching. 
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Figure 115: Overlapped visible region of UV-vis spectra for both isomers of azoPROTAC1 at the PSS with 415 and 530 nm 
141 
 
4.3.7. Photophysical characterisation of azoPROTAC1 
The next photophysical characterisation investigated was the switching PSS. This was measured using 
1H NMR, enabled by the distinctly different chemical shifts of selected functionalities within the two 
isomers leading to simple analysis of the isomer ratios. The most distinct shift was a doublet observed 
at 4.70 – 4.85 ppm which was used to measure the ratio between isomers (figure 116A). The sample 
was irradiated with 415 nm light and the 1H NMR spectrum taken, complete shift of the doublet to 
4.82 ppm was observed, indicating >98% trans-conversion after 10 minutes of irradiation. To establish 
whether the change in wavelength from 405 nm to 415 nm influenced this PSS, the experiment was 
repeated with 405 nm light. No difference was observed, both light wavelengths exhibited complete 
conversion. Pleasingly, this demonstrated that 415 nm LEDs were equally as effective as 405 nm, whilst 
importantly, being more red-shifted and further from the damaging UV region. 
 
Figure 116: A: 1H NMR of azoPROTAC1 following 530, 415 and 405 nm irradiation, B: overlaid 1H NMR of 530 nm irradiation 
for 10, 15, 25 and 40 minute timepoints 
Next, the cis-conversion was tested using the 530 nm LEDs. This switch was found to be considerably 
slower than the trans-conversion which occurred within 10 minutes. After 25 minutes of 530 nm 
irradiation the PSS was reached, which was found to contain ~80% of the cis-isomer (figure 116B). 
Although this was less effective than the trans-conversion, this was still a highly cis enriched state 
which was expected to produce strong differential biological activity in the two isomers PSS. 
Additionally, the incomplete cis-conversion was in line with expected literature values.285,290   
Next, the reversibility of the switching process and the photostability of azoPROTAC1 were 
investigated. It was important to identify whether these azobenzene cores would be susceptible to 
photobleaching after extensive switching, as high stability is vital for therapeutic applications. This 
property was analysed by conducting eight isomerisation cycles. AzoPROTAC1 was irradiated for 10 
minutes with 415 nm light, followed by 25 minutes of 530 nm irradiation. The resultant UV-vis spectra 
A B 
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recorded following each radiation were overlaid (figure 117A), and the absorption at λmax of the n-π* 
transition was then plotted (figure 117B). Fortunately, no instability was observed for azoPROTAC1. 
No drop-off in the UV-vis absorption was observed after eight cycles, with a cumulative irradiation 
time of 80 and 200 minutes for 415 and 530 nm respectively. Importantly, this highlighted the utility 
and robust nature of the ortho-fluoroazobenzene photoswitches. 
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Figure 117: A: overlaid UV-vis spectra of eight switching cycles to observe change in intensity to indicate degradation, B: 
plot of absorption at maximum peak wavelength for eight switching cycles 
Finally, the kinetic stability of azoPROTAC1 was assessed at the biologically relevant temperature of 
37 °C. AzoPROTAC1 was irradiated to its excited trans PSS then incubated at 37 °C for 30 h, longer 
than the ideal 24 h biological assay timepoint, the UV-vis spectra were then overlaid to assess the 
extent of relaxation (figure 118A). After a 30 h incubation, no relaxation was observed, indicating high 
thermal stability in this PSS. To further study the kinetic stability of azoPROTAC1, an isomeric mixture 
was incubated for 1 h at 60 °C. UV-vis analysis demonstrated that there was no change in 
azoPROTAC1’s composition, indicating high kinetic stability of both isomers (figure 118B). 
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Figure 118: A: Overlaid UV-vis spectra of t = 0 h trans azoPROTAC1 isomer and t = 30 h incubation at 37 °C; B: Overlaid UV-
vis spectra of azoPROTAC1 isomeric mixture incubated at 60 °C 
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This result further validated the use of this azobenzene core for biological application. With these 
results in hand, it was hypothesised that azoPROTAC1 could be irradiated on the assay plate at the 
beginning of biological studies. The plate could then be incubated at 37 °C for the full time course 
without the composition of azoPROTAC1 changing. Importantly, this prevented repeated irradiation 
throughout the assay, which could complicate the experimental set-up, in addition to introducing 
further variations which could affect the cells. 
 
4.3.8. Biological evaluation of azoPROTAC1 
Following the thorough assessment of azoPROTAC1’s photophysical properties, the effect of this 
PROTAC on AR-positive cell-lines was investigated. This was done in collaboration with Dr Andreas 
Hock at AstraZeneca, Cambridge. The imaging assay used for azoPROTAC analysis was described in 
Chapter 3. Initially, AR-positive LNCaP cells were treated with azoPROTAC1 and then irradiated with 
either 415 nm or 530 nm LEDs on the assay plate (figure 119). The plate was then incubated in a dark 
incubator at 37 °C for 24 h before the cells were fixed. The cells were then stained with fluorescent 
antibodies to quantify AR levels within the cells following confocal microscopy. It was hypothesised 
that azoPROTAC1 could be irradiated on the assay plate, rather than before dosing as this would be 
logistically simpler. If the compounds were irradiated prior to dosing, then the dosing procedure would 
require completely dark conditions to minimise the levels of ambient light, which could influence the 
results. Importantly, clear bottomed assay plates were used to ensure high light penetration. 
 
Figure 119: Procedure for biological evaluation of azoPROTAC1, compound switching carried out on the assay plate 
The control compounds used to validate the experimental procedure were negative control DMSO, 
and positive control niclosamide. The assay was run in triplicate and the compound was dosed twice 
onto cells on the same plate. The plate was then irradiated for 10 minutes in two sections, with 415 
and 530 nm LEDs to generate both isomers. The plate was then incubated for 24 h. Including the 
dosing of the compounds and irradiation, the cells were outside the incubator for ca. 1 h. After fixing, 
staining, and imaging, the fluorescence response was plotted for the two different irradiation 
wavelengths, essentially the two isomers (figure 120). This preliminary biological data showed some 
AR degradation, with the AR levels changing from ca. 200,000 units with no PROTAC to almost 120,000 
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units with PROTAC. Although only partial AR degradation was observed, there was differential activity 
between the wavelengths. Higher activity was observed following 415 nm irradiation. Interestingly, a 
hook effect was observed at high concentration, which is a common feature of PROTAC dose response 
curves. This is where activity is reduced at high concentrations due to greater formation of the binary 
protein complex between the PROTAC and one protein, over the active tertiary protein complex.  
 
Figure 120: Dose-response curve of azoPROTAC1 following on-plate irradiation with 415 and 530 nm LEDs, 24 h incubation 
With these promising initial results in hand, further PROTACs were designed in an attempt at 
optimising the potency and extent of AR degradation. It was hypothesised that through linker length 
and property modification, improved efficacy and more complete AR degradation could be promoted.  
 
4.3.9. Development of azoPROTAC2 
One strategy hypothesised to improve the activity of this PROTAC, was reduction of the number of 
amide bond linkages, which could lead to instability and poor pharmacokinetic properties. An ether 
linkage was chosen between the enzalutamide AR binding motif and the azobenzene as this would 
alleviate the requirement for an amide linkage and was synthetically tractable.  
Modification of the enzalutamide core through this strategy required an ether-linked aryl-fragment to 
build the diarylthiohydantoin core (scheme 74). Initially, commercially available 4-bromophenol 197 
was alkylated using 2-(Boc-amino)ethyl bromide in the presence of K2CO3 to generate aryl-bromide 
198 in almost quantitative yield. Next, the aryl-bromide 198 reacted via an Ullmann coupling with 2-
aminoisobutyric acid to form acid 199 in 22% yield. The poor yield of this reaction was hypothesised 
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to be due to the challenging purification, in combination with the incomplete reaction. It was expected 
that optimisation of the reaction conditions could improve this yield, however, enough material was 
supplied for the synthesis of this series of azoPROTACs. With acid 199 in hand, methylation using 
iodomethane and K2CO3 formed ester 200 in 59% yield. This reaction gave complete conversion of 
starting material, however over-methylation of the aryl-amine group also occurred, which reduced 
the yield of the desired product. The diarylthiohydantoin core was then constructed via reaction of 
the amino-ester 200 with isothiocyanate 5. Pleasingly, this reaction generated almost quantitative 
yield of desired enzalutamide derivative 201. Finally, the N-Boc protecting group was removed using 
TFA to yield enzalutamide-amine 202, ready for subsequent amide coupling to the azobenzene core. 
 
Scheme 74: Synthesis of new ether enzalutamide derivative 202 through O-alkylation, Ullmann coupling, esterification and 
cyclisation of central diarylthiohydantoin core 
Next, the new enzalutamide fragment 202 was attached to 195 through amide coupling methodology 
to generate desired azoPROTAC2 in moderate yield (scheme 75).  
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Scheme 75: Synthesis of azoPROTAC2 through sequential amide couplings 
 
4.3.10. Further biological assessment of azoPROTAC1 and azoPROTAC2 
With the new PROTAC in hand, additional biological testing was conducted with Dr Andreas Hock at 
AstraZeneca for further validation of azoPROTAC1’s activity and for comparison to the newly 
developed azoPROTAC2.  
A modified procedure was proposed where the cells would be fixed after 6 h rather than the full 24 h 
as previously conducted. AR-degrading PROTACs have been shown to completely eradicate AR in 
under 6 h,290 hence reducing the assay length could give improved results if there was any instability 
of the azoPROTACs over 24 hours. In addition, the longer time course of the assay could result in 
greater background noise due to variability between cells over 24 h, this could lead to greater difficulty 
in analysing the data due to less pronounced differences in degradation.  
An additional modification was also proposed. The compounds were dosed across two plates to 
reduce the potential for cross-contamination of the light sources when irradiating the plate in 
portions. Finally, following the full photophysical characterisation of azoPROTAC1 it was established 
that 530 nm irradiation required greater time to reach the PSS compared to 415 nm irradiation. This 
was implemented for the subsequent biological studies; the cells would be irradiated for 30 minutes 
with 530 nm LEDs rather than the 10 minutes previously used. 
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The next run incorporated all of these modifications. The cells were plated across two assay plates 
and after PROTAC dosing were irradiated with each respective LED. The plates were then incubated 
for 6 h and the cells were examined. Unfortunately, on this occasion all cells were found to be dead, 
including both positive and negative controls across both plates. The specific reason for cell death was 
unknown and could have been completely independent of the assay procedure. However, it was 
hypothesised that potentially keeping the cells outside of the incubator for close to 1.5 h during dosing 
and the subsequent irradiation could have been a contributing factor to the cell death.  
In the next assay, to reduce the length of time the cells were outside the incubator, it was proposed 
that the compounds would be irradiated with 530 nm LEDs for 30 minutes prior to dosing. This 
procedure enabled the 530 nm irradiated plate to be placed straight into the incubator after dosing, 
avoiding the lengthy plate irradiation procedure. Once again, the assay length was 6 h, and at this 
point, the cells across both plates were noted to be healthy. The plates were then fixed, stained, and 
imaged to assess the AR levels. 
The results of this assay were not very promising, and the AR levels were found to fluctuate more 
significantly than previously observed (figure 121). AzoPROTAC1 reduced AR levels by just 15%, 
considerably lower than the previously observed 40% AR reduction. The two wavelengths generated 
very similar profiles in the dose response curves, indicating little difference between isomers. In 
addition, the variability in AR levels between the plates was around 10%, which made it extremely 
difficult to analyse minor differences between the two plates. Despite variability in the data, a slight 
downward trend was observed in AR levels at increased concentration of PROTAC. Once again, a very 
slight hook effect was also observed at the maximum concentration. 
 
Figure 121: Dose-response curves of azoPROTAC1 and azoPROTAC2 following initial compound irradiation with 530 nm 
then on-plate irradiation with 415 nm and incubation for 6 h 
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It was thought that the irradiation process for this assay was not ideal. Following the 30 minute 
irradiation with 530 nm LEDs, the compounds needed to be kept completely in the dark, whilst being 
dosed to avoid any undesired photoswitching caused by ambient light. Unfortunately, this was very 
challenging to achieve in the laboratory used for this assay, particularly as the automated dosing 
machine used a blue LED to guide compound input. Hence, the compounds were exposed to light 
which may have been responsible for the extremely low difference in biological activity between the 
two irradiated forms of both PROTACs.  
To overcome these issues and to verify the initial biological results observed for azoPROTAC1, it was 
proposed that the original assay conditions would be repeated with both PROTACs. This would enable 
confirmation of the reproducibility of the assay and facilitate comparison between the two PROTACs 
to establish whether the structural changes affect biological activity. These studies are ongoing.   
 
4.3.11. Development of azoPROTAC3 
The linker conjugation strategy is well-established to be vital for achieving active and highly potent 
PROTACs.290 After the ether linkage approach was employed to attached the AR-binding motif to the 
azobenzene, it was hypothesised that a similar approach to the VHL binding motif could also enhance 
activity. In PROTAC literature there are few examples of the VHL ligand directly attached to an aryl 
amide, hence it is unknown whether this attachment type may hinder activity. One approach to alter 
this is to modify the para-linkages of the azobenzene core, from two carboxylic acids to one carboxylic 
acid and an aniline or phenol group (figure 122). This would also reduce the number of amide bonds 
required to form the PROTAC hence improving both the chemical stability and drug-like properties of 
the overall structure. Another fundamental advantage to these alternative azobenzenes is their ease 
of synthesis. The previous azobenzene cores were prepared through a Mills reaction of a nitroso-aryl 
combined with an aniline. This reaction was low yielding, difficult to purify and had very long reaction 
times which made it a poor choice for long-term supply.  
 
Figure 122: Structure of initial azobenzene core compared to new aniline and phenol-based azobenzene cores 
Aniline azobenzene derivative 205 could be prepared through an azo-coupling reaction by reacting a 
diazonium salt with an aniline (scheme 76). Azo-coupling reactions are well-known to be high yielding 
and fast, which would be a substantial improvement on the Mills reaction. The azo-coupling was 
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initially attempted using 3-fluoroaniline derivative 204 as an available test substrate to scope out the 
viability of the reaction. Unfortunately, this reaction resulted in a complex mixture of products, and 
no desired azobenzene 205 was observed by LCMS or 1H NMR. The reasons for this failure were 
unknown, however progression to the well-precedented phenol azo-coupling reaction was a sensible 
alternative to try, due to the subsequent O-alkylation conjugation strategy which would be beneficial 
in reducing the overall number of amide bonds. 
 
Scheme 76: Attempted synthetic route to aniline azobenzene core 205 through azo-coupling chemistry 
Due to the higher cost of the ortho-fluoroester 183, this phenol azo-coupling reaction was first 
attempted on commercially available ethyl-4-aminobenzoate 206, which was treated with sodium 
nitrite in acid to form the diazonium sulfuric acid salt intermediate 207. Intermediate 207 was 
immediately treated with 3,5-difluorophenol 208 in a one-pot reaction to yield desired azobenzene 
209 in high yield (scheme 77). Due to the simplicity of this reaction, it was proposed that a PROTAC 
would be directly prepared from this di-fluorinated core. Additionally, this would enable comparison 
of the new core properties with the previously synthesised azoPROTACs. 
 
Scheme 77: Azo-coupling route to new azobenzene core 209 via diazonium salt intermediate 207 
The new azobenzene core 209 was first alkylated with tert-butyl bromoacetate, in the presence of 
K2CO3 and catalytic potassium iodide to produce diester 210 in high yield (scheme 78). The difference 
in stability of the two esters made them orthogonal, hence the tert-butyl ester was selectively 
deprotected in TFA to yield acid 211 in reasonable yield. Next, the VHL binder 154 was then coupled 
to acid 211 using HATU and DIPEA, to produce ester 212 in high yield. Finally, the ethyl ester was 
deprotected using LiOH and the revealed acid reacted immediately in a final HATU mediated amide 
coupling with enzalutamide amine 202 to produce azoPROTAC3 in high yield.   
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Scheme 78: Synthesis of azoPROTAC3 via O-alkylation of core 209 and subsequent deprotection and amide coupling  
With azoPROTAC3 in hand, photophysical characterisation was repeated to compare the new 
azobenzene core to those previously used. The new azoPROTAC was irradiated with 415 nm LEDs for 
a series of timepoints and 1H NMR spectra were recorded following each irradiation to establish the 
PSS. After complete switching was observed, the PROTAC was then irradiated with 530 nm LEDs to 
switch back (figure 123A). The trans PSS was reached after 10 minutes of 415 nm LED irradiation and 
was found to contain ca. 85% trans isomer. Photoswitching to the cis PSS using 530 nm with this 
azobenzene core took just 10 minutes, which was considerably faster compared to the previous 
azobenzene which took 25 minutes of irradiation to reach the PSS. The PSS following 530 nm 
irradiation was ca. 56%, lower than previously observed for azoPROTAC1. UV-vis spectroscopy was 
also used to study the overlap in absorption between the two species in the n-π* visible region (figure 
123B). This showed a high degree of overlap in the absorption of the two species, considerably greater 
than observed for the earlier scaffolds. This overlap reflected the poorer PSS observed following 530 
nm irradiation. However, there was greater differential between the two isomers at 415 nm, which 
corresponded well to the higher PSS reached. 
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Figure 123: PSS of azoPROTAC3 following 415 and 530 nm irradiation for 10 minutes; A: 1HNMR showing isomer 
composition at PSS; B: overlaid UV-vis spectra of visible region showing overlap of n-π* absorption 
Although these PSS were lower than those reached for the previously used scaffold, they were 
predicted to be satisfactory for further biological testing. Additionally, the UV-vis spectra of 
azoPROTAC1 overlaid with azoPROTAC3 showed a significant shift in λmax (figure 124).  Optimisation 
of either the core substitution or the wavelengths used for PROTAC excitation could be undertaken 
following the validation of biological activity.  
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Figure 124: Overlaid UV-vis spectra of azoPROTAC1 and azoPROTAC3 showing the difference in n-π* absorptions 
This new azoPROTAC along with all previously synthesised PROTACs are currently undergoing further 
biological testing with collaborators to validate the previously observed activity and establish activity 
of the new series. 
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4.3.12. Photoswitchable PROTACs targeting the estrogen receptor (ER) 
Next, an additional protein of interest was chosen to validate the proof-of-concept photoswitchable 
linker technology and prove its generalisability. For this purpose, the estrogen receptor (ER) was 
chosen due to its importance in breast cancer and precedence in PROTAC literature.  
A recent publication by Hu et al. reported a potent new ER degrading PROTAC, ERD-308 with a DC50 of 
0.17 and 0.43 nM in two different ER+ cell-lines (figure 125).317 Impressively, this PROTAC induced 
>95% degradation at just 5 nM and was found to be a more complete degrader than successful SERD 
fulvestrant (section 1.3.1). This optimised PROTAC incorporated selective estrogen receptor 
modulator (SERM) raloxifene to bind ER, and computational modelling was used to determine a 
suitable solvent exposed vector for the PROTAC linkage. Raloxifene is a clinically approved treatment 
for osteoporosis, which is also used to lower the risk of breast cancer.318 Extensive optimisation of all 
three PROTAC components was carried out by the researchers to afford the most potent degrader. 
Alternative ER binders were also screened in addition to raloxifene, including tamoxifen and 
bazedoxifene and although all PROTACs were effective, the raloxifene binding motif was reported to 
be the most potent. Both VHL and cereblon recruiting PROTACs were also synthesised in the study, 
however only VHL was shown to degrade ER effectively. The cereblon recruiting PROTACs exhibited 
no degradation at concentrations up to 1 µM. The linker was also studied extensively, with different 
lengths, hydrophilicities and flexibilities considered. Overall, more flexible linkers were most effective 
with 6-9 atom linker lengths providing optimum degradation. However, the less flexible linkers also 
degraded ER, albeit at 10 nM concentrations compared to 1 nM for the flexible variants. 
 
Figure 125: Structure of PROTAC ERD-308 discovered to eradicate ER at 1 nM dosing in two ER+ cell lines 
Based on these findings, it was hypothesised that the ER protein system would be amenable to the 
photoswitching linker technology, due to the high potencies and extensive range of PROTAC structures 
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that were demonstrated to induce extensive ER degradation. Specifically, the raloxifene warhead was 
incorporated for ER binding, combined with the previously used VHL ligand (figure 126).  
 
Figure 126: Design of ER degrading photoswitchable PROTAC recruiting VHL 
Synthesis of ER warhead 219 was carried out according to the literature preparation in six steps 
(scheme 79).317 Phenol 213 was first acylated to form 214 in almost quantitative yield. The acyl 
chloride was then generated in situ using oxalyl chloride, before directly undergoing a Friedel Crafts 
acylation with commercially available benzothiophene 215 to form 216 in 35% yield over two steps.  
 
Scheme 79: Synthesis of raloxifene-based SERM 219 
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Next, the acyl-phenol 216 was deprotected with sodium acetate in high yield and the free phenol 217 
was alkylated with 1,2-dibromoethane before being directly treated with ethylamine to form 218 in 
35% yield over the two steps. This step was hypothesised to be low yielding due to the high potential 
side reactivity in both steps. Finally, the methyl groups were cleaved with boron tribromide to 
generate desired ER degrader 219 in good yield. Although the yields in this route were highly variable, 
enough ER degrader was attained for PROTAC generation, hence no reaction optimisation was 
undertaken. 
With this SERM in hand, it could be combined with the previously generated PROTAC core to form 
photoswitchable ER-targeting azoPROTAC4 (scheme 80). This was conjugated through the previously 
used protocol of in situ hydrolysis of ester 195 and subsequent amide coupling with SERM 219 forming 
desired azoPROTAC4 in 35% yield. 
 
Scheme 80: Synthesis of photoswitchable ER degrading azoPROTAC4 
Next, photophysical characterisation of azoPROTAC4 was carried out. Initially, UV-vis spectroscopy 
was considered for observing the switching. Unfortunately, due to the strongly absorbing 
chromophore present in the core structure of raloxifene this was extremely difficult to observe. The 
UV-vis spectrum of SERM 219 alone showed high absorption between 250 - 325 nm, saturating the 
detector and an additional absorption shoulder from 325 - 425 nm (figure 127). This absorption 
complicates analysis of the full PROTAC spectra, as without clear observation of the n-π* azobenzene 
absorption, switching efficiency cannot be easily assessed by UV-vis spectroscopy.  
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Figure 127: UV-vis spectrum of SERM 219 
1H NMR was therefore used to determine the PSS composition at the two wavelengths (figure 80). 
Irradiation of azoPROTAC4 with 415 nm LEDs took 20 minutes to reach PSS, which was comprised of 
92% trans isomer. This time was twice as long as previously observed for the AR PROTAC series, likely 
due to light absorption by raloxifene, lowering the intensity of radiation available to the azobenzene. 
Subsequent irradiation with 530 nm light required 40 minutes to reach PSS, also slightly longer than 
previously observed. The PSS reached after 530 nm radiation contained 81% of the cis isomer. The 
composition of both PSS was very similar to those attained previously for the AR PROTACs, validating 
the hypothesis that this photoswitching technology could be applicable to a range of protein targets. 
 
Scheme 81: 1HNMR used to determine PSS of ER targeting azoPROTAC4 following irradiation with 415 nm (red trace) and 
530 nm (blue trace) light 
Biological evaluation of this PROTAC is currently under investigation with collaborators at AZ. 
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4.3.13. Photoswitchable PROTACs recruiting E3 ligase cereblon 
An additional important avenue to explore to increase the versatility of the photoswitchable PROTAC 
technology, was alternative E3 ligases which could be hijacked for protein degradation. VHL has been 
extensively validated in the literature as an effective mediator of protein degradation, however 
cereblon-recruiting PROTACs have also exhibited great success.25,319,320 To maximise the possibility of 
identifying a successful light-induced degrader, it was proposed that both E3 ligases would be 
investigated. An additional benefit of using cereblon binders over VHL binders is the lower molecular 
weight and higher lipophilicity of the core thalidomide scaffold, which may lead to more permeable 
and ‘drug-like’ PROTACs. 
A small toolbox of cereblon binding motifs was proposed to increase the efficiency of PROTAC 
formation and to enable rapid incorporation into both the AR and ER degrading PROTACs (figure 128). 
These cereblon binders all incorporated a small linking unit connected to a reactive amine handle to 
allow facile amide coupling to the azobenzene cores. The linkers were different lengths and rigidities 
to enable access to a variety of 3D structures, which are important for optimal protein ternary complex 
formation. The binder-linker pomalidomide conjugates could all be accessed from fluoro-thalidomide 
223 through SNAr reaction with the linker amine nucleophiles. 
 
Figure 128: Design of cereblon binding motifs with functional synthetic handles 
Synthesis of the cereblon binding ligand was simple (scheme 82). Commercially available 3-
fluorophthalic acid 224 was refluxed in acetic anhydride to form anhydride 225, which was treated 
with commercially available 226 to construct the thalidomide core of 223 in almost quantitative yield. 
 
Scheme 82: Synthesis of fluoro-thalidomide 223 in high yield over two steps 
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From this fluoro-thalidomide common intermediate, SNAr chemistry was used to displace the fluoride 
and form the desired pomalidomide scaffold. These reactions with the N-Boc diamine linkers gave the 
N-Boc products 227, 228, and 229 in high yields (scheme 83). Unfortunately, these yellow solids 
suffered from very poor solubility in all solvents except DMSO and DMF, making them challenging to 
work with due to the high volumes of solvent required for extractions and purifications. 
 
Scheme 83: Synthesis of N-Boc protected pomalidomide-linkers through SNAr   
It was thought that deprotecting the N-Boc amines could drastically improve the solubility of these 
compounds to make them easier to handle. With this in mind, the ethylene-linked amine 227 was 
deprotected with TFA yielding amine 220 in quantitative yield (scheme 84). 
 
Scheme 84: N-Boc deprotection of ethylene linked cereblon binder 220 
Unfortunately, the remaining N-Boc protected amines were considerably more challenging to 
deprotect. Following treatment of piperazine derivative 229 with TFA, a complex mixture of products 
was formed, none of which resembled amine product 222 by LCMS or 1H NMR (scheme 85A). 
Deprotection of amino-azetidine derivative 228 also resulted in no observed amine product 221, 
despite additional deprotection attempts trialling 4 M HCl in addition to TFA (scheme 85B). Although 
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these deprotections were reported in patent literature, unfortunately they were unsuccessful in 
yielding the respective amines.  
 
Scheme 85: Attempts at acid-mediated N-Boc deprotection of pomalidomide units, A: piperazine derivative 229; B: amino-
azetidine derivative 228 
Incorporation of the cereblon recruiting moiety 220 into a photoswitchable PROTAC is currently 
ongoing (figure 129). The proposed synthetic route for this new azoPROTAC would involve attaching 
the cereblon binder to the azobenzene core via HATU-mediated amide coupling, followed by ester 
hydrolysis and final amide coupling to attach the enzalutamide binder. 
 
Figure 129: Proposed structure of azoPROTAC5 synthesised through amide coupling reactions 
 
  
159 
 
4.4. Chapter 4: Conclusions 
Overall, a series of photoswitchable PROTACs were designed and synthesised, primarily recruiting VHL 
for the degradation of AR. This approach was expected to greatly improve a PROTAC’s selectivity by 
existing as two isomers with differential biological activity which can be interconverted using light. 
This means that the inactive PROTAC could be dosed and the active conformation generated at the 
site of action using visible light to reduce toxicity and widen the therapeutic index. 
The photoswitchable PROTACs incorporated ortho-fluorosubstituted azobenzenes, which were found 
to switch using visible wavelengths of light with high efficiency. These PROTACs switched from the cis 
conformation to the trans with 415 nm light and were highly stable at physiological temperatures. In 
initial AR degradation assays of azoPROTAC1, some AR degradation was observed. Further 
optimisation of the linkage type and length between the protein binding motifs and the core 
azobenzene was hypothesised to improve potency and cellular stability. 
Additionally, the generality of this technology was investigated through targeting an alternative 
protein of interest for degradation. In this case, potent ER binder raloxifene was incorporated, aiming 
to degrade ER, a key target for breast cancer treatment. This PROTAC is currently under biological 
investigation with collaborators at AZ. In addition, initial efforts were made to incorporate the 
cereblon binding warhead thalidomide instead of the commonly used VHL binder. Synthesis of this 
PROTAC is currently on-going. 
The recent publication of additional photoswitchable PROTACs (section 4.2) targeting bromodomains 
with VHL and cereblon has reduced the impact of this research. However, the photoswitch strategy 
has been validated as a method to achieve light-enabled protein degradation. Despite their 
therapeutic potential, currently no photoswitchable PROTACs targeting either AR or ER have been 
reported. Therefore, applying this photoswitch technology to AR and ER degradation would be a useful 
advance. 
  
160 
 
4.5. Chapter 4: Future work 
Further biological evaluation of this series of photoswitchable PROTACs is required to validate their 
potency and importantly, the differential activity between the two isomers. Currently, fundamental 
issues with assay reproducibility have limited the investigation of this PROTAC series, hence assay 
optimisation is required. In addition, important controls are necessary to validate the proteasomal 
mediated degradation. Competition experiments with the VHL binder would validate that the 
mechanism is via recruitment of E3 ligase VHL. Additionally, dosing a proteasomal inhibitor will further 
validate that AR degradation is through the UPS. 
In addition, further photoswitch optimisation is required. It was hypothesised that one method of 
enhancing the differential biological activity of the two isomers would be through modification of the 
enzalutamide coupling strategy to a direct C-C conjugation (figure 130). This would further increase 
rigidity, which theoretically would lead to greater conformational differences between the cis and 
trans isomers, in addition to forming a highly stable C-C bond. To achieve this conjugation strategy, it 
was envisioned that a palladium-catalysed cross coupling reaction could combine an aryl-bromide or 
boronic ester enzalutamide derivative with the aryl bromide azobenzene core. This bi-phenyl 
enzalutamide motif has been reported in literature hence it is postulated that AR binding would not 
be affected by this attachment.74  
 
Figure 130: Palladium-catalysed cross coupling strategy to directly conjugate AR binder to photoswitchable linker 
The application of photopharmacology to a wider range of diseases is intrinsically limited by the 
wavelengths of light required to induce a biological effect. Currently, most wavelengths used have 
very poor tissue penetration, which means that light is unable to reach vital organs without invasive 
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procedures. Shifting to red or near IR wavelengths would greatly improve tissue penetration, however 
this is challenging due to its low energy, which is generally unable to induce these chemical changes. 
One way to shift photoswitching wavelengths further into the bio-optical window is through two-
photon photoswitching. Azobenzene photoswitches can undergo two-photon absorption, however 
typically the cross-section and absorption intensity are poor. To improve these intrinsic characteristics, 
the push-pull character of the core must be optimised.321,322 However, it is challenging to achieve high 
photostability and complete absorption using these approaches. An alternative method used to 
enhance near-IR absorption properties is the incorporation of a light-harvesting antenna into the 
photoswitch. This antenna then absorbs near-IR photons and switching occurs via resonant electronic 
energy transfer to the azobenzene core. This approach was applied to a light-gated glutamate receptor 
ion channel with photoswitch MAGA2p (figure 131).323,324 This photoswitch was found to control the 
opening of the ion channel in response to near-IR light. The light sources required for these processes 
are typically specialised and high energy due to this slow and inefficient process, which limits their 
usage. In addition, incorporation of an antenna may hinder the biological activity of the photoswitch 
due to its large size and high lipophilicity, which promotes non-specific binding. These techniques 
could be applied to the photoswitchable PROTACs to enable their switching through two-photon 
absorption. Extensive core optimisation would be required, which may affect the biological activity. 
Attachment of an antenna would promote this process without requiring extensive optimisation, 
however it also may hinder ternary complex formation and prevent efficient protein degradation. One 
possibility of bypassing this problem would be to incorporate a protein binding ligand with good 
absorption properties, which may act as an antenna in addition to protein binding. However, assessing 
the absorption properties of common drug structures is not trivial and requires bespoke set-ups and 
high energy light sources. 
 
Figure 131: Structure of two-photon photoswitch targeting the glutamate receptor ion channel323  
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Alternatively, novel photoswitching scaffolds are in continuous development, many of which use 
alternative frameworks to lower the energy of the light required for switching. A recently published 
example of a substituted azobenzene that undergoes substantially red-shifted switching is DOM-azo 
(figure 132).325 Wavelengths in the near-IR range (~ 720 nm) were demonstrated to switch this core, 
however, constant light pulsing was required to maintain the switch due to the poor thermal half-life 
in the order of seconds. Interestingly, this low stability could be desirable for long-term clinical 
applications as inactivation of the drug outside of the site of action is vital for reducing off-target 
toxicity. 
 
Figure 132: Novel substituted azobenzene with near-IR absorption325 
The hemiindigo photoswitches described in section 4.3.1. would also be a useful alternative to the 
azobenzene series, however conditions to promote the challenging N-alkylation must be identified. 
Incorporating these photoswitches into PROTACs would also require extensive optimisation of the 
conjugation methods and linker lengths, however the benefit of the more clinically relevant bio-optical 
window would be substantial. 
A final approach to achieve red-shifted switching wavelengths is through up-conversion methods. This 
method has gained considerable traction over the past decade for a multitude of purposes, including 
therapeutics, imaging and photovoltaic applications.326 Up-conversion is a nonlinear optical process 
where multiple low energy photons are absorbed and converted into a single higher energy photon 
which is emitted. This can be used to produce the high energy photons required to induce switching 
within a cellular environment, bypassing the penetration limitations of high energy light. For this 
process to occur, a sensitizer is needed to absorb the low energy photon and transfer this energy to 
an annihilator. This annihilator combines with another annihilator to yield a higher energy excited 
state annihilator, which can emit a high energy photon.326 
Upconversion nanoparticles are commonly used for this purpose through doping of lanthanide ions, 
which can be varied in composition and size to achieve the required absorption and emission 
characteristics.327 These types of nanoparticles have previously been applied to the two-way 
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photoswitching of azobenzene,328 dithienylethene329 and spiropyran330 switches. In addition, toxicity 
studies have shown no obvious toxicity both in vitro and in vivo.331 Despite many advancements in this 
field, the brightness and emission efficiencies of these nanoparticles must be improved for better 
clinical applications.327 Once again, limitations of these materials also include the requirement of 
expensive custom light sources, poorly explored pharmacokinetic properties and the potential for 
water heating at particularly high wavelengths, which may be damaging to cells.332 
Small molecule sensitizers and annihilators may also be used to achieve tuneable emission from low 
energy photons.326 However, these approaches commonly require biologically incompatible 
conditions such as non-polar solvents and oxygen free conditions, limiting their use. Recent advances 
have been made to overcome these limitations through encapsulation of the sensitizer and annihilator 
in micelles.333 
Upconversion methods may be combined with photoswitchable PROTACs to achieve red-shifted 
switching. Importantly, the wavelengths of the absorption and emission must be carefully chosen to 
optimise photoconversion.  
Overall, there are many methods which could be used to improve the long-term applications of 
photoswitchable PROTACs, primarily by optimising the light wavelengths required and penetration 
levels, ultimately leading to more clinically viable photopharmacology applications. 
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5. Experimental details 
5.1. General experimental procedures 
 
All reagents were obtained from commercial sources with no further purification. Solvents were 
freshly distilled unless specified. THF was dried over sodium wire and distilled from calcium hydride 
and lithium aluminium hydride with indicator triphenylmethane. Diethyl ether was distilled from 
calcium hydride and lithium aluminium hydride. Acetonitrile, dichloromethane, hexane, MeOH, and 
toluene were all distilled from calcium hydride. Petroleum ether (PE 40–60) refers to the petroleum 
fraction with boiling point of 40–60 °C. Reactions were under a dry nitrogen atmosphere unless stated. 
Yields refer to chromatographically and spectroscopically pure compounds. Flash column 
chromatography was carried out on silica gel (Merck Kieselgel 60 F254, 230-400 mesh) with distilled 
solvents under a positive pressure of nitrogen. Thin layer chromatography used silica-coated glass 
plates (Merck Kieselgel 60, F254), the plates were observed using potassium permanganate dip, or UV 
fluorescence (254 nm). 
Melting points were measured using a Buchi B-545 melting point apparatus and are uncorrected. The 
term “did not melt” refers to gradual decomposition over temperature ramp up to 300 °C. 
Infrared (IR) spectroscopy was recorded neat on a Perkin Elmer Spectrum One FT-IR Spectrometer 
fitted with an attenuated total reflectance (ATR) sampling accessory; maximum absorptions are 
quoted to the nearest 1 cm-1, and classified using the following abbreviations: w, weak; m, medium; 
s, strong; br, broad; and combinations thereof. 
Proton (1H), carbon (13C), and fluorine (19F) nuclear magnetic resonance (NMR) spectra were recorded 
using Bruker Ultrashield 400 or 500 spectrometers. Assignments were supported by COSY, DEPT-135, 
HSQC, and HMBC spectra. Proton chemical shifts (δ) were measured in parts per million (ppm) relative 
to tetramethylsilane (δ =0 ppm), referenced to the appropriate solvent peak, and are quoted to the 
nearest 0.01 ppm, with coupling constants (J) reported to the nearest 0.1 Hz. Carbon chemical shifts 
(δ) were also measured in parts per million (ppm) relative to tetramethylsilane (δ =0), referenced to 
the appropriate solvent peak, and are quoted to the nearest 0.1 ppm with coupling constants quoted 
to 3 significant figures. Multiplicity is indicated using the following abbreviations: br, broad; s, singlet; 
d, doublet; t, triplet; q, quartet; quin, quintet; m, multiplet; and combinations thereof. The term ‘CQ’ 
refers to a quaternary carbon. 
High resolution mass spectrometry (HRMS) was carried out using a Waters LCT Premier Time of Flight 
mass spectrometer, Micromass Quadrupole Time of Flight mass spectrometer or Waters Vion IMS 
Qtof mass spectrometer.  
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LCMS chromatographs were recorded on an Agilent 1200 series LC with an ESCi Multi-Mode ionisation 
Waters ZQ spectrometer. The following conditions were used: solvent A: 10 mM ammonium acetate 
+ 0.1% formic acid in water; solvent B: 95% acetonitrile + 5% H2O + 0.05% formic acid; linear gradient: 
0.0-0.7 mins: 0% B, 0.7-4.2 mins: 0-100% B, 4.2-7.7 mins: 100% B, 7.7-8.5 mins: 100-0% B; using a 
Supelcosil ABZ+PLUS column (33 mm × 4.6 mm,3 µm). 
High-performance liquid chromatography (HPLC) analytical chromatographs were recorded on an 
Agilent 1260 Infinity using a Supelcosil ABZ+PLUS column (150 mm x 4.6 mm, 3 µm) eluting with a 
linear gradient system (solvent A: 0.05% (v/v) TFA in water, solvent B: 0.05% (v/v) TFA in acetonitrile) 
over 15 min at a flow rate of 1 mL/min. UV absorbance at 220 and 254 nm was recorded. 
Semi-preparative HPLC was carried out on an Agilent 1260 Infinity using a Supelcosil ABZ+PLUS column 
(250 mm x 21.2 mm, 5 µm) eluting with a linear gradient system (solvent A: 0.1% (v/v) TFA in water, 
solvent B: 0.05% (v/v) TFA in acetonitrile) over 20 min at a flow rate of 20 mL/min.  
UV-vis spectroscopy was carried out using a Perkin-Elmer Lambda 950 spectrophotometer, using a 
quartz cuvette with path length of 1 mm.  
Initial photoswitching studies of azoPROTAC1 were carried out using a 405 nm and 520 nm 
wavelength continuous wave lasers. All subsequent photoswitching was carried out using mounted 
LEDs at 415 nm and 530 nm wavelengths purchased from Thorlabs. 
 
5.2. General Synthetic procedures 
 
Manual Fmoc SPPS 
Peptide sequence P1 was prepared through SPPS on Wang resin (0.37 mmol/g) and N-terminal capped 
with acetic anhydride. The couplings were carried out using Fmoc-protected amino acids (4 eq) pre-
activated with HATU (4 eq), and N,N-diisopropylethylamine (8 eq) in DMF for 10 min, and coupled for 
1 h. The coupling of unnatural ornithine residue involved shaking for an additional 1 h to ensure 
complete coupling. The side-chain protecting groups used were: t-Bu for glutamic acid, serine, and 
threonine; Boc for tryptophan; and Trt for glutamine. 
The coupling progression was monitored by acetaldehyde/chloranil test. A small amount of resin 
swelled in dichloromethane was taken and acetaldehyde (200 μL) was added followed by a saturated 
solution of chloranil in toluene (50 μL). After shaking at r.t. for ca. 5 mins no resin colour change 
signified complete coupling, whereas green colouration indicated incomplete coupling. 
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Fmoc deprotections were performed by shaking for ca. 10 mins with a solution of 20% piperidine in 
DMF. N-terminal capping was achieved by adding acetic anhydride (5 eq), and 
N,N-diisopropylethylamine (10 eq) to the resin in DMF and shaking for 3 h.  
Peptide cleavage from the resin and side-chain deprotection were carried out by treatment with 
TFA/H2O/dichloromethane/TIPS 92.5:2.5:2.5:2.5 over 3 h. Solvent was then removed under a stream 
of nitrogen, and the resulting residue triturated with diethyl ether (4 x 5 mL) and purified by semi-
preparative HPLC. 
 
Automated SPPS: 
Peptide sequence P2 was prepared through automated SPPS on Wang resin (0.37 mmol/g) using a 
CEM Liberty Automated Microwave Peptide Synthesiser. Peptide couplings used Fmoc-protected 
amino acids (5 eq) dissolved in DMF, HATU (5 eq) in DMF, and N,N-diisopropylethylamine (10 eq) in 
NMP. Amino acids were coupled with 25 W power at 75 °C for 15 min. Fmoc deprotection was carried 
out with 20% piperidine in DMF over 3 mins, using 45 W power at 75 °C.  
The final deprotection, N-terminal acetyl capping and resin cleavage were all performed manually as 
previously stated. 
 
General copper-catalysed double-click stapling: 
Copper(II) sulfate pentahydrate (1 eq) and tris(3-hydroxypropyltriazolylmethyl)amine (1 eq) were 
dissolved in degassed water and stirred for 10 mins before sodium ascorbate (3 eq) was added. The 
solution was then added to the diazido-peptide (1 eq; 1 mL/mg) and dialkynyl linker (1.1 eq) which 
were dissolved in degassed t-butanol/water (1:1) at rt under nitrogen. The reaction mixture was 
stirred for 1 h, monitored by LC-MS analysis of the reaction mixture, and upon completion, dried under 
a stream of nitrogen. Purification by semi-preparative HPLC gave PROTACs 1-6. 
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5.3. Synthetic Characterisation 
5.3.1. Peptide analysis 
 
Peptide Mass m/z found m/z calculated Species 
P1 1577.8 1579.1 1578.7 [M+H]+ 
P2 1450.7 1451.3 1451.7 [M+H]+ 
PROTAC-1 2444.6 1223.6 1223.3 [M+2H]2+ 
PROTAC-2 2315.6 1159.5 1158.8 [M+2H]2+ 
PROTAC-3 2312.4 1157.5 1157.2 [M+2H]2+ 
PROTAC-4 2280.0 2281.3 2281.0 [M+H]+ 
PROTAC-5 2393.0 2394.7 2394.1 [M+H]+ 
PROTAC-6 2247.7 1125.3 1124.9 [M+2H]2+ 
 
 
5.3.2. Synthetic protocols 
 
4-Isothiocyanato-2-(trifluoromethyl)benzonitrile (5) 
 
To a stirring solution of 4-amino-2-(trifluoromethyl)benzonitrile (0.60 g, 3.2 mmol) in DCM (12 mL) 
was added thiocarbonyldiimidazole (0.86 g, 4.8 mmol). After stirring for 7 h at r.t., H2O (15 mL) was 
added, and the product extracted into dichloromethane (3 x 15 mL). The organic phase was washed 
with brine (15 mL), dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified 
through silica gel column chromatography (9:1, PE 40-60:EtOAc) to give the title compound as a white 
amorphous solid (0.546 g, 74%). 
Rf: 0.18 (9:1, PE 40-60:EtOAc); IR (neat film, νmax, cm-1): 2075 (s, C≡N), 2039 (s br, NCS), 1608 (s), 1567 
(w, C=C), 1496 (w, C=C), 1430 (m, C=C), 1321 (s), 1179 (s), 1140 (s), 1051 (m), 970 (w), 895 (m), 840 
(m), 677 (w); 1H NMR (400 MHz, CDCl3) δ: 7.84 (d, J = 8.3 Hz, 1H, Ha), 7.59 (d, J = 1.8 Hz, 1H, Hc), 7.48 
(dd, J = 8.3, 1.8 Hz, 1H, Hb); 13C NMR (101 MHz, CDCl3) δ: 142.1 (-NCS), 136.9 (-C-CN), 136.2 (Ca), 134.8 
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(q, J = 34 Hz, -C-CF3), 129.0 (Cb), 124.1 (q, J = 4.7 Hz, Cc), 121.6 (q, J = 280 Hz, -CF3), 114.7 (-C≡N), 107.9 
(q, J = 2 Hz, -C-NCS); 19F NMR (376 MHz, CDCl3) δ: -63.3 (CF3). 
Data are in accordance with those reported previously in literature.334  
 
4-((2-carboxypropan-2-yl)amino)-2-fluorobenzoic acid (11) 
 
To a stirring solution of 4-bromo-2-fluorobenzoic acid (2.00 g, 9.1 mmol) in DMF (20 mL) were added 
2-aminoisobutyric acid (1.13 g, 11.0 mmol), copper (I) iodide (0.26 g, 1.37 mmol), potassium carbonate 
(5.03 g, 36.4 mmol), 2-acetylcycohexanone (0.24 mL, 1.82 mmol), and water (6 mL). The mixture was 
heated to 90 °C for 24 h before concentrating in vacuo and washing with EtOAc (2 x 20 mL). The 
aqueous was acidified with citric acid to pH 3, before being extracted into EtOAc (3 x 20 mL), washed 
with brine (15 mL), dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified 
through silica gel column chromatography (1:1 PE 40-60:EtOAc to EtOAc) to give the title compound 
as a white amorphous solid (1.02 g, 46%). 
Rf: 0.17 (EtOAc); IR (neat film, νmax, cm-1): 3440 (w, N-H), 3000 (w br, O-H), 1701 (m, C=O), 1670 (s, 
C=O), 1615 (s), 1582 (m, C=C), 1527 (m, C=C), 1415 (m, C=C), 1363 (m), 1311 (s), 1270 (s), 1252 (s), 
1169 (s), 1098 (m), 925 (m), 827 (s), 770 (m), 761 (m), 685 (w); 1H NMR (400 MHz, DMSO-d6) δ: 12.51 
(br s, 2H, 2 x COOH), 7.59 (t, J = 8.8 Hz, 1H, Hc), 6.94 (br s, 1H, N-H), 6.33 (dd, J = 2.1, 8.8 Hz, 1H, Hb), 
6.15 (d, J = 2.1, 14.5 Hz, 1H, Ha), 1.45 (s, 6H, 2 x CH3); 13C NMR (101 MHz, DMSO-d6) δ: 176.8 (βC=O), 
165.4 (d, J = 3.5 Hz, αC=O), 163.5 (d, J = 250 Hz, C-F), 152.8 (d, J = 12 Hz, -C-COOH), 134.4 (d, J = 3.1 
Hz, Cc), 109.5 (Cb), 105.4 (d, J = 9.5 Hz, Ar-C-NH), 99.7 (d, J = 27 Hz, Ca), 56.7 (C-(CH3)3), 26.0 (2 x CH3); 
19F NMR (376 MHz, CDCl3) δ: -108.3 (C-F);  HRMS: m/z [M+H]+ calculated for C11H13FNO4: 242.0823; 
Found: 242.0819. 
 
Methyl-2-fluoro-4-((1-methoxy-2-methyl-1-oxopropan-2-yl)amino)benzoate (4) 
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To a stirring solution of 11 (0.15 g, 0.62 mmol) in MeOH (2 mL) was added thionyl chloride (0.11 mL, 
1.6 mmol). The solution was heated to reflux and stirred for 16 h, before being concentrated in vacuo. 
The residue was dissolved in water (5 mL) and EtOAc (5 mL) before sodium hydrogen carbonate 
(0.08 g) was added, and the organic layer separated, and concentrated in vacuo. The residue was 
purified through silica gel column chromatography (9:1 to 3:2 PE 40-60:EtOAc) to give the title 
compound as a white amorphous solid (0.11 g, 67%).       
Rf: 0.52 (3:2 PE 40-60:EtOAc); IR (neat film, νmax, cm-1): 3381 (w, N-H), 2993 (w), 2952 (w), 1703 (m br, 
overlapped C=O), 1617 (s), 1523 (m, C=C), 1434 (m), 1273 (s), 1190 (m), 1140 (s), 1091 (m), 967 (w), 
835 (w), 769 (m), 692 (w); 1H NMR (400 MHz, CDCl3) δ:  7.72 (t, J = 8.6 Hz, 1H, Hc), 6.27 (dd, J = 8.8, 
2.4 Hz, 1H, Hb), 6.16 (dd, J = 13.7, 2.3 Hz, 1H, Ha), 4.72 (br s, 1H, -NH), 3.84 (s, 3H, αCOO-CH3), 3.72 (s, 
3H, βCOO-CH3), 1.58 (s, 6H, 2 x -CH3); 13C NMR (101 MHz, CDCl3) δ: 175.5 (βC=O), 165.0 (d, J = 1.4 Hz, 
αC=O), 163.7 (d, J = 260 Hz, C-F), 151.2 (d, J = 12 Hz, -C-αC), 133.4 (d, J = 2.9 Hz, Cc), 109.6 (d, J = 2.2 
Hz, Cb), 106.9 (d, J = 10 Hz, Ar-C-NH-), 100.7 (d, J = 27 Hz, Ca), 57.3 (-C-(CH3)3), 52.8 (βCOO-CH3), 51.7 
(αCOO-CH3), 25.9 (2 x CH3); 19F NMR (376 MHz, CDCl3) δ: -109.4 (C-F); HRMS: m/z [M+H]+ calculated 
for C13H17FNO4: 270.1136; Found: 270.1141. 
 
4-Amino-2-fluorobenzamide (13) 
 
To a stirring solution of 4-bromo-2-fluorobenzoic acid (1.50 g, 6.7 mmol) in dichloromethane (25 mL) 
cooled to 0 °C was added oxalyl chloride (2.3 mL, 26.8 mmol). DMF (2 mL) was carefully added, and 
the mixture was stirred at r.t. for 3 h. The mixture was then concentrated in vacuo, dissolved in THF 
(25 mL), and cooled to 0 °C, before ammonia (2.3 mL, aq.) was slowly added. After stirring for 30 mins, 
the mixture was concentrated in vacuo, and azeotropic distillation with toluene gave the title 
compound as a white amorphous solid (1.03 g, 70%). 
Rf: 0.68 (EtOAc); IR (neat film, νmax, cm-1): 3347 (m, N-H), 3176 (m, N-H), 1653 (s, C=O), 1625 (s, C=C), 
1599 (s, C=C), 1565 (m, C=C), 1485 (m, C=C), 1390 (s), 1383 (s), 1213 (s), 1065 (m), 879 (s), 860 (s), 832 
(m), 763 (m), 677 (w); 1H NMR (400 MHz, CDCl3) δ:  8.04 (t, J = 8.5 Hz, 1H, Hb), 7.45 (dd, J = 8.5, 1.7 Hz, 
1H, Hc), 7.37 (dd, J = 11.2, 1.7 Hz, 1H, Ha), 6.64 (br s, 1H, amide NH), 6.28 (br s, 1H, amide NH); 13C 
NMR (101 MHz, CDCl3) δ: 164.0 (d, J = 2.9 Hz, C=O), 160.5 (d, J = 250 Hz, C-F), 133.5 (d, J = 2.6 Hz, Cb), 
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128.4 (d, J = 3.3 Hz, Cc), 127.2 (d, J = 10 Hz, -C-NH2), 119.7 (d, J = 28 Hz, Ca), 119.2 (d, J = 12 Hz, -C-
CON-); 19F NMR (376 MHz, CDCl3) δ: -111.5 (C-F). 
Data are in accordance with those reported previously in literature.153 
 
Methyl-2-((4-carbamoyl-3-fluorophenyl)amino)-2-methylpropanoate (15) 
 
To a stirring solution of 13 (50 mg, 0.23 mmol) in DMF (1 mL) were added 2-aminoisobutyric acid 
(28 mg, 0.28 mmol), copper (I) iodide (7 mg, 0.04 mmol), potassium carbonate (0.127 g, 0.92 mmol), 
2-acetylcycohexanone (6 µL, 0.05 mmol), and water (150 µL). The mixture was heated to 90 °C for 
24 h, before concentrating in vacuo and washing with EtOAc (2 x 3 mL). The aqueous was acidified 
with citric acid to pH 3, before being extracted into EtOAc (3 x 3 mL), washed with brine (1 x 3 mL), 
dried over MgSO4, filtered, and concentrated in vacuo. This residue was directly methylated by 
dissolving in DMF (1 mL) before the addition of potassium carbonate (48 mg, 0.35 mmol), and 
iodomethane (22 µL, 0.35 mmol). The solution was stirred at 45 °C for 2 h before an additional portion 
of iodomethane was added (22 µL, 0.35 mmol). The solution was stirred for a further 6 h, before being 
concentrated in vacuo. The residue was purified through silica gel column chromatography (1:1 to 4:1 
EtOAc:PE 40-60) to give the title compound as a colourless oil (49 mg, 84% over two steps).      
Rf: 0.33 (4:1 EtOAc:PE 40-60); IR (neat film, νmax, cm-1): 3507 (w, NH), 3332 (w, NH), 2291 (w), 1729 (m, 
C=O), 1649 (m, C=O), 1621 (s), 1597 (s, C=C), 1527 (m, C=C), 1431 (m, C=C), 1381 (m), 1219 (m), 1146 
(s), 1094 (m), 833 (w), 771 (w); 1H NMR (400 MHz, CDCl3) δ:  7.88 (t, J = 8.8 Hz, 1H, Hc), 6.50 (br s, 1H, 
NH), 6.36 (dd, J = 8.8, 2.3 Hz, 1H, Hb), 6.16 (dd, J = 2.3, 15.0 Hz, 1H, Ha), 5.78 (br s, 1H, NH), 4.72 (br s, 
1H, NH), 3.72 (s, 3H, -O-CH3), 1.59 (s, 6H, 2 x CH3); 13C NMR (101 MHz, CDCl3) δ: 175.6 (-βC=O), 165.2 
(d, J = 3.4 Hz, αC=O) 162.4 (d, J = 250 Hz, C-F), 150.7 (d, J = 13 Hz, -C-αCO), 133.2 (d, J = 4.0 Hz, Cc), 
110.6 (Cb), 108.7 (d, J = 12 Hz, Ar-C-N-), 99.7 (d, J = 30 Hz, Ca), 57.3 (-C-(CH3)2), 52.8 (O-CH3), 25.9 (2 x 
CH3); 19F NMR (376 MHz, CDCl3) δ: -111.8 (C-F). 
Data are in accordance with those reported previously in literature.153 
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4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-
fluorobenzamide (16) 
 
To a stirring solution of 15 (0.076 g, 0.3 mmol) in DMF (0.5 mL) was added 5 (0.13 g, 0.6 mmol). The 
mixture was stirred at 90 °C for 4 h before being cooled, diluted with H2O (5 mL) and extracted into 
EtOAc (3 x 5 mL). The combined organic was washed with brine (10 mL), dried over MgSO4, filtered, 
and concentrated in vacuo. The residue was purified through silica gel column chromatography (3:7 
Acetone:Hexane) to give the title compound as a yellow oil (0.085 g, 63%). 
Rf: 0.29 (50% Acetone:Hexane); IR (neat film, νmax, cm-1): 3344 (w, NH), 2922 (w), 2851 (w), 1755 (m, 
C=O), 1672 (m, C=O), 1619 (m), 1501 (m, C=C), 1415 (s, C=C), 1309 (s), 1216 (s), 1176 (s), 1135 (s), 1056 
(m), 922 (w), 815 (m), 735 (m), 677 (w); 1H NMR (400 MHz, CDCl3) δ: 8.29 (t, J = 8.4 Hz, 1H, Hb), 7.98 
(d, J = 8.3 Hz, 1H, Hf), 7.95 (s, 1H, Hd), 7.82 (dd, J = 1.9, 8.3 Hz, 1H, He), 7.28 – 7.25 (m, 1H, Hc), 7.18 
(dd, J = 1.8, 11.6 Hz, 1H, Ha), 6.67 (br d, J = 9.7 Hz, 1H, NH), 6.30 (br s, 1H, NH), 1.62 (s, 6H, 2 x CH3); 
13C NMR (101 MHz, CDCl3) δ: 179.8 (C=S), 174.4 (βC=O), 165.3 (d, J = 2.9 Hz, αC=O), 160.7 (d, J = 250 
Hz, Ar-C-F), 139.7 (d, J = 11 Hz, ArC-CONH2), 136.8 (-C-CN), 135.3 (Cf), 133.7 (q, J = 34 Hz, C-CF3), 133.7 
(d, J = 34 Hz, Cb), 132.2 (Ce), 127.1 (q, J = 4.8 Hz, Cd), 126.2 (d, J = 3.4 Hz, Cc), 121.8 (q, J = 280 Hz, -
CF3), 121.7 (d, J = 12 Hz, -C-N-(CH3)2-), 118.1 (d, J = 27 Hz, Ca), 114.7 (-C≡N), 110.4 (q, J = 2.0 Hz, -C-
NCO-), 66.7 (-C-(CH3)3), 23.9 (2 x -CH3); 19F NMR (376 MHz, CDCl3) δ: -63.0 (CF3), -111.8 (ArC-F). 
Data are in accordance with those reported previously in literature.153 
 
4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-
fluorobenzoic acid (2) 
 
16 (50 mg, 0.11 mmol) was dissolved in conc. HCl (0.5 mL) and heated to 120 °C in a sealed tube for 
48 h. After cooling to r.t., the residue was dissolved in EtOAc (2 mL) and the organic was separated 
and concentrated in vacuo. The residue was purified through silica gel column chromatography 
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(dichloromethane to 1:19 MeOH:dichloromethane) to give the title compound as a yellow oil (40 mg, 
80%). 
Rf: 0.11 (3:47 MeOH/dichloromethane); IR (neat film, νmax, cm-1): ~3000 (w br, OH), 2925 (w), 1758 (m, 
C=O), 1718 (m, C=O), 1618 (m), 1502 (m, C=C), 1414 (s, C=C), 1311 (s), 1222 (s), 1179 (s), 1135 (s), 1054 
(m), 842 (w); 1H NMR (400 MHz, CDCl3) δ: 8.20 (t, J = 8.0 Hz, 1H, Hb), 8.00 (d, J = 8.4 Hz, 1H, Hf), 7.95 
(s, 1H, Hd), 7.82 (d, J = 8.4 Hz, 1H, He), 7.24 (d, J = 8.0 Hz, 1H, Hc), 7.19 (d, J = 11.1 Hz, 1H, Ha), 1.63 (s, 
6H, 2 x CH3); 13C NMR (101 MHz, CDCl3) δ: 179.7 (C=S), 174.4 (βC=O), 167.8 (αC=O), 162.7 (d, J = 270 
Hz, C-F), 141.3 (C-αCO), 136.8 (-C-CN), 135.4 (Cf), 133.9 (d, J = 6.2 Hz, Cb), 133.8 (q, J = 33 Hz, -C-CF3) 
132.1 (Ce), 127.1 (q, J = 4.5 Hz, Cd), 125.7 (Cc), 120.5 (-C-N-(CH3)2-), 119.1 (d, J = 24 Hz, Ca), 114.7 (-
C≡N), 110.5 (-C-NCO-), 66.7 (-C-(CH3)3), 23.9 (2 x CH3); 19F NMR (376 MHz, CDCl3) δ: -63.0 (CF3), -105.8 
(ArC-F). 
Data are in accordance with those reported previously in literature.153 
 
Ethyl-3,5-dibromobenzoate (18) 
 
To a stirring solution of 3,5-dibromobenzoic acid (3.00 g, 10.7 mmol) in ethanol (30 mL) was added 
conc. sulfuric acid (0.57 mL, 10.7 mmol). The solution was heated to reflux and stirred for 20 h. The 
mixture was cooled and ca. half the solvent was removed in vacuo before being poured into iced 
water. The precipitate was filtered and washed with ethanol (2 x 5 mL), before drying in vacuo to give 
the title compound as an orange amorphous solid (3.24 g, 98%). 
m.p.: 55 – 57 °C (ethanol, lit. 54 – 56 °C335); Rf: 0.59 (1:1 PE 40-60:EtOAc); IR (neat film, νmax, cm-1): 
3084 (w), 2983 (w), 1725 (s, C=O), 1557 (m, C=C), 1425 (m, C=C), 1414 (m, C=C), 1364 (m), 1268 (s), 
1140 (m), 1100 (m), 1020 (m), 871 (m), 762 (s), 746 (m), 658 (w); 1H NMR (400 MHz, CDCl3) δ: 8.10 (d, 
J = 1.8 Hz, 2H, Ha), 7.84 (t, J = 1.8 Hz, 1H, Hb), 4.39 (q, J = 7.1 Hz, 2H, -CH2), 1.40 (t, J = 7.1 Hz, 3H, -CH3); 
13C NMR (101 MHz, CDCl3) δ: 164.0 (C=O), 138.1 (Cb), 133.7 (C-COO), 131.3 (Ca), 123.0 (C-Br), 61.9 
(CH2), 14.2 (CH3). 
Data are in accordance with those reported previously in literature.157 
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Ethyl 3,5-bis(3-hydroxy-3-methylbut-1-yn-1-yl)benzoate (19) 
 
To a stirring solution of 18 (2.00 g, 6.5 mmol) in THF (20 mL) were added 2-methyl-3-butyn-2-ol 
(1.89 mL, 19.5 mmol) and triethylamine (3.6 mL, 26 mmol). The solution was stirred at r.t. for 30 mins 
before copper (I) iodide (0.124 g, 0.65 mmol) and bis(triphenylphosphine)palladium(II) dichloride 
(0.228 g, 0.33 mmol) were added. The mixture was heated to reflux and stirred for a further 24 h, 
before being cooled and concentrated in vacuo. The residue was purified through silica gel column 
chromatography (9:1 to 4:1, PE 40-60:EtOAc) to give the title compound as a yellow amorphous solid 
(1.85 g, 90%). 
Rf: 0.45 (1:1 PE 40-60:EtOAc); IR (neat film, νmax, cm-1): 3362 (w br, OH), 2980 (m), 1723 (m, C=O), 1705 
(m), 1593 (w, C=C), 1437 (m, C=C), 1369 (m), 1332 (s), 1242 (s), 1192 (s), 1111 (s), 1024 (m), 945 (s), 
895 (m), 858 (w), 768 (m), 734 (w), 678 (w); 1H NMR (400 MHz, CDCl3) δ: 7.98 (d, J = 1.5 Hz, 2H, Ha), 
7.61 (d, J = 1.5 Hz, 1H, Hb), 4.37 (q, J = 7.1 Hz, 2H, -O-CH2), 2.18 – 2.14 (br d, 2H, OH), 1.61 (s, 12H, 4 x 
CH3), 1.39 (t, J = 7.1 Hz, 3H, CH2-CH3); 13C NMR (101 MHz, CDCl3) δ: 165.3 (C=O), 138.4 (Cb), 132.2 (Ca), 
130.9 (-C-COO-), 123.5 (ArC-C≡C-), 95.3 (ArC-C≡C-), 80.5 (ArC-C≡C-), 65.6 (C-OH), 61.5 (-CH2-), 31.4 (4 
x -CH3), 14.3 (-CH2-CH3). 
Data are in accordance with those reported previously in literature.157 
 
3,5-Diethynylbenzoic acid (6) 
 
To a stirring solution of 19 (1.85 g, 5.9 mmol) in isopropanol (20 mL) was added potassium hydroxide 
(1.98 g, 35.3 mmol). The solution was heated to reflux and stirred for 6 h, before it was acidified to pH 
1 with HCl (3 M, aq), and extracted into EtOAc (3 x 20 mL). The organic layer was then washed with 
brine (20 mL), dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified through 
silica gel column chromatography (250:50:1 dichloromethane:EtOAc:AcOH) to give the title 
compound as a cream amorphous solid (1.00 g, 99%). 
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Rf: 0.07 (1:24 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 3287 (m), ~3000 (w br, OH), 1686 (s, 
C=O), 1626 (m), 1589 (m), 1444 (m), 1312 (m), 1241 (m), 900 (m), 828 (s), 773 (m), 723 (m), 670 (w); 
1H NMR (400 MHz, DMSO-d6) δ: 13.46 (br s, 1H, -COOH), 7.93 (d, J = 1.6 Hz, 2H, Ha), 7.79 (t, J = 1.6 Hz, 
1H, Hb), 4.38 (s, 2H, C≡C-H); 13C NMR (101 MHz, DMSO-d6) δ: 165.9 (-COOH), 138.6 (Cb), 132.9 (Ca), 
132.5 (-C-COOH), 123.3 (-C-C≡CH), 83.2 (-C≡C-H), 81.9 (-C≡C-H). 
Data are in accordance with those reported previously in literature.157 
 
17-Hydroxy-3,6,9,12,15-pentaoxaheptadecyl 4-methylbenzenesulfonate (21) 
 
To a stirring solution of hexaethylene glycol (0.50 mL, 2.0 mmol) in dichloromethane (7 mL) cooled to 
0 °C were added p-toluenesulfonyl chloride (0.42 g, 2.2 mmol), potassium iodide (0.07 g, 0.4 mmol), 
and silver (I) oxide (0.70 g, 3 mmol). After stirring at r.t. for 3 h, the mixture was filtered through silica 
and washed with EtOAc (4 x 10 mL) before concentrating in vacuo. The residue was purified through 
silica gel column chromatography (1:24 isopropanol:dichloromethane) to give the title compound as 
a colourless oil (0.77 g, 88%). 
Rf: 0.29 (1:24 isopropanol/dichloromethane); IR (neat film, νmax, cm-1): 3444 (w br, OH), 2870 (m), 1597 
(w), 1454 (w), 1351 (m), 1175 (s), 1095 (s), 1017 (m), 919 (m), 817 (m), 774 (m), 662 (m); 1H NMR (400 
MHz, CDCl3) δ: 7.79 (d, J = 8.2 Hz, 2H, Ha), 7.33 (d, J = 8.2 Hz, 2H, Hb), 4.15 (t, J = 4.1 Hz, 2H, -CH2-OTs), 
3.72 – 3.58 (m, 22H, 11 x CH2), 2.70 (s, 1H, OH), 2.44 (s, 3H, CH3); 13C NMR (101 MHz, CDCl3) δ: 144.9 
(-C-SO3-), 133.1 (C-CH3), 129.9 (Ca), 128.1 (Cb), 72.6, 70.8, 70.7, 70.7, 70.6, 70.6, 70.6, 70.4, 69.4 (-CH2-
OTs), 68.9, 61.8 (CH2-OH), 21.7 (-CH3). 
Data are in accordance with those reported previously in literature.162 
 
17-Azido-3,6,9,12,15-pentaoxaheptadecan-1-ol (22) 
 
To a stirring solution of 21 (1.86 g, 4.3 mmol) in DMF (8 mL) was added sodium azide (0.42 g, 6.4 
mmol). The solution was heated to 50 °C and stirred for 16 h, before the mixture was extracted with 
dichloromethane (6 x 10 mL), washed with brine (10 mL), dried over MgSO4, filtered, and concentrated 
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in vacuo to give the title compound as a pale-yellow oil (1.22 g, 93%), with no need for further 
purification. 
Rf: 0.17 (1:19 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 3467 (w br, OH), 2867 (m), 2097 (m, 
N3), 1451 (w), 1348 (w), 1285 (m), 1250 (m), 1097 (s), 940 (m), 847 (m); 1H NMR (400 MHz, CDCl3) δ: 
3.72 – 3.62 (m, 20H, 10 x CH2), 3.59 (t, J = 4.9 Hz, 2H, -CH2-CH2-N3), 3.37 (t, J = 4.9 Hz, 2H, CH2-N3), 2.68 
(t, J = 6.2 Hz, 1H, OH); 13C NMR (101 MHz, CDCl3) δ: 72.5, 70.7, 70.7, 70.6, 70.6, 70.5, 70.3, 70.0, 61.7 
(CH2-OH), 50.7 (-C-N3). 
Data are in accordance with those reported previously in literature.162 
 
17-Amino-3,6,9,12,15-pentaoxaheptadecan-1-ol (23) 
 
To a stirring solution of 22 (0.136 g, 0.33 mmol) in THF (5 mL) was added triphenylphosphine (0.132 g, 
0.50 mmol). The solution was stirred at r.t. for 16 h, before water (1 mL) was added to induce 
precipitation. The organic phase was removed in vacuo before the residue was washed twice with 
toluene (2 x 10 mL). The aqueous was then concentrated in vacuo to give the title compound as a 
colourless oil (0.130 g, >98%), with no need for further purification. 
Rf: 0.51 (1:9 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 3362 (w br, OH), 2863 (m), 1455 (w), 
1349 (m), 1296 (w), 1248 (w), 1094 (s), 944 (m), 884 (m), 838 (w); 1H NMR (400 MHz, CDCl3) δ: 3.74 – 
3.71 (m, 2H), 3.69 – 3.59 (m, 18H, 9 x CH2), 3.53 (t, J = 5.2 Hz, 2H), 2.87 (t, J = 5.1 Hz, 2H, CH2-N), 2.31 
(s br, 3H, OH and NH2); 13C NMR (101 MHz, CDCl3) δ: 73.3, 72.9, 70.6, 70.6 – 70.5 (overlapping region), 
70.3, 70.2, 61.5 (CH2-OH), 41.7 (-C-NH2). 
Data are in accordance with those reported previously in literature.162 
 
tert-Butyl(17-hydroxy-3,6,9,12,15-pentaoxaheptadecyl)carbamate (7) 
 
To a stirring solution of 23 (0.63 g, 2.2 mmol) in MeOH (7 mL) were added di-tert-butyl dicarbonate 
(0.56 mL, 2.5 mmol) and triethylamine (0.37 mL, 2.7 mmol). The solution was stirred at r.t. for 16 h 
before the mixture was concentrated in vacuo to give the title compound as a colourless oil (0.83 g, 
>98%), with no need for further purification. 
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Rf: 0.73 (1:9 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 3452 (w br, OH), 2900 (m), 2868 (m), 
1708 (m, C=O), 1520 (m), 1452 (w), 1365 (m), 1275 (m), 1249 (m), 1170 (m), 1098 (s), 944 (m), 864 
(w); 1H NMR (400 MHz, CDCl3) δ: 5.16 (br s, 1H, NH), 3.71 (t, J = 4.8 Hz, 2H, CH2), 3.67 – 3.59 (18H, m), 
3.52 (t, J = 5.1 Hz, 2H, -CH2-CH2-NHBoc), 3.29 (q, J = 5.1 Hz, 2H, -CH2-NHBoc), 2.82 (br s, 1H, OH), 1.43 
(s, 9H, 3 x CH3); 13C NMR (101 MHz, CDCl3) δ: 156.1 (C=O), 79.1 (-C-(CH3)3), 72.6, 70.6, 70.6, 70.6, 70.6, 
70.6, 70.5, 70.3, 70.3, 70.2, 61.7, 40.4 (C-N), 28.4 (3 x CH3). 
Data are in accordance with those reported previously in literature.162 
 
2,2-Dimethyl-4-oxo-3,8,11,14,17,20-hexaoxa-5-azadocosan-22-yl 3,5-diethynylbenzoate (24) 
 
To a stirring solution of 6 (0.335 g, 2.0 mmol) in dichloromethane (10 mL) cooled to 0 °C were added 
DCC (0.488 g, 2.4 mmol) and DMAP (0.036 g, 0.3 mmol). The solution was stirred for 3 h at r.t., before 
a solution of 7 (0.825 g, 2.2 mmol) in dichloromethane (5 mL) was added. The mixture was stirred for 
a further 18 h, before being filtered, washed with dichloromethane (5 mL), and concentrated in vacuo. 
Et2O (7 mL) was added, and the mixture was filtered, and concentrated in vacuo. The residue was 
purified through silica gel column chromatography (1:1 PE 40-60:EtOAc to EtOAc) to give the title 
compound as a colourless oil (0.450 g, 48%). 
Rf: 0.37 (EtOAc); IR (neat film, νmax, cm-1): 3232 (w br, NH), 2929 (m), 2856 (m), 1710 (m, C=O), 1650 
(m, C=O), 1512 (m, C=C), 1450 (m, C=C), 1364 (m), 1305 (m), 1213 (m), 1105 (s), 1042 (m), 897 (m), 
769 (w); 1H NMR (400 MHz, CDCl3) δ: 8.11 (d, J = 1.4 Hz, 2H, Ha), 7.75 (m, 1H, Hb), 5.03 (br s, 1H, NH), 
4.47 (m, 2H, -CH2-COO-), 3.82 (t, J = 4.7 Hz, 2H), 3.70 – 3.58 (m, 16H), 3.52 (m, 2H), 3.30 (m, 2H, CH2-
N), 3.15 (s, 2H, -C≡C-H), 1.43 (s, 9H, 3 x CH3); 13C NMR (101 MHz, CDCl3) δ: 164.9 (C=O), 156.0 (BocC=O), 
139.4 (Cb), 133.3 (Ca), 130.8 (-C-COO-), 123.0 (C-C≡C-), 81.6 (C≡C-H), 79.1 (-C-(CH3)3), 79.0 (C≡C-H), 
70.7, 70.7, 70.6, 70.5, 70.2, 69.0, 64.6 (CH2-COO), 40.4 (CH2-NH), 28.4 (3 x CH3); HRMS: m/z [M+H]+ 
calculated for C28H40NO9: 534.2698; Found: 534.2690.  
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17-Amino-3,6,9,12,15-pentaoxaheptadecyl 3,5-diethynylbenzoate (3) 
 
To a stirring solution of 24 (0.420 g, 0.79 mmol) in dichloromethane (3 mL) was added trifluoroacetic 
acid (3 mL). The solution was stirred for 3 h at r.t. before being concentrated in vacuo. The residue 
was purified through silica gel column chromatography (5:0.1:95 MeOH:NEt3:dichloromethane) to 
give the title compound as a colourless oil (0.331 g, 97%). 
Rf: 0.06 (1:19 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 3226 (w, NH), 2916 (m), 2874 (m), 
1722 (m, C=O), 1676 (m), 1436 (w, C=C), 1306 (m), 1200 (s), 1179 (s), 1111 (s), 1030 (m), 949 (m), 899 
(m), 831 (m), 798 (m), 768 (m), 720 (m); 1H NMR (400 MHz, CDCl3) δ: 8.09 (d, J = 1.5 Hz, 2H, Ha), 7.76 
(t, J = 1.5 Hz, 1H, Hb), 4.49 (t, J = 4.8 Hz, 2H, -CH2-COO-), 3.85 – 3.80 (m, 4H), 3.71 – 3.60 (m, 18H), 3.15 
(br s, 4H, 2 x -C≡C-H and NH2); 13C NMR (101 MHz, CDCl3) δ: 164.8 (C=O), 139.4 (Hb), 133.2 (Ca), 130.7 
(-C-COO-), 123.1 (C-C≡C-), 81.5 (C≡C-H), 79.1 (C≡C-H), 70.1, 70.1, 69.9, 69.9, 69.8, 68.9, 67.1, 64.2 (CH2-
COO-), 40.1 (-CH2-NH2); HRMS: m/z [M+H]+ calculated for C23H32NO7: 434.2173; Found: 434.2155. 
 
3,6,9,12,15-Pentaoxaheptadecane-1,17-diyl bis(4-methylbenzenesulfonate) (27) 
 
To a stirring solution of hexaethylene glycol (1.00 mL, 4.0 mmol) in THF (7 mL) cooled to 0 °C was 
added a solution of sodium hydroxide (0.64 g, 16 mmol) in water (5 mL). After stirring for ca. 15 mins 
a solution of p-toluenesulfonyl chloride (1.98 g, 10.4 mmol) in THF (7 mL) was added dropwise. The 
solution was warmed to r.t. before stirring for 3 h. At this point, further p-toluenesulfonyl chloride 
(1.00 g, 5.1 mmol) was added until complete conversion. The solution was concentrated in vacuo to 
ca. 5 mL then extracted into CHCl3 (3 x 20 mL). The combined organic was washed with brine (20 mL), 
dried over MgSO4, filtered, and concentrated in vacuo. The residue was purified through silica gel 
column chromatography (1:19 MeOH:dichloromethane) to give the title compound as a colourless oil 
(2.195 g, 93%). 
Rf: 0.30 (1:19 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 2870 (m), 1597 (w), 1451 (w), 1351 
(s), 1292 (w), 1188 (m), 1175 (s), 1095 (s), 1011 (m), 917 (s), 815 (s), 774 (m), 662 (s); 1H NMR (400 
MHz, CDCl3) δ: 7.78 (d, J = 8.2 Hz, 4H, Ha), 7.33 (d, J = 8.2 Hz, 4H, Hb), 4.14 (t, J = 5.0 Hz, 4H, -CH2-OTs), 
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3.67 (t, J = 5.0 Hz, 4H, -CH2CH2-OTs), 3.64 – 3.51 (m, 16H), 2.43 (s, 6H, 2 x -CH3); 13C NMR (101 MHz, 
CDCl3) δ: 144.8 (-C-SO3), 133.0 (-C-CH3), 129.8 (Cb), 128.0 (Ca), 70.7, 70.7, 70.6, 70.5, 70.5, 69.3 (-CH2-
OTs), 68.7 (-CH2CH2-OTs), 21.6 (2 x CH3). 
Data are in accordance with those reported previously in literature.336 
 
1,17-Diazido-3,6,9,12,15-pentaoxaheptadecane (28) 
 
To a stirring solution of 27 (2.180 g, 3.7 mmol) in dry DMF (25 mL) was added sodium azide (0.959 g, 
14.8 mmol). The solution was heated to 50 °C for 18 h. After cooling to r.t., water (50 mL) was added 
and the mixture was extracted into dichloromethane (6 x 15 mL). The combined organic was washed 
with brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo to give the title compound 
as a colourless oil (1.08 g, 86%), with no need for further purification. 
Rf: 0.36 (1:19 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 2867 (m), 2096 (m, N3), 1451 (w), 
1347 (w), 1284 (m), 1250 (m), 1098 (s br), 937 (m), 850 (m); 1H NMR (400 MHz, CDCl3) δ: 3.68 – 3.65 
(m, 20H), 3.38 (t, J = 5.2 Hz, 4H, CH2-N3); 13C NMR (101 MHz, CDCl3) δ: 70.8, 70.8, 70.7, 70.7, 70.1 (-
CH2CH2-N3), 50.8 (-CH2-N3). 
Data are in accordance with those reported previously in literature.337 
 
2,2-Dimethyl-4-oxo-3,8,11,14,17,20-hexaoxa-5-azadocosan-22-yl 4-methylbenzenesulfonate (31) 
 
To a stirring solution of 7 (0.36 g, 0.9 mmol) in THF (3 mL) was added a solution of sodium hydroxide 
(0.075 g, 1.9 mmol) in H2O (0.7 mL). After cooling to 0 °C, a solution of p-toluenesulfonyl chloride 
(0.22 g, 1.1 mmol) in THF (2.0 mL) was added dropwise. The mixture was stirred at r.t. for 18 h before 
concentrating in vacuo. H2O (4 mL) was added before extracting into CHCl3 (2 x 10 mL). The combined 
organic was washed with brine (10 mL), dried over MgSO4, filtered, and concentrated in vacuo. The 
residue was purified through silica gel column chromatography (1:19 isopropanol/CHCl3) to give the 
title compound as a colourless oil (0.505 g, >98%). 
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Rf: 0.23 (1:19 isopropanol/CHCl3); IR (neat film, νmax, cm-1): 3356 (w, N-H), 2870 (m), 1708 (m, C=O), 
1514 (m), 1454 (m), 1363 (m), 1249 (m), 1174 (s), 1095 (s), 1017 (m), 919 (m), 816 (m), 776 (m), 663 
(m); 1H NMR (400 MHz, CDCl3) δ: 7.79 (d, J = 8.2 Hz, 2H, Ha), 7.33 (d, J = 8.2 Hz, 2H, Hb), 5.03 (br s, 1H, 
NH), 4.15 (t, J = 4.7 Hz, 2H, -CH2-OTs), 3.68 (t, J = 4.7 Hz, 2H, -CH2-CH2-OTs), 3.64 – 3.57 (m, 16H), 3.52 
(t, J = 5.2 Hz, 2H, CH2-CH2-NHBoc), 3.30 (q, J = 5.2 Hz, 2H, -CH2-NHBoc), 2.44 (s, 3H, tol-CH3), 1.43 (s, 
9H, 3 x -CH3); 13C NMR (101 MHz, CDCl3) δ: 156.0 (C=O), 144.8 (C-SO3), 133.0 (-C-CH3), 129.8 (Ca), 128.0 
(Cb), 79.1 (-C-(CH3)3), 70.6, 70.6, 70.6, 70.5, 70.2, 69.2, 68.7, 40.4 (CH2-N), 28.4 (3 x CH3), 21.6 (tol-
CH3). 
Data are in accordance with those reported previously in literature.162 
 
tert-Butyl (17-azido-3,6,9,12,15-pentaoxaheptadecyl)carbamate (32) 
 
To a stirring solution of 31 (0.505 g, 0.9 mmol) in DMF (5 mL) was added sodium azide (0.092 g, 
1.4 mmol). The solution was stirred at 50 °C for 18 h before H2O (8 mL) was added and the mixture 
was extracted into dichloromethane (8 x 10 mL). The combined organic was washed with brine 
(15 mL), dried over MgSO4, filtered, and concentrated in vacuo to give the title compound as a 
colourless oil (0.35 g, 92%), with no need for further purification. 
Rf: 0.37 (1:19 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 3347 (w, NH), 2869 (m), 2104 (m, N3), 
1709 (m, C=O), 1513 (m), 1365 (m), 1276 (m), 1249 (m), 1168 (m), 1101 (s), 1039 (m), 943 (m), 862 
(m); 1H NMR (400 MHz, CDCl3) δ: 5.03 (br s, 1H, NH), 3.68 – 3.59 (m, 18H), 3.53 (t, J = 5.1 Hz, 2H, -CH2-
CH2-NHBoc), 3.38 (t, J = 5.0 Hz, 2H, -CH2-N3), 3.30 (q, J = 5.1 Hz, 2H, -CH2-NHBoc), 1.43 (s, 9H, 3 x CH3); 
13C NMR (101 MHz, CDCl3) δ: 156.0 (C=O), 79.1 (-C-(CH3)3), 70.7, 70.7, 70.6, 70.6, 70.5, 70.3, 70.2, 70.0, 
50.7 (C-N3), 40.4 (C-NHBoc), 28.4 (3 x CH3).  
Data are in accordance with those reported previously in literature.162 
 
tert-Butyl (17-amino-3,6,9,12,15-pentaoxaheptadecyl)carbamate (30) 
 
To a stirring solution of 32 (0.136 g, 0.33 mmol) in THF (5 mL) was added triphenylphosphine (0.132 g, 
0.50 mmol). The solution was stirred for 18 h at r.t. before H2O (2 mL) was added. The organic was 
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removed in vacuo, and the aqueous washed with toluene (2 x 5 mL), before being concentrated in 
vacuo to give the title compound as a colourless oil (0.130 g, >98%), with no need for further 
purification. 
Rf: 0.16 (94:4:2 dichloromethane:MeOH:NEt3); IR (neat film, νmax, cm-1): 3349 (w, NH), 2868 (m), 1707 
(m, C=O), 1521 (m), 1365 (m), 1270 (m), 1250 (m), 1171 (m), 1103 (s); 1H NMR (400 MHz, CDCl3) δ: 
5.19 (br s, 1H, NH), 3.64 – 3.58 (m, 16H), 3.53 – 3.48 (m, 4H), 3.29 (q, J = 5.0 Hz, 2H, -CH2-NHBoc), 2.84 
(t, J = 5.2 Hz, 2H, -CH2-NH2), 1.71 (br s, 2H, NH2), 1.42 (s, 9H, 3 x CH3); 13C NMR (101 MHz, CDCl3) δ: 
156.1 (C=O), 79.1 (-C-(CH3)3), 73.2, 70.6, 70.6, 70.5, 70.5, 70.3, 70.2, 41.7 (-CH2-NHBoc), 40.4 (CH2-
NH2), 28.4 (3 x CH3). 
Data are in accordance with those reported previously in literature.162 
 
tert-Butyl (1-(3,5-diethynylphenyl)-1-oxo-5,8,11,14,17-pentaoxa-2-azanonadecan-19-yl)carbamate 
(33) 
 
To a stirring solution of 6 (11 mg, 0.07 mmol) in dichloromethane (0.50 mL) were added PyAOP (47 mg, 
0.09 mmol) and 30 (25 mg, 0.07 mmol). The mixture was stirred for 4 h at r.t., before being 
concentrated in vacuo. The residue was purified through silica gel column chromatography (EtOAc to 
49:1 EtOAc:MeOH) to give the title compound as a colourless oil (24 mg, 65%). 
Rf: 0.11 (EtOAc); IR (neat film, νmax, cm-1): cm-1; 3283 (w, NH), 2916 (m), 2871 (m), 1697 (m, C=O), 1656 
(m, C=O), 1586 (w, C=C), 1534 (m, C=C), 1454 (w, C=C), 1366 (m), 1248 (m), 1167 (m), 1101 (s), 844 
(s); 1H NMR (400 MHz, CDCl3) δ: 7.92 (d, J = 1.5 Hz, 2H, Ha), 7.69 (t, J = 1.5 Hz, 1H, Hb), 7.13 (br s, 1H, 
NH), 5.05 (br s, 1H, NH), 3.70 – 3.59 (m, 20H), 3.52 (t, J = 4.7 Hz, 2H, -CH2-CH2-NHBoc), 3.31 (q, J = 4.7 
Hz, 2H, -CH2-NHBoc), 3.14 (s, 2H, -C≡C-H), 1.43 (s, 9H, 3 x CH3); 13C NMR (126 MHz, CDCl3) δ: 166.0 
(C=O amide), 156.5 (BocC=O), 137.9 (Cb), 135.2 (C-C=O), 131.0 (Ca), 122.9 (C-C≡C), 81.8 (C≡C-H), 79.3 
(-C-(CH3)3), 78.9 (C≡C-H), 70.8, 70.3, 70.1, 70.0, 40.3 (CH2-NHBoc), 39.9 (CH2-NCOAr), 28.4 (3 x CH3); 
HRMS: m/z [M+H]+ calculated for C28H40N2O8: 533.2857; Found: 533.2836. 
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N-(17-Amino-3,6,9,12,15-pentaoxaheptadecyl)-3,5-diethynylbenzamide (26) 
 
To a stirring solution of 33 (11 mg, 0.02 mmol) in dichloromethane (0.25 mL) was added trifluoroacetic 
acid (0.25 mL). The mixture was stirred for 3 h at r.t. before being concentrated in vacuo. The residue 
was purified through silica gel column chromatography (2:98 NEt3:dichloromethane to 5:2:93 
MeOH:NEt3:dichloromethane) to give the title compound as a colourless oil (9 mg, >98%). 
Rf: 0.29 (1:19 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 3237 (w, NH), 2916 (m), 2875 (m), 
1688 (m, C=O), 1676 (m), 1652 (m), 1585 (m, C=C), 1542 (m, C=C), 1300 (m), 1200 (m), 1126 (s), 829 
(m), 799 (m), 719 (m); 1H NMR (400 MHz, CDCl3) δ: 8.05 (d, J = 1.5 Hz, 2H, Ha), 8.00 (br s, 1H, HN-CO), 
7.68 (t, J = 1.5 Hz, 1H, Hb), 3.74 (t, J = 5.2 Hz, 2H, -CH2CH2-NCO), 3.67 – 3.56 (m, 20H), 3.12 (s, 2H, -
C≡C-H), 2.91 (t, J = 4.8 Hz, 2H, CH2-NH2); 13C NMR (101 MHz, CDCl3) δ: 165.9 (C=O), 137.8 (Cb), 135.2 
(C-C=O), 131.3 (Ca), 122.8 (C-C≡C), 81.9 (-C≡C-H), 78.6 (-C≡C-H), 70.5, 70.3, 70.3, 70.2, 70.2, 70.1, 69.6, 
69.6, 41.3 (CH2-NH2), 39.9 (CH2-NCO); HRMS: m/z [M+H]+ calculated for C23H33N2O6: 433.2333; Found: 
433.2323. 
 
4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-N-(1-(3,5-
diethynylphenyl)-1-oxo-5,8,11,14,17-pentaoxa-2-azanonadecan-19-yl)-2-fluorobenzamide (34) 
 
To a stirring solution of 2 (16 mg, 0.035 mmol) in DMF (100 µL) was added PyAOP (23 mg, 0.043 mmol). 
The mixture was stirred for ca. 10 mins at r.t. before a solution of 26 (15 mg, 0.035 mmol) in DMF 
(100 µL) was added. The mixture was stirred for a further 6 h at r.t. before being concentrated in 
vacuo. The residue was purified through silica gel column chromatography (dichloromethane to 1:19 
MeOH:dichloromethane) to give the title compound as a colourless oil (6 mg, 20%). 
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Rf: 0.61 (1:9 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 3388 (m, NH), 3200 (m), 1736 (m, C=O), 
1714 (m, C=O), 1679 (s, C=O), 1647 (m), 1439 (m, C=C), 1373 (m), 1203 (s), 1137 (s); 1H NMR (500 MHz, 
CDCl3) δ: 8.18 (t, J = 8.4 Hz, 1H, Hc), 8.00 (d, J = 8.2 Hz, 1H, Hg), 7.95 – 7.93 (m, 3H, Ha and Hh), 7.83 
(dd, J = 8.1, 1.8 Hz, 1H, Hf), 7.69 (t, J = 1.5 Hz, 1H, Hb), 7.33 (br s, 1H, NH), 7.22 (dd, J = 8.2, 1.7 Hz, 1H, 
Hd), 7.13 (dd, J = 11.4, 1.8 Hz, 1H, He), 3.76 – 3.61 (m, 20H, 10 x CH2), 3.18 – 3.13 (m, 6H, 2 x CH2-NH 
and -C≡C-H), 1.61 (s, 6H, 2 x CH3); 13C NMR (126 MHz, CDCl3) δ: 179.7 (C=S), 174.5 (χC=O), 166.2 (αC=O), 
162.8 (βC=O), 160.4 (d, J = 260 Hz, C-F), 139.0 (d, J = 8.0 Hz, -C-βC), 138.0 (Cb), 136.8 (-C-CN), 135.3 
(Cg), 135.0 (-C-αC), 133.8 (q, J = 35 Hz, -C-CF3), 133.1 (Cc), 132.1 (Cf), 131.1 (Ca), 127.1 (d, J = 6.3 Hz, 
Ch), 126.1 (Cd), 123.0 (-C-C≡C-), 122.9 (-C-N-C-(CH3)2-), 122.9 (Ch), 118.0 (d, J = 25 Hz, Ce), 114.7 (-
C≡N), 110.5 (-C-NCO-), 81.8 (-C≡C-H), 78.9 (-C≡C-H), 70.3, 70.2, 70.1, 70.0, 69.9, 66.7 (-C-(CH3)2), 45.8 
(-CH2-NβCO), 39.8 (-CH2-NαCO), 23.9 (2 x CH3); 19F NMR (376 MHz, CDCl3) δ: -63.0 (s, 3 F, CF3), -111.2 
(s, 1 F, ArC-F); HRMS: m/z [M+H]+ calculated for C43H44F4N5O8S: 866.2841; Found: 866.2811. 
 
tert-Butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (36) 
 
To a stirring solution of 2,2′-(ethylenedioxy)bis(ethylamine) (0.29 mL, 2.0 mmol) in dichloromethane 
(15 mL) cooled to 0 °C, was added a solution of Boc2O (0.07 mL, 0.3 mmol) in dichloromethane (10 mL) 
over ca. 1 h. The solution was stirred for a further 3 h at 0 °C, before warming to r.t. and stirring for 
18 h. The solution was washed with water (6 x 15 mL), and brine (15 mL), dried over MgSO4, filtered, 
and concentrated in vacuo to give the title compound as a colourless oil (0.130 g, 27%), with no need 
for further purification. 
Rf: 0.04 (1:24 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 3341 (w, NH), 2968 (m), 2932 (m), 
2873 (m), 1697 (s, C=O), 1517 (m), 1365 (m), 1272 (m), 1250 (m), 1170 (s), 1105 (s); 1H NMR (400 MHz, 
CDCl3) δ: 5.16 (br s, 1H, NHBoc), 3.59 (s, 4H, -O-CH2-CH2-), 3.53 – 3.49 (m, 4H, 2 x -CH2-CH2-N-), 3.29 
(q, J = 4.9 Hz, 2H, CH2-NHBoc), 2.86 (t, J = 4.9 Hz, 2H, -CH2-NH2), 1.77 (br s, 2H, -NH2), 1.41 (s, 9H, 3 x 
CH3); 13C NMR (101 MHz, CDCl3) δ: 156.0 (C=O), 79.1 (-C-(CH3)3), 73.2, 70.2, 70.2, 70.2, 41.6 (-CH2-NH2), 
40.3 (CH2-NHBoc), 28.4 (3 x CH3). 
Data are in accordance with those reported previously in literature.338 
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tert-Butyl (2-(2-(2-(3,5-diethynylbenzamido)ethoxy)ethoxy)ethyl)carbamate (37) 
 
To a stirring solution of 6 (10 mg, 0.06 mmol) in DMF (100 µL) were added DCC (21 mg, 0.1 mmol) and 
HOAt (0.6 M in DMF, 42 µL, 0.07 mmol). The mixture was stirred at r.t. for 3 h, before a solution of 36 
(15 mg, 0.06 mmol) in DMF (100 µL) was added. After stirring for a further 3 h, the mixture was filtered, 
washed with dichloromethane (2 mL), and concentrated in vacuo. Et2O (2 mL) was added to the 
residue and the mixture was filtered and concentrated in vacuo. The residue was purified through 
silica gel column chromatography (1:3 to 3:1 EtOAc:PE 40-60) to give the title compound as a 
colourless oil (10 mg, 42%). 
Rf: 0.46 (EtOAc); IR (neat film, νmax, cm-1): 3297 (m, NH), 2873 (m), 1699 (s, C=O), 1657 (s, C=O), 1586 
(m, C=C), 1535 (s, C=C), 1249 (m), 1171 (s), 1103 (s); 1H NMR (400 MHz, CDCl3) δ: 7.88 (s, 2H, Ha), 7.70 
(s, 1H, Hb), 6.80 (br s, 1H, -NH-COAr), 4.97 (br s, 1H, -NHBoc), 3.67 – 3.64 (m, 8H, 4x CH2), 3.58 – 3.54 
(m, 2H, CH2), 3.34 – 3.29 (m, 2H, -CH2-NHBoc), 3.14 (br s, 2H, -C≡C-H), 1.42 (s, 9H, 3 x CH3); 13C NMR 
(101 MHz, CDCl3) δ: 165.7 (ArC=O), 156.0 (C=O Boc), 137.9 (Cb), 135.2 (-C-C=O-), 130.8 (Ca), 123.1 (-
C-C≡C-), 81.7 (-C≡C-H), 79.4 (-C-(CH3)3), 79.0 (-C≡C-H), 70.3, 70.3, 70.1, 69.7 (4 x O-CH2), 40.3 (-CH2-
NHBoc), 39.9 (-CH2-NCOAr), 28.4 (3 x CH3); HRMS: m/z [M+Na]+ calculated for C22H28N2O5Na: 
423.1890; Found: 423.1905. 
 
N-(2-(2-(2-Aminoethoxy)ethoxy)ethyl)-3,5-diethynylbenzamide (38) 
 
To a stirring solution of 37 (8 mg, 0.020 mmol) in dichloromethane (100 µL) was added trifluoroacetic 
acid (100 µL). The mixture was stirred at r.t. for 4 h, before being concentrated in vacuo. The residue 
was purified through silica gel column chromatography (6:0.1:94 MeOH:NEt3:dichloromethane) to 
give the title compound as a yellow oil (6 mg, >98%). 
Rf: 0.15 (3:47 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 3286 (m, NH), 2920 (m), 2878 (m), 
1642 (s, C=O), 1585 (s, C=C), 1540 (s, C=C), 1324 (m), 1201 (m), 1123 (s), 894 (m), 799 (w), 683 (w); 1H 
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NMR (400 MHz, CDCl3) δ: 7.94 (d, J = 1.4 Hz, 2H, Ha), 7.66 (m, 1H, Hb), 7.56 (t, J = 5.2 Hz, 1H, NH), 3.68 
– 3.61 (m, 12H, 5 x CH2 and NH2), 3.15 (s, 2H, -C≡C-H), 3.04 (t, J = 4.6 Hz, 2H, -CH2-NH2); 13C NMR (101 
MHz, CDCl3) δ: 166.0 (C=O), 137.9 (Cb), 135.0 (C-CON-), 131.1 (Ca), 122.9 (C-C≡C-), 81.8 (-C≡C-H), 79.0 
(-C≡C-H), 70.2, 70.1, 69.8, 68.9 (4x O-CH2), 40.3 (-CH2-NH2), 40.0 (-CH2-NH-); HRMS: m/z [M+H]+ 
calculated for C17H21N2O3: 301.1547; Found: 301.1528. 
 
4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-N-(2-(2-(2-
(3,5-diethynylbenzamido)ethoxy)ethoxy)ethyl)-2-fluorobenzamide (39) 
 
To a stirring solution of 2 (11 mg, 0.025 mmol) in DMF (100 µL) were added DCC (8 mg, 0.04 mmol) 
and HOAt (0.6 M in DMF, 63 µL, 0.04 mmol). The solution was stirred for 1 h at r.t. before a further 
portion of DCC (5 mg, 0.02 mmol) was added. After stirring for a further 30 mins, a solution of 38 (8 
mg, 0.025 mmol) in DMF (180 µL) was added, and the mixture stirred for 4 h before being diluted with 
dichloromethane (2 mL), filtered, and concentrated in vacuo. Diethyl ether (3 mL) was then added and 
the mixture filtered and concentrated in vacuo. The residue was purified through silica gel column 
chromatography (1:1 EtOAc:PE 40-60 to EtOAc) to give the title compound as a colourless oil (6.5 mg, 
36%). 
Rf: 0.33 (EtOAc); IR (neat film, νmax, cm-1): 3286 (w br, NH), 2920 (w), 2869 (w), 1757 (m, C=O), 1710 
(m, C=O), 1650 (m, C=O), 1620 (m), 1585 (w, C=C), 1537 (m, C=C), 1500 (m, C=C), 1440 (m), 1312 (s), 
1220 (m), 1178 (m), 1136 (m), 1057 (w), 841 (s), 679 (w); 1H NMR (500 MHz, CDCl3) δ: 8.22 (t, J = 8.5 
Hz, 1H, Hc), 7.99 (d, J = 8.2 Hz, 1H, Hg), 7.94 (d, J = 2.0 Hz, 1H, Hh), 7.86 (d, J = 1.5 Hz, 2H, Ha), 7.82 
(dd, J = 8.2, 2.0 Hz, 1H, Hf), 7.69 (t, J = 1.5 Hz, 1H, Hb), 7.22 (dd, J = 8.5, 1.9 Hz, 1H, Hd), 7.10 (dd, J = 
11.7, 1.9 Hz, 1H, He), 6.70 (t, J = 4.8 Hz, 1H, NH), 3.71 – 3.65 (m, 10H, 5 x CH2), 3.13 (s, 2H, -C≡C-H), 
1.63 – 1.55 (m, 8H, CH2 and 2 x CH3); 13C NMR (126 MHz, CDCl3) δ: 179.9 (C=S), 174.6 (χC=O), 165.8 
(αC=O), 162.3 (βC=O), 160.6 (d, J = 250 Hz, C-F), 139.2 (d, J = 11 Hz, -C-Cβ), 138.2 (Cb), 136.9 (-C-CN), 
135.5 (C-Cα), 135.3 (Cg), 133.9 (d, J = 33 Hz, C-CF3), 133.5 (Cc), 132.3 (Cf), 130.9 (Ca), 127.2 (d, J = 5.2 
Hz, Ch), 126.3 (Cd), 123.2 (-C-C≡C), 122.7 (d, J = 16 Hz, -C-N-C-(CH3)2-), 122.0 (q, J = 280 Hz, CF3), 118.1 
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(d, J = 27 Hz, Ce), 114.9 (-C≡N), 110.6 (-C-NχCO-), 81.8 (-C≡C-H), 79.2 (-C≡C-H), 70.5, 70.4, 69.8, 69.7 
(4x O-CH2), 66.8 (-C-(CH3)2), 40.0 (2C, 2 x CH2-NH), 24.0 (2 x CH3); 19F NMR (376 MHz, CDCl3) δ: -63.0 
(CF3), -111.4 (ArC-F); HRMS: m/z [M+H]+ calculated for C37H32F4N5O5S: 734.2055; Found: 734.2031. 
 
3-Azidosulfonyl-3H-imidazol-1-ium hydrogen sulfate (40) 
 
To a stirring solution of sodium azide (0.65 g, 10 mmol) in acetonitrile (15 mL) cooled to 0 °C, was 
added sulfuryl chloride (0.81 mL, 10 mmol) dropwise. The mixture was stirred at r.t. for 16 h before 
cooling to 0 °C. Imidazole (1.29 g, 19 mmol) was added and the mixture stirred for a further 5 h at r.t. 
before the mixture was diluted with EtOAc (20 mL) and H2O (20 mL). The organic layer was separated, 
washed twice with NaHCO3 (2 x 20 mL), dried over MgSO4, and filtered. The volume was reduced to 
ca. 10 mL in vacuo and the mixture was cooled to 0 °C, before conc. sulfuric acid (0.53 mL, 10 mmol) 
was added dropwise. The mixture was stirred for 16 h at r.t. The precipitate was then filtered, washed 
with EtOAc (3 x 3 mL), and dried in vacuo to give the title compound as a white amorphous solid (1.64 
g, 61%), with no need for further purification. 
Rf: 0.80 (1:24 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 3110 (w), 3082 (w), 2982 (w), 2751 
(w), 2433 (w), 2177 (m, N3), 1586 (m, C=C), 1516 (m), 1430 (m), 1302 (m, S=O), 1233 (s), 1190 (m), 
1151 (s), 1127 (s, S=O), 1099 (s), 1067 (m), 1018 (m), 983 (m), 883 (m), 872 (m), 834 (m), 773 (s), 739 
(s); 1H NMR (400 MHz, DMSO-d6) δ: 14.27 (br s, 1H, NH+), 12.71 (br s, 3H, H2SO4 expected 1H), 9.09* 
(t, J = 1.2 Hz, 1H, C-H), 8.63 (m, 1H, Hc), 7.99 (t, J = 1.6 Hz, 1 H, Ha), 7.69* (d, J = 1.2 Hz, 2H), 7.36 (dd, 
J = 1.6, 0.8 Hz, Hb); 13C NMR (100 MHz, DMSO-d6) δ: 138.2 (Cc), 134.9*, 131.0 (Ca), 119.8*, 119.4 (Cb). 
Product partially decomposes in DMSO-d6 to form 1,3H-imidazol-1-ium salts, these are marked with 
an asterisk (*). 
Data are in accordance with those reported previously in literature.169 
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Fmoc-Orn-OH.HCl (42) 
 
To a stirring solution of Fmoc-Orn(Boc)-OH (1.75 g, 3.8 mmol) in 1,4-dioxane (13 mL) was added HCl 
solution (13 mL, 4 M in dioxane) in a single portion. The mixture was stirred at r.t. for 18 h before Et2O 
(60 mL) was added. The white precipitate was filtered, washed with Et2O (4 x 10 mL), and dried in 
vacuo to give the title compound as a white amorphous powder (1.74 g, >98%), with no need for 
further purification. 
Rf: 0.0 (1:24 MeOH:dichloromethane); IR (neat film, νmax, cm-1): 3330 (w, NH), 2993 (m br, OH), 1725 
(m, C=O), 1689 (s, C=O), 1530 (s, C=C), 1477 (m, C=C), 1450 (m, C=C), 1286 (m), 1260 (m), 1221 (m), 
1120 (m), 1036 (m), 984 (m), 870 (m), 759 (m), 734 (s); 1H NMR (400 MHz, DMSO-d6) δ: 12.71 (br s, 
1H, COOH), 8.02 (br s, 3H, NH3+), 7.90 (d, J = 7.5 Hz, 2H, Hd), 7.73 (t, J = 8.0 Hz, 2H, Ha), 7.42 (t, J = 7.4 
Hz, 2H, Hc), 7.34 (t, J = 7.4 Hz, 2H, Hb), 4.32 – 4.22 (m, 3H, Fmoc CH and CH2), 3.99 – 3.94 (m, 1H, Ce), 
2.77 (br s, 2H, Hh), 1.84 – 1.60 (m, 4H, Hf and Hg); 13C NMR (101 MHz, DMSO-d6) δ: 174.0 (COOH), 
156.6 (CONH), 144.3 (2 x CQAr), 141.2 (2 x CQAr), 128.1 (2 x CHAr), 127.6 (2 x CHAr), 125.7 (2 x CHAr), 
120.6 (2 x CHAr), 66.1 (Fmoc-CH2), 53.9 (Ce), 47.1 (Fmoc-CH), 38.8 (CH), 28.2 (Cf), 24.4 (Cg); [α]D20: - 
2.9 (c = 1.0, MeOH, lit. [α]D27 - 3.0168). 
Data are in accordance with those reported previously in literature.168 
 
Fmoc-Orn(N3)-OH (43) 
 
To a stirring, biphasic mixture of H2O (40 mL), MeOH (80 mL), and dichloromethane (68 mL) were 
added Fmoc-Orn-OH.HCl (2.80 g, 7.2 mmol), copper(II) sulfate pentahydrate (14 mg, 0.058 mmol), and 
3-azidosulfonyl-3H-imidazol-1-ium hydrogen sulfate (7.16 g, 26.5 mmol). Aqueous potassium 
carbonate solution was added to pH 9, and the mixture was stirred for 16 h. Dichloromethane (90 mL) 
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was added and the two phases separated, before the organic was further extracted with saturated 
NaHCO3 (2 x 120 mL). The combined aqueous was then washed with Et2O (2 x 120 mL), acidified to pH 
2 using conc. HCl, and extracted into Et2O (3 x 140 mL). The organic layer was dried over MgSO4, 
filtered, and concentrated in vacuo to give the title compound as a cream amorphous solid (1.62 g, 
59%), with no need for further purification. 
Rf: 0.10 (1:24 MeOH:dichloromethane); m.p.: 130 – 132 °C (Et2O, lit. 127 – 128 °C339); IR (neat film, 
νmax, cm-1): 3283 (m, NH), 3070 (br m, OH), 2098 (s, N3), 1715 (s br, C=O), 1522 (m, C=C), 1450 (m, C=C), 
1231 (s), 1183 (m), 1041 (s), 760 (m), 741 (s); 1H NMR (400 MHz, DMSO-d6) δ: 12.63 (br s, 1H, COOH), 
7.89 (d, J = 7.6 Hz, 2H, Hd), 7.73 – 7.68 (m, 2H, Ha), 7.42 (t, J = 7.5 Hz, 2H, Hc), 7.33 (t, J = 7.4 Hz, 2H, 
Hb), 4.34 – 4.21 (m, 3H, Fmoc CH and CH2), 4.00 – 3.94 (m, 1H, He), 3.39 – 3.29 (m, 2H, Hh), 1.83 – 
1.55 (m, 4H, Hf and Hg); 13C NMR (101 MHz, DMSO-d6) δ: 174.1 (COOH), 156.6 (CONH), 144.3 (CQAr), 
144.2 (CQAr), 141.2 (CQAr), 141.2 (CQAr), 128.1 (Cc), 127.5 (Cb), 125.7 (Ca), 125.7 (Ca), 120.6 (2 x Cd), 
66.1 (Fmoc-CH2), 53.8 (Ce), 50.7 (Ch), 47.1 (Fmoc-CH), 28.5 (Cf), 25.6 (Cg); [α]D20: - 3.8 (c = 1.0, MeOH, 
lit. [α]D27 – 2 .3340). 
Data are in accordance with those reported previously in literature.339 
 
tert-Butyl (6-(3,5-diethynylbenzamido)hexyl)carbamate (44) 
 
To a stirring solution of 6 (0.144 g, 0.85 mmol) in dichloromethane (2 mL) were added PyAOP (0.574 g, 
1.1 mmol) and N-Boc-1,6-hexanediamine (0.19 mL, 0.85 mmol). The mixture was stirred at r.t. for 3 h 
before H2O (2 mL) was added. The organic was separated, and the aqueous further extracted with 
dichloromethane (3 x 2 mL), before the combined organics were washed with brine (3 mL), dried over 
MgSO4, filtered, and concentrated in vacuo. The residue was purified through silica gel column 
chromatography (1:1 EtOAc:Hexane) to give the title compound as a white amorphous solid (0.193 g, 
62%). 
Rf: 0.40 (1:1 EtOAc:Hexane); IR (neat film, νmax, cm-1): 3360 (m, NH), 3294 (m, NH), 2936 (m), 1679 (s, 
C=O), 1634 (s, C=O), 1585 (m, C=C), 1519 (s, C=C), 1480 (m, C=C), 1344 (m), 1283 (m), 1249 (m), 1167 
(s), 1042 (w), 888 (m), 759 (w), 657 (w); 1H NMR (500 MHz, CDCl3) δ: 7.88 (s, 2H, Ha), 7.69 (t, J = 1.4 
Hz, 1H, Hb), 6.49 (br s, 1H, ArCONH), 4.56 (br s, 1H, -NHBoc), 3.43 (dd, J = 6.8, 6.2 Hz, 2H, -CH2-
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NHCOAr), 3.13 (br m, 4H, -C≡C-H and -CH2-NHBoc), 1.61 (quin, J = 7.0 Hz, 2H, -CH2-CH2-NHBoc), 1.51 – 
1.33 (m, 15H, 3 x CH3 and 3 x CH2); 13C NMR (126 MHz, CDCl3) δ: 165.7 (Ar-C=O), 156.2 (C=O-Boc), 
137.8 (Cb), 135.4 (-C-CON-), 130.8 (Ca), 123.0 (-C-C≡C-H), 81.8 (-C≡C-H), 79.2 (-C-(CH3)3), 78.9 (-C≡C-
H), 39.9 (-CH2-NHBoc), 39.6 (-CH2-NHCOAr), 30.1, 29.3, 28.4 (3 x CH3), 25.9, 25.7; HRMS: m/z [M+H]+ 
calculated for C22H29N2O3: 369.2173; Found: 369.2185. 
 
N-(6-Aminohexyl)-3,5-diethynylbenzamide (45) 
 
To a stirring solution of 44 (0.193 g, 0.52 mmol) in dichloromethane (1 mL) was added trifluoroacetic 
acid (1 mL). After stirring at r.t. for 4 h, the mixture was concentrated in vacuo before H2O (2 mL) was 
added. The aqueous was extracted into CHCl3 (8 x 5 mL), and the combined organics were dried over 
MgSO4, filtered, and concentrated in vacuo. The residue was purified through silica gel column 
chromatography (10:0.1:90 MeOH:NEt3:dichloromethane) to give the title compound as a colourless 
oil (0.122 g, 87%). 
Rf: 0.06 (10:2:88 MeOH:NEt3:dichloromethane); IR (neat film, νmax, cm-1): 3289 (m, NH), 2929 (m), 2857 
(m), 1637 (s, C=O), 1584 (s, C=C), 1542 (s, C=C), 1436 (m, C=C), 1324 (m), 1245 (m), 932 (w), 893 (m), 
737 (w), 683 (w); 1H NMR (400 MHz, DMSO-d6) δ: 8.64 (t, J = 5.3 Hz, 1H, NH), 7.95 (d, J = 1.4 Hz, 2H, 
Ha), 7.70 (t, J = 1.3 Hz, 1H, Hb), 4.37 (s, 2H, -C≡C-H), 3.24 (dd, J = 6.8, 6.0 Hz, 2H, -CH2-NCOAr), 2.60 – 
2.50 (m, 4H, -CH2NH2), 1.51 (quin, J = 6.5 Hz, 2H, -CH2-NCOAr), 1.36- 1.29 (m, 6H, 3x CH2); 13C NMR 
(101 MHz DMSO-d6) δ: 164 (C=O), 137.0 (Cb), 136.0 (-C-CON-), 131.1 (Ca), 122.9 (-C-C≡C-H), 82.8 (-
C≡C-H), 82.3 (-C≡C-H), 42.0 (-CH2-NH2), 39.8 (-CH2-NCOAr), 33.5, 29.4, 26.9, 26.6 (4x CH2); HRMS: ESI 
m/z: mass not found. 
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4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-N-(6-(3,5-
diethynylbenzamido)hexyl)-2-fluorobenzamide (46) 
 
To a stirring solution of 2 (8 mg, 0.022 mmol) in dichloromethane (200 µL) were added PyAOP (16 mg, 
0.031 mmol) and 45 (4.7 mg, 0.022 mmol). The mixture was stirred at r.t. for 3 h before being 
concentrated in vacuo. The residue was purified through silica gel column chromatography (3:2 
EtOAc:Hexane) to give the title compound as a yellow oil (9 mg, 60%). 
Rf: 0.35 (3:2 EtOAc:Hexane); IR (neat film, νmax, cm-1): 3292 (w br, NH), 2926 (w), 2856 (w), 1756 (m, 
C=O), 1649 (m, C=O), 1620 (m, C=O), 1585 (w, C=C), 1535 (m, C=C), 1498 (m, C=C), 1437 (m, C=C), 1412 
(m, C=C), 1310 (s), 1218 (m), 1177 (m), 1137 (s), 1056 (m), 923 (w), 893 (w), 813 (w), 736 (w); 1H NMR 
(500 MHz, CDCl3) δ: 8.24 (t, J = 8.4 Hz, 1H, Hc), 7.98 (d, J = 8.2 Hz, 1H, Hg), 7.94 (d, J = 1.8 Hz, 1H, Hh), 
7.87 (d, J = 1.6 Hz, 2H, Ha), 7.82 (dd, J = 8.2, 1.8 Hz, 1H, Hf), 7.69 (t, J = 1.6 Hz, 1H, Hb), 7.23 (dd, J = 
8.4, 2.0 Hz, 1H, Hd), 7.14 (dd, J = 11.7, 2.0 Hz, 1H, He), 6.73 (dt, J = 11.5, 5.9 Hz, 1H, βCONH), 6.32 (t, J 
= 5.4 Hz, 1H, αCONH), 3.52 (dd, J = 12.8, 6.3 Hz, 2H, CH2-NHβC-), 3.45 (dd, J = 13.1, 6.9 Hz, 2H, CH2-
NHαC-), 3.12 (s, 2H, -C≡C-H), 1.68 – 1.60 (m, 10H, 2 x CH2 and 2 x CH3), 1.46 – 1.44 (m, 2H, CH2), 1.27 
– 1.23 (m, 2H, CH2); 13C NMR (126 MHz, CDCl3) δ: 179.8 (C=S), 174.4 (χC=O), 165.7 (αC=O), 162.1 (d, J 
= 3.3 Hz, βC=O), 160.3 (d, J = 250 Hz, C-F), 139.0 (d, J = 11 Hz, -C-Cβ), 137.9 (Cb), 136.8 (-C-CN), 135.4 
(C-Cα), 135.3 (Cg), 133.7 (q, J = 34 Hz, -C-CF3), 133.4 (d, J = 3.3 Hz, Cc), 132.1 (Cf), 130.7 (Ca), 127.1 (q, 
J = 4.6 Hz, Ch), 126.2 (d, J = 3.2 Hz, Cd), 123.1 (-C-C≡C-H), 122.9 (-C-N-C-(CH3)2-), 121.8 (q, J = 270 Hz, -
CF3), 117.9 (d, J = 26 Hz, Ce), 114.7 (-C≡N), 110.5 (q, J = 2.0 Hz, -C-NχC-), 81.7 (-C≡C-H), 78.9 (-C≡C-H), 
66.6 (-C-(CH3)2), 39.7 (2 x -CH2-NH-), 29.7, 29.4, 29.4, 26.1, 23.9 (2 x CH3); 19F NMR (376 MHz, CDCl3) δ: 
-63.0 (s, 3 F, CF3), -111.6 (s, 1 F, ArC-F); HRMS: m/z [M+H]+ calculated for C37H32F4N5O3S: 702.2156; 
Found: 702.2164.  
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6-((tert-Butoxycarbonyl)amino)hexanoic acid (47) 
 
To a stirring solution of 6-aminocaproic acid (2.62 g, 20.0 mmol) in 1,4-dioxane (17 mL) and H2O (8 mL) 
cooled to 0 °C, were added NaOH (1 M, 20 mL) and Boc2O (5.05 mL, 22.0 mL). The mixture was stirred 
at r.t. for 3 h, before being concentrated in vacuo, washed with EtOAc (25 mL), and acidified with HCl 
(1 M) to pH 1. The aqueous layer was then extracted into EtOAc (3 x 25 mL), and the combined organic 
was dried over MgSO4, filtered, and concentrated in vacuo to give the title compound as a white 
crystalline solid (3.50 g, 76%), with no need for further purification. 
m.p.: 35 – 37 °C (EtOAc, lit. 35 - 37 °C341); Rf: 0.70 (EtOAc); IR (neat film, νmax, cm-1): 3342 (w br, NH), 
~3000 (w br, OH), 2976 (m), 2861 (m), 1705 (s br, C=O), 1519 (m), 1454 (m), 1366 (m), 1249 (m), 1163 
(s), 864 (w), 779 (w); 1H NMR (400 MHz, CDCl3) δ: 4.57 (br s, 1H, -NH), 3.13 – 3.05 (m, 2H, CH2-NHBoc), 
2.34 (t, J = 7.4 Hz, 2H, CH2-COOH), 1.64 (quin, J = 7.4 Hz, 2H, -CH2-CH2-COOH), 1.52 – 1.32 (m, 13H); 
13C NMR (101 MHz, CDCl3) δ: 179.0 (HO-C=O), 156.0 (-N-C=O), 79.2 (-C-(CH3)3), 40.4 (CH2-NH-), 33.9 
(CH2-COOH), 29.7 (-CH2), 28.4 (3x -CH3), 26.2 (-CH2), 24.3 (CH2).  
Data are in accordance with those reported previously in literature.342 
 
tert-Butyl (6-((6-(3,5-diethynylbenzamido)hexyl)amino)-6-oxohexyl)carbamate (48) 
 
To a stirring solution of 47 (43 mg, 0.19 mmol) in dichloromethane (0.5 mL) were added PyAOP 
(0.149 g, 0.29 mmol) and 45 (50 mg, 0.19 mmol). The mixture was stirred at r.t. for 4 h before being 
concentrated in vacuo. The residue was purified through silica gel column chromatography (EtOAc) to 
give the title compound as a yellow amorphous solid (0.067 g, 74%). 
Rf: 0.35 (EtOAc); IR (neat film, νmax, cm-1): 3288 (m, NH), 2932 (m), 2858 (m), 1683 (m, C=O), 1631 (s, 
C=O), 1586 (m, C=C), 1534 (s, C=C), 1463 (m, C=C), 1364 (m), 1248 (m), 1168 (s), 893 (m), 762 (w); 1H 
NMR (400 MHz, CDCl3) δ: 7.89 (d, J = 1.4 Hz, 2H, Ha), 7.69 (t, J = 1.4 Hz, 1H, Hb), 6.65 (t, J = 5.0 Hz, 1H, 
Ar-CO-NH), 5.68 (br s, 1H, NH), 4.58 (br s, 1H, -NHBoc), 3.43 (dd, J = 6.7, 6.2 Hz, 2H, -CH2-NHBoc), 3.24 
(dd, J = 6.7, 6.2 Hz, 2H, Hc), 3.13 (s, 2H, -C≡C-H), 3.08 (dd, J = 6.5, 6.7 Hz, 2H, -CH2-NCOAr), 2.17 (t, J = 
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7.4 Hz, 2H, Hd), 1.80 – 1.57 (m, 6H, 2 x CH2 and NH2), 1.54 – 1.25 (m, 17H, 4 x CH2 and 3 x CH3); 13C 
NMR (101 MHz, CDCl3) δ: 173.0 (CH2C=O), 165.8 (Ar-C=O), 156.1 (C=OBoc), 137.8 (Cb), 135.4 (ArC-
CON-), 130.8 (Ca), 123.0 (-C-C≡C-H), 81.8 (-C≡C-H), 79.1 (-C-(CH3)3), 78.9 (-C≡C-H), 40.4 (-CH2-NCOAr), 
39.6 (CH2-NHBoc), 38.8 (Cc), 36.6 (Cd), 29.8, 29.5, 29.3, 28.3 (3 x CH3), 26.4, 25.9, 25.8, 25.4; HRMS: 
m/z [M+H]+ calculated for C28H40N3O4: 482.3013; Found: 482.3026. 
 
N-(6-(6-aminohexanamido)hexyl)-3,5-diethynylbenzamide (49) 
 
To a stirring solution of 48 (0.056 g, 0.12 mmol) in dichloromethane (1 mL) was added trifluoroacetic 
acid (1 mL). The mixture was stirred at r.t. for 3 h, before being concentrated in vacuo. The residue 
was purified through silica gel column chromatography (dichloromethane to 10:0.1:90 
MeOH:NEt3:dichloromethane) to give the title compound as a yellow oil (34 mg, 77%). 
Rf: 0.10 (10:0.1:90 MeOH:NEt3); IR (neat film, νmax, cm-1): 3291 (m, NH), 2935 (m), 1638 (s, C=O), 1583 
(m, C=C), 1547 (s, C=C), 1462 (w, C=C), 1327 (w), 1201 (w), 1175 (w), 1024 (w); 1H NMR (400 MHz, 
DMSO-d6) δ: 8.65 – 8.63 (br m, 1H, NH), 7.94 (m, 2H, Ha), 7.78 – 7.73 (br m, 1H, NH), 7.69 (m, 1H, Hb), 
4.38 – 4.36 (m, 2H, -C≡C-H), 3.26 – 3.20 (m, 2H, -CH2-NCOAr), 3.03 – 2.95 (m, 2H, Hc), 2.65 (t, J = 7.3 
Hz, 2H, -CH2-NH2), 2.07 – 2.00 (m, 2H, Hd), 1.49 – 1.21 (m, 16H, 7 x -CH2 and -NH2); 13C NMR (101 MHz, 
DMSO-d6) δ: 171.8 (-CH2-C=O), 164.2 (Ar-C=O), 136.6 (Cb), 135.6 (ArC-CON-), 130.8 (Ca), 122.6 (-C-
C≡C-H), 82.5 (-C≡C-H), 81.9 (-C≡C-H), 39.8 (-CH2-NH2), 39.4 (-CH2-NCOAr), 38.4 (Cc), 35.3 (Cd), 29.2, 
29.1, 29.0, 26.2, 26.2, 25.8, 25.0; HRMS: m/z [M+H]+ calculated for C23H32N3O2: 382.2489; Found: 
382.2539.  
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4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-N-(6-((6-
(3,5-diethynylbenzamido)hexyl)amino)-6-oxohexyl)-2-fluorobenzamide (50) 
 
To a stirring solution of 2 (15 mg, 0.03 mmol) in dichloromethane (100 µL) was added PyAOP (26 mg, 
0.05 mmol). The mixture was stirred at r.t. for 10 mins before a solution of 49 (13 mg, 0.03 mmol) in 
dichloromethane (100 µL) was added. The solution was stirred for a further 6 h at r.t. before being 
concentrated in vacuo. The residue was purified through silica gel column chromatography 
(dichloromethane to 10:0.1:90 MeOH:NEt3:dichloromethane) to give the title compound as a yellow 
oil (6 mg, 22%). 
Rf: 0.28 (EtOAc); IR (neat film, νmax, cm-1): 3293 (w, NH), 2930 (w), 2857 (w), 1756 (m, C=O), 1709 (m, 
C=O), 1642 (s, C=O), 1617 (m, C=O), 1585 (m, C=C), 1537 (m, C=C), 1499 (m, C=C), 1412 (s, C=C), 1310 
(s), 1219 (s), 1176 (s), 1137 (s), 1056 (m), 923 (w), 893 (w), 840 (w), 813 (w), 678 (w); 1H NMR (500 
MHz, CDCl3) δ: 8.22 (t, J = 8.5 Hz, 1H, Hc), 7.99 (d, J = 8.0 Hz, 1H, Hg), 7.95 (d, J = 1.9 Hz, 1H, Hh), 7.88 
(d, J = 1.5 Hz, 2H, Ha), 7.82 (dd, J = 8.0, 1.9 Hz, 1H, Hf), 7.69 (t, J = 1.5 Hz, 1H, Hb), 7.23 (dd, J = 8.5, 2.0 
Hz, 1H, Hd), 7.14 (dd, J = 11.6, 2.0 Hz, 1H, He), 6.75 (dt, J = 11.3, 5.5 Hz, 1H, NH), 6.52 (t, J = 5.6 Hz, 1H, 
NH), 5.60 (t, J = 5.7 Hz, 1H, NH), 3.51 (dd, J = 13.0, 6.7 Hz, 2H, CH2-NHαC=O), 3.44 (dd, J = 13.0, 7.0 Hz, 
2H, CH2-NH-δC=O), 3.27 (dd, J = 13.0, 6.7 Hz, 2H, CH2-NH-Cβ), 3.13 (s, 2H, 2 x -C≡C-H), 2.21 (t, J = 6.9 
Hz, 2H, -CH2-Cβ-), 1.74 – 1.61 (m, 10H, 2 x CH2 and 2 x CH3), 1.53 – 1.36 (m, 8H, 4 x CH2), 1.28 – 1.22 
(m, 2H, CH2); 13C NMR (126 MHz, CDCl3) δ:  179.8 (C=S), 174.4 (βC=O), 172.9 (δC=O), 165.8 (αC=O), 
162.1 (χC=O), 160.3 (d, J = 250 Hz, C-F), 138.9 (d, J = 9.7 Hz, C-Cχ), 137.9 (Cb), 136.8 (-C-CN), 135.4 (C-
Cα), 135.3 (Cg), 133.7 (q, J = 34 Hz, -C-CF3), 133.4 (Cc), 132.1 (Cf), 130.8 (Ca), 127.1 (q, J = 4.5 Hz, Ch), 
126.2 (d, J = 2.1 Hz, Cd), 123.0 (-C-C≡C), 122.9 (d, J = 6.0 Hz, -C-N-C-(CH3)2),121.8 (q, J = 280 Hz, CF3), 
118.0 (d, J = 28 Hz, Ce), 114.7 (-C≡N), 110.5 (-C-NαCO-), 81.8 (-C≡C-H), 78.9 (-C≡C-H), 66.6 (-C-(CH3)2), 
40.0 (CH2-NHαC=O), 39.6 (CH2-NH-δC=O), 38.8 (CH2-NH-Cβ), 36.6 (CH2-Cβ), 29.7, 29.5, 29.4, 29.2, 26.4, 
25.8, 25.2, 23.9 (2 x CH3); 19F NMR (376 MHz, CDCl3) δ: -63.0 (CF3), -111.5 (ArC-F); HRMS: m/z [M+H]+ 
calculated for C43H43F4N6O4F: 815.2997; Found: 815.2928. 
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(5S,8R,9S,10S,13S,14S,17S)-10,13-Dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthren-
17-yl 6-((tert-butoxycarbonyl)amino)hexanoate (52) 
 
To a stirring solution of 5α-dihydrotestosterone (0.079 g, 0.34 mmol) in dichloromethane (1 mL) were 
added DCC (0.091 g, 0.44 mmol) and DMAP (0.006 g, 0.05 mmol). The mixture was stirred at r.t. for 
3 h before DHT (0.100 g, 0.34 mmol) was added, and the solution was stirred for a further 6 h. The 
mixture was then filtered and concentrated in vacuo. The residue was purified through silica gel 
column chromatography (1:3 EtOAc:Hexane) to give the title compound as a colourless oil (0.170 g, 
99%). 
Rf:  0.67 (1:1 EtOAc:Hexane); IR (neat film, νmax, cm-1): 3373 (w, NH), 2937 (m), 1731 (m, C=O), 1718 (s, 
C=O), 1691 (m, C=O), 1520 (w), 1442 (w), 1365 (m), 1234 (m), 1218 (m), 1174 (m); 1H NMR (500 MHz, 
CDCl3) δ: 4.60 (dd, J = 8.9, 8.1 Hz, 1H, Ha), 4.51 (br s, 1H, NH), 3.10 (dd, J = 12.6, 6.3 Hz, 2H, -CH2-NH), 
2.41 – 2.23 (m, 4H, CH2-Cα and CH2-Cβ), 2.18 – 1.99 (m, 4H, CH2-Cα and 2 x DHT CH), 1.69 – 1.24 (m, 
27H, including 3 x BocCH3), 1.17 (dt, J = 12.8, 4.2 Hz, 1H, DHT-CH), 1.08 – 1.04 (m, 1H, DHT-CH), 1.01 
(s, 3H, CcH3), 0.96 – 0.88 (m, 1H, DHT-CH), 0.80 (s, 3H, CbH3), 0.78 – 0.72 (m, 1H, DHT-CH); 13C NMR 
(126 MHz, CDCl3) δ: 211.9 (αC=O), 173.6 (βC=O), 156.0 (χC=O), 82.5 (Ca), 79.1 (-C-(CH3)3), 53.7, 50.6, 
46.6, 44.7 (C-Cα), 42.7, 40.4 (CH2-NH), 38.5, 38.1 (C-Cα), 36.9, 35.7, 35.2, 34.4, 31.2, 29.8, 28.8, 28.4 
(Boc 3 x CH3), 27.6, 26.3, 24.7, 23.6, 20.9, 12.2 (CbH3), 11.5 (CcH3); HRMS: m/z [M+H]+ calculated for 
C30H50NO5: 504.3684; Found: 504.3688; [α]D20 20.3 (c = 0.4, MeOH). 
 
tert-Butyl 6-aminohexanoate (56) 
 
 
6-Aminohexanoic acid (1.00 g, 7.5 mmol) was dissolved in thionyl chloride (2.50 mL, 35 mmol) and 
stirred for 3 h at r.t. before being concentrated in vacuo. A slurry of NaHCO3 (1.30 g, 15 mmol) in tert-
butanol (2.5 mL) was then added and the reaction was stirred for a further 3 h at r.t. The reaction was 
then concentrated in vacuo, and dissolved in EtOAc (30 mL), before being washed with 1 M NaOH (4 
194 
 
x 25 mL), H2O (3 x 25 mL), brine (25 mL), dried over MgSO4, filtered, and concentrated in vacuo to give 
the title compound as a colourless oil (0.744 g, 53%) which was used directly with no further 
purification. 
Rf: 0.18 (6% MeOH/DCM); IR (neat film, νmax, cm-1): 3267 (w, NH), 2980 (m, CH), 2933 (m, CH), 2865 
(m, CH), 1726 (s, C=O), 1649 (m), 1554 (w), 1457 (w), 1391 (w), 1366 (s), 1254 (m), 1149 (s, C-O), 1107 
(m); 1H NMR (400 MHz, CDCl3) δ: 2.71 (t, J = 7.1 Hz, 2 H, CH2-N), 2.21 (t, J = 7.1 Hz, 2 H, CH2-CO), 2.08 
(br s, 2 H, NH2), 1.59 (quin., J = 7.7 Hz, 2 H, CH2), 1.51 – 1.43 (m, 11 H, 3 x CH3 and CH2), 1.38 – 1.30 (m, 
2 H, CH2); 13C NMR (101 MHz, CDCl3) δ: 173.3 (C=O), 80.2, 41.9, 35.6, 33.0, 28.2, 26.4, 25.0. 
Data are in accordance with those reported previously in literature.343 
 
tert-Butyl 6-(3,5-diethynylbenzamido)hexanoate (57) 
 
To a stirring solution of 6 (0.150 g, 0.88 mmol) in N,N-dimethylformamide (1.5 mL) were added PyAOP 
(0.573 g, 1.1 mmol) and 56 (0.181 g, 0.97 mmol). The mixture was stirred at r.t. for 18 h before 
concentrating in vacuo. The residue was purified through silica gel column chromatography (3:1 
Hexane:EtOAc) to give the title compound as a colourless oil (0.220 g, 74%).  
Rf: 0.50 (1% MeOH/DCM); IR (neat film, νmax, cm-1): 3294 (w, NH), 2980 (w, CH), 2934 (w, CH), 2865 
(w, CH), 1722 (m, C=O), 1639 (m), 1585 (m), 1540 (m), 1455 (w), 1366 (m), 1320 (m), 1244 (m), 1148 
(s), 1102 (w); 1H NMR (400 MHz, CDCl3) δ: 7.85 (d, J = 1.2 Hz, 2 H, Hb), 7.69 (s, 1 H, Ha), 6.36 (br s, 1 
H, NH), 3.46 (q, J = 6.6 Hz, 2 H, CH2-N), 3.13 (s, 2 H, C≡C-H), 2.24 (t, J = 7.2 Hz, 2 H, CH2-CO), 1.66 – 1.58 
(m, 4 H, 2 x CH2), 1.43 – 1.36 (m, 11 H, 3 x CH3 and CH2); 13C NMR (101 MHz, CDCl3) δ: 173.3 (C=O), 
165.8 (C=O), 138.0 (Cb), 135.5 (C-CON), 130.9 (Ca), 123.2 (C-C≡C-H), 81.9 (C≡C-H), 80.4 (C≡C-H), 39.9 
(CH2-N), 35.3 (CH2-CO), 29.1, 28.3 (3 x CH3), 26.3, 24.4; HRMS m/z [M+Na]+ calculated for C21H25NO3Na: 
362.1726; Found: 362.1725 
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6-(3,5-Diethynylbenzamido)hexanoic acid (58) 
 
To a stirring solution of 57 (38 mg, 0.112 mmol) in dichloromethane (0.25 mL) was added 
trifluoroacetic acid (0.25 mL). The reaction was stirred for 2 h before being concentrated in vacuo to 
give the title compound as a white amorphous solid (31 mg, 97%) which was used directly with no 
further purification. 
Rf: 0.25 (1% MeOH/DCM); IR (neat film, νmax, cm-1): 3233 (m, NH), ~3000 (br w, OH), 2943 (w, CH), 
1712 (s, C=O), 1652 (s), 1628 (s), 1583 (m), 1551 (m), 1521 (s), 1406 (w), 1372 (w), 1252 (w), 1185 (s), 
1102 (m); 1H NMR (400 MHz, MeOD) δ: 7.89 (d, J = 1.3 Hz, 2 H, Hb), 7.66 (s, 1 H, Ha), 3.66 (s, 2 H, C≡C-
H), 3.36 (t, J = 7.0 Hz, 2 H, CH2-N), 2.31 (t, J = 7.3 Hz, 2 H, CH2-COOH), 1.69 – 1.59 (m, 4 H, 2x CH2), 1.45 
– 1.38 (m, 2 H, CH2); 13C NMR (101 MHz, MeOD) δ: 176.1 (C=O), 166.6 (C=O), 137.1 (Cb), 135.3 (C-
CON), 130.4 (Ca), 123.2 (C-C≡C-H), 81.1 (C≡C-H), 79.2 (C≡C-H), 39.5 (CH2-N), 33.3 (CH2-COOH), 28.6, 
26.2, 24.3 (3x CH2); HRMS: m/z [M-H]- calculated for C17H16NO3: 282.1135; Found: 282.1135 
 
tert-butyl 6-(6-(3,5-diethynylbenzamido)hexanamido)hexanoate (60) 
 
To a stirring solution of 58 (50 mg, 0.176 mmol) in N,N-dimethylformamide (0.1 mL) were added 
PyAOP (0.110 g, 0.21 mmol) and 56 (35 mg, 0.185 mmol). The mixture was stirred at r.t. for 18 h before 
concentrating in vacuo. The residue was purified through silica gel column chromatography (1:1 
Hexane:EtOAc) to give the title compound as a colourless oil (38 mg, 48%).  
Rf: 0.29 (2% MeOH/DCM); IR (neat film, νmax, cm-1): 3290 (m, NH), 2934 (m, CH), 2864 (w, CH), 1717 
(m, C=O), 1638 (s), 1585 (m), 1539 (s), 1455 (m), 1366 (m), 1322 (m), 1245 (m), 1149 (s); 1H NMR (400 
MHz, CDCl3) δ: 7.91 (d, J = 1.5 Hz, 2 H, H1), 7.69 (t, J = 1.5 Hz, 1 H, H2), 6.65 (br s, 1 H, NH), 5.58 (br s, 
1 H, NH), 3.48 (q, J = 6.9 Hz, 2 H, H3), 3.25 (q, J = 6.6 Hz, 2 H, H5), 3.13 (s, 2 H, C≡C-H), 2.22 – 2.18 (m, 
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4 H, C4 and C6), 1.71 – 1.63 (m, 4 H, 2x CH2), 1.61 – 1.37 (m, 15 H, 3x CH3 and 3x CH2), 1.35 – 1.30 (m, 
2 H, CH2);  13C NMR (101 MHz, CDCl3) δ: 173.1 (C6-C=O), 172.8 (C4-C=O), 165.7 (Ar-C=O), 137.8 (C2), 
135.4 (ArC-CON), 130.9 (C1), 123.0 (-C-C≡), 81.8 (C≡C-H), 80.2 (C-(CH3)3), 78.8 (C≡C-H), 39.5 (C3), 39.2 
(C5), 36.1, 35.3 (C4 and C6), 29.2, 28.7, 28.1 (3 x CH3), 26.3, 26.0, 24.5, 24.4; HRMS: m/z [M+K]+ 
calculated for C27H36N2O4K: 491.2307; Found: 491.2299 
 
6-(6-(3,5-Diethynylbenzamido)hexanamido)hexanoic acid (61) 
 
To a stirring solution of 60 (42 mg, 0.093 mmol) in dichloromethane (0.25 mL) was added 
trifluoroacetic acid (0.25 mL). The reaction was stirred for 2 h before being concentrated in vacuo to 
give the title compound as a white amorphous solid (36 mg, 98%) which was used directly with no 
further purification. 
Rf: 0.09 (1:1 EtOAc/Hex + 2% AcOH); IR (neat film, νmax, cm-1): 3283 (m, NH), 3194 (w, CH), 2946 (w, 
CH), 2867 (w, CH), 1734 (m, C=O), 1638 (s), 1582 (m), 1533 (s), 1458 (m), 1412 (m), 1390 (m), 1328 
(m), 1299 (m), 1257 (m), 1205 (m), 1186 (m), 1169 (m); 1H NMR (400 MHz, MeOD) δ: 7.90 (d, J = 1.5 
Hz, 2 H, H1), 7.66 (t, J = 1.5 Hz, 1 H, H2), 3.66 (s, 2H, ≡C-H), 3.36 (t, J = 7.0 Hz, 2 H, H3), 3.15 (t, J = 7.0 
Hz, 2 H, H5), 2.26 – 2.17 (m, 4 H, H4 and H6),  1.67 – 1.58 (m, 6 H, 3x CH2), 1.51 – 1.48 (m, 2 H, CH2), 
1.41 – 1.32 (m, 4 H, 2x CH2); 13C NMR (101 MHz, MeOD) δ: 178.1 (acid C=O), 174.6 (C4-C=O), 166.6 
(Ar-C=O), 137.1 (C2), 135.3 (ArC-CON), 130.4 (C1), 123.2 (-C-C≡), 81.1 (C≡C-H), 79.2 (C≡C-H), 39.5 (C3), 
38.8 (C5), 35.6, 34.9 (C4 and C6), 28.7, 28.6, 26.3, 26.1, 25.3, 24.9 (6x CH2); HRMS: m/z [M-H]- 
calculated for C23H27N2O4: 395.1976; Found: 395.1970 
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(5S,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthren-
17-yl 6-(6-(3,5-diethynylbenzamido)hexanamido)hexanoate (59) 
 
To a stirring solution of 61 (12 mg, 0.0303 mmol) in DMF (0.1 mL) were added N,N'-
dicyclohexylcarbodiimide (8 mg, 0.039 mmol), and 4-dimethylaminopyridine (0.6 mg, 0.0045 mmol). 
The mixture was stirred at r.t. for 3 h before dihydrotestosterone (10 mg, 0.033 mmol) was added and 
the reaction was stirred for a further 18 h. The mixture was then concentrated and triturated in 
dichloromethane. The residue was purified through silica gel column chromatography (9:1 
Hexane:EtOAc to EtOAc) to give the title compound as a colourless oil (4 mg, 20%). 
Rf: 0.50 (EtOAc); IR (neat film, νmax, cm-1): 3301 (w, NH), 2926 (m, CH), 2854 (m, CH), 1709 (m, C=O), 
1640 (s), 1583 (m), 1541 (s), 1447 (m), 1379 (w), 1318 (m), 1250 (m), 1171 (m), 1088 (w), 1026 (w); 1H 
NMR (500 MHz, CDCl3) δ: 7.91 (d, J = 1.5 Hz, 2 H, H2), 7.70 (s, 1 H, H1), 6.59 (br s, 1 H, NH), 5.52 (br s, 
1 H, NH), 4.59 (t, J = 8.5 Hz, 1 H, H7), 3.48 (q, J = 6.6 Hz, 2 H, H3), 3.26 (q, J = 6.8 Hz, 2 H, H5), 3.13 (s, 2 
H, ≡C-H), 2.42 – 1.93 (m, 10 H), 1.75 – 1.60 (m, 8 H), 1.54 – 1.27 (m, 15 H), 1.18 – 0.99 (m, 5 H), 0.93 – 
0.71 (m, 6 H); 13C NMR (126 MHz, CDCl3) δ: 211.9 (C10), 173.7 (C=O ester), 172.8 (C=O amide), 165.6 
(Ar-C=O), 137.8 (C1), 135.3 (ArC-CON), 130.8 (C2), 123.0 (-C-C≡), 82.6 (C7), 81.8 (C≡C-H), 78.8 (C≡C-H), 
53.7, 50.6, 46.6, 44.6, 42.7, 39.5 (C3), 39.2 (C5), 38.5, 38.1, 36.9, 36.1, 35.7, 35.2, 34.3, 31.2, 29.7, 29.3, 
28.8, 28.7, 27.6, 26.3, 26.0, 24.6, 23.5, 20.9, 12.2 (C8), 11.5 (C9); HRMS: m/z [M+H]+ calculated for 
C42H57N2O5: 669.4262; Found: 669.4258; [α]D25:  +154.2 (c = 0.048, MeOH) 
 
2-azido-1-(4-chlorophenyl)ethan-1-ol (66) 
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Following a modified version of a reported procedure,344 to a stirring solution of 2-bromo-4′-
chloroacetophenone (1.17 g, 5.0 mmol) in dimethylsulfoxide (20 mL) was added sodium azide (0.65 g, 
10.0 mmol). The mixture was stirred at r.t. for 30 mins before being extracted with Et2O (3 x 20 mL), 
washed with H2O (40 mL), and brine (40 mL), dried over Na2SO4, filtered, and concentrated in vacuo. 
The crude oil was immediately dissolved in methanol (20 mL), and sodium borohydride (0.378 g, 10.0 
mmol) was added and the reaction was stirred at r.t. for 1 h. The mixture was then extracted with 
DCM (3 x 20 mL), washed with H2O (40 mL), and brine (40 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo to give the title compound as an orange oil (0.692 g, 70%).  
Rf: 0.79 (1:1 EtOAc:Hex); IR (neat film, νmax, cm-1): 3384 (br w, OH), 2917 (w, CH), 2099 (s, N3), 1597 
(w, C=C), 1491 (m), 1254 (m), 1088 (s), 1013 (s); 1H NMR (400 MHz, CDCl3) δ: 7.35 (d, J = 8.5 Hz, 2H), 
7.30 (d, J = 8.5 Hz, 2H), 4.84 (dd, J = 5.4, 6.7 Hz, 1H), 3.47 – 3.40 (m, 2H), 2.54 (br s, 1H); 13C NMR (101 
MHz, CDCl3) δ: 139.1, 134.2, 129.0, 127.4, 72.8, 58.1; 
The spectroscopic data are in agreement with those previously reported in the literature.345 
 
tert-Butyl pent-4-yn-2-ylcarbamate (67) 
 
To a stirring solution of pent-4-yn-2-amine (190 mg, 2.3 mmol) in THF (5 mL) was added di-tert-butyl 
dicarbonate (0.523 mL, 2.3 mmol). The mixture was stirred at r.t. for 3 h before concentrating in vacuo. 
The residue was purified through silica gel column chromatography (1:19 to 1:9 EtOAc:Hexane) to give 
the title compound as a colourless oil (175 mg, 42%)  
Rf: 0.41 (1:9 EtOAc:Hexane); IR (neat film, νmax, cm-1): 3305 (w, NH), 2977 (w, CH), 2931 (w), 1686 (s, 
C=O), 1504 (s), 1454 (m), 1391 (m), 1365 (s), 1247 (s), 1159 (s), 1053 (s); 1H NMR (400 MHz, CDCl3) δ: 
4.64 (br s, 1H, NH), 3.83 (br s, 1H, H2), 2.44 – 2.30 (m, 2H, H1), 1.99 (t, J = 2.7 Hz, 1H, C≡C-H), 1.42 (s, 
9H, Boc-3x CH3), 1.21 (d, J = 6.5 Hz, 3H, H3); 13C NMR (101 MHz, CDCl3) δ: 155.2 (C=O), 80.6 (C≡C-H), 
79.4 (C≡C-H), 70.8 (qC), 44.7 (C2), 28.5 (Boc-CH3), 26.3 (C1), 19.9 (C3); HRMS (ESI): m/z calcd for 
C10H17NO2Na [M+Na]+: 206.1152; found: 206.1149  
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tert-butyl (1-(1-(2-(4-chlorophenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-5-yl)propan-2-yl)carbamate 
(74) 
 
To a stirring solution of chloro(pentamethylcyclopentadienyl)(cyclooctadiene)ruthenium(II) (0.6 mg, 
0.0016 mmol) in degassed toluene (0.2 mL) were added 67 (15 mg, 0.08 mmol) and 66 (16.2 mg, 
0.08 mmol). The mixture was heated to 75 °C for 2 h before being cooled and concentrated in vacuo. 
The residue was purified through silica gel column chromatography (8:2 EtOAc:Hexane) to give the 
title compounds, an inseparable mixture of diastereoisomers (d.r. 1:1 determined by 1H NMR) as a 
colourless oil (29 mg, 94%). 
Rf: 0.29 (8:2 EtOAc/PE 40-60); IR (neat film, νmax, cm-1): 3306 (br m, NH), 2975 (m, CH), 1688 (s, C=O), 
1518 (m, C=C), 1494 (m, C=C), 1454 (m, C=C), 1366 (m), 1248 (m), 1167 (s), 1089 (m); Data reported 
for mixture of isomers; 1H NMR (400 MHz, CDCl3) δ: 7.45 – 7.32 (m, 10H, Ar-H), 5.32 (dd, J = 8.7, 2.4 
Hz, 1H, H5), 5.25 (dd, J = 8.7, 2.4 Hz, 1H, H5), 4.69 – 4.21 (m, 8H, H2, H3, NH), 3.91 – 3.77 (m, 2H, OH), 
2.88 – 2.75 (m, 2H, H4), 2.70 – 2.64 (m, 2H, H4), 1.41 – 1.37 (2 x s, 18H, Boc-CH3), 1.19 – 1.13 (2 x d, J 
= 6.7 Hz, 6H, H1); 13C NMR (101 MHz, CDCl3) δ: 155.5, 155.5 (C=O), 139.1, 138.9 (qC), 134.0, 133.9 (Ar-
H), 128.9, 128.8 (Ar-H), 128.8, 128.7 (qC), 127.5, 127.4 (Ar-H), 80.2, 80.1 (qC), 72.7, 72.6 (C5), 55.3, 
54.7 (C3), 45.8, 45.8 (C2), 31.0, 30.5 (C4), 28.3, 28.3 (Boc-CH3), 20.3, 19.7 (C1); HRMS (ESI): m/z calcd 
for C18H26ClN4O3 [M+H]+: 381.1688; found: 381.1692 
 
2-(5-(2-aminopropyl)-1H-1,2,3-triazol-1-yl)-1-(4-chlorophenyl)ethan-1-ol (62) 
 
To a stirring solution of 74 (24 mg, 0.06 mmol) in dichloromethane (0.4 mL) was added trifluoroacetic 
acid (0.1 mL). The mixture was stirred at r.t. for 4 h before diluting in sat. aq. NaHCO3 (4 mL) and 
extracting into dichloromethane (3 x 10 mL). The combined organics were dried over Na2SO4, filtered 
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and concentrated in vacuo to give the title compounds as an inseparable mixture of diastereoisomers 
(d.r. 1:1 determined by 1H NMR) as a colourless oil (11.5 mg, 65%) which required no further 
purification. 
IR (neat film, νmax, cm-1): 3083 (br m, OH), 2925 (CH), 1676 (m), 1597, 1547 (m), 1491 (m), 1456 (m), 
1394 (m), 1242 (m), 1202 (m), 1089 (s), 1014 (m); Data reported for mixture of isomers; 1H NMR (500 
MHz, CDCl3) δ: 7.51 (d, J = 11.6 Hz, 2H, Ar-H), 7.41 (d, J = 8.4 Hz, 2H, Ar-H), 7.36 – 7.32 (m, 6H, Ar-H), 
5.23 (dd, J = 8.7, 2.6 Hz, 1H, H5), 5.14 – 5.13 (m, 1H, H5), 4.62 (dd, J = 14.6, 1.9 Hz, 1H, H3), 4.51 (dd, J 
= 14.6, 2.3 Hz, 1H, H3), 4.32 – 4.23 (m, 2H, H2), 3.38 – 3.31 (m, 2H, OH), 3.31 – 3.16 (m, 4H, NH2), 2.82 
– 2.75 (m, 3H, H4), 2.71 – 2.67 (m, 1H, H4), 1.27 (d, J = 6.4 Hz, 3H, H1), 1.21 (d, J = 6.4 Hz, 3H, H1); 13C 
NMR (126 MHz, CDCl3) δ: 139.5, 139.3 (qC), 136.0, 134.9 (qC), 134.0, 133.9 (qC), 133.2, 132.6 (Ar-H), 
129.0 (Ar-H), 127.5, 127.4 (Ar-H), 72.8, 72.4 (C5), 56.7, 55.6 (C3), 47.3, 46.1 (C2), 32.0, 31.6 (C4), 23.3 
(C1); HRMS (ESI): m/z calcd for C13H18ClN4O [M+H]+: 281.1164; found: 281.1166 
 
(E)-1-cyclohexyl-N-(4-methoxyphenyl)methanimine (75) and N-(1-cyclohexylbuta-2,3-dien-1-yl)-4-
methoxyaniline (76) 
         
To a stirring solution of p-anisidine (0.246 g, 2.0 mmol) in dichloromethane (10 mL) were added 
magnesium sulfate (2.0 g) and 63 (0.24 mL, 2.0 mmol). The mixture was stirred at r.t. for 1 h before 
being filtered through Celite®, washed with dichloromethane (10 mL), and concentrated in vacuo. The 
crude residue was dissolved in DMF (18 mL) and cooled to 0 °C, before propargyl bromide (80% in 
toluene 0.30 mL, 2.7 mmol) and activated zinc (0.241 g, 3.7 mmol) were added. After stirring at r.t. for 
1 h the mixture was cooled to 0 °C and quenched with sat. aq. NH4Cl (25 mL). The mixture was then 
extracted into EtOAc (3 x 25 mL), washed with brine (25 mL), dried over Na2SO4, filtered and 
concentrated in vacuo to give the title compounds as an inconsequential mixture of allene:alkyne 
(ratio of 0.56:1 determined by 1H NMR), isolated as a yellow oil (0.323 g, 63%). 
Rf: 0.24 (1:19 EtOAC:PE 40-60); IR (neat film, νmax, cm-1): 3292 (w, NH), 2925 (m, CH), 2852 (m), 1510 
(s), 1449 (w), 1234 (m), 1179 (w), 1038 (w); Reported as 0.56:1 allene:alkyne mixture; 1H NMR (400 
MHz, CDCl3) δ: 6.79 – 6.76 (m, 3H, H3/4), 6.61 (m, 3H, H3/4), 5.05 (dd, J = 6.7, 13.5 Hz, 0.56 H, allene-
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H), 4.81 – 4.72 (m, 1.2 H, 2 x allene-H), 3.75 (s, 4.5H, H1) 3.68 – 3.48 (m, 2H), 3.23 – 3.19 (m, 1H), 2.51 
– 2.39 (m, 2H, alkyne-CH2), 1.98 (t, J = 2.6 Hz, 1H, alkyne-H), 1.90 – 1.52 (m, 8.5H), 1.34 – 0.98 (m, 
7.9H); 13C NMR (101 MHz, CDCl3) δ: 208.3 (allene =C=), 152.2 (C2), 142.0 (C5), 115.2, 115.1, 114.9 
(C3/C4), 91.9 (allene), 81.5 (alkyne), 76.5 (allene), 70.3 (alkyne), 58.8, 57.7 (C9), 55.9 (C1), 43.2, 40.9 
(C10), 30.1 (C8), 29.7, 29.4, 29.3, 26.7, 26.6, 26.4, 26.4, 26.3, 21.2 (C11-15); HRMS (ESI): m/z calcd for 
C17H24NO [M+H]+: 258.1858; found: 258.1866 
 
tert-Butyl (1-cyclohexylbut-3-yn-1-yl)carbamate (68) 
 
To a stirring solution of 75 (0.296 g, 1.15 mmol) in acetonitrile (8 mL) cooled to 0 °C, was dropwise 
added a solution of ammonium cerium(IV) nitrate (1.26 g, 2.3 mmol) in water (8 mL). The reaction was 
stirred for 2 h at r.t. before being treated with 2 M HCl to pH 1. The aqueous phase was then washed 
with EtOAc (3 x 10 mL), and then taken to basic by addition of Na2CO3. The suspension was then 
extracted with dichloromethane (3 x 30 mL), dried over Na2SO4, filtered, and concentrated in vacuo. 
The crude residue was then dissolved in THF (2 mL) and di-tert-butyl decarbonate (0.26 mL, 1.15 
mmol) was added. The mixture was stirred at r.t. for 3 h before concentrating in vacuo. The residue 
was purified through silica gel column chromatography (1% EtOAc/PE 40-60) to give the title 
compound as a colourless oil (85 mg, 29%). 
Rf: 0.15 (1% EtOAc/PE 40-60); IR (neat film, νmax, cm-1): 2984 (w, CH), 2937 (w), 1799 (m), 1755 (m), 
1460 (w), 1396 (w), 1371 (m), 1306 (w), 1262 (w), 1210 (m), 1111 (s), 1056 (s); 1H NMR (400 MHz, 
CDCl3) δ: 4.62 (d, J = 8.7 Hz, 1H, NH),  3.53 – 3.49 (m, 1H, H4), 2.43 – 2.41 (m, 2H, H3), 1.96 (t, J = 2.6 
Hz, 1H, H1), 1.82 – 1.62 (m, 6H), 1.43 (s, 9H, 3x CH3), 1.28 – 1.08 (m, 3H), 1.03 – 0.92 (m, 2H); 13C NMR 
(101 MHz, CDCl3) δ: 155.8 (C=O), 80.9 (Boc-qC), 79.3 (C≡C-H), 70.5 (C≡C-H), 53.3 (C4), 40.5 (C5), 30.0 
(C3), 29.0, 28.5 (Boc-CH3), 26.4, 26.2, 26.1, 22.4; HRMS (ESI): mass not found. 
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tert-butyl (2-(1-(2-(4-chlorophenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-5-yl)-1-cyclohexylethyl) 
carbamate (79) 
 
To a stirring solution of chloro(pentamethylcyclopentadienyl)(cyclooctadiene)ruthenium(II) (1.0 mg, 
0.002 mmol) in degassed toluene (0.5 mL) were added 68 (25 mg, 0.1 mmol) and 66 (20 mg, 0.1 mmol). 
The mixture was heated to 70°C for 2 h before being cooled and concentrated in vacuo. The residue 
was purified through silica gel column chromatography (1:1 EtOAc:Hexane) to give the title compound 
as an inseparable mixture of diastereoisomers (d.r. 1:1 determined by 1H NMR) as a colourless oil (42 
mg, 94%).  
Rf: 0.10 (1:1 EtOAc:Hexane); IR (neat film, νmax, cm-1): 3307 (w, NH), 2925 (s, CH), 2853 (m, CH), 1685 
(s, C=O), 1520 (m), 1493 (m), 1450 (m), 1391 (m), 1366 (m), 1249 (m), 1169 (s), 1089 (m), 1014 (m); 
Data reported for the mixture of isomers; 1H NMR (400 MHz, CDCl3) δ: 7.45 – 7.40 (m, 4H), 7.36 – 7.32 
(m, 6H), 5.36 – 5.26 (m, 2H, H1), 4.87 (d, J = 3.2 Hz, 1H), 4.52 – 4.44 (m, 4H, H4), 4.38 – 4.33 (m, 1H, 
H5), 4.27 – 4.22 (m, 1H, H5), 4.01 (d, J = 4.1 Hz, 1H), 3.78 – 3.73 (m, 1H), 3.69 – 3.62 (m, 1H), 2.79 – 
2.73 (m, 2H, H2), 2.65 – 2.56 (m, 2H, H2), 1.81 – 1.68 (m, 12H, 6x CH2), 1.36 – 1.33 (2 x s, 18H, Boc-
CH3), 1.25 – 0.97 (m, 10H, 5x CH2); 13C NMR (101 MHz, CDCl3) δ: 156.1, 155.8 (C=O), 139.0 (qC), 135.2, 
135.1 (qC), 134.0, 133.8 (Ar-H), 133.5, 133.4 (qC), 128.9, 128.8 (Ar-H), 127.4 (Ar-H), 80.2, 79.9 (Boc-
qC), 72.58, 72.5 (C1), 55.7, 54.8 (C4), 54.2, 53.9 (C5), 41.4, 40.9 (C6), 30.0, 29.9 (C2), 28.4, 28.3, 28.3 
(Boc-CH3), 27.9, 26.7, 26.2, 26.0, 26.0; HRMS (ESI): m/z calcd for C23H34ClN4O3 [M+H]+: 449.2314; 
found: 449.2298 
 
2-(5-(2-amino-2-cyclohexylethyl)-1H-1,2,3-triazol-1-yl)-1-(4-chlorophenyl)ethan-1-ol (63) 
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To a stirring solution of 79 (18 mg, 0.06 mmol) in dichloromethane (0.2 mL) was added trifluoroacetic 
acid (0.05 mL). The mixture was stirred at r.t. for 4 h before diluting in sat. aq. NaHCO3 (4 mL) and 
extracting into dichloromethane (3 x 10 mL). The combined organics were dried over Na2SO4, filtered 
and concentrated in vacuo to give the title compound as an inseparable mixture of diastereoisomers 
(d.r. 1:1 determined by 1H NMR) as a colourless oil (13.1 mg, 94%) which required no further 
purification.  
IR (neat film, νmax, cm-1): 3219 (br, w, OH), 2925 (s, CH), 2852 (m, CH), 1664 (w), 1593 (w), 1548 (w), 
1491 (m), 1449 (m), 1406 (w), 1240 (w), 1089 (m), 1014 (m); Data reported for the mixture of isomers; 
1H NMR (400 MHz, CDCl3) δ: 7.52 – 7.32 (m, 10H, Ar-H), 5.22 (dd, J = 8.2, 2.8 Hz, 1H, H1), 5.12 (dd, J = 
9.0, 1.5 Hz, 1H, H1), 4.65 (dd, J = 14.4, 2.0 Hz, 1H), 4.53 (dd, J = 14.4, 2.8 Hz, 1H), 4.38 – 4.32 (m, 1H), 
4.25 – 4.19 (m, 1H), 2.91 – 2.62 (m, 10H), 1.79 – 1.70 (m, 10H), 1.43 – 1.41 (m, 1H), 1.34 – 0.95 (m, 
13H); 13C NMR (101 MHz, CDCl3) δ: 139.6, 139.3 (qC), 136.6, 135.7 (qC), 133.8, 133.7 (Ar-H), 132.7, 
132.3 (qC), 128.8 (Ar-H), 127.3, 127.3 (Ar-H), 72.8, 72.3 (C1), 56.9, 56.4 (C4), 55.6, 55.2 (C5), 43.5, 43.3 
(C6), 29.7, 29.6 (C2), 29.3, 28.7, 28.6, 27.6, 27.4, 26.3, 26.3, 26.2, 26.1, 26.1; HRMS (ESI): m/z calcd for 
C18H26ClN4O [M+H]+: 349.1790; found: 349.1793 
 
N-cyclohexylidene-2-methylpropane-2-sulfinamide (80) 
 
Following a modified version of a reported procedure346, To a stirring solution of cyclohexanone (0.912 
mL, 8.8 mmol) in DCM (22 mL) were added 2-methyl-2-propanesulfinamide (0.968 g, 8.0 mmol) and 
titanium (IV) ethoxide (3.32 mL, 16 mmol). The mixture was heated to 45 °C for 2 h before methanol 
(5 mL) was added, followed by NaHCO3 added dropwise until precipitation of titanium salts. The 
mixture was then filtered through Na2SO4, washed with EtOAc, and concentrated in vacuo. The residue 
was purified through silica gel column chromatography (7:13 EtOAc:Hexane) to give the title 
compound as a yellow oil (1.095 g, 62%).  
Rf: 0.75 (1:1 EtOAc:Hex); IR (neat film, νmax, cm-1): 2962 (w), 2924 (w), 2869 (w), 1673 (w), 1472 (w), 
1456 (w), 1363 (m), 1297 (s), 1218 (w), 1181 (w), 1124 (s); 1H NMR (400 MHz, CDCl3) δ: 2.92 – 2.85 (m, 
1H), 2.75 – 2.68 (m, 1H), 2.42 (t, J = 6.4 Hz, 2H), 1.84 – 1.61 (m, 6H), 1.22 (s, 9H); 13C NMR (101 MHz, 
CDCl3) δ: 188.8, 56.1, 40.8, 34.5, 28.0, 27.5, 25.5, 22.2 
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The spectroscopic data are in agreement with those previously reported in the literature.347 
 
2-methyl-N-(1-(prop-2-yn-1-yl)cyclohexyl)propane-2-sulfinamide (81) 
 
To a stirring solution of magnesium turnings (10.3 g, 424 mmol) and zinc bromide (1.90 g, 8.44 mmol) 
in Et2O (120 mL) was carefully added 3-bromopropyne (80% wt. in tol, 15.9 mL, 184 mmol). The 
mixture was then stirred at r.t. for 1 h, and then titrated using (-)-menthol and 1,10-phenanthroline in 
THF to give a concentration of 0.10 M. 80 (0.550 g, 2.7 mmol) was dissolved in DCM (19 mL) and cooled 
to -78 °C before the Grignard solution (30 mL) was added slowly. After stirring for 1 h, the solution 
was quenched with sat. aq. NH4Cl (10 mL) and warmed to r.t. The mixture was then extracted with 
EtOAc (3 x 20 mL), dried over Na2SO4, filtered, and concentrated in vacuo to give the title compound 
as a yellow oil (0.639 g, 97%) which required no further purification. 
Rf: 0.35 (1:1 EtOAc:Hex); IR (neat film, νmax, cm-1): 3308 (w, NH), 3225 (w, NH), 2929 (m, CH), 2859 (m, 
CH), 1473 (w), 1453 (w), 1362 (w) 1184 (w), 1154 (w), 1052 (s); 1H NMR (400 MHz, CDCl3) δ: 3.49 (s, 
1H, NH), 2.62 (dd, J = 16.5, 2.6 Hz, 1H, H1), 2.40 (dd, J = 16.5, 2.6 Hz, 1H, H1), 2.06 (t, J = 2.6 Hz, 1H, 
C≡C-H), 1.95 – 1.92 (m, 1H, H3), 1.78 – 1.32 (m, 9H, H3 – H7), 1.23 (s, 9H); 13C NMR (101 MHz, CDCl3) 
δ: 80.7 (C≡C-H), 71.8 (C≡C-H), 56.4 (C2), 56.0 (qC), 37.2, 34.7 (C3/C7), 32.7 (C1), 25.6 (C5), 22.9 (CH3), 
21.8, 21.7 (C4/C6); HRMS (ESI): m/z calcd for C13H23NOSNa [M+Na]+: 264.1392; found: 264.1381 
 
tert-butyl (1-(prop-2-yn-1-yl)cyclohexyl)carbamate (69) 
 
To a stirring solution of 81 (0.611 g, 2.5 mmol) in methanol (25 mL) was carefully added hydrochloric 
acid (4 M in dioxane, 6.33 mL). The mixture was then heated to 90 °C for 2 h before being cooled to 
r.t. and concentrated in vacuo. NaHCO3 (sat. aq. 5 mL) was added and the mixture was extracted with 
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DCM (3 x 15 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude amine was then 
dissolved in THF (10 mL) and di-tert-butyl decarbonate (0.58 mL, 2.5 mmol) was added. The solution 
was stirred at r.t. for 4 h before concentrating in vacuo. The residue was purified through silica gel 
column chromatography (1:19 EtOAc:Hexane) to give the title compound as a colourless oil (0.589 g, 
98%). 
Rf: 0.23 (1:19 EtOAc:Hexane); IR (neat film, νmax, cm-1): 3305 (w, NH), 2982 (w, CH), 2936 (w, CH), 1804 
(m), 1756 (m, C=O), 1716 (m), 1497 (w), 1371 (m), 1211 (m), 1167 (m), 1112 (s), 1060 (s); 1H NMR (400 
MHz, CDCl3) δ: 4.42 (br s, 1H, NH), 2.00 (br s, 2H, H1), 1.96 (t, J = 2.6 Hz, 1H, C≡C-H), 1.62 – 1.43 (m, 
17H), 1.27 – 1.25 (m, 1H); 13C NMR (101 MHz, CDCl3) δ: 146.8 (C=O), 85.3 (Boc-qC), 81.2 (C≡C-H), 70.2 
(C≡C-H), 53.8 (C2), 34.4 (C1), 28.5 (CH3), 27.5, 25.6, 21.7 (C3-5); HRMS (ESI): mass not found. 
 
tert-butyl (1-((1-(2-(4-chlorophenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-5-yl)methyl)cyclohexyl) 
carbamate (82) 
 
To a stirring solution of chloro(pentamethylcyclopentadienyl)(cyclooctadiene)ruthenium(II) (0.99 mg, 
0.0026 mmol) in degassed toluene (0.3 mL) were added 69 (27 mg, 0.11 mmol) and 66 (22.5 mg, 
0.11 mmol). The mixture was heated to 50 °C for 2 h before being cooled and concentrated in vacuo. 
The residue was purified through silica gel column chromatography (1:1 EtOAc:Hexane) to give the 
title compound as a colourless oil (32 mg, 84%)  
Rf: 0.16 (1:1 EtOAc:Hexane); IR (neat film, νmax, cm-1): 3306 (br, m, OH), 2931 (m, CH), 2857 (w, CH), 
1704 (m, C=O), 1493 (m), 1451 (m), 1391 (w), 1366 (m), 1245 (m), 1162 (s), 1088 (s), 1014 (w); 1H NMR 
(400 MHz, CDCl3) δ: 7.39 (s, 1H, H5), 7.31 (s, 4H, H1, H2), 5.21 (m, 1H, H3), 4.47 – 4.37 (m, 2H, H4), 
4.23 (s, 1H, NH), 4.07 (s, 1H, OH), 3.03 – 2.90 (m, 2H, CH2), 1.90 (m, 2H, H6), 1.62 – 1.50 (m, 3H), 1.38 
– 1.20 (m, 14H, 3x CH3); 13C NMR (101 MHz, CDCl3) δ: 154.6 (C=O), 139.0 (qC), 134.5 (qC), 134.1 (qC), 
133.8 (C5), 128.9 (Ar-H), 127.5 (Ar-H), 79.6 (Boc-qC), 72.5 (C3), 54.7 (C4), 54.3 (C7), 34.9 (C6), 32.0, 
28.4 (Boc CH3), 25.4, 21.4; HRMS (ESI): m/z calcd for C22H32ClN4O3 [M+H]+: 435.2158; found: 435.2178. 
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2-(5-((1-aminocyclohexyl)methyl)-1H-1,2,3-triazol-1-yl)-1-(4-chlorophenyl)ethan-1-ol (64) 
 
To a stirring solution of 82 (31 mg, 0.07 mmol) in dichloromethane (0.4 mL) was added trifluoroacetic 
acid (0.1 mL). The mixture was stirred at r.t. for 4 h before diluting in sat. aq. NaHCO3 (4 mL) and 
extracting into dichloromethane (3 x 10 mL). The combined organics were dried over Na2SO4, filtered 
and concentrated in vacuo to give the title compound as a colourless oil (20 mg, 84%), which required 
no further purification. 
IR (neat film, νmax, cm-1): 3079 (w, NH), 2929 (m, CH), 2850 (w, CH), 1582 (m, C=C), 1540 (w), 1489 (m), 
1450 (m), 1291 (w), 1230 (w), 1135 (w), 1074 (m); 1H NMR (400 MHz, CDCl3) δ: 7.51 (s, 1H, H5), 7.44 
– 7.41 (m, 2H), 7.40 – 7.33 (m, 2H), 5.15 (dd, J = 1.7, 8.9 Hz, 1H, H3), 4.67 (dd, J = 2.0, 14.4 Hz, 1H, H4), 
4.28 (dd, J = 8.9, 14.4 Hz, 1H, H4), 3.19 (br s, 2H, NH2), 2.83 (s, 2H, H6), 1.59 – 1.24 (m, 11H); 13C NMR 
(101 MHz, CDCl3) δ: 139.8 (qC), 134.0 (qC), 133.7 (qC), 133.3 (C5), 128.9, 127.5 (C1/C2), 72.7 (C3), 57.1 
(C4), 51.6 (C7), 39.0, 38.5, 34.9 (C6), 25.5, 22.1, 21.9 (C7-12); HRMS (ESI): m/z calcd for C17H24ClN4O 
[M+H]+: 335.1633; found: 335.1621. 
 
 
tert-Butyl 2-(6-methoxy-1-(naphthalen-1-yl)-9H-pyrido[3,4-b]indol-9-yl)acetate (90) 
 
To a stirring solution of SP-141 (9 mg, 0.03 mmol) in DMF (133 µl) was added caesium carbonate (12.66 
mg, 0.04 mmol). The reaction was stirred for ca. 15 mins before a solution of tert-butyl 2-
bromoacetate (5.74 µl, 0.04 mmol) in DMF (133 µl) was slowly added. The reaction was stirred for a 
further 4 h before being dissolved in DCM (5 mL) and water (5 mL), extracted thrice into DCM (3 x 10 
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mL), dried over MgSO4, filtered and concentrated in vacuo to give the title compound (12.00 mg, 
>98%) as a yellow oil used without further purification. 
IR (neat film, νmax, cm-1): 2976 (w, CH), 1743 (s, C=O), 1586 (w), 1561 (m), 1489 (s), 1454 (m), 1437 (m), 
1394 (w), 1368 (m), 1296 (m), 1280 (m), 1229 (s), 1196 (s), 1155 (s), 1046 (w); 1H NMR (500 MHz, 
CDCl3) δ: 8.59 (d, J = 5.2 Hz, 1 H, H9), 8.03 (d, J = 5.2 Hz, 1 H, H8), 7.99 (dd, J = 7.2, 2.3 Hz, 1 H, H15), 
7.94 (d, J = 8.2 Hz, 1 H, H20), 7.67 (d, J = 2.4 Hz, 1 H, H5), 7.54 – 7.61 (m, 2 H, H13, H14), 7.49 (ddd, J = 
8.2, 6.7, 1.2 Hz, 1 H, H18/H19), 7.42 (d, J = 8.2 Hz, 1 H, H17), 7.34 (ddd, J = 8.2, 6.7, 1.2 Hz, 1 H, 
H18/H19), 7.21 (dd, J = 8.9, 2.5 Hz, 1 H, H3), 7.12 (d, J = 8.9 Hz, 1 H, H2), 4.28 (d, J = 18.2 Hz, 1 H, -CH2), 
4.05 (d, J = 18.2 Hz, 1 H, -CH2), 3.96 (s, 3 H, -OMe), 1.15 (s, 9 H, tBu-CH3); 13C NMR (126 MHz, CDCl3) δ: 
167.1 (C=O), 154.6 (C4), 142.7 (C10), 138.6 (C9), 137.5 (C1), 136.5 (C16), 136.2 (C11), 133.7 (C21), 
132.4 (C12), 130.1 (C7), 129.1 (C15), 128.3 (C20), 127.4 (C13/C14), 126.9 (C18/C19), 126.3 (C18/C19), 
126.0 (C17), 125.4 (C13/C14), 122.0 (C6), 118.6 (C3), 114.0 (C8), 110.4 (C2), 103.8 (C5), 82.0 (q-ali-C), 
56.2 (OMe), 46.4 (CH2), 27.7 (CH3); HRMS: m/z [M+H]+ calculated for C28H27N2O3: 439.2016; Found: 
439.2013. 
 
2-(6-methoxy-1-(naphthalen-1-yl)-9H-pyrido[3,4-b]indol-9-yl)acetic acid (91) 
 
To a stirring solution of 90 (20 mg, 0.05 mmol) in DCM (228 µl) was added 2,2,2-trifluoroacetic acid 
(520 mg, 4.56 mmol). The reaction was stirred at r.t for 2 h before concentrating. The residue was 
then twice dissolved in toluene (2 x 5 mL) and concentrated in vacuo to give the title compound (17.00 
mg, 97%) as a yellow oil used without further purification. 
IR (neat film, νmax, cm-1): 2926 (w, CH), 2853 (w, CH), 1708 (s, C=O), 1666 (m), 1602 (m), 1496 (m), 1478 
(m), 1361 (m), 1296 (m), 1224 (m), 1178 (s), 1131 (s), 1090 (m), 1046 (m); 1H NMR (500 MHz, Acetone) 
δ: 8.75 (s, 2 H), 8.23 (d, J = 8.2 Hz, 1 H), 8.12 – 8.08 (m, 2 H), 7.74 (dd, J = 7.0, 1.1 Hz, 1 H), 7.71 – 7.59 
(m, 3 H), 7.48 – 7.39 (m, 2 H), 7.35 (d, J = 8.4 Hz, 1 H), 4.74 (d, J = 18.6 Hz, 1 H, CH2), 4.22 (d, J = 18.6 
Hz, 1 H, CH2), 3.99 (s, 3 H, OMe); 13C NMR (126 MHz, Acetone) δ:  168.9 (C=O), 156.8 (C4), 141.4, 138.2, 
136.0, 135.4, 134.2, 132.9, 132.4 (Ar-H), 132.0 (Ar-H), 130.4 (Ar-H), 129.7 (Ar-H), 128.8 (Ar-H), 128.5, 
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127.9 (Ar-H), 126.1 (Ar-H), 125.6 (Ar-H), 123.5 (Ar-H), 121.6, 117.4 (Ar-H), 113.0 (Ar-H), 104.7 (Ar-H), 
56.4 (OMe), 46.3 (CH2); HRMS: m/z [M+H]+ calculated for C24H19N2O3: 383.1390; Found: 383.1394. 
 
tert-Butyl (1-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-
yl)-2-fluorophenyl)-1-oxo-5,8,11-trioxa-2-azatridecan-13-yl)carbamate (93) 
 
To a stirring solution of 2 (27 mg, 0.06 mmol) in DMF (267 µl) were added HATU (27.3 mg, 0.07 mmol) 
and DIPEA (12.50 µl, 0.07 mmol). After stirring at r.t. for ca. 15 mins 92 (19.99 µl, 0.07 mmol) was 
added and the reaction stirred for a further 3 h. The mixture was then dissolved in EtOAc (10 mL) and 
H2O (5 mL) and extracted into EtOAc (3 x 10 mL), dried over MgSO4, filtered and concentrated in vacuo. 
The residue was then purified by silica gel chromatography (50 to 100% EtOAc/Heptane) to give the 
title compound (30.0 mg, 69%) as a yellow oil. 
IR (neat film, νmax, cm-1): 3365 (br w, NH), 2932 (w, CH), 1758 (m, C=O), 1702 (m, C=O), 1659 (m, C=O), 
1620 (m), 1532 (m), 1499 (m), 1438 (s), 1411 (s), 1366 (m), 1311 (s), 1286 (s), 1220 (s), 1176 (s), 1134 
(s), 1056 (w); 1H NMR (400 MHz, CDCl3) δ: 8.23 (t, J = 8.3 Hz, 1 H, H14), 7.99 (d, J = 8.3 Hz, 1 H, H6), 
7.95 (d, J = 2.0 Hz, 1 H, H3), 7.83 (dd, J = 8.3, 1.9 Hz, 1 H, H5), 7.24 (dd, J = 8.3, 1.8 Hz, 1 H, H15), 7.16 
(dd, J = 11.4, 1.9 Hz, 2 H, H11, NH), 5.00 (br s, 1 H, NH), 3.73 – 3.58 (m, 12 H, 6x CH2), 3.52 (t, J = 5.2 
Hz, 2 H, CH2), 3.32 – 3.22 (m, 2 H, CH2), 1.61 (s, 6 H), 1.43 (s, 9 H); 8.14 (t, J = 8.2 Hz, 1 H, H14), 7.98 (d, 
J = 8.3 Hz, 1 H, H6), 7.95 (d, J = 1.8 Hz, 1 H, H3), 7.82 (dd, J = 8.3, 1.9 Hz, 1 H, H5), 7.56 (s, 1 H, NH), 7.21 
(dd, J = 8.3, 1.8 Hz, 1 H, H15), 7.15 (dd, J = 11.2, 1.7 Hz, 1 H, H11), 4.35 (br s, 2 H, NH2), 3.82 – 3.50 (m, 
14 H, 7x CH2), 3.07 – 2.90 (m, 2 H, N-CH2), 1.60 (s, 6 H, H9); 13C NMR (126 MHz, CDCl3) δ: 179.8 (C=S), 
174.5 (C=O), 162.3 (C=O), 160.4 (d, J = 250 Hz, C12), 156.0 (Boc C=O), 139.0 (d, J = 10 Hz, C13), 136.9 
(C1), 135.3 (C6), 133.7 (q, J = 34 Hz, C2), 133.2 (C14), 132.2 (C5),127.1 (q, J = 5.2 Hz, C3), 126.1 (C15), 
123.0 (d, J = 11.6 Hz, C10), 121.8 (q, J = 275 Hz, CF3), 118.0 (d, J = 28 Hz, C11), 114.7 (-C≡N), 110.4 (C4), 
79.3 (Boc qC), 70.5, 70.4, 70.3, 70.2 (2C), 69.6 (overlapping 6x O-CH2), 66.6 (C8), 40.4, 39.9 (2x N-CH2), 
28.4 (Boc-CH3), 23.8 (C9); 19F NMR (471 MHz, CDCl3) δ: -61.98, -110.36; HRMS (ESI): m/z calcd for 
C33H39F4N5O7SNa [M+Na]+: 748.2399; found: 748.2407. 
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N-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-
dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamide (94) 
 
To a stirring solution of 93 (21 mg, 0.03 mmol) in DCM (0.2 mL) was added 2,2,2-trifluoroacetic acid 
(0.2 mL, 2.61 mmol). The reaction was stirred at 25 °C for 2 h before concentrating and dissolving in 
sat. aq. NaHCO3 (5 mL) and extracting into EtOAc (3 x 10 mL), drying over MgSO4, filtering and 
concentrating in vacuo to give the title compound (17.00 mg, 94%) as a yellow oil used without further 
purification. 
IR (neat film, νmax, cm-1): 3397 (br w, NH), 2921 (w, CH), 1757 (m, C=O), 1706 (m, C=O), 1656 (m), 1620 
(m), 1540 (m), 1500 (m), 1438 (m), 1415 (m), 1363 (m), 1311 (s), 1221 (s), 1202 (m), 1177 (s), 1129 (s), 
1090 (s), 1056 (m); 1H NMR (500 MHz, CDCl3) δ: 8.14 (t, J = 8.2 Hz, 1 H, H14), 7.98 (d, J = 8.3 Hz, 1 H, 
H6), 7.95 (d, J = 1.8 Hz, 1 H, H3), 7.82 (dd, J = 8.3, 1.9 Hz, 1 H, H5), 7.56 (s, 1 H, NH), 7.21 (dd, J = 8.3, 
1.8 Hz, 1 H, H15), 7.15 (dd, J = 11.2, 1.7 Hz, 1 H, H11), 4.35 (br s, 2 H, NH2), 3.82 – 3.50 (m, 14 H, 7x 
CH2), 3.07 – 2.90 (m, 2 H, N-CH2), 1.60 (s, 6 H, H9); 13C NMR (126 MHz, CDCl3) δ: 179.8 (C=S), 174.5 
(C=O), 162.9 (C=O), 160.3 (d, J = 250 Hz, C12), 138.9 (d, J = 10 Hz, C13), 136.9 (C1), 135.3 (C6), 133.7 
(q, J = 34 Hz, C2), 133.0 (C14), 132.2 (C5), 127.1 (q, J = 5.2 Hz, C3), 126.0 (C15), 123.4 (d, J = 11.6 Hz, 
C10), 121.8 (q, J = 275 Hz, CF3), 118.0 (d, J = 28 Hz, C11), 114.7 (-C≡N), 110.4 (C4), 70.5, 70.3, 70.1, 
70.0, 69.8, 69.6 (6x O-CH2), 66.7 (C8), 40.4, 39.9 (2x N-CH2), 23.8 (C9); 19F NMR (471 MHz, CDCl3) δ: -
62.0, -110.4; HRMS (ESI): m/z calcd for C28H32F4N5O5S [M+H]+: 626.2055; found: 626.2055. 
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4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-
(1-(6-methoxy-1-(naphthalen-1-yl)-9H-pyrido[3,4-b]indol-9-yl)-2-oxo-6,9,12-trioxa-3-
azatetradecan-14-yl)benzamide (PROTAC-7) 
 
To a stirring solution of 91 (3 mg, 7.84 µmol) in DMF (77 µl) were added HATU (4.18 mg, 10.98 µmol) 
and DIPEA (1.913 µl, 10.98 µmol). After stirring at r.t. for ca. 15 mins 94 (5.15 mg, 8.24 µmol) was 
added and the reaction stirred for a further 3 h. The mixture was then dissolved in EtOAc (10 mL) and 
H2O (5 mL) and extracted into EtOAc (3 x 10 mL), dried over MgSO4, filtered and concentrated in 
vacuo. The residue was then purified by silica gel chromatography (0 to 5% MeOH/DCM) to give the 
title compound (2.60 mg, 34%) as a yellow oil. 
Rf: 0.30 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 3322 (w, NH), 2929 (w, CH), 1758 (m, C=O), 1658 
(m, C=O), 1620 (m, C=O), 1535 (w), 1489 (m), 1438 (m), 1409 (m), 1311 (m), 1261 (m), 1221 (m), 1198 
(m), 1178 (m), 1132 (m), 1105 (m), 1057 (m), 1023 (w), 837 (s), 728 (s); 1H NMR (500 MHz, CDCl3) δ: 
8.51 (d, J = 5.2 Hz, 1 H), 8.14 (t, J = 8.3 Hz, 1 H, H14), 8.05 (d, J = 5.2 Hz, 1 H, ), 8.01 - 7.89 (m, 4H), 7.82 
(dd, J = 8.3, 1.8 Hz, 1 H, H5), 7.66 (d, J = 2.2 Hz, 1H), 7.60 – 7.54 (m, 2H), 7.48 (t, J = 7.3 Hz, 1H), 7.37 – 
7.30 (m, 2H), 7.23 – 7.10 (m, 5H), 5.65 (t, J = 5.7 Hz, 1 H, NH), 4.24 (d, J = 17.8 Hz, 1 H, H18), 4.05 (d, J 
= 17.8 Hz, 1 H, H18), 3.95 (s, 3 H, OMe), 3.68 (p, J = 6.7 Hz, 3 H), 3.59 (d, J = 3.2 Hz, 2 H), 3.53 (dd, J = 
5.6, 3.0 Hz, 2 H), 3.48 (dd, J = 5.5, 3.2 Hz, 2 H), 3.41 (s, 2 H), 3.30 (qt, J = 9.7, 5.0 Hz, 2 H), 3.15 (q, J = 
7.4 Hz, 3 H), 1.57 (s, 6 H, H9); 13C NMR (126 MHz, CDCl3) δ: 179.8 (C=S), 174.4 (C=O), 167.3 (C=O), 162.3 
(C=O), 160.3 (d, J = 250 Hz, C12), 155.0 (C-OMe), 142.6, 139.0, 138.4, 137.3, 136.8, 135.7, 135.3 (C6), 
135.1 (C1), 133.7 (d, J = 34 Hz, C2), 133.5, 133.1, 132.2 (2C), 130.5, 129.6, 128.6, 127.4, 127.1 (d, J = 5 
Hz, C3), 126.9, 126.4, 126.1 (C15), 125.5, 125.2, 123.0 (d, J = 11 Hz, C10), 121.9, 121.8 (q, J = 275 Hz, 
CF3), 119.2, 118.0 (d, J = 27 Hz, C11), 114.7 (-C≡N), 114.2, 110.9, 110.4 (d, J = 2.2 Hz, C4), 103.7, 70.3 
(2C), 70.2, 70.1, 69.5, 69.3 (6x O-CH2), 66.6 (C8), 55.8 (OMe), 43.7 (C18), 39.8, 39.0 (2x N-CH2), 23.8 
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(C9); 19F NMR (471 MHz, CDCl3) δ: -62.0, -110.5; HRMS (ESI): m/z calcd for C52H48F4N7O7S [M+H]+: 
990.3267; found: 990.3251. 
 
Methyl (3,3-diphenylpropanoyl)-L-tyrosinate (86) 
 
To a stirring solution of 96 (2.00 g, 8.6 mmol) in chloroform (30 mL) cooled to 0 °C, were added 
EDCI.HCl (1.81 g, 9.46 mmol) and HOBt (80%, 1.74 g, 10.3 mmol). After stirring for ca. 20 mins 3,3-
diphenylpropionic acid (1.946 g, 8.6 mmol) was added and the reaction was stirred at r.t for a further 
18 h. The reaction was then diluted with dichloromethane (30 mL), washed with 1 M HCl (2 x 20 mL), 
sat. aq. NaHCO3 (2 x 20 mL), brine (20 mL), dried over Na2SO4, filtered, and concentrated in vacuo to 
give the title compound as a yellow oil (3.24 g, 93%) used without further purification. 
Rf: 0.56 (1:1 EtOAc:PE 40-60); IR (neat film, νmax, cm-1): 3304 (m), 3027 (m), 2948 (m), 1742 (m), 1647 
(s), 1613 (m), 1597 (m), 1515 (s), 1492 (m), 1448 (m), 1374 (w), 1260 (m), 1221 (m), 1171 (m); 1H NMR 
(400 MHz, CDCl3) δ: 7.35 – 7.18 (m, 11 H, Ar-H), 6.69 – 6.61 (m, 4 H, H2 and H3), 5.96 (d, J = 7.5 Hz, 1 
H, NH), 4.82 – 4.77 (m, 1 H, H6), 4.60 (t, J = 8.0 Hz, 1 H, H10), 3.67 (s, 3 H, CH3), 3.00 – 2.80 (m, 4 H, H5 
and H9); 13C NMR (101 MHz, CDCl3) δ: 172.0 (C7), 170.9 (C8), 155.4 (C1), 143.6, 143.4, 130.3 (C3), 128.7 
(Ar-CH), 128.6 (Ar-CH), 127.9, 127.6, 126.9 (C4), 126.7, 126.6 (Ar-CH), 115.5 (C2), 53.2 (C6), 52.3 (CH3), 
47.2 (C10), 43.0 (C9), 37.1 (C5); [α]D25 0.364 (c = 1.1, MeOH). 
Data are in accordance with those reported previously in literature231. 
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(3,3-diphenylpropanoyl)-L-tyrosine (97) 
 
To a stirring solution of 86 (0.631 g, 1.56 mmol) in a mixture of THF (9 mL) and H2O (3 mL), was added 
lithium hydroxide (0.131 g, 3.13 mmol). The reaction was stirred at r.t. for 3 h before concentrating in 
vacuo. The residue was then dissolved in H2O (10 mL) and washed with EtOAc (3 x 8 mL), before being 
acidified with 1 M HCl and extracted into EtOAc (3 x 10 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo to give the title compound as a white amorphous solid (0.498 g, 82%) used 
without further purification. 
IR (neat film, νmax, cm-1): 3341 (w), 3030 (w), 1722 (m), 1696 (m), 1641 (m), 1611 (m), 1513 (s), 1494 
(m), 1448 (m), 1417 (w), 1217 (m), 1197 (m), 1173 (m), 1106 (w); 1H NMR (400 MHz, DMSO) δ: 12.56 
(br s, 1 H, COOH), 9.19 (s, 1 H, Ar-OH), 8.14 (d, J = 8.1 Hz, 1 H, NH), 7.26 – 7.13 (m, 10 H, Ar-H), 6.86 (d, 
J = 8.4 Hz, 2 H, H3), 6.62 (d, J = 8.4 Hz, 2 H, H2), 4.43 (t, J = 7.9 Hz, 1 H, H6), 4.29 – 4.24 (m, 1 H, H10), 
2.96 – 2.91 (m, 1 H, H9), 2.84 – 2.79 (m, 2 H, H5 and H9), 2.70 – 2.64 (m, 1 H, H5); 13C NMR (101 MHz, 
DMSO) δ: 173.5 (C7), 170.5 (C8), 156.3 (C1), 145.0, 144.7, 130.4 (C3), 128.7 (2C), 128.0 (2C), 127.9, 
126.5 (C4), 115.4 (C2), 54.1 (C6), 47.0 (C10), 41.3 (C9), 36.6 (C5); [α]D25 2.17 (c = 1.2, MeOH). 
Data are in accordance with those reported previously in literature231. 
 
 
 
 
 
 
213 
 
tert-Butyl (S)-(11-(4-hydroxybenzyl)-10,13-dioxo-15,15-diphenyl-3,6-dioxa-9,12-
diazapentadecyl)carbamate (98) 
 
To a stirring solution of 97 (30 mg, 0.077 mmol) in dichloromethane (1 mL), were added EDCI.HCl (18 
mg, 0.092 mmol), HOBt (80%, 16 mg, 0.092 mmol) and 36 (20 µL, 0.085 mmol). The reaction was 
stirred at r.t. for 18 h before being diluted with dichloromethane (10 mL), washed with sat. aq. NaHCO3 
(5 mL), brine (5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The residue was then 
purified by silica gel chromatography (1 to 5 % MeOH/DCM) to give the title compound as a yellow oil 
(46 mg, 96%). 
Rf: 0.11 (2% MeOH/DCM); IR (neat film, νmax, cm-1): 3296 (m), 2976 (m), 2927 (m), 1641 (s), 1613 (m), 
1597 (m), 1520 (s), 1494 (m), 1451 (m), 1366 (m), 1264 (m), 1248 (m), 1170 (m), 1101 (m); 1H NMR 
(400 MHz, CDCl3) δ: 7.71 (br s, 1 H, OH), 7.30 – 7.16 (m, 10 H, Ar-H), 6.89 (d, J = 8.2 Hz, 2 H, H3), 6.72 
(d, J = 8.2 Hz, 2 H, H2), 6.42 (d, J = 7.9 Hz, 1 H, NH), 6.04 (br s, 1 H, NH), 5.17 (br s, 1 H, NH), 4.58 (t, J = 
8.0 Hz, 1 H, H6), 4.52 – 4.46 (m, 1 H, H10), 3.67 – 3.29 (m, 12 H, 6x CH2), 3.00 – 2.89 (m, 2 H, H5), 2.82 
– 2.77 (m, 1 H, H9), 2.66 – 2.64 (m, 1 H, H9), 1.46 (s, 9 H, 3x CH3); 13C NMR (101 MHz, CDCl3) δ: 171.0 
(C7), 170.7 (C8), 156.4 (Boc-C=O), 155.6 (C1), 143.5, 143.4, 130.3 (C3), 128.6 (2C), 127.8, 127.7, 126.6, 
126.5 (C4), 115.6 (C2), 79.7 (qC), 70.3, 70.1, 69.9, 69.4 (4x O-CH2), 54.8 (C6), 47.4 (C10), 42.9 (C9), 40.3, 
39.2 (2x N-CH2), 37.9 (C5), 28.4 (CH3); HRMS (ESI): m/z calcd for C35H45N3O7Na [M+Na]+: 642.3150; 
found: 642.3128; [α]D25 -4.31 (c = 0.116, MeOH). 
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(S)-N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-(3,3-diphenylpropanamido)-3-(4-hydroxyphenyl) 
propenamide (100) 
 
 
To a stirring solution of 98 (45 mg, 0.07 mmol) in dichloromethane (0.3 mL) was added trifluoroacetic 
acid (0.3 mL). The reaction was stirred for 3 h at r.t. before being concentrated, diluted with sat. aq. 
NaHCO3 (2 mL), extracted into dichloromethane (3 x 10 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo to give the title compound as a yellow oil (24 mg, 64%) used without further 
purification. 
IR (neat film, νmax, cm-1): 3286 (m, NH), 2920 (m, CH), 2849 (m, CH), 1641 (s, C=O), 1613 (m), 1597 (m), 
1542 (m), 1515 (s), 1450 (m), 1376 (w), 1264 (m), 1201 (m), 1177 (m), 1132 (m); 1H NMR (400 MHz, 
MeOD) δ: 7.26 – 7.13 (m, 10 H, ArH), 6.92 (d, J = 8.4 Hz, 2 H, H3), 6.66 (d, J = 8.4 Hz, 2 H, H2), 4.46 (t, J 
= 7.9 Hz, 1 H, H6), 4.34 (t, J = 7.3 Hz, 1 H, H10), 3.64 – 3.52 (m, 6 H, 3x CH2), 3.40 – 3.33 (m, 2H, CH2), 
3.29 – 3.15 (m, 2 H, CH2), 3.03 – 2.81 (5 H, CH2, H5 and H9), 2.68 – 2.63 (m, 1 H, H9); 13C NMR (101 
MHz, MeOD) δ:172.4 (C7), 172.1 (C8), 155.9 (C1), 143.8, 143.6, 129.8 (C3), 128.1 (2C), 127.5, 127.4 
(2C), 126.1, 126.0 (C4), 114.8 (C2), 69.9 (2C), 69.0, 67.4 (4x O-CH2), 55.0 (C6), 47.3 (C10), 41.5 (C9), 
39.5, 38.8 (2x N-CH2), 36.7 (C5); HRMS (ESI): m/z calcd for C30H37N3O5Na [M+Na]+: 542.2625; found: 
542.2639; [α]D25 -3.03 (c = 0.132, MeOH). 
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(S)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-
fluoro-N-(11-(4-hydroxybenzyl)-10,13-dioxo-15,15-diphenyl-3,6-dioxa-9,12-
diazapentadecyl)benzamide (PROTAC-8) 
 
To a stirring solution of 2 (7 mg, 0.016 mmol) in DMF (0.1 mL), were added HATU (7 mg, 0.019 mmol) 
and DIPEA (6.6 µL, 0.0341 mmol). The reaction was stirred at r.t. for ca. 15 mins before 100 (8.9 mg, 
0.017 mmol) in DMF (0.1 mL) was added. The reaction was stirred for a further 18 h before being 
diluted with EtOAc (5 mL) and H2O (3 mL), extracted into EtOAc (2 x 5 mL), washed with brine (5 mL), 
dried over Na2SO4, filtered, and concentrated in vacuo. The residue was then purified by silica gel 
chromatography (1 to 5% MeOH/DCM) to give the title compound as a yellow oil (11 mg, 74%). 
Rf: 0.09 (3% MeOH/DCM); IR (neat film, νmax, cm-1): 3304 (w), 2921 (w), 1758 (m), 1730 (w), 1646 (s), 
1618 (m), 1536 (m), 1515 (s), 1497 (s), 1440 (s), 1415 (s), 1311 (s), 1219 (m), 1177 (m), 1140 (s), 1056 
(m); 1H NMR (400 MHz, CDCl3) δ: 8.21 (t, J = 8.2 Hz, 1 H, H17), 7.96 – 7.94 (m, 2 H, H23 and H26), 7.80 
(dd, J = 8.1, 1.5 Hz, 1 H, H22), 7.27 – 7.16 (m, 12 H, 10x Ar-H, H14 and H16), 6.87 (d, J = 8.2 Hz, 2 H, 
H3), 6.74 (br s, 1 H, NH), 6.68 (d, J = 8.2 Hz, 2 H, H2), 6.20 (d, J = 8.0 Hz, 1 H, NH), 5.84 (t, J = 6.1 Hz, 1 
H, NH), 4.52 (t, J = 7.9 Hz, 1 H, H6), 4.43 – 4.38 (m, 1 H, H10), 3.69 – 3.63 (m, 4 H, 2x CH2), 3.58 – 3.56 
(m, 2 H, CH2), 3.51 – 3.46 (m, 2 H, CH2), 3.39 – 3.22 (m, 4 H, 2x CH2), 2.94 – 2.84 (m, 2 H, H5), 2.76 (dd, 
J = 13.6, 5.1 Hz, 1 H, H9), 2.57 (dd, J = 13.6, 8.8 Hz, H9), 1.68 (s, 6 H, 2x CH3); 13C NMR (101 MHz, CDCl3) 
δ: 179.8 (C=S), 174.4 (C19), 170.8 (C7), 170.5 (C8), 162.7 (C11), 160.4 (d, J = 250 Hz, C13), 155.3 (C1), 
143.4 (2C), 139.3 (d, J = 10.6 Hz, C12), 136.8 (C24), 135.3 (C23), 133.5 (C25), 133.3 (d, J = 3.2 Hz, C17), 
132.1 (C22), 130.4, 128.6 (2C), 128.0, 127.8, 127.6, 127.1 (q, J = 4.6 Hz, C26), 126.7, 126.6, 126.2 (d, J 
= 2.8 Hz, C16), 122.6 (d, J =  12 Hz, C15), 121.8 (q, J = 275 Hz, CF3), 118.1 (d, J = 26 Hz, C14), 115.6 (C2), 
114.7 (-C≡N), 110.5 (C21), 70.4, 70.3, 69.5, 69.5 (4x O-CH2), 66.7 (C20), 54.8 (C6), 47.3 (C10), 43.0 (C9), 
40.0, 39.1 (2x N-CH2), 38.0 (C5), 23.8 (2x CH3); 19F NMR (376 MHz, CDCl3) δ: -62.0, -110.2; HRMS (ESI): 
m/z calcd for C50H48F4N6O7SNa [M+Na]+: 975.3133; found: 975.3125; [α]D25 3.29 (c = 0.4, MeOH). 
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tert-Butyl (S)-(14-(4-hydroxybenzyl)-13,16-dioxo-18,18-diphenyl-3,6,9-trioxa-12,15-diazaoctadecyl) 
carbamate (99) 
 
To a stirring solution of 97 (20 mg, 0.05 mmol) in dichloromethane (2 mL), were added EDCI.HCl (11.5 
mg, 0.06 mmol), HOBt (80%, 10 mg, 0.06 mmol) and 1-Boc-amine-11-amino-3,6,9-trioxaundecane (15 
mg, 0.05 mmol). The reaction was stirred at r.t. for 18 h before being diluted with dichloromethane 
(10 mL), washed with sat. aq. NaHCO3 (5 mL), brine (5 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo. The residue was then purified by silica gel chromatography (4% MeOH/DCM) 
to give the title compound as a yellow oil (30 mg, 91%). 
Rf: 0.40 (6% MeOH/DCM); IR (neat film, νmax, cm-1): 3286 (m), 2964 (w), 2876 (w), 1686 (m), 1641 (s), 
1615 (m), 1515 (s), 1451 (m), 1366 (m), 1268 (m), 1248 (m), 1170 (m), 1099 (m); 1H NMR (400 MHz, 
CDCl3) δ: 7.28 – 7.17 (m, 10 H, Ar-H), 6.91 (d, J = 8.4 Hz, 2 H, H3), 6.73 (d, J = 8.4 Hz, 2 H, H2), 6.33 (d, 
J = 6.4 Hz, 1 H, NH), 5.85 (br s, 1 H, NH), 5.21 (br s, 1 H, NH), 4.59 (t, J = 8.1 Hz, 1 H, H6), 4.47 – 4.42 
(m, 1 H, H10), 3.65 – 3.54 (m, 8 H, 4x CH2), 3.47 – 3.44 (m, 2 H, CH2), 3.39 – 3.17 (m, 6 H, 3x CH2), 3.00 
– 2.82 (m, 3 H, H5 and H9), 2.54 (dd, J = 13, 9.0 Hz, H9), 1.45 (s, 9 H, 3x CH3); 13C NMR (101 MHz, CDCl3) 
δ: 170.6 (C7), 170.5 (C8), 156.3 (Boc-C=O), 155.5 (C1), 143.5 (2C), 130.3 (C3), 128.6 (2C), 127.9, 127.7, 
126.6, 126.5 (C4), 115.8 (C2), 79.5 (qC), 70.5, 70.4, 70.3, 70.2, 70.1, 69.6 (6x O-CH2), 54.8 (C6), 47.4 
(C10), 43.0 (C9), 40.3, 39.1 (2x N-CH2), 38.2 (C5), 28.4 (CH3); HRMS (ESI): m/z calcd for C37H49N3O8Na 
[M+Na]+: 686.3412; found: 686.3417; [α]D25 -5.00 (c = 0.08, MeOH). 
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(S)-N-(1-amino-15-(4-hydroxyphenyl)-13-oxo-3,6,9-trioxa-12-azapentadecan-14-yl)-3,3-
diphenylpropanamide (101) 
 
To a stirring solution of 99 (27 mg, 0.041 mmol) in dichloromethane (0.4 mL) was added trifluoroacetic 
acid (0.2 mL). The reaction was stirred for 3 h at r.t. before being concentrated, diluted with sat. aq. 
NaHCO3 (2 mL), extracted into dichloromethane (3 x 10 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo to give the title compound as a yellow oil (21 mg, 91%) used without further 
purification. 
IR (neat film, νmax, cm-1): 3284 (w), 3054 (w), 2919 (w), 2865 (w), 1639 (s), 1596 (m), 1544 (m), 1515 
(s), 1494 (m), 1450 (m), 1348 (w), 1263 (m), 1248 (m), 1098 (s), 1030 (w); 1H NMR (400 MHz, CDCl3) δ: 
7.31 – 7.16 (m, 10 H, Ar-H), 6.91 (d, J = 8.5 Hz, 2 H, H3), 6.71 (d, J = 8.5 Hz, 2 H, H2), 6.47 (d, J = 7.9 Hz, 
1 H, NH), 6.29 (br s, 1 H, NH), 4.60 – 4.42 (m, 4 H, H6, H10 and NH2), 3.63 – 3.55 (m, 8 H, 4x CH2), 3.48 
– 3.46 (m, 2 H, CH2), 3.41 – 3.21 (m, 4 H, 2x CH2), 3.00 – 2.82 (m, 5 H, CH2, H5 and H9), 2.56 (dd, J = 
13.5, 8.9 Hz, 1 H, H9); 13C NMR (101 MHz, CDCl3) δ: 170.7 (2C, C7, C8), 156.3 (C1), 143.5, 130.4, 128.6 
(2C), 127.8, 127.7, 127.2, 126.6, 126.5 (C4), 115.8 (C2), 71.6, 70.5, 70.4, 70.2, 70.1, 69.6 (6x O-CH2), 
54.8 (C6), 47.4 (C10), 43.0 (C9), 41.0, 39.2 (2x N-CH2), 38.2 (C5); HRMS (ESI): m/z calcd for C32H42N3O6 
[M+H]+: 564.3068; found: 564.3067; [α]D25 2.632 (c = 0.228, MeOH). 
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(S)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-
fluoro-N-(14-(4-hydroxybenzyl)-13,16-dioxo-18,18-diphenyl-3,6,9-trioxa-12,15-
diazaoctadecyl)benzamide (PROTAC-9) 
 
To a stirring solution of 2 (5 mg, 0.011 mmol) in DMF (0.1 mL), were added HATU (4.6 mg, 0.012 mmol) 
and DIPEA (2.3 µL, 0.012 mmol). The reaction was stirred at r.t. for ca. 15 mins before 101 (6.6 mg, 
0.012 mmol) in DMF (0.1 mL) was added. The reaction was stirred for a further 18 h before being 
diluted with EtOAc (5 mL) and H2O (3 mL), extracted into EtOAc (2 x 5 mL), washed with brine (5 mL), 
dried over Na2SO4, filtered, and concentrated in vacuo. The residue was then purified by silica gel 
chromatography (3% MeOH/DCM) to give the title compound as a yellow oil (6.8 mg, 62%). 
Rf: 0.18 (3% MeOH/DCM); IR (neat film, νmax, cm-1): 3284 (w), 2956 (w), 2921 (m), 2849 (w), 1758 (m), 
1647 (s), 1619 (m), 1515 (m), 1497 (s), 1438 (s), 1411 (s), 1311 (s), 1262 (m), 1219 (s), 1177 (m), 1135 
(s), 1105 (s), 1056 (m); 1H NMR (400 MHz, CDCl3) δ: 8.17 (t, J = 8.5 Hz, 1 H, H17), 8.01 – 7.94 (m, 2 H, 
H23 and H26), 7.82 (dd, J = 8.3, 1.7 Hz, 1 H, H22), 7.33 – 7.15 (m, 11 H, 10x Ar-H and H16), 7.11 (dd, J 
= 11.4, 1.7 Hz, 1 H, H14), 6.89 (d, J = 8.1 Hz, 2 H, H3), 6.82 (br s, 1 H, NH), 6.70 (d, J = 8.1 Hz, 2 H, H2), 
6.22 (d, J = 7.9 Hz, 1 H, NH), 5.64 (br s, 1 H, NH), 4.55 (t, J = 8.0 Hz, 1 H, H6), 4.40 – 4.35 (m, 1 H, H10), 
3.72 – 3.60 (m, 6 H, 3x CH2), 3.51 (t, J = 4.3 Hz, 2 H, O-CH2), 3.39 – 3.37 (m, 2 H, O-CH2), 3.34 – 3.26 (m, 
2 H, O-CH2), 3.16 – 3.08 (m, 2 H, N-CH2), 2.96 – 2.79 (m, 5 H, N-CH2, H5 and H9), 2.45 (dd, J = 13.5, 9.7 
Hz, 1 H, H9), 1.59 (s, 6 H, 2x CH3); 13C NMR (101 MHz, CDCl3) δ: 179.8 (C=S), 174.5 (C19), 170.5 (C7), 
170.3 (C8), 162.6 (C11), 160.4 (d, J = 250 Hz, C13), 155.2 (C1), 143.5, 143.4, 139.0 (d, J = 10.4 Hz, C12), 
136.8 (C24), 135.3 (C23), 133.6 (C25), 133.1 (d, J = 3.3 Hz, C17), 132.2 (C22), 130.2, 128.6 (2C), 128.1, 
127.8, 127.6, 127.1 (d, J = 5.5 Hz, C26), 126.6 (2C), 126.1 (d, J = 3.5 Hz, C16), 123.0 (d, J = 13.5 Hz, C15), 
118.0 (d, J = 25.7 Hz, C14), 115.9 (C2), 114.7 (-C≡N), 110.4 (d, J = 2.2 Hz, C21), 70.5, 70.4, 70.3, 70.0, 
69.9, 69.6 (6x O-CH2), 66.6 (C20), 54.9 (C6), 47.4 (C10), 43.1 (C9), 40.0, 39.0 (2x N-CH2), 38.3 (C5), 23.8 
(2x CH3); 19F NMR (376 MHz, CDCl3) δ: -62.0, -110.0; HRMS (ESI): m/z calcd for C52H52F4N6O8S [M+Na]+: 
1019.3395; found: 1019.3385; [α]D25 1.25 (c = 0.4, MeOH). 
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2-(2-((tert-Butoxycarbonyl)amino)ethoxy)ethyl methanesulfonate (104) 
 
To a stirring solution of 102 (0.200 g, 1.0 mmol) in Et2O (2 mL) cooled to 0 °C, were added triethylamine 
(163 µL, 1.17 mmol) and methanesulfonyl chloride (90 µL, 1.17 mmol). The reaction was stirred at r.t. 
for 6 h before being poured over brine (5 mL), extracted into Et2O (3 x 10 mL), dried over Na2SO4, 
filtered and concentrated in vacuo to give the title compound as a colourless oil (0.219 g, 79%) used 
without further purification. 
Rf: 0.25 (1:1 Hex:EtOAc); IR (neat film, νmax, cm-1): 3398 (w), 2978 (w), 2933 (w), 2876 (w), 1695 (m), 
1515 (m), 1455 (w), 1392 (w), 1348 (s), 1273 (m), 1249 (m), 1169 (s), 1127 (s), 1016 (m); 1H NMR (400 
MHz, CDCl3) 1.44 (s, 9 H, 3 x CH3), 3.05 (s, 3 H, CH3), 3.32 (q, J = 5.2 Hz, CH2-NHBoc), 3.55 (t, J = 5.2 Hz, 
-CH2), 3.71 – 3.73 (m, 2 H, -CH2-CH2-OMs), 4.35 – 4.37 (m, 2 H, -CH2-OMs), 4.89 (br s, 1 H, -NH); 13C 
NMR (101 MHz, CDCl3) 28.5 (3 x CH3), 37.8 (CH3), 40.4 (CH2-NHBoc), 68.8 (CH2-O), 68.9 (CH2-O), 70.9 
(CH2-OMs), 79.6 (C-(CH3)3), 156.0 (C=O). 
Data are in accordance with those reported previously in literature.348 
 
tert-Butyl (2-(2-(2-iodoethoxy)ethoxy)ethyl)carbamate (106) 
 
To a stirring solution of 1H-imidazole (61.4 mg, 0.90 mmol) and triphenylphosphane (237 mg, 0.90 
mmol) in THF (2.7 ml) cooled to 0 °C, was added iodine (229 mg, 0.90 mmol). The mixture was then 
vigorously stirred at r.t. for 15 mins before a solution of tert-butyl (2-(2-(2-
hydroxyethoxy)ethoxy)ethyl)carbamate (150 mg, 0.60 mmol) in THF (2.7 ml) was added. The mixture 
was stirred at r.t. for 2 h then filtered and washed with EtOAc before concentrating in vacuo. The 
residue was then purified through flash silica gel chromatography (0 to 50% EtOAc in Heptane) to give 
the title compound (138 mg, 64%) as a pale yellow oil. 
Rf: 0.62 (1:1 Hex:EtOAc); IR (neat film, νmax, cm-1): 3374 (w, NH), 2975 (w, CH), 2866 (w, CH), 1707 (s, 
C=O), 1505 (m), 1454 (w), 1390 (w), 1364 (m), 1270 (m), 1249 (s), 1167 (s), 1094 (s), 1037 (m); 1H NMR 
(500 MHz, CDCl3) 5.00 (s, 1H), 3.76 – 3.70 (m, 2H), 3.61 (dddd, J = 9.8, 6.0, 3.3, 1.9 Hz, 4H), 3.53 (t, J = 
5.2 Hz, 2H), 3.30 (d, J = 5.0 Hz, 2H), 3.22 – 3.27 (m, 2H), 1.42 (s, 9H). 13C NMR (126 MHz, CDCl3) 156.0, 
79.2, 71.9, 70.3, 70.2, 70.1, 40.3, 28.4, 2.8. 
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Data are in accordance with those reported previously in literature.349 
 
Methyl (S)-3-(4-(2-(2-((tert-butoxycarbonyl)amino)ethoxy)ethoxy)phenyl)-2-(3,3-
diphenylpropanamido)propanoate (103) 
 
To a stirring solution of 86 (40 mg, 0.1 mmol) in DMF (0.5 mL), were added potassium carbonate (28 
mg, 0.2 mmol), and 104 (56 mg, 0.2 mmol). The reaction was heated to 70 °C for 18 h before being 
cooled, diluted with H2O (2 mL), extracted into EtOAc (3 x 10 mL), washed with brine (5 mL), dried 
over Na2SO4, filtered, and concentrated in vacuo. The residue was then purified by silica gel 
chromatography (1:1 Hex:EtOAc) to give the title compound as a yellow oil (24 mg, 41%). 
Rf: 0.37 (1:1 Hex:EtOAc); IR (neat film, νmax, cm-1): 3335 (w), 2928 (w), 2865 (w), 1742 (m), 1710 (m), 
1651 (m), 1511 (s), 1451 (m), 1366 (m), 1247 (s), 1173 (s), 1124 (m), 1065 (m); 1H NMR (400 MHz, 
CDCl3) δ: 7.34 – 7.20 (m, 10 H, Ar-H CDCl3 overlapped), 6.76 (d, J = 8.6 Hz, 2 H, H3), 6.67 (d, J = 8.6 Hz, 
2 H, H2), 5.91 – 5.83 (br m, 1 H, NH), 4.99 (br s, 1 H, NH), 4.80 – 4.78 (m, 1 H, H6), 4.62 (t, J = 7.9 Hz, 1 
H, H10), 4.10 (t, J = 4.5 Hz, 2H, O-CH2), 3.83 (t, J = 4.9 Hz, 2 H, O-CH2), 3.67 (s, 3 H, OMe), 3.63 (t, J = 
4.9 Hz, 2 H, O-CH2), 3.37 – 3.36 (m, 2 H, N-CH2), 2.99 – 2.92 (m, 3 H, H5 and H9), 2.84 (dd, J = 13.9, 5.7 
Hz, 1 H, H9), 1.47 (s, 9 H, 3x CH3); 13C NMR (101 MHz, CDCl3) δ: 171.8 (C7), 170.3 (C8), 157.7 (C1), 156.0 
(Boc-C=O), 143.8, 143.6, 130.2, 128.6 (2C), 128.0, 127.6, 126.6, 126.5 (C4), 121.9, 114.6 (C2), 79.3 (qC), 
70.4, 69.5, 67.3 (3x O-CH2), 53.1 (C6), 52.2 (OMe), 47.1 (C10), 43.0 (C9), 40.4 (N-CH2), 37.0 (C5), 28.4 
(3x CH3); HRMS (ESI): m/z calcd for C34H42N2O7Na [M+Na]+: 613.2884; found: 613.2893; [α]D25 8.00 (c 
= 0.1, MeOH). 
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Methyl (S)-3-(4-(2-(2-aminoethoxy)ethoxy)phenyl)-2-(3,3-diphenylpropanamido) propanoate (108) 
 
To a stirring solution of 103 (15 mg, 0.025 mmol) in dichloromethane (0.4 mL) was added 
trifluoroacetic acid (0.1 mL). The reaction was stirred for 3 h at r.t. before being concentrated, diluted 
with sat. aq. NaHCO3 (2 mL), extracted into dichloromethane (3 x 10 mL), dried over Na2SO4, filtered, 
and concentrated in vacuo to give the title compound as a yellow oil (8 mg, 67%) used without further 
purification. 
IR (neat film, νmax, cm-1): 3311 (m), 2927 (m), 1740 (m), 1646 (s), 1536 (m), 1510 (s), 1492 (m), 1450 
(m), 1367 (m), 1245 (s), 1218 (s), 1176 (m), 1122 (m), 1065 (m), 1030 (m); 1H NMR (400 MHz, CDCl3) 
δ: 7.34 – 7.20 (m, 10 H, Ar-H CDCl3 overlapped), 6.76 (d, J = 8.9 Hz, 2 H, H3), 6.65 (d, J = 8.9 Hz, 2 H, 
H2), 5.94 (d, J = 7.9 Hz, 1 H, NH), 4.82 – 4.77 (m, 1 H, H6), 4.64 – 4.61 (m, 1 H, H10), 4.14 – 4.11 (m, 2 
H, O-CH2), 3.84 (t, J = 4.9 Hz, 2 H, O-CH2), 3.68 (s, 3 H, OMe), 3.59 (t, J = 4.9 Hz, O-CH2), 3.02 – 2.81 (m, 
6 H, N-CH2, H5 and H9); 13C NMR (101 MHz, CDCl3) δ: 171.8 (C7), 170.3 (C8), 157.8 (C1), 143.8, 143.6, 
130.2, 128.6 (2C), 128.0, 127.7, 126.6, 126.5 (C4), 121.9, 114.7 (C2), 73.6, 69.6, 67.3 (3x O-CH2), 53.1 
(C6), 52.2 (OMe), 47.1 (C10), 43.0 (C9), 41.8 (N-CH2), 37.0 (C5); HRMS (ESI): m/z calcd for C29H35N2O5 
[M+H]+: 491.2541; found: 491.2531; [α]D25 35.0 (c = 0.1, MeOH). 
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Methyl (S)-3-(4-(2-(2-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-
thioxoimidazolidin-1-yl)-2-fluorobenzamido)ethoxy)ethoxy)phenyl)-2-(3,3-
diphenylpropanamido)propanoate (PROTAC-10) 
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To a stirring solution of 2 (5 mg, 0.011 mmol) in DMF (0.1 mL), were added HATU (4.6 mg, 0.012 mmol) 
and DIPEA (2.3 µL, 0.012 mmol). The reaction was stirred at r.t. for ca. 15 mins before 108 (5.7 mg, 
0.012 mmol) in DMF (0.1 mL) was added. The reaction was stirred for a further 18 h before being 
diluted with EtOAc (5 mL) and H2O (3 mL), extracted into EtOAc (2 x 5 mL), washed with brine (5 mL), 
dried over Na2SO4, filtered, and concentrated in vacuo. The residue was then purified by silica gel 
chromatography (1% MeOH/DCM) to give the title compound as a yellow oil (5.5 mg, 54%). 
Rf: 0.44 (3% MeOH/DCM); IR (neat film, νmax, cm-1): 3330 (w), 2928 (m), 2853 (w), 1752 (m), 1655 (s), 
1620 (m), 1530 (m), 1510 (s), 1499 (s), 1439 (s), 1413 (s), 1367 (m), 1312 (s), 1286 (m), 1246 (m), 1219 
(s), 1177 (s), 1139 (s), 1057 (m); 1H NMR (400 MHz, CDCl3) δ: 8.25 (t, J = 8.4 Hz, 1 H, H17), 7.98 – 7.94 
(m, 2 H, H23 and H26), 7.82 (dd, J = 8.4, 1.9 Hz, 1 H, H22), 7.30 – 7.07 (m, 13 H, 10x Ar-H, H14, H16, 
NH, overlapped CHCl3), 6.73 (d, J = 8.4 Hz, 2 H, H3), 6.65 (d, J = 8.4 Hz, 2 H, H2), 5.80 (d, J = 8.2 Hz, 1 H, 
NH), 4.77 – 4.74 (m, 1 H, H6), 4.60 – 4.57 (m, 1 H, H10), 4.11 – 4.09 (m, 2 H, O-CH2), 3.87 – 3.85 (m, 2 
H, O-CH2), 3.76 (s, 3 H, OMe), 3.67 – 3.64 (m, 2 H, O-CH2), 2.97 – 2.83 (m, 6 H, N-CH2, H5 and H9), 1.60 
(s, 6 H, 2x CH3); 13C NMR (101 MHz, CDCl3) δ 179.8 (C=S), 174.4 (C19), 171.8 (C7), 170.3 (C8), 162.1 (d, 
J = 3.2 Hz, C11), 160.4 (d, J = 250 Hz, C13), 157.7 (C1), 143.8, 143.5, 139.1 (d, J = 11.6 Hz, C12), 136.8 
(C24), 135.3 (C23), 133.6 (C25), 133.3 (d, J = 3.2 Hz, C17), 132.1 (C22), 130.3, 128.6 (2C), 128.0 (2C), 
127.6, 127.1 (q, J = 4.6 Hz, C26), 126.6, 126.5, 126.1 (d, J = 3.2 Hz, C16), 122.9 (d, J = 7 Hz, C15), 121.8 
(q, J = 273 Hz, CF3), 118.0 (d, J = 25.6 Hz, C14), 114.7 (C2), 114.5 (-C≡N), 110.5 (d, J = 2.2 Hz, C21), 69.7, 
69.6, 67.3 (3x O-CH2), 66.6 (C20), 53.1 (C6), 52.2 (OMe), 47.1 (C10), 43.0 (C9), 39.9 (N-CH2), 38.6 (C5), 
23.9 (2x CH3); 19F NMR (376 MHz, CDCl3) δ: -62.0, -110.1; HRMS (ESI): m/z calcd for C49H45F4N5O7SNa 
[M+Na]+: 946.2868; found: 946.2841; [α]D25 0.143 (c = 0.7, MeOH). 
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Methyl (S)-3-(4-((2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatridecan-13-yl)oxy)phenyl)-2-(3,3-
diphenylpropanamido)propanoate (107) 
 
To a stirring solution of 86 (51 mg, 0.13 mmol) in DMF (1 mL), were added potassium carbonate (19 
mg, 0.14 mmol), and 106 (50 mg, 0.14 mmol). The reaction was heated to 70 °C for 18 h before being 
cooled, diluted with H2O (2 mL), extracted into EtOAc (3 x 10 mL), washed with brine (5 mL), dried 
over Na2SO4, filtered, and concentrated in vacuo. The residue was then purified by silica gel 
chromatography (1:1 Hex:EtOAc) to give the title compound as a yellow oil (53 mg, 67%). 
Rf: 0.22 (1:1 Hex:EtOAc); IR (neat film, νmax, cm-1): 3310 (w), 2931 (w), 1742 (m), 1707 (m), 1652 (m), 
1612 (w), 1510 (s), 1451 (m), 1365 (m), 1245 (s), 1171 (s), 1119 (s), 1108 (s), 1064 (m); 1H NMR (400 
MHz, CDCl3) δ: 7.34 – 7.20 (m, 10 H, Ar-H CDCl3 overlapped), 6.75 (d, J = 8.6 Hz, 2 H, H3), 6.66 (d, J = 
8.6 Hz, 2 H, H2), 5.85 (br s, 1 H, NH), 5.02 (br s, 1 H, NH), 4.81 – 4.76 (m, 1 H, H6), 4.64 – 4.60 (m, 1 H, 
H10), 4.12 (t, J = 4.5 Hz, 2 H, O-CH2), 3.87 (t, J = 5.1 Hz, 2 H, O-CH2), 3.75 – 3.72 (m, 2 H, O-CH2), 3.68 – 
3.65 (m, 5 H, O-CH2 and OMe), 3.57 (t, J = 5.1 Hz, 2 H, O-CH2), 3.34 – 3.33 (m, 2 H, N-CH2), 3.00 – 2.90 
(m, 3 H, H5 and H9), 2.83 (dd, J = 14.0, 5.7 Hz, 1 H, H9), 1.46 (s, 9 H, 3x CH3); 13C NMR (101 MHz, CDCl3) 
δ: 171.8 (C7), 170.3 (C8), 157.8 (C1), 156.0 (Boc-C=O), 143.8, 143.6, 130.2, 128.6 (2C), 128.0, 127.8, 
127.6, 126.6, 126.5 (C5), 114.6 (C2), 79.2 (qC), 70.8, 70.3 (2C), 69.8, 67.3 (5x O-CH2), 53.1 (C6), 52.2 
(OMe), 47.1 (C10), 43.0 (C9), 40.4 (N-CH2), 37.0 (C5), 28.4 (3x CH3); HRMS (ESI): m/z calcd for 
C36H46N2O8Na [M+Na]+: 657.3146; found: 657.3156; [α]D25 4.167 (c = 0.24, MeOH). 
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Methyl (S)-3-(4-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)phenyl)-2-(3,3-
diphenylpropanamido)propanoate (109) 
 
To a stirring solution of 107 (47 mg, 0.0472mmol) in dichloromethane (0.8 mL) was added 
trifluoroacetic acid (0.2 mL). The reaction was stirred for 3 h at r.t. before being concentrated, diluted 
with sat. aq. NaHCO3 (2 mL), extracted into dichloromethane (3 x 10 mL), dried over Na2SO4, filtered, 
and concentrated in vacuo to give the title compound as a yellow oil (27 mg, 70%) used without further 
purification. 
IR (neat film, νmax, cm-1): 3397 (w), 2988 (m), 2925 (m), 1741 (m), 1706 (s), 1648 (s), 1612 (m), 1536 
(m), 1511 (s), 1451 (m), 1361 (m), 1246 (s), 1222 (s), 1179 (m), 1111 (s), 1065 (s); 1H NMR (400 MHz, 
CDCl3) δ: 7.34 – 7.18 (m, 10 H, Ar-H CDCl3 overlapped), 6.75 (d, J = 8.6 Hz, 2 H, H3), 6.64 (d, J = 8.6 Hz, 
2 H, H2), 6.14 (d, J = 7.4 Hz, 1 H, NH), 4.82 – 4.78 (m, 1 H, H6), 4.65 – 4.61 (m, 1 H, H10), 4.12 (t, J = 4.6 
Hz, 2 H, O-CH2), 3.88 – 3.86 (m, 2 H, O-CH2), 3.76 – 3.74 (m, 2 H, O-CH2), 3.68 – 3.66 (m, 5 H, O-CH2 and 
OMe), 3.52 (t, J = 4.9 Hz, 2 H, N-CH2), 2.98 – 2.87 (m, 3 H, H5 and H9), 2.82 (dd, J = 13.8, 5.7 Hz, 1 H, 
H9); 13C NMR (101 MHz, CDCl3) δ: 171.8 (C7), 170.3 (C8), 157.8 (C1), 143.8, 143.6, 130.3, 128.6 (2C), 
128.0, 127.9, 127.7, 126.6, 126.5 (C5), 114.5 (C2), 73.6, 70.8, 70.4, 69.8, 67.4 (5x O-CH2), 53.1 (C6), 
52.2 (OMe), 47.1 (C10), 42.9 (C9), 41.7 (N-CH2), 37.0 (C5); HRMS (ESI): m/z calcd for C31H39N2O6 
[M+H]+: 535.2803; found: 535.2814; [α]D25 11.058 (c = 0.208, MeOH). 
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Methyl (S)-3-(4-(2-(2-(2-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-
thioxoimidazolidin-1-yl)-2-fluorobenzamido)ethoxy)ethoxy)ethoxy)phenyl)-2-(3,3-
diphenylpropanamido)propanoate (PROTAC-11) 
 
To a stirring solution of 2 (10 mg, 0.022 mmol) in DMF (0.1 mL), were added HATU (10.1 mg, 0.027 
mmol) and DIPEA (5.2 µL, 0.027 mmol). The reaction was stirred at r.t. for ca. 15 mins before 109 (13 
mg, 0.024 mmol) in DMF (0.1 mL) was added. The reaction was stirred for a further 18 h before being 
diluted with EtOAc (5 mL) and H2O (3 mL), extracted into EtOAc (2 x 5 mL), washed with brine (5 mL), 
dried over Na2SO4, filtered, and concentrated in vacuo. The residue was then purified by silica gel 
chromatography (1% MeOH/DCM) to give the title compound as a yellow oil (15 mg, 70%). 
Rf: 0.36 (3% MeOH/DCM); IR (neat film, νmax, cm-1): 3304 (w), 2916 (w), 1751 (m), 1654 (m), 1620 (m), 
1532 (m), 1497 (m), 1437 (m), 1411 (m), 1310 (s), 1246 (m), 1217 (s), 1176 (s), 1134 (s), 1055 (m); 1H 
NMR (400 MHz, CDCl3) δ: 8.22 (t, J = 8.2 Hz, 1 H, H17), 7.98 – 7.95 (m, 2 H, H23 and H26), 7.83 – 7.81 
(m, 1 H, H22), 7.30 – 7.09 (m, 13 H, 10x Ar-H, H14, H16, NH), 6.71 (d, J = 8.5 Hz, 2 H, H3), 6.63 (d, J = 
8.5 Hz, 2 H, H2), 5.84 (d, J = 7.7 Hz, 1 H, NH), 4.77 – 4.72 (m, 1 H, H6), 4.58 (t, J = 7.9 Hz, 1 H, H10), 4.07 
(t, J = 4.2 Hz, 2 H, O-CH2), 3.85 (t, J = 5.0 Hz, 2 H, O-CH2), 3.76 – 3.73 (m, 2 H, O-CH2), 3.71 – 3.67 (m, 4 
H, 2x O-CH2), 3.64 (s, 3 H, OMe), 2.97 – 2.78 (m, 6 H, N-CH2, H5 and H9), 1.58 (s, 6 H, 2x CH3); 13C NMR 
(101 MHz, CDCl3) δ: 179.7 (C=S), 174.4 (C19), 171.8 (C7), 170.3 (C8), 162.1 (d, J = 3.0 Hz, C11), 160.4 
(d, J = 250 Hz, C13), 157.7 (C1), 143.8, 143.5, 138.9 (d, J = 10.9 Hz, C12), 136.8 (C24), 135.3 (C23), 133.9 
(C25), 133.3 (d, J = 3.3 Hz, C17), 132.1 (C22), 130.2, 128.6 (2C), 127.9 (2C), 127.6, 127.1 (d, J = 4.8 Hz, 
C26), 126.6, 126.5, 126.1 (d, J = 3.3 Hz, C16), 123.0 (d, J = 12.0 Hz, C15), 121.8 (q, J = 275 Hz, CF3), 117.9 
(d, J = 27 Hz, C14), 114.7 (C2), 114.5 (-C≡N), 110.4 (d, J = 2.1 Hz, C21), 70.8, 70.4, 69.8, 69.6, 67.3 (5x 
O-CH2), 66.6 (C20), 53.1 (C6), 52.2 (OMe), 47.1 (C10), 42.9 (C9), 39.9 (N-CH2), 37.0 (C5), 23.8 (2x CH3); 
19F NMR (376 MHz, CDCl3) δ: -62.0, -110.3; HRMS (ESI): m/z calcd for C51H49F4N5O8SNa [M+Na]+: 
990.3130; found: 990.3131; [α]D25 0.286 (c = 0.7, MeOH). 
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Ethyl 6-chloro-3-formyl-1H-indole-2-carboxylate (112) 
 
Following a modified literature procedure,350 to a stirring solution of ethyl 6-chloroindole-2-
carboxylate (0.336 g, 1.5 mmol) in DMF (1.5 mL), was dropwise added POCl3 (0.17 mL, 1.8 mmol). The 
reaction was heated to 50 °C for 18 h before cooling and quenching with sat. aq. NaHCO3 (10 mL). The 
reaction was then extracted into EtOAc (3 x 20 mL), washed with H2O (10 mL) and brine (10 mL), dried 
over Na2SO4, filtered, and concentrated in vacuo. The residue was then triturated in Et2O and filtered 
to give the title compound as a beige amorphous solid (0.240 g, 64%). 
Rf: 0.71 (1:1 Hex:EtOAc); IR (neat film, νmax, cm-1): 3140 (m), 2985 (w), 1725 (s, C=O), 1638 (s, C=O), 
1570 (m), 1531 (m), 1430 (s), 1391 (m), 1373 (m), 1299 (m), 1219 (s), 1192 (s), 1145 (m), 1099 (m), 
1063 (m), 1028 (m); 1H NMR (400 MHz, d6-DMSO) δ: 12.88 (s, 1 H, NH) , 10.57 (s, 1 H, -CHO), 8.21 (d, 
J = 8.6 Hz, 1 H, H3), 7.55 (d, J = 1.8 Hz, 1 H, H1), 7.31 (dd, J = 8.6, 1.8 Hz, 1H, H2), 4.46 (q, J = 7.1 Hz, 2 
H, CH2), 1.40 (t, J = 7.1 Hz, 3 H, CH3); 13C NMR (101 MHz, d6-DMSO) δ: 187.4 (CHO), 159.9 (COO), 136.1, 
133.5, 130.4, 124.0, 123.9 (ArCH), 123.4 (ArCH), 118.2, 112.6 (ArCH), 62.0 (CH2), 14.0 (CH3).  
Data are in accordance with those reported previously in literature350. 
 
N-((4-fluorophenyl)(tosyl)methyl)formamide (115) 
 
Following a literature procedure,234 to a stirring solution of sodium p-toluenesulfinate (3.56 g, 20 
mmol) in a 1:1 mixture of Et2O and H2O (50 mL) cooled to 0 °C, was dropwise added conc. HCl (1.8 mL). 
The mixture was stirred for 1 h at r.t. before being separated, extracted into Et2O (3 x 20 mL), dried 
over Na2SO4, filtered, and the volume reduced by 2/3 in vacuo. PE 40-60 (20 mL) was then added and 
the solid was filtered, washed with petroleum ether (5 mL) and dried in vacuo to give p-toluenesulfinic 
acid as a white solid (2.79 g, 89%), which was then combined with 4-fluorobenzaldehyde (1.28 mL, 12 
mmol), formamide (1.19 mL, 30 mmol), chlorotrimethylsilane (1.68 mL, 13.2 mmol) in a 1:1 mixture 
of toluene and acetonitrile (14 mL). The reaction was heated to 50 °C for 5 h before being cooled to 0 
°C and H2O (20 mL) and MTBE (5 mL) were added. The mixture was stirred for a further 30 mins before 
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being filtered and dried in vacuo to give the title compound as an amorphous white powder (2.39 g, 
65%). 
Rf: 0.76 (6:4 Hex:EtOAc); IR (neat film, νmax, cm-1): 3174 (m), 3064 (m), 2896 (m), 1699 (w), 1599 (w), 
1456 (m), 1426 (m), 1155 (s), 1125 (s); 1H NMR (400 MHz, CDCl3) δ: 8.16 (s, 1 H, CHO), 7.73 (d, J = 7.8 
Hz, 2 H, ), 7.45 – 7.42 (m, 2 H), 7.16 – 7.08 (m, 3 H), 6.33 (d, J = 10.3 Hz, 1 H), 2.47 (s, 3 H); 13C NMR 
(101 MHz, CDCl3) δ: 163.7 (d, J = 250 Hz, C-F), 159.6 (C=O), 145.8, 132.8, 130.8 (d, J = 8.6 Hz), 129.9, 
129.4, 116.2, 115.9, 69.8, 21.8; 19F NMR (376 MHz, CDCl3) δ: -111.3. 
Data are in accordance with the literature.351 
 
1-Fluoro-4-(isocyano(tosyl)methyl)benzene (116) 
 
Following a literature procedure,234 to a stirring solution of 115 (1.20 g, 4.0 mmol) in tetrahydrofuran 
(20 mL) cooled to 0 °C, were dropwise added POCl3 (1.12 mL, 12 mmol) and triethylamine (2.81 mL, 
20 mmol) in tetrahydrofuran (2 mL). The reaction was stirred at 0 °C for 2 h before being poured into 
H2O (35 mL). The mixture was then extracted into EtOAc (3 x 20 mL), washed with sat. aq. NaHCO3 (10 
mL), dried over Na2SO4, filtered, and concentrated in vacuo. The residue was then triturated in hexane 
to give the title compound as a brown amorphous powder (1.00 g, 87%). 
Rf: 0.70 (6:4 Hex:EtOAc); IR (neat film, νmax, cm-1): 3079 (w), 2937 (w), 2137 (m), 1689 (m), 1596 (m), 
1508 (m), 1330 (m), 1304 (m), 1289 (m), 1232 (m), 1145 (s), 1083 (m); 1H NMR (400 MHz, CDCl3) δ: 
7.65 (d, J = 8.5 Hz, 2 H), 7.38 – 7.35 (m, 4 H), 7.12 (t, J = 8.5 Hz, 2 H), 5.62 (s, 1 H), 2.50 (s, 3 H); 13C NMR 
(101 MHz, CDCl3) δ: 165.9 (d, J = 250 Hz, CF), 162.9 (NC), 146.8, 130.5 (overlapping signals), 129.9, 
122.5 (d, J = 4 Hz), 116.2, 115.9, 75.7, 21.8; 19F NMR (376 MHz, CDCl3) δ: -109.0. 
Data are in accordance with the literature.351 
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Ethyl 6-chloro-3-(1-(4-chlorobenzyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-1H-indole-2-carboxylate 
(118) 
 
To a stirring solution of 112 (100 mg, 0.4 mmol) in ethanol (2 mL) was added 4-chlorobenzylamine 
(48.7 µL, 0.4 mmol). The reaction was stirred at r.t. for 30 mins before 116 (115.7 mg, 0.4 mmol) and 
triethylamine (56 µL, 0.4 mmol) were added. The reaction was then heated to 50 °C for 3 h before 
cooling to r.t., stirring for a further 16 h, and concentrating in vacuo. The residue was then purified by 
silica gel chromatography (7:3 to 1:1 Hex/EtOAc) to give the title compound as a yellow oil (118 mg, 
58%). 
Rf: 0.35 (1:1 Hex:EtOAc); IR (neat film, νmax, cm-1): 2983 (w), 1704 (s), 1601 (w), 1568 (w), 1527 (m), 
1493 (m), 1439 (m), 1410 (m), 1365 (m), 1312 (m), 1218 (s), 1194 (m), 1155 (m), 1121 (m), 1090 (m), 
1060 (m), 1015 (m); 1H NMR (400 MHz, CDCl3) δ: 9.89 (s, 1H, NH), 7.81 (s, 1 H, H11), 7.46 – 7.42 (m, 3 
H, H7 and H13), 7.13 – 7.05 (m, 4 H, H4, H5 and H19), 6.86 – 6.80 (m, 2 H, H14), 6.76 (d, J = 8.3 Hz, 2 
H, H18), 4.91 – 4.82 (m, 2 H, H16), 4.19 – 4.10 (m, 2 H, O-CH2), 1.12 (t, J = 7.2 Hz, CH3); 13C NMR (101 
MHz, CDCl3) δ: 161.7 (d, J = 246 Hz, C15), 160.8 (C=O), 139.9 (C10), 137.6 (C11), 136.2 (C8), 134.5 (C17), 
133.9 (C20), 132.3 (C6), 130.6 (d, J = 2.9 Hz, C12), 128.7 (C19), 128.6 (C18), 127.5 (d, J = 7.6 Hz, C13), 
126.7, 126.5 (C1 and C3), 122.9 (C5), 122.1 (C4), 119.3 (C9), 115.1 (d, J = 21 Hz, C14), 112.1 (C7), 110.7 
(C2), 61.3 (O-CH2), 48.8 (C16), 14.0 (CH3); 19F NMR (376 MHz, CDCl3) δ: -115.9; HRMS (ESI): m/z calcd 
for C27H21Cl2FN3O2 [M+H]+: 508.0990; found: 508.0990. 
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6-Chloro-3-(1-(4-chlorobenzyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-1H-indole-2-carboxylic acid 
(87) 
 
To a stirring solution of 118 (66 mg, 0.13 mmol) in ethanol (1 mL) was added 2 M NaOH (aq, 1 mL). 
The mixture was heated to reflux for 3 h before being cooled, poured over ice and acidified with 3 M 
HCl. The mixture was then extracted into EtOAc (3 x 10 mL), washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo to give the title compound as a yellow oil (62 mg, >98%) used 
without further purification. 
IR (neat film, νmax, cm-1): 3404 (w), 1704 (s), 1592 (w), 1565 (w), 1510 (m), 1493 (m), 1433 (m), 1361 
(s), 1327 (m), 1222 (s), 1162 (m), 1090 (m), 1015 (m); 1H NMR (400 MHz, MeOD) δ: 8.28 (s, 1H, H11), 
7.46 (d, J = 1.7 Hz, 1 H, H7), 7.39 – 7.35 (m, 2 H), 7.00 (d, J = 8.4 Hz, 2 H), 6.88 – 6.84 (m, 3 H), 6.80 – 
6.78 (m, 3 H), 5.11 (d, J = 15.2 Hz, 1 H, H16), 4.99 (d, J = 15.2 Hz, H16); 13C NMR (101 MHz, MeOD) δ: 
162.0 (d, J = 248 Hz, C15), 162.7 (C=O), 137.2 (2C), 136.8 (C10, C11, C8), 136.4 (C17), 134.5 (C20), 133.3 
(C6), 130.7 (C19), 128.9 (d, J = 3.2 Hz, C12), 128.8 (C18), 128.1 (C1), 127.8 (d, J = 8.2 Hz, C13), 126.0 
(C3), 121.4, 121.3, 121.0 (C4, C5, C9), 114.6 (d, J = 22 Hz, C14), 111.8 (C7), 107.6 (C2), 48.9 (C16); 19F 
NMR (376 MHz, MeOD) δ: -116.4; HRMS (ESI): m/z calcd for C25H15Cl2FN3O2 [M-H]-: 478.0531; found: 
478.0518. 
 
4-((3,4-difluorobenzyl)oxy)benzonitrile (121) 
 
To a stirring solution of 4-cyanophenol (0.50 g, 4.2 mmol) in acetone (50 mL), were added potassium 
carbonate (2.10 g, 15.2 mmol) and 3,4-difluorobenzylbromide (0.49 mL, 3.8 mmol). The reaction was 
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heated to 65 °C for 6 h before cooling and concentrating in vacuo. The reaction was then diluted in 
dichloromethane (20 mL), washed with H2O (2 x 10 mL), dried over Na2SO4, filtered, and concentrated 
in vacuo to give the title compound as a white amorphous solid (0.910 g, 98%) used without further 
purification. 
Rf: 0.22 (9:1 PE 40-60:EtOAc); IR (neat film, νmax, cm-1): 3053 (w), 2905 (w), 2219 (m, CN), 1603 (m), 
1519 (m), 1506 (m), 1438 (m), 1383 (w), 1291 (m), 1248 (s), 1170 (m), 1116 (m), 1001 (m); 1H NMR 
(400 MHz, CDCl3) δ: 7.60 (d, J = 8.9 Hz, 2H, H2), 7.12 – 7.28 (m, 3H, H6, H7 and H10), 7.00 (d, J = 8.9 
Hz, 2H, H3), 5.06 (s, 2H, CH2); 13C NMR (101 MHz, CDCl3) δ: 161.5 (C4), 150.6 (dd, J = 250, 26 Hz, C-F), 
150.5 (dd, J = 250, 26 Hz, C-F), 134.1 (C2), 132.7 (dd, J = 5.4, 3.9 Hz, C5), 123.4 (dd, J = 6.5, 3.7 Hz, C6), 
119.0 (C≡N), 117.6 (d, J = 18.6 Hz, C7/10), 116.5 (d, J = 18.6 Hz, C7/10), 115.5 (C3), 104.7 (C1), 69.0 (d, 
J = 1.3 Hz, CH2); 19F NMR (376 MHz, CDCl3) δ: -138.86 (d, J = 21.0 Hz), -137.66 (d, J = 21.0 Hz); HRMS 
(ESI): m/z calcd for C14H10F2NO [M+H]+: 246.0725; found 246.0734. 
 
(4-((3,4-difluorobenzyl)oxy)phenyl)methanamine (122) 
 
To a stirring solution of 121 (0.90 g, 3.67 mmol) in tetrahydrofuran (25 mL) cooled to 0 °C, was added 
lithium aluminium hydride (0.836 g, 22 mmol). The reaction was stirred at r.t. for 15 h before cooling 
to 0 °C and quenching with H2O (2 mL), followed by 15% NaOH (1 mL), and H2O (2 mL). The mixture 
was stirred for a further 2 h before filtering and concentrating in vacuo to give the title compound as 
a yellow oil (0.807 g, 88%) used without further purification. 
IR (neat film, νmax, cm-1): 3304 (w), 2928 (w), 2869 (w), 1610 (m), 1584 (m), 1509 (s), 1462 (m), 1435 
(m), 1381 (m), 1285 (s), 1236 (s), 1210 (s), 1176 (m), 1114 (m), 1020 (w); 1H NMR (400 MHz, CDCl3) δ: 
7.31 – 7.25 (m, 3 H, ), 7.22 – 7.14 (m, 2 H, ), 6.96 – 6.91 (m, 2 H, ), 5.02 (s, 2 H, H6), 3.83 (s, 2 H, H1), 
1.64 (br s, 2 H, NH2); 13C NMR (101 MHz, CDCl3) δ: 157.3 (C5), 150.5 (dd, J = 250, 49 Hz, C-F), 150.4 (dd, 
J = 250, 49 Hz, C-F), 136.2 (C3), 134.2 – 134.1 (m, C7), 128.4 (C2), 123.2 (dd, J = 6.4, 3.7 Hz, C8), 117.3 
(d, J = 17.4 Hz, C9 or C12), 116.4 (d, J = 17.4 Hz, C9 or C12), 114.9 (C4), 68.8 (C6), 45.9 (C1); 19F NMR 
(376 MHz, CDCl3) δ:  -138.3 (d, J = 21 Hz), -140.0 (d, J = 21 Hz); HRMS (ESI): m/z calcd for C14H14F2NO 
[M+H]+: 250.1038; found 250.1046. 
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Ethyl 6-chloro-3-(1-(4-((3,4-difluorobenzyl)oxy)benzyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-1H-
indole-2-carboxylate (123) 
 
To a stirring solution of 112 (100 mg, 0.4 mmol) in ethanol (2 mL) was added 122 (99 mg, 0.4 mmol). 
The reaction was stirred at r.t. for 30 mins before 116 (115.7 mg, 0.4 mmol) and triethylamine (56 µL, 
0.4 mmol) were added. The reaction was then heated to 50 °C for 3 h before cooling to r.t., stirring for 
a further 16 h, and concentrating in vacuo. The residue was then purified by silica gel chromatography 
(7:3 to 1:1 Hex/EtOAc) to give the title compound as a yellow oil (160 mg, 65%). 
Rf: 0.23 (6:4 EtOAc/Hex); IR (neat film, νmax, cm-1): 3038 (w), 1706 (m), 1669 (m), 1612 (m), 1513 (s), 
1435 (m), 1308 (m), 1290 (m), 1233 (s), 1199 (s), 1178 (s), 1137 (m), 1117 (m), 1061 (w), 1023 (w); 1H 
NMR (400 MHz, CDCl3) δ: 10.81 (br s, 1 H, -NH), 8.57 (s, 1 H, H11), 7.54 (s, 1 H, H7), 7.34 – 7.40 (m, 2 
H, H13), 7.08 – 7.22 (m, 3H, H23, H24, H27), 6.97 – 7.02 (m, 2 H, H4, H5), 6.75 – 6.88 (m, 4H, H18 and 
H14), 6.66 (d, J = 8.6 Hz, 2H, H19), 4.83 - 4.96 (m, 4H, 2 x CH2), 4.06 – 4.20 (m, 2H, CH2), 1.11 (t, J = 7.1 
Hz, 3H, CH3); 13C NMR (101 MHz, CDCl3) δ: 162.6 (d, J = 250 Hz, C15), 160.5 (C=O), 159.2 (C12), 158.7 
(C20), 151.5 (dd, J = 37, 13 Hz, C25), 149.1 (dd, J = 37, 13 Hz, C26), 136.6 (C8), 136.2 (C11), 135.0 (C10), 
133.6 (m, C22), 132.4 (C6), 129.6 (C18), 128.3 (d, J = 8.1 Hz, C13), 127.7 (C1), 126.3 (C3), 126.2 (C17), 
123.5 (m, C23), 123.4 (C5), 121.4 (C4), 121.1 (C9), 117.5 (d, J = 17.5 Hz, C24), 116.5 (d, J = 17.5 Hz, 
C27), 115.9 (d, J = 21.5 Hz, C14), 115.2 (C19), 112.8 (C7), 107.5 (C2), 68.9 (C21), 61.7 (-CH2-CH3), 50.4 
(C16), 14.1 (CH3); 19F NMR (376 MHz, CDCl3) δ:  -116.26, -137.21 (d, J = 21.0 Hz), -138.69 (d, J = 21.0 
Hz); HRMS (ESI): m/z calcd for C34H26ClF3N3O3 [M+H]+: 616.1610; found: 616.1599. 
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6-Chloro-3-(1-(4-((3,4-difluorobenzyl)oxy)benzyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-1H-indole-
2-carboxylic acid (110) 
 
To a stirring solution of 123 (76 mg, 0.12 mmol) in ethanol (1 mL) was added 2 M NaOH (aq, 1 mL). 
The mixture was heated to reflux for 3 h before being cooled, poured over ice and acidified with 3 M 
HCl. The mixture was then extracted into EtOAc (3 x 10 mL), washed with brine, dried over Na2SO4, 
filtered, and concentrated in vacuo to give the title compound as a yellow solid (53 mg, 73%) used 
without further purification. 
IR (neat film, νmax, cm-1): 1700 (w), 1612 (m), 1513 (s), 1437 (m), 1369 (m), 1325 (m), 1289 (m), 1241 
(s), 1177 (m), 1115 (m); 1H NMR (400 MHz, MeOD) δ: 8.44 (s, 1 H, H11), 7.48 (d, J = 1.6 Hz, 1 H, H7), 
7.40 – 7.35 (m, 2 H, H13), 7.30 – 7.15 (m, 3 H, H23, H24, H27), 6.89 (t, J = 8.7 Hz, 2 H, H18), 6.84 (dd, J 
= 8.6, 1.6 Hz, 1H, H5), 6.78 – 6.75 (m, 3 H, H4 and 14), 6.62 (d, J = 8.7 Hz, 2 H, H19), 5.12 (d, J = 14.7 
Hz, 1 H, H16), 4.94 (d, J = 14.7 Hz, 1 H, H16), 4.86 (m, 2 H, H21); 13C NMR (101 MHz, MeOD) δ: 162.8 
(C=O), 162.1 (d, J = 250 Hz, C15), 158.2 (2C, C12 and C20), 151.4 (C25), 148.4 (C26), 136.6 (C11), 136.4 
(C8), 134.7, 131.2, 130.5, 128.9, 128.0 (d, J = 8 Hz), 127.8 (2C), 126.1, 123.5 (m), 121.3, 121.1, 116.9 
(d, J = 18 Hz, ), 116.0 (d, J = 17.5 Hz, ), 115.2, 114.9 (d, J = 22 Hz), 114.5, 111.8 (C7), 107.1 (C2), 68.3 
(C21), 49.6 (C16); 19F NMR (376 MHz, MeOD) δ: -117.0, -141.5 (d, J = 21 Hz), -143.0 (d, J = 21 Hz); HRMS 
(ESI): m/z calcd for C32H20ClF3N3O3 [M-H]-: 586.1151; found: 586.1134. 
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tert-Butyl (2-(2-(2-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-
thioxoimidazolidin-1-yl)-2-fluorobenzamido)ethoxy)ethoxy)ethyl)carbamate (124) 
 
To a stirring solution of 2 (15 mg, 0.03 mmol) in DMF (159 µl) were added HATU (15.16 mg, 0.04 mmol) 
and DIPEA (6.95 µl, 0.04 mmol). The reaction was stirred for ca. 10 mins at 25 °C before 36 (9.90 mg, 
0.04 mmol) was added. The reaction was stirred for a further 3 h before being dissolved in EtOAc (5 
mL) and H2O (3 mL), extracted into EtOAc (3 x 5 mL), dried over MgSO4 and concentrated in vacuo. 
The residue was then purified by flash column chromatography (0 to 100% EtOAc/Heptane) to give 
the title compound (17.00 mg, 75%) as a yellow oil. 
Rf: 0.30 (80% EtOAc/Hex); IR (neat film, νmax, cm-1): 3361 (w, NH), 2931 (w, CH), 2865 (w, CH), 1758 (m, 
C=O), 1702 (m, C=O), 1659 (m, C=O), 1619 (m), 1528 (m), 1499 (m), 1434 (m), 1413 (m), 1366 (m), 
1311 (s), 1288 (m), 1219 (m), 1176 (s), 1135 (s), 1056 (m); 1H NMR (500 MHz, CDCl3) δ: 8.24 (t, J = 7.5 
Hz, 1 H, H14), 7.99 (d, J = 8.3 Hz, 1 H, H6), 7.95 (d, J = 1.9 Hz, 1 H, H3), 7.83 (dd, J = 8.3, 2.0 Hz, 1 H, H5), 
7.22 – 7.26 (m, 1 H, H15), 7.15 – 7.19 (m, 1 H, H11), 4.99 (s, 1 H, NH), 3.74 – 3.62 (m, 8 H, 4x CH2), 3.55 
(t, J = 5.2 Hz, 2 H, CH2), 3.38 – 3.27 (m, 2 H, CH2), 1.62 (s, 6 H, H9), 1.43 (s, 9 H, 3x CH3); 13C NMR (126 
MHz, CDCl3) δ: 179.7 (C=S), 174.5 (C7), 162.2 (C=O), 160.4 (d, J = 250 Hz, C12), 156.1 (Boc-C=O), 139.0 
(d, J = 11 Hz, C13), 136.8 (C1), 135.3 (C6), 133.7 (q, J = 33 Hz, C2), 133.3 (C14), 132.1 (C5), 127.1 (q, J = 
3.5 Hz, C3), 126.1 (d, J = 3 Hz, C15), 122.9 (d, J = 13 Hz, C10), 121.8 (q, J = 275 Hz, CF3), 118.0 (d, J = 28 
Hz, C11), 114.7 (-C≡N), 110.4 (C4), 79.5 (boc-qC), 70.4, 70.3, 70.2, 69.6 (4x O-CH2), 66.6 (C8), 40.5, 39.9 
(2x N-CH2), 28.4 (3x CH3), 23.9 (C9); 19F NMR (471 MHz, CDCl3) δ: -62.96, -111.31; HRMS (ESI): m/z 
calcd for C31H36F4N5O6S [M+H]+: 682.2317; found: 682.2308.  
 
 
N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-
oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamide (125) 
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To a stirring solution of 124 (15 mg, 0.02 mmol) in dichloromethane (110 µl) was added 2,2,2-
trifluoroacetic acid (251 mg, 2.20 mmol). The reaction was stirred at 25 °C for 2 h before concentrating 
and dissolving in sat. aq. NaHCO3 (5 mL) and extracting into EtOAc (3 x 10 mL), drying over MgSO4, 
filtering and concentrating in vacuo to give the title compound (11.00 mg, 86 %) as a colourless oil 
used without further purification. 
IR (neat film, νmax, cm-1): 3350 (w, NH), 2919 (w, CH), 2849 (w, CH), 1757 (m, C=O), 1655 (m, C=O), 1620 
(m), 1534 (m), 1499 (m), 1438 (m), 1413 (m), 1311 (s), 1219 (m), 1177 (m), 1133 (s), 1056 (m); 1H NMR 
(500 MHz, CDCl3) δ: 8.21 (t, J = 8.3 Hz, 1 H, H14), 7.99 (d, J = 8.3 Hz, 1 H, H6), 7.95 (d, J = 1.5 Hz, 1 H, 
H3), 7.83 (dd, J = 8.2, 1.8 Hz, 1 H, H5), 7.28 – 7.37 (m, 1 H, NH), 7.23 (dd, J = 8.3, 1.8 Hz, 1 H, H15), 7.16 
(d, J = 10.3 Hz, 1 H, H11), 3.72 – 3.62 (m, 8 H, 4x CH2), 3.58 – 3.50 (m, 2 H, CH2), 2.96 – 2.80 (m, 2 H, 
CH2), 1.61 (s, 6 H, H9); 13C NMR (126 MHz, CDCl3) δ: 179.8 (C=S), 174.5 (C7), 162.3 (C=O), 160.4 (d, J = 
250 Hz, C12), 138.9 (d, J = 11 Hz, C13), 136.8 (C1), 135.3 (C6), 133.7 (q, J = 33 Hz, C2), 133.2 (C14), 
132.1 (C5), 127.1 (q, J = 3.5 Hz, C3), 126.1 (C15), 123.1 (d, J = 11.6 Hz, C10), 121.9 (q, J = 275 Hz, CF3), 
118.0 (d, J = 28 Hz, C11), 114.7 (-C≡N), 110.4 (C4), 72.4, 70.4, 70.2, 69.6 (4x O-CH2), 66.6 (C8), 41.3, 
39.9 (2x N-CH2), 23.8 (C9); 19F NMR (471 MHz, CDCl3) δ:  -61.99, -110.42; HRMS (ESI): m/z calcd for 
C26H28F4N5O4S [M+H]+: 582.1793; found: 582.1793. 
 
6-Chloro-3-(1-(4-chlorobenzyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-N-(2-(2-(2-(4-(3-(4-cyano-3-
(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-
fluorobenzamido)ethoxy)ethoxy)ethyl)-1H-indole-2-carboxamide (PROTAC-12) 
 
To a stirring solution of 87 (8.0 mg, 0.017 mmol) in DMF (0.1 mL), were added HATU (7.6 mg, 0.020 
mmol), DIPEA (3.5 µL, 0.020 mmol), and a solution of 125 (10.7 mg, 0.018 mmol) in DMF (0.1 mL). The 
reaction was stirred for 18 h before being diluted with EtOAc (5 mL) and H2O (3 mL), extracted into 
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EtOAc (2 x 5 mL), washed with brine (5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. 
The residue was then purified by silica gel chromatography (1 to 3% MeOH/DCM) to give the title 
compound as a yellow oil (7 mg, 41%). 
Rf: 0.51 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 3388 (w), 3259 (w), 2924 (w), 2873 (w), 1758 (m), 
1654 (s), 1621 (m), 1538 (s), 1523 (s), 1495 (s), 1439 (s), 1411 (s), 1311 (s), 1220 (s), 1178 (s), 1140 (s), 
1057 (w); 1H NMR (500 MHz, CDCl3) δ: 9.89 (s, 1 H, NH), 8.19 (t, J = 8.1 Hz, 1 H, H14), 7.98 (d, J = 8.1 
Hz, 1 H, H6), 7.94 (d, J = 1.6 Hz, 1 H, H3), 7.82 – 7.79 (m, 2 H, H5, H20), 7.51 – 7.38 (m, 4 H), 7.20 (dd, 
J = 7.2 Hz, 1 H, H15), 7.13 – 7.00 (m, 4 H), 6.83 (t, J = 8.3 Hz, 2 H), 6.68 (d, J = 8.3 Hz, 2 H), 6.24 – 6.20 
(m, 1 H), 4.84 (d, J = 15.1 Hz, 1 H, H23), 4.72 (d, J = 15.1 Hz, 1 H, H23), 1.59 (s, 6 H, H9); 13C NMR (126 
MHz, CDCl3) δ: 179.7 (C=S), 174.4 (C7), 162.4 (C=O), 162.2 (d, J = 250 Hz, C-F), 160.3 (d, J = 250 Hz, C-
F), 160.0 (C=O), 140.6, 139.0, 138.9 (d, J = 11 Hz, C13), 136.8, C1), 135.4, 135.3 (C5), 134.2 (2C), 134.0, 
133.7 (q, J = 35 Hz, C2), 133.1 (d, J = 3 Hz, C14), 132.1 (C5), 131.5, 130.0, 129.6 (2C), 128.8, 128.6, 127.5 
(d, J = 8 Hz), 127.1 (q, J = 5 Hz, C3), 126.7, 126.1 (d, J = 3.5 Hz, C15), 125.9, 123.3, 123.2, 123.1, 122.8, 
121.4, 120.4, 118.0 (d, J = 30 Hz, C11), 118.0, 117.7, 115.4 (d, J = 22 Hz), 114.7 (-C≡N), 112.3, 110.4 (d, 
J = 2 Hz, C4), 104.4, 70.4, 70.2, 69.6, 69.2 (4x O-CH2), 66.6 (C8), 48.9 (C23), 39.9, 39.2 (2x N-CH2), 23.8 
(C9);  19F NMR (471 MHz, CDCl3) δ: -62.0, -110.4, -114.5; HRMS (ESI): m/z calcd for C51H42Cl2F5N8O5S 
[M+H]+: 1043.2291; found: 1043.2301. 
 
6-Chloro-3-(1-(4-chlorobenzyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-N-(1-(4-(3-(4-cyano-3-
(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorophenyl)-1-oxo-
5,7,10-trioxa-2-azadodecan-12-yl)-1H-indole-2-carboxamide (PROTAC-13) 
 
 
To a stirring solution of 87 (6.5 mg, 0.014 mmol) in DMF (0.1 mL), were added HATU (6.2 mg, 0.016 
mmol), DIPEA (2.8 µL, 0.016 mmol), and a solution of 94 (9.3 mg, 0.015 mmol) in DMF (0.1 mL). The 
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reaction was stirred for 5 h before being diluted with EtOAc (5 mL) and H2O (3 mL), extracted into 
EtOAc (2 x 5 mL), washed with brine (5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. 
The residue was then purified by silica gel chromatography (1 to 3% MeOH/DCM) to give the title 
compound as a yellow oil (8.6 mg, 59%). 
Rf: 0.20 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 3237 (w), 2917 (w), 1759 (m), 1726 (w), 1654 (m), 
1620 (m), 1538 (m), 1523 (m), 1496 (m), 1439 (s), 1409 (s), 1311 (s), 1219 (s), 1178 (m), 1140 (s), 1092 
(m), 1057 (m), 1015 (w); 1H NMR (500 MHz, CDCl3) δ: 10.06 (br s, 1 H, NH), 8.21 (t, J = 7.6 Hz, 1 H, H14), 
7.97 (d, J = 8.2 Hz, 1 H, H6), 7.93 (d, J = 1 Hz, 1 H, H3), 7.89 (s, 1 H, H17), 7.81 (dd, J = 8.1, 2 Hz, 1 H, 
H5), 7.50 – 7.45 (m, 3 H), 7.31 – 7.27 (m, 1 H), 7.21 (dd, J = 8.4, 1.6 Hz, 1 H, H15), 7.14 (dd, J = 11.7, 2 
Hz, 1 H, H11), 7.09 – 7.02 (m, 4 H), 6.83 (t, J = 8.6 Hz, 2 H), 6.69 (d, J = 8.3 Hz, 2 H), 6.20 (d, J = 5.0 Hz, 
1 H), 4.84 (d, J = 15.6 Hz, 1 H, H16), 4.77 (d, J = 15.6 Hz, 1 H, H16), 3.71 – 3.57 (m, 8 H, 4x CH2), 3.56 – 
3.47 (m, 2 H, CH2), 3.43 – 3.33 (m, 4 H, 2x CH2), 3.27 – 3.18 (m, 2 H, CH2), 1.59 (s, 6 H, H9); 13C NMR 
(126 MHz, CDCl3) δ: 179.8 (C=S), 174.5 (C7), 162.2 (C=O), 162.0 (d, J = 275 Hz, C-F), 160.3 (d, J = 275 
Hz, C-F), 160.1 (C=O), 140.5, 139.2, 138.9 (d, J = 11 Hz, C13), 136.8 (C1), 135.5, 135.3 (C5), 134.2, 134.1 
(2C), 133.7 (q, J = 33 Hz, C2), 133.2 (d, J = 3 Hz, C14), 132.1 (C5), 131.4, 129.9, 129.6 (2C), 128.8, 128.6, 
127.4 (d, J = 8 Hz), 127.1 (q, J = 5 Hz, C3), 126.7, 126.1 (d, J = 3.5 Hz, C15), 125.9, 123.2, 123.1, 123.0, 
122.7, 121.4, 120.4, 118.0 (d, J = 26 Hz, C11), 117.9 (2C), 115.4 (d, J = 22 Hz), 114.7 (-C≡N), 112.3, 110.4 
(C4), 104.5, 70.5, 70.4 (2C), 70.3, 69.6, 69.1 (6x O-CH2), 66.6 (C7), 48.8 (C16), 39.9, 39.3 (2x N-CH2), 
23.8 (C9); 19F NMR (471 MHz, CDCl3) δ: -62.0, -110.3, -114.7; HRMS (ESI): m/z calcd for 
C53H46Cl2F5N8O6S [M+H]+: 1087.2553; found: 1087.2501. 
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6-Chloro-N-(2-(2-(2-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-
thioxoimidazolidin-1-yl)-2-fluorobenzamido)ethoxy)ethoxy)ethyl)-3-(1-(4-((3,4-
difluorobenzyl)oxy)benzyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-1H-indole-2-carboxamide 
(PROTAC-14) 
 
To a stirring solution of 110 (10.1 mg, 0.017 mmol) in DMF (0.1 mL), were added HATU (7.8 mg, 0.020 
mmol), DIPEA (3.6 µL, 0.020 mmol), and a solution of 125 (11.0 mg, 0.019 mmol) in DMF (0.1 mL). The 
reaction was stirred for 18 h before being diluted with EtOAc (5 mL) and H2O (3 mL), extracted into 
EtOAc (2 x 5 mL), washed with brine (5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. 
The residue was then purified by silica gel chromatography (1 to 3% MeOH/DCM) to give the title 
compound as a yellow oil (10.8 mg, 55%). 
Rf: 0.52 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 3383 (w), 3239 (w), 2928 (w), 2876 (w), 1758 (m), 
1729 (w), 1648 (m), 1619 (m), 1538 (m), 1520 (s), 1497 (s), 1436 (s), 1412 (s), 1309 (s), 1287 (s), 1218 
(s), 1177 (s), 1139 (s), 1113 (s), 1056 (m), 1013 (w); 1H NMR (500 MHz, CDCl3) δ: 9.99 (br s, 1 H, NH), 
8.18 (t, J = 8.2 Hz, 1 H, H14), 7.97 (d, J = 8.1 Hz, 1 H, H6), 7.94 (d, J = 1.6 Hz, 1 H, H3), 7.82 – 7.80 (m, 2 
H, H5, H21), 7.51 – 7.40 (m, 4 H), 7.21 – 6.99 (m, 7 H), 6.82 (t, J = 8.8 Hz, 2 H), 6.69 – 6.64 (m, 3 H), 6.25 
(t, J = 4.6 Hz, 1 H, NH), 4.86 (s, 2 H, H17), 4.77 (d, J = 14.8 Hz, 1 H, H16), 4.70 (d, J = 14.8 Hz, 1 H, H16), 
3.73 – 3.61 (m, 4 H, 2x CH2), 3.55 – 3.30 (m, 6 H, 3x CH3), 3.25 – 3.19 (m, 2 H, CH2), 1.58 (s, 6 H, H9); 
13C NMR (126 MHz, CDCl3) δ: 179.7 (C=S), 174.4 (C7), 162.3 (C=O), 162.0 (d, J = 250 Hz, C-F), 160.3 (d, 
J = 250 Hz, C12), 160.2 (C=O), 158.1 (O-ArC), 150.3 (dd, J = 250, 40 Hz, C-F), 150.2 (dd, J = 250, 40 Hz, 
C-F), 140.5, 138.9, 138.8, 136.8 (C1), 135.5, 135.3 (C5), 133.7 (q, J = 34 Hz, C2), 133.7, 133.6 (2C), 133.1 
(d, J = 3 Hz, C14), 132.1 (C5), 131.3, 130.0, 129.8, 129.7, 128.8, 128.1, 127.4 (d, J = 8 Hz), 127.1 (q, J = 
5 Hz, C3), 126.9, 126.0 (d, J = 3.2 Hz, C15), 125.9, 123.3 – 123.2 (m, 3C), 122.6, 121.6, 120.5, 117.9 (d, 
J = 26 Hz, C11), 117.9, 117.5, 117.3, 116.4 (d, J = 16 Hz), 115.4 (d, J = 22 Hz), 114.9, 114.7 (-C≡N), 112.2, 
110.5 (d, J = 2 Hz, C4), 104.8, 70.4, 70.2, 69.6, 69.2, 68.8 (5x O-CH2), 66.6 (C8), 49.1 (C16), 39.9, 39.2 
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(2x N-CH2), 23.8 (C9); 19F NMR (471 MHz, CDCl3) δ: -62.0, -110.4, -114.7, -137.1 (d, J = 20.5 Hz), -138.6 
(d, J = 20.5 Hz); HRMS (ESI): m/z calcd for C58H47ClF7N8O6S [M+H]+: 1151.2911; found: 1151.2892. 
 
6-Chloro-N-(1-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-
1-yl)-2-fluorophenyl)-1-oxo-5,8,11-trioxa-2-azatridecan-13-yl)-3-(1-(4-((3,4-
difluorobenzyl)oxy)benzyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-1H-indole-2-carboxamide 
(PROTAC-15) 
 
To a stirring solution of 110 (7.9 mg, 0.0135 mmol) in DMF (0.1 mL), were added HATU (6.2 mg, 0.016 
mmol), DIPEA (2.8 µL, 0.016 mmol), and a solution of 94 (9.3 mg, 0.015 mmol) in DMF (0.1 mL). The 
reaction was stirred for 5 h before being diluted with EtOAc (5 mL) and H2O (3 mL), extracted into 
EtOAc (2 x 5 mL), washed with brine (5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. 
The residue was then purified by silica gel chromatography (1 to 3% MeOH/DCM) to give the title 
compound as a yellow oil (7.0 mg, 44%). 
Rf:  0.23 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 3369 (w), 3227 (w), 2920 (w), 1758 (m), 1728 (w), 
1654 (m), 1619 (m), 1538 (m), 1521 (s), 1437 (s), 1411 (s), 1310 (s), 1288 (s), 1219 (s), 1177 (s), 1141 
(s), 1057 (m); 1H NMR (500 MHz, CDCl3) δ: 9.87 (br s, 1 H, NH), 8.20 (t, J = 8.3 Hz, 1 H, H14), 7.97 (d, J 
= 8.1 Hz, 1 H, H6), 7.94 (d, J = 1.5 Hz, 1 H, H3), 7.87 (s, 1 H, H16), 7.81 (dd, J = 8.3, 1.8 Hz, 1 H, H5), 7.51 
– 7.43 (m, 3 H), 7.29 – 7.27 (m, 1 H, NH), 7.22 – 6.99 (m, 7 H), 6.82 (t, J = 8.8 Hz, 2 H), 6.69 – 6.64 (m, 
4 H), 6.23 – 6.19 (m, 1 H, NH), 4.86 (s, 2 H, H17), 4.76 (s, 2 H, H16), 3.69 – 3.17 (m, 16 H, 8x CH2), 1.58 
(s, 6 H, H9); 13C NMR (126 MHz, CDCl3) δ: 179.8 (C=S), 174.5 (C7), 162.2 (C=O), 162.0 (d, J = 250 Hz, C-
F), 160.3 (d, J = 250 Hz, C12), 160.2 (C=O), 158.1 (O-ArC), 150.3 (dd, J = 250, 40 Hz, C-F), 150.2 (dd, J = 
250, 40 Hz, C-F), 140.4, 139.1, 138.9 (d, J = 11 Hz, C13), 136.8 (C1), 135.5, 135.3 (C5), 133.7 (q, J = 34 
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Hz, C2), 133.7, 133.6 (2C), 133.2 (d, J = 3 Hz, C14), 132.1 (C5), 131.2, 129.9, 129.8 (2C), 128.8, 128.1, 
127.4 (d, J = 8 Hz), 127.1 (q, J = 4 Hz, C3), 126.9, 126.0 (d, J = 3 Hz, C15), 125.9, 123.3 – 123.2 (m, 3C), 
122.6, 121.6, 120.4, 118.0 (d, J = 26 Hz, C11), 117.9, 117.5, 117.3, 116.4 (d, J = 16 Hz), 115.4 (d, J = 23 
Hz), 114.9, 114.7 (-C≡N), 112.1, 110.5 (C4), 104.9, 70.5, 70.4 (2C), 70.3, 69.6, 69.2, 68.8 (7x O-CH2), 
66.6 (8), 49.1 (C16), 39.9, 39.3 (2x N-CH2), 23.8 (C9);  19F NMR (471 MHz, CDCl3) δ: -61.9, -110.3, -114.9, 
-137.2 (d, J = 21.3 Hz), -138.6 (d, J = 21.3 Hz); HRMS (ESI): m/z calcd for C60H51ClF7N8O6S [M+H]+: 
1195.3173; found: 1195.3119 . 
 
tert-butyl (S)-(1-(4-bromophenyl)ethyl)carbamate (127) 
 
Following the reported procedure,235 to a stirring solution of (S)-(−)-1-(4-bromophenyl)ethylamine 
(0.55 mL,  3.7 mmol) in EtOAc (1.8 mL) and water (1.8 mL) cooled to 0 °C, were added sodium hydrogen 
carbonate (0.30 g, 3.6 mmol) and Boc2O (1.04 mL, 4.5 mmol). The reaction mixture was stirred at r.t. 
for 3 h before filtering. The white solid was suspended in hexane (3 mL) and water (3 mL) for 30 mins 
before filtering to give the title compound as a white amorphous solid (1.07 g, 97%).  
 
Rf: 0.76 (6:4 Hex:EtOAc); IR (neat film, νmax, cm-1): 3380 (m, NH), 2979 (m, CH), 1680 (s), 1508 (s), 1487 
(m), 1443 (m), 1389 (w), 1364 (m), 1343 (m), 1309 (m), 1294 (w), 1244 (m), 1166 (s), 1094 (m), 1059 
(s), 1007 (s); 1H NMR (400 MHz, CDCl3) δ: 7.44 (d, J = 8.4 Hz, 2 H, H2), 7.17 (d, J = 8.4 Hz, 2 H, H1), 4.78 
– 4.73 (br d, 2 H, NH and -CH-), 1.41 – 1.40 (br m, 12 H, 4 x CH3); 13C NMR (101 MHz, CDCl3) δ: 155.0 
(C=O), 143.3 (C-Br), 131.6 (C2), 127.6 (C1), 120.8 (ArC), 79.6 (O-C-(CH3)3), 49.7 (-CH-), 28.4 (3 x CH3), 
22.6 (CH3); [α]D25: -71.8 (c = 0.22, MeOH). 
The spectroscopic data are in agreement with those previously reported in the literature for the title 
compound.352 
 
tert-Butyl (S)-(1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamate (128) 
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Following the reported procedure,235 to a stirring solution of 127 (0.976 g, 4.9 mmol) in N,N-
dimethylacrylamide (2.5 mL) were added 4-methylthiazole (1.11 mL, 9.9 mmol), potassium acetate 
(2.22 g, 9.9 mmol), and palladium acetate (5.0 mg, 0.05 mmol). The reaction mixture was heated to 
90 °C for 18 h before cooling and filtering. H2O (2 mL) was added to the filtrate and the mixture was 
stirred for a further 4 h at r.t. before filtering to give the title compound as a white amorphous solid 
(1.23 g, 79%).  
Rf: 0.24 (7:3 Hex:EtOAc); IR (neat film, νmax, cm-1): 3381 (m, NH), 3052 (w, CH), 2978 (w, CH), 2924 (w, 
CH), 1677 (s), 1510 (s), 1450 (m), 1406 (m), 1392 (m), 1366 (m), 1310 (m), 1294 (m), 1247 (s), 1166 (s), 
1100 (w), 1059 (s), 1003 (m); 1H NMR (400 MHz, CDCl3) δ: 8.67 (s, 1 H, H3), 7.41 (d, J = 8.3 Hz, 2 H, 
H2), 7.35 (d, J = 8.3 Hz, 2 H, H1), 4.84 (br s, H6), 2.53 (s, 3 H, H4), 1.48 – 1.43 (m, 12 H, H5 and 3 x CH3); 
13C NMR (101 MHz, CDCl3) δ: 155.2 (C=O), 150.3 (C3), 148.6 (Cb), 144.1 (Cc), 131.8 (Ca), 130.8 (Cd), 
129.6 (C2), 126.3 (C1), 79.7 (-C-(CH3)3), 50.0 (C6), 28.5 (3 x CH3), 22.8 (C5), 16.2 (C4); [α]D25: -87.2 (c = 
0.18, MeOH). 
The spectroscopic data are in agreement with those previously reported in the literature for the title 
compound.235 
 
(S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethanamine hydrochloride (129) 
 
Following the reported procedure,235 acetyl chloride (0.7 mL, 9.8 mmol) was carefully added to 
methanol (1.8 mL) cooled to 0 °C, to this 128 (1.213 g, 3.8 mmol) was then added. The slurry was 
stirred at r.t. for 2 h before concentrating in vacuo to give the title compound as a yellow amorphous 
powder (0.69 g, 70%).  
IR (neat film, νmax, cm-1): 3400 (m, NH), 2912 (w, CH), 1704 (w), 1641 (w), 1536 (w), 1417 (w), 1365 (w), 
1290 (w), 1226 (w), 1048 (m), 1024 (s), 994 (s); 1H NMR (400 MHz, d6-DMSO) δ: 9.22 (s, 1 H, H3), 8.79 
(br s, 3 H, NH3), 7.68 (d, J = 7.8 Hz, 2 H, H2), 7.57 (d, J = 7.8 Hz, 2 H, H1), 4.47 – 4.41 (m, 1 H, H6), 2.49 
(s, 3 H, H4), 1.56 (d, J = 6.2 Hz, H5); 13C NMR (101 MHz, d6-DMSO) δ: 153.0 (C3), 147.5 (Cb), 140.0 (Cc), 
131.8 (Ca), 131.4 (Cd), 129.6 (C1), 128.1 (C2), 50.1 (C6), 21.2 (C5), 15.9 (C4); [α]D25: -2.73 (c = 0.367, 
MeOH). 
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The spectroscopic data are in agreement with those previously reported in the literature for the title 
compound.235 
 
(2S,4R)-4-hydroxy-2-(methoxycarbonyl)pyrrolidin-1-ium chloride (131) 
 
Following a modified version of the reported procedure,353 to a stirring solution of L-hydroxyproline 
(2.54 g, 19.4 mmol) in methanol (18 mL) was slowly added acetyl chloride (1.94 mL, 27.4 mmol). The 
reaction mixture was heated to reflux for 7 h before cooling. Diethyl ether (10 mL) was added to induce 
precipitation and the slurry was filtered and washed with diethyl ether (5 mL) to give the title 
compound as a white amorphous powder (3.02 g, 87%).  
Rf: 0.28 (12% MeOH/DCM 1% NEt3); IR (neat film, νmax, cm-1): 3379 (m, NH), 3323 (w), 3022 (m, CH), 
2948 (s, CH), 2749 (w), 2599 (w), 1738 (s, C=O) , 1592 (m), 1438 (m), 1422 (m), 1390 (m), 1346 (w), 
1284 (m), 1265 (m), 1218 (s), 1181 (s), 1073 (s); 1H NMR (400 MHz, d6-DMSO) δ: 5.59 (br s, 1 H, NH), 
4.50 – 4.42 (m, 2 H, H1 and H3), 3.77 (s, 3 H, CH3), 3.38 – 3.34 (m, 2 H and overlapping H2O, H4 and 
OH), 3.08 (dt, J = 12.1, 1.2 Hz, 1 H, H4), 2.23 – 2.06 (m, 2 H, H2); 13C NMR (101 MHz, d6-DMSO) δ: 169.6 
(C=O), 68.9 (C1), 57.9 (C3), 53.6 (C4), 53.5 (CH3), 37.4 (C2); [α]D25: -24.9 (c = 1.0, MeOH, lit. [α]D = -
25.3354). 
The spectroscopic data are in agreement with those previously reported in the literature for the title 
compound.353 
 
(2S,4R)-1-((R)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-
carboxylic acid (134) 
 
Following the reported procedure,235 to a stirring solution of (S)-N-Boc-2-amino-3,3-dimethylbutyric 
acid (0.715 g, 3.1 mmol) in DMF (7.1 mL) were added HATU (1.25 g, 3.3 mmol) and DIPEA (2.0 mL, 10.2 
mmol). The reaction mixture was stirred at r.t. for 15 mins before 131 (0.676 g, 3.7 mmol) was added. 
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The mixture was then stirred for a further 18 h before diluting in water (10 mL) and extracting into 
EtOAc (4 x 20 mL). The combined organics were then washed with 5% citric acid (aq., 2 x 10 mL), sat. 
NaHCO3 (2 x 10 mL), brine (2 x 10 mL), before being dried over Na2SO4, filtered and concentrated in 
vacuo. The crude product was then dissolved in THF (5 mL) and water (2.5 mL) and lithium hydroxide 
monohydrate (1.30 g, 31 mmol) was added. The slurry was stirred at r.t. for 18 h before concentrating 
in vacuo. The residue was diluted with ice water (10 mL) and the pH adjusted to 2 with 3M HCl. After 
stirring for a further 30 mins the slurry was filtered to give the title compound as a white amorphous 
powder (0.748 g, 70%) used without further purification.  
IR (neat film, νmax, cm-1): 3323 (br m, OH), 2971 (m, CH), 2869 (w, CH), 1686 (br m, C=O), 1625 (s), 1508 
(m), 1439 (m), 1394 (m), 1368 (m), 1333 (w), 1247 (m), 1166 (s), 1082 (w), 1057 (w), 1013 (w); 1H NMR 
(400 MHz, d6-DMSO) δ: 6.46 (d, J = 9.3 Hz, 1 H, NH), 4.33 (br s, 1 H, H3), 4.27 (t, J = 8.2 Hz, 1 H, H1), 
4.16 (d, J = 9.3 Hz, 1 H, H5), 3.66 – 3.57 (m, 2 H, H4), 2.14 – 2.09 (m, 1 H, H2’), 1.91 – 1.85 (m, 1 H, 
H2’’), 1.38 (s, 9 H, Boc-CH3), 0.94 (s, 9 H, 3 x CH3); 13C NMR (101 MHz, d6-DMSO) δ: 173.7 (acid C=O), 
170.4 (amide C=O), 155.8 (Boc-C=O), 78.6 (O-C-(CH3)3), 69.2 (C3), 58.6 (C5), 58.2 (C1), 56.5 (C4), 37.7 
(C2), 35.8 (C6), 28.6 (Boc-CH3), 26.7 (CH3); [α]D25: -27.1 (c = 0.188, MeOH). 
The spectroscopic data are in agreement with those previously reported in the literature for the title 
compound.235 
 
tert-butyl((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)carbamoyl) 
pyrrolidine-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate (135) 
 
Following a reported procedure,235 to a stirring solution of 134 (0.748 g, 2.17 mmol) in DMF (7.5 mL) 
were added HATU (0.991 g, 2.61 mmol) and DIPEA (1.27 mL, 6.51 mmol). The reaction mixture was 
stirred at r.t. for 15 mins before 129 (0.608 g, 2.39 mmol) was added. The mixture was then stirred for 
a further 18 h before diluting in water (10 mL) and extracting into EtOAc (4 x 20 mL). The combined 
organics were then washed with brine (2 x 10 mL), before being dried over Na2SO4, filtered and 
concentrated in vacuo. The residue was purified through silica gel column chromatography (1:20 
MeOH/DCM) to give the title compound as a white amorphous solid (1.082 g, 90%).  
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Rf: 0.40 (6% MeOH/DCM); IR (neat film, νmax, cm-1): 3288 (w, NH), 2969 (w, CH), 2932 (w, CH), 2876 (w, 
CH), 1680 (s, C=O), 1631 (s), 1538 (m), 1501 (m), 1433 (m), 1365 (s), 1237 (m), 1165 (s), 1085 (m), 1050 
(m), 1012 (m); 1H NMR (400 MHz, CDCl3) δ: 8.69 (s, 1 H, H1), 7.63 (d, J = 7.7 Hz, NH), 7.43 – 7.37 (m, 4 
H, Ar-H), 5.28 (d, J = 8.8 Hz, 1 H, Boc-NH), 5.09 (quin, J = 7.4 Hz, 1 H, H8), 4.77 (t, J = 8.3 Hz, 1 H, H10), 
4.52 (br s, 1 H, H12), 4.24 (d, J = 9.1 Hz, 1 H, H13), 3.61 (dd, J = 11.5, 3.6 Hz, 1 H, H13’), 2.54 – 2.51 (m, 
4 H, Ar-CH3 and H11), 2.10 – 2.03 (m, 1 H, H11’), 1.49 ( d, J = 7.4 Hz, 3 H, ali-CH3), 1.43 (s, 9 H, Boc-CH3), 
1.04 (s, 9 H, 3 x CH3); 13C NMR (101 MHz, CDCl3) δ: 172.8 (C14), 169.6 (C9), 156.5 (Boc C=O), 150.3 (C1), 
148.5 (C2), 143.2 (C7), 131.6 (C3), 130.8 (C4), 129.6 (C5), 126.4 (C6), 80.5 (Boc-qC), 70.0 (C12), 59.0 
(C15), 58.2 (C10), 56.5 (C13), 48.9 (C8), 35.2 (C11), 34.8 (C16), 28.3 (Boc-CH3), 26.4 (3 x CH3), 22.3 (ali-
CH3), 16.0 (Ar-CH3); [α]D25: -151.9 (c = 0.052, MeOH). 
Data are in accordance with those reported previously in literature.235 
 
(2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-
yl)phenyl)ethyl)pyrrolidine-2-carboxamide (136) 
 
Following a reported procedure,235 to a stirring solution of 135 (0.112 g, 0.206 mmol) in 
dichloromethane (1 mL) was added trifluoroacetic acid (0.25 mL). The reaction mixture was stirred at 
r.t. for 3 h before concentrating in vacuo. The residue was then dissolved in NaHCO3 (15 mL) and 
extracted into dichloromethane (3 x 20 mL). The combined organic was dried over Na2SO4, filtered 
and concentrated in vacuo. The residue was purified through silica gel column chromatography 
(1:19:0.2 MeOH/DCM/NEt3) to give the title compound as a colourless oil (59 mg, 65%). 
Rf: 0.40 (6% MeOH/DCM); IR (neat film, νmax, cm-1): 3333 (w, NH), 3280 (w, NH), 2947 (w, CH), 2869 
(w, CH), 1693 (s, C=O), 1603 (s), 1548 (m), 1437 (m), 1413 (m), 1370 (m), 1318 (w), 1258 (w), 1224 (m), 
1202 (m), 1079 (w), 1013 (w); 1H NMR (400 MHz, CDCl3) δ: 8.68 (s, 1 H, H1), 7.85 (d, J = 7.6 Hz, 1 H, 
NH), 7.41 – 7.37 (m, 4 H, Ar-H), 5.08 (quin, J = 6.8 Hz, 1 H, H8), 4.78 (t, J = 7.7 Hz, 1 H, H10), 4.48 (br s, 
1 H, H12), 3.76 (d, J = 11.2 Hz, 1 H, H13), 3.60 (dd, J = 11.2, 3.9 Hz, 1 H, H13’), 3.37 (s, 1 H, H15), 2.85 
(br s, 2 H, NH2), 2.53 (s, 3 H, Ar-CH3), 2.42 – 2.36 (m, 1 H, H11), 2.13 – 2.07 (m, 1 H, H11’), 1.50 (d, J = 
6.8 Hz, 3 H, ali-CH3), 1.01 (s, 9 H, 3 x CH3); 13C NMR (101 MHz, CDCl3) δ: 174.1 (C14), 170.2 (C9), 150.3 
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(C1), 148.4 (C2), 143.5 (C7), 131.6 (C3), 130.7 (C4), 129.5 (C5), 126.4 (C6), 69.9 (C12), 60.5 (C15), 58.6 
(C10), 56.5 (C13), 48.9 (C8), 36.4 (C11), 35.7 (C16), 26.2 (3 x CH3), 22.3 (ali-CH3), 16.1 (Ar-CH3); [α]D25: 
-112.8 (c = 0.18, MeOH). 
Data are in accordance with those reported previously in literature235. 
 
(2S,4R)-1-((S)-2-(6-aminohexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-
methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (138) 
 
To a stirring solution of 47 (39 mg, 0.17 mmol) in DMF (0.75 mL) were added HATU (77.6 mg, 0.20 
mmol) and DIPEA (79 µL, 0.41 mmol). The reaction mixture was stirred at r.t. for 15 mins before 136 
(75 mg, 0.17 mmol) was added. The mixture was then stirred for a further 16 h before diluting in water 
(5 mL) and extracting into EtOAc (4 x 10 mL). The combined organics were then washed with brine (2 
x 5 mL), before being dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified 
through silica gel column chromatography (DCM to 1:9 MeOH/DCM) to give the crude compound 
which was then dissolved in a mixture of dichloromethane (0.2 mL) and trifluoroacetic acid (30 µL). 
The reaction mixture was stirred at r.t. for 3 h before concentrating in vacuo. The residue was then 
dissolved in NaHCO3 (1 mL) and extracted into dichloromethane (3 x 5 mL). The combined organic was 
dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified through silica gel 
column chromatography (1:9:0.2 MeOH/DCM/NEt3) to give the title compound as a yellow oil (8 mg, 
80%). 
Rf: 0.09 (1:9:0.2 MeOH/DCM/NEt3); IR (neat film, νmax, cm-1): 3284 (m, NH), 2964 (w, CH), 2869 (w, CH), 
1625 (br m, C=O), 1539 (w), 1449 (w), 1413 (w), 1375 (w), 1228 (w), 1201 (w), 1082 (w); 1H NMR (400 
MHz, CDCl3) δ: 8.66 (s, 1 H, H1), 7.87 (d, J = 7.6 Hz, 1 H, NH), 7.41 – 7.34 (m, 4 H, Ar-H), 7.11 (d, J = 8.5 
Hz, 1 H, NH), 5.10 – 5.07 (m, 1 H, H8), 4.74 – 4.70 (m, 1 H, H10), 4.62 – 4.58 (m, 1 H, H15), 4.50 – 4.43 
(m, 1 H, H12), 4.01 (d, J = 9.9 Hz, 1 H, H13), 3.63 (d, J = 9.9 Hz, 1 H, H13’), 2.87 (br s, 2 H, H20), 2.49 (s, 
3 H, aryl-CH3), 2.26 – 2.22 (m, 4 H, CH2 and H11), 1.61 – 1.26 (m, 11 H, alkyl-CH3 and 4 x CH2), 1.05 (s, 
9 H, 3 x CH3); 13C NMR (101 MHz, CDCl3) δ: 174.1 (C14), 171.7 (C18), 170.3 (C9), 150.3 (C1), 148.4 (C2), 
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143.6 (C7), 131.6 (C3), 130.7 (C4), 129.4 (C5), 126.4 (C6), 69.9 (C12), 59.0 (C15), 57.9 (C10), 57.3 (C13), 
48.8 (C8), 40.1 (C20), 38.6 (C11), 35.5 (C16), 35.4 (C19), 28.4 (CH2), 26.6 (C17), 25.6 (CH2), 24.8 (CH2), 
22.4 (ali-CH3), 16.1 (Aryl-CH3); HRMS: m/z [M+H]+ calculated for C29H44N5O4S: 558.3109; Found: 
558.3118; [α]D25: -89.167 (c = 0.12, MeOH). 
 
tert-Butyl (6-((6-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-
yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-
oxohexyl)amino)-6-oxohexyl)carbamate (139) 
 
To a stirring solution of 47 (3.3 mg, 0.014 mmol) in DMF (0.1 mL) were added HATU (6 mg, 0.016 
mmol) and DIPEA (6.1 µL, 0.031 mmol). The reaction mixture was stirred at r.t. for 15 mins before 138 
(8 mg, 0.014 mmol) was added. The mixture was then stirred for a further 16 h before diluting in water 
(5 mL) and extracting into EtOAc (4 x 10 mL). The combined organics were then washed with brine (2 
x 5 mL), before being dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified 
through silica gel column chromatography (DCM to 1:9 MeOH/DCM) to give the title compound as a 
colourless oil (8 mg, 73%). 
Rf: 0.18 (6% MeOH/DCM); IR (neat film, νmax, cm-1): 3289 (w, NH), 2927 (m, CH), 2865 (w, CH), 1686 (s, 
C=O), 1630 (s, C=O), 1533 (s), 1452 (m), 1366 (m), 1272 (m), 1249 (m), 1167 (s), 1086 (w); 1H NMR 
(400 MHz, CDCl3) δ: 8.71 (s, 1 H, C1), 7.47 – 7.38 (m, 5 H, Ar-H and, NH), 6.63 (br s, 1 H, NH), 6.06 (br 
s, 1 H, NH), 5.11 (quin, J = 7.3 Hz, 1 H, H8), 4.73 (t, J = 7.8 Hz, 1 H, H10), 4.59 (d, J = 8.4 Hz, 1 H, H15), 
4.53 (br s, 1 H, H12), 4.12 (d, J = 10.1 Hz, 1 H, H13), 3.63 (d, J = 11.0 Hz, 1 H, H13’), 3.22 – 3.11 (m, 6 H, 
3 x CH2), 2.54 (s, 3 H, Ar-CH3), 2.46 – 2.32 (m, 3 H, H11 and CH2), 2.27 – 2.16 (m, 5 H, H11’ and 2 x CH2), 
1.70 – 1.61 (m, 4 H, 2 x CH2), 1.48 – 1.45 (m, 12 H, ali-CH3 and Boc CH3), 1.41 – 1.30 (m, 6 H, 3 x CH3), 
1.06 (s, 9 H, 3 x CH3); 13C NMR (101 MHz, CDCl3) δ: 173.2 (C18), 172.2 (C14), 170.3 (C21), 169.8 (C9), 
150.3 (C1), 148.5 (C2), 143.2 (C7), 131.6 (C3), 130.9 (C4), 129.6 (C5), 126.4 (C6), 79.2 (Boc qC), 70.0 
(C12), 58.4 (C15), 57.7 (C10), 56.8 (C13), 48.8 (C8), 40.3, 39.1 (C20 and C23), 36.6, 36.0 (C19 and C22), 
35.7 (C11), 34.9 (C16), 29.8 (CH2), 29.7 (CH2), 29.1 (CH2), 28.4 (Boc CH3), 26.5 (3 x CH3), 26.3 (CH2), 25.3 
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(CH2), 24.9 (CH2), 22.2 (ali-CH3), 16.1 (Ar-CH3); HRMS: m/z [M+Na]+ calculated for C40H62N6O7S: 
793.4293; Found: 793.4301; [α]D25:  -50.0 (c = 0.04, MeOH). 
 
(2S,4R)-1-((S)-2-(6-(6-aminohexanamido)hexanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-
(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (140) 
 
 
To a stirring solution of 139 (8 mg, 0.010 mmol) in dichloromethane (0.2 mL) was added trifluoroacetic 
acid (30 µL). The reaction mixture was stirred at r.t. for 3 h before concentrating in vacuo. The residue 
was then dissolved in NaHCO3 (1 mL) and extracted into dichloromethane (3 x 5 mL). The combined 
organic was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified through 
silica gel column chromatography (1:9:0.2 MeOH/DCM/NEt3) to give the title compound as a yellow 
oil (5 mg, 71%). 
Rf: 0.06 (1:9:0.2 MeOH/DCM/NEt3); IR (neat film, νmax, cm-1): 3264 (w, NH), 2959 (m, CH), 2920 (m, 
CH), 2854 (w, CH), 1630 (br s, C=O), 1536 (m), 1445 (m), 1417 (m), 1375 (m), 1260 (m), 1200 (w), 1086 
(m), 1016 (m); 1H NMR (500 MHz, CDCl3) δ: 8.67 (s, 1 H, H1), 7.64 (d, J = 7.9 Hz, 1 H, NH), 7.41 – 7.36 
(m, 4 H, Ar-H), 6.70 – 6.64 (br m, 2 H, 2 x NH), 5.09 (quin, J = 7.3 Hz, 1 H, H8), 4.71 (t, J = 7.8 Hz, 1 H, 
H10), 4.58 (d, J = 8.7 Hz, 1 H, H15), 4.50 (s, 1 H, H12), 4.01 (d, J = 10.5 Hz, 1 H, H13), 3.66 – 3.58 (m, 1 
H, H13’), 3.23 – 3.16 (m, 2 H, CH2-N), 2.87 (m, 2 H, CH2-N), 2.52 (s, 3 H, aryl-CH3), 2.39 – 2.32 (m, 1 H, 
H11), 2.27 – 2.12 (m, 5 H, H11’ and 2 x CH2), 1.65 – 1.54 (m, 6 H, 3 x CH2), 1.50 – 1.46 (m, 5 H, alky-CH3 
and CH2), 1.39 – 1.37 (m, 2 H, CH2), 1.33 – 1.28 (m, 2 H, CH2), 1.04 (s, 9 H, H17); 13C NMR (126 MHz, 
CDCl3) δ: 173.9 (C18), 173.5 (C14), 171.8 (C21), 170.1 (C9), 150.3 (C1), 148.5 (C2), 143.4 (C7), 131.6 
(C3), 130.8 (C4), 129.5 (C5), 126.4 (C6), 69.8 (C12), 58.9 (C15), 57.7 (C10), 57.1 (C13), 48.8 (C8), 40.4, 
39.0 (C20 and C23), 36.3, 35.9 (C19 and C22), 35.8 (C11), 35.3 (C16), 29.7 (CH2), 28.9 (CH2), 26.6 (C17), 
26.1, 25.6, 25.0, 24.8 (CH3), 22.3 (ali-CH3), 16.1 (Ar-CH3); HRMS: m/z [M+H]+ calculated for C35H55N6O5S: 
671.3949; Found: 671.3946; [α]D25: 57.5 (c = 0.04, MeOH). 
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(2S,4R)-1-((S)-2-(6-(6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-
thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexanamido)hexanamido)-3,3-dimethylbutanoyl)-4-
hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (PROTAC-16) 
 
To a stirring solution of 2 (2.8 mg, 0.00625 mmol) in DMF (0.2 mL) were added HATU (2.85 mg, 0.0075 
mmol) and DIPEA (1.3 µL, 0.0075 mmol). The reaction mixture was stirred at r.t. for 15 mins before 
140 (4.4 mg, 0.0066 mmol) was added. The mixture was then stirred for a further 16 h before diluting 
in water (5 mL) and extracting into EtOAc (4 x 10 mL). The combined organics were then washed with 
brine (2 x 5 mL), before being dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
purified through silica gel column chromatography (1:19 MeOH/DCM) to give the title compound as a 
colourless oil (3.0 mg, 45%). 
Rf: 0.24 (7% MeOH/DCM); IR (neat film, νmax, cm-1): 3290 (w, NH), 2925 (m, CH), 2853 (w, CH), 1756 
(m, C=O), 1724 (w, C=O), 1644 (s, C=O), 1622 (s, C=O), 1535 (m), 1500 (m), 1437 (s), 1412 (s), 1373 
(m), 1311 (s), 1264 (m), 1219 (m), 1177 (m), 1140 (m), 1056 (w), 1015 (w); 1H NMR (500 MHz, CDCl3) 
δ: 8.68 (s, 1 H, H1), 8.21 (t, J = 8.3 Hz, 1 H, H29), 7.99 (d, J = 8.3 Hz, 1 H, H39), 7.95 (d, J = 1.7 Hz, 1 H, 
H36), 7.82 (dd, J = 8.3, 1.9 Hz, 1 H, H40), 7.41 – 7.36 (m, 5 H, H5, H6 and NH), 7.24 (dd, J = 8.2, 1.9 Hz, 
1 H, H30), 7.16 (dd, J = 11.6, 1.9 Hz, 1 H, H27), 6.84 – 6.80 (m, 1 H, NH), 6.25 (d, J = 8.7 Hz, 1 H, NH), 
5.77 (t, J = 5.3 Hz, 1 H, NH), 5.08 (quin, J = 6.9 Hz, 1 H, H8), 4.74 (t, J = 8.2 Hz, 1 H, H10), 4.57 (d, J = 8.2 
Hz, 1 H, H15), 4.51 (s, 1 H, H12), 4.12 (d, J = 11.9 Hz, 1 H, H13), 3.58 (dd, J = 11.9, 3.4, 1 H, H13’), 3.51 
– 3.49 (m, 2 H, CH2-N), 3.23 – 3.19 (m, 2 H, CH2-N), 2.53 – 2.51 (m, 4 H, Ar-CH3 and H11), 2.24 – 2.11 
(m, 5 H, H11’ and 2 x CH2), 1.71 – 1.61 (m, 8 H, 2 x CH3 and CH2), 1.51 – 1.38 (m, 9 H, CH3-C8), 1.33 – 
1.27 (m, 4 H, 2 x CH2); 13C NMR (126 MHz, CDCl3) δ: 179.8 (C31), 174.5 (C34), 173.8, 173.1, 172.3, 169.7 
(amide C=O), 162.3 (C24), 160.3 (d, J = 250 Hz, CF), 150.3, 148.5, 143.1, 140.0 (C25, d, J = 11.1 Hz), 
136.8 (C38), 135.3 (C39), 133.7 (C37, q, J = 33.8 Hz), 133.3 (C29), 132.1 (C40), 131.6, 130.9, 129.6, 
127.1 (C36, q, J = 6 Hz), 126.4, 126.2 (C30), 122.9 (C28), 121.9 (q, J = 273 Hz, CF3), 118.0 (C27, d, J = 26 
Hz), 114.8 (C≡N), 110.5 (C35), 70.0 (C12), 66.7 (C20), 58.4 (C15), 57.7 (C10), 56.8 (C13), 48.9 (C8), 39.9, 
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39.1 (C20 and C23), 36.4, 36.0 (C19 and C22), 35.6 (C11), 34.9 (C16), 29.7, 29.1, 26.5 (C17), 26.4, 26.0, 
25.1, 24.9 (C33), 23.9, 22.3 (ali-CH3), 16.1 (Ar-CH3); 19F NMR (471 MHz, CDCl3) δ: -63.0, -111.5; HRMS: 
(ESI) m/z [M+H]+ calculated for C55H65F4N9O7S2Na: 1126.4277; Found: 1126.4311. 
 
4-((6-(((S)-1-((2S,4R)-4-hydroxy-2-(((S)-1-(4-(4-methylthiazol-5-
yl)phenyl)ethyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-6-
oxohexyl)amino)-4-oxobutanoic acid (141) 
 
To a stirring solution of 138 (31 mg, 0.055 mmol) in tetrahydrofuran (0.3 mL) was added succinic 
anhydride (11 mg, 0.11 mmol). The reaction mixture was stirred at r.t. for 24 h before concentrating 
in vacuo. The residue was purified through silica gel column chromatography (1:9:0.1 
MeOH/DCM/acetic acid) to give the title compound as a white amorphous solid (30 mg, 83%). 
Rf: 0.08 (1:9:0.1 MeOH/DCM/acetic acid); IR (neat film, νmax, cm-1): 2929 (m, CH), 1713 (s, C=O), 1614 
(s, C=O), 1547 (m), 1416 (m), 1330 (w), 1233 (m), 1205 (m), 1170 (m); 1H NMR (400 MHz, CDCl3) δ: 
8.87 (s, 1 H, H1), 7.45 – 7.41 (m, 4 H, Ar-H), 5.02 – 4.96 (m, 1 H, H8), 4.62 (s, 1 H, H10), 4.59 – 4.55 (m, 
1 H, H15), 4.43 – 4.42 (m, 1 H, H12), 3.88 (d, J = 11.1 Hz,  1 H, H13), 3.75 (dd, J = 10.9, 4.0 Hz, 1 H, H13’), 
3.16 (t, J = 7.0 Hz, 2 H, H20), 2.59 – 2.56 (m, 2 H, CH2), 2.48 – 2.44 (m, 5 H, Ar-CH3 and CH2), 2.33 – 2.26 
(m, 2 H, H23), 2.23 – 2.17 (m, 1 H, H11), 1.98 – 1.92 (m, 1 H, H11’), 1.65 – 1.61 (m, 2 H, CH2), 1.54 – 
1.48 (m, 5 H, ali-CH3 and CH2), 1.38 – 1.31 (m, 2 H, CH2), 1.04 (s, 9 H, 3 x CH3); 13C NMR (101 MHz, 
MeOD) δ: 175.2 (C24), 174.6 (C18), 173.1 (C21), 171.8 (C9), 170.9 (C21), 151.5 (C1), 147.7 (C2), 144.3 
(C7), 132.0 (C3), 130.1 (C4), 129.1 (C5), 126.2 (C6), 69.6 (C12), 59.2 (C15), 57.6 (C10), 56.6 (C13), 48.7 
(C8), 38.9 (C20), 37.4 (C11), 35.1 (C23), 35.1 (C16), 30.3, 28.8, 28.6, 26.1 (4 x CH2), 25.6 (C17), 25.2 
(CH2), 21.0 (ali-CH3), 14.4 (Ar-CH3); HRMS: (ESI) m/z [M+Na]+ calculated for C33H47N5O7SNa: 680.3088; 
Found: 680.3120; [α]D25: 875.0 (c = 0.06, MeOH). 
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tert-Butyl (1-(6-chloro-3-(1-(4-chlorobenzyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-1H-indol-2-yl)-1-
oxo-5,8,11,14,17-pentaoxa-2-azanonadecan-19-yl)carbamate (142) 
 
To a stirring solution of 87 (11 mg, 0.023 mmol) in DMF (0.1 mL), were added HATU (10 mg, 0.027 
mmol) and DIPEA (4.7 µL, 0.027 mmol). The reaction was stirred at r.t. for ca. 15 mins before 30 (10 
mg, 0.025 mmol) was added. The reaction was stirred for a further 18 h before being diluted with 
EtOAc (5 mL) and H2O (3 mL), extracted into EtOAc (2 x 5 mL), washed with brine (5 mL), dried over 
Na2SO4, filtered, and concentrated in vacuo. The residue was then purified by silica gel 
chromatography (2% MeOH/DCM) to give the title compound as a yellow oil (10 mg, 53%). 
Rf: 0.09 (2% MeOH/DCM); IR (neat film, νmax, cm-1): 2921 (m), 1752 (m), 1654 (s), 1619 (m), 1538 (m), 
1509 (s), 1439 (s), 1407 (s), 1365 (m), 1312 (s), 1250 (s), 1220 (s), 1179 (s), 1138 (s), 1054 (m); 1H NMR 
(400 MHz, CDCl3) δ: 10.10 (br s, 1 H, NH), 7.90 (s, 1 H, H4), 7.51 – 7.46 (m, 3 H, H1 H7), 7.10 – 7.04 (m, 
4 H, H2, H3, H6), 6.83 (t, J = 8.7 Hz, 2 H, H8), 6.71 (d, J = 8.7 Hz, 2 H, H5), 6.31 (br s, 1 H, NH), 5.09 (br 
s, 1 H, NH), 4.86 (d, J = 15.3 Hz, 1 H, H9), 4.79 (d, J = 15.3 Hz, 1 H, H9), 3.68 – 3.19 (m, 24 H, 12x CH2), 
1.42 (s, 9 H, 3x CH3); 13C NMR (101 MHz, CDCl3) δ: 161.4 (d, J = 250 Hz, C-F), 160.1 (C=O), 156.1 (Boc 
C=O), 140.5, 139.1 (C11), 135.6, 134.1, 134.0, 131.3, 130.0, 129.7, 128.8 (C6), 128.6 (C5), 127.4 (d, J = 
8 Hz, C7), 126.7, 122.6 (C2), 121.4 (C3), 118.1, 115.3 (d, J = 22 Hz, C8), 112.3 (C1), 104.8, 79.2 (boc-qC), 
70.6 – 70.1 (overlapping 9C), 69.1, 48.8 (C9), 40.3, 39.3 (2x N-CH2), 28.4 (3x CH3); 19F NMR (471 MHz, 
CDCl3) δ: -114.8; HRMS (ESI): m/z calcd for C42H50Cl2FN5O8Na [M+Na]+: 864.2912; found: 864.2943. 
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6-Chloro-3-(1-(4-chlorobenzyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-N-(1-(4-(3-(4-cyano-3-
(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorophenyl)-1-oxo-
5,8,11,14,17-pentaoxa-2-azanonadecan-19-yl)-1H-indole-2-carboxamide (PROTAC-17) 
 
 
To a stirring solution of 142 (8 mg, 0.009 mmol) in dichloromethane (0.4 mL) was added trifluoroacetic 
acid (0.1 mL). The reaction mixture was stirred for 2 h before being quenched with NaHCO3 (sat. aq.), 
extracted into dichloromethane (3x 5 mL), washed with brine (5 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. The crude residue was taken directly through with no further purification. To 
a stirring solution of 2 (3 mg, 0.0067 mmol) in DMF (0.1 mL), were added HATU (3 mg, 0.008 mmol), 
DIPEA (1.4 µL, 0.008 mmol), and a solution of crude 142 (5 mg, 0.0067 mmol) in DMF (0.1 mL). The 
reaction was stirred for 18 h before being diluted with EtOAc (5 mL) and H2O (3 mL), extracted into 
EtOAc (2 x 5 mL), washed with brine (5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. 
The residue was then purified by silica gel chromatography (5% MeOH/DCM) to give the title 
compound as a yellow oil (4 mg, 51%). 
Rf: 0.20 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 2988 (w, CH), 2921 (w, CH), 1760 (w, C=O), 1654 
(m, C=O), 1617 (m), 1541 (m), 1522 (m), 1496 (m), 1438 (s), 1411 (s) ,1312 (s), 1221 (s), 1179 (m), 1136 
(s), 1088 (s); 1H NMR (500 MHz, CDCl3) δ: 9.99 (br s, 1 H, NH), 8.22 (t, J = 8.3 Hz, 1 H, H14), 8.00 – 7.90 
(m, 3 H), 7.83 (dd, J = 8.6, 2.0 Hz, 1 H, H5), 7.52 – 7.47 (m, 3 H), 7.25 – 7.03 (m, 7 H), 6.84 (t, J = 8.9 Hz, 
2 H, H19), 6.72 (d, J = 8.6 Hz, 2 H, H23), 6.32 (br s, 1 H, NH), 4.87 (d, J = 15.2 Hz, 1 H, H22), 4.80 (d, J = 
15.2 Hz, 1 H, H22), 3.72 – 3.20 (m, 24 H, 12x CH2), 1.61 (s, 6 H, H9); 13C NMR (126 MHz, CDCl3) δ: 179.8 
(C=S), 174.5 (C7), 162.2 (C=O), 162.0 (d, J = 250 Hz, C-F), 160.3 (d, J = 250 Hz, C-F), 160.0 (C=O), 139.0 
(2C), 138.9 (d, J = 11 Hz, C13), 136.8 (C1), 135.4, 135.3 (C5), 134.2, 134.1, 134.0, 133.7 (q, J = 33 Hz, 
C2), 133.2 (d, J = 3 Hz, C14), 132.1 (C5), 131.3, 130.1, 129.5, 129.1, 128.8, 128.7, 127.4 (d, J = 8 Hz), 
127.1 (q, J = 5 Hz, C3), 126.7, 126.1 (d, J = 3.5 Hz, C15), 125.1, 123.1, 123.0, 122.9, 122.7, 121.3, 120.7, 
118.6, 118.2, 118.0 (d, J = 26 Hz, C11), 115.4 (d, J = 22 Hz), 114.7 (-C≡N), 112.2, 110.5 (C4), 104.7, 70.5 
– 70.3, 69.5, 69.1 (overlapping O-CH2), 66.6 (C8), 48.9 (C22), 40.0, 39.3 (2x N-CH2), 23.8 (C9); 19F NMR 
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(471 MHz, CDCl3) δ: -63.0, -111.2, -115.8; HRMS (ESI): m/z calcd for C57H53Cl2F5N8O8SNa [M+Na]+: 
1197.2896; found: 1197.2943. 
 
2,2-Dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl methanesulfonate (144) 
 
To a stirring solution of 143 (120 mg, 0.41 mmol) in Et2O (0.5 mL) cooled to 0 °C, were added 
triethylamine (74 µL, 0.53 mmol), and methanesulfonyl chloride (41 µL, 0.53 mmol). The reaction was 
stirred at r.t. for 5 h before being diluted with brine (5 mL), extracted into Et2O (3 x 10 mL) and dried 
over Na2SO4, filtered, and concentrated in vacuo to give the title compound as a colourless oil (134 
mg, 88%) used without further purification. 
Rf: 0.67 (9:1 DCM:MeOH); IR (neat film, νmax, cm-1): 3368 (w, NH), 2976 (w, CH), 2873 (w, CH), 1707 (m, 
C=O), 1511 (m), 1454 (m), 1391 (w), 1350 (m), 1274 (m), 1247 (m), 1200 (s), 1102 (s), 1016 (m); 1H 
NMR (400 MHz, CDCl3) δ: 5.02 (br s, 1 H, NH), 4.41 – 4.38 (m, 2 H), 3.80 – 3.78 (m, 2 H), 3.69 – 3.63 
(m, 8 H), 3.56 – 3.54 (m, 2 H), 3.32 (br m, 2 H), 3.09 (s, 3 H, CH3), 1.46 (s, 9 H, 3x CH3); 13C NMR (101 
MHz, CDCl3) δ: 156.0 (C=O), 79.2 (qC), 70.7, 70.5, 70.2, 69.2, 69.0 (overlapping O-CH2), 52.6 (CH2-OMs), 
40.4 (N-CH2), 37.7 (S-CH3), 28.4 (3x CH3). 
Data are in accordance with those reported previously in literature.348 
 
Methyl (S)-3-(4-((2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azahexadecan-16-yl)oxy)phenyl)-2-(3,3-
diphenylpropanamido)propanoate (145) 
 
To a stirring solution of 86 (47 mg, 0.12 mmol) in DMF (0.5 mL), were added potassium carbonate (32 
mg, 0.23 mmol), and 144 (65 mg, 0.18 mmol). The reaction was heated to 80 °C for 5 h before being 
cooled, diluted with H2O (2 mL), extracted into EtOAc (3 x 10 mL), washed with brine (5 mL), dried 
over Na2SO4, filtered, and concentrated in vacuo. The residue was then purified by silica gel 
chromatography (1:1 to 45:55 Hex:EtOAc) to give the title compound as a yellow oil (31 mg, 39%). 
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Rf: 0.31 (7:3 EtOAc:Hex); IR (neat film, νmax, cm-1): 3338 (w), 2921 (m), 1742 (m), 1708 (m), 1653 (m), 
1611 (w), 1511 (s), 1451 (m), 1365 (m), 1247 (s), 1173 (s), 1110 (s); 1H NMR (400 MHz, CDCl3) δ: 7.34 
– 7.20 (m, 10 H, Ar-H), 6.74 (d, J = 8.6 Hz, 2 H, H3), 6.66 (d, J = 8.6 Hz, 2 H, H2), 5.87 (d, J = 7.5 Hz, 1 H, 
NH), 5.07 (br s, 1 H, NH), 4.80 – 4.76 (m, 1 H, H6), 4.62 (t, J = 8.0 Hz, 1 H, H10), 4.11 (t, J = 4.5 Hz, 2 H, 
O-CH2), 3.87 (t, J = 4.5 Hz, 2 H, O-CH2), 3.77 – 3.75 (m, 2 H, O-CH2), 3.72 – 3.62 (m, 9 H, OMe and 3x O-
CH2), 3.55 (t, J = 4.9 Hz, 2 H, O-CH2), 3.33 – 3.31 (m, 2 H, N-CH2), 2.97 – 2.84 (m, 4 H, H5 and H9), 1.46 
(s, 9 H, 3x CH3); 13C NMR (101 MHz, CDCl3) δ: 171.8 (C7), 170.3 (C8), 157.8 (C1), 156.0 (Boc-C=O), 143.8, 
143.6, 130.2 (C3), 128.6 (2C), 128.0, 127.8, 127.7, 126.6 (C4), 126.5, 114.5 (C2), 79.2 (qC), 70.8, 70.6 
(2C), 70.5, 70.2, 69.8, 67.3 (7x O-CH2), 53.1 (C6), 52.2 (OMe), 47.1 (C10), 43.0 (C9), 40.4 (N-CH2), 37.0 
(C5), 28.4 (3x CH3); HRMS (ESI): m/z calcd for C38H50N2O9Na [M+Na]+: 701.3408; found: 701.3424; 
[α]D25 1.0° (c = 0.1, MeOH). 
 
Methyl (S)-3-(4-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)phenyl)-2-(3,3-
diphenylpropanamido)propanoate (146) 
 
To a stirring solution of 145 (28 mg, 0.041 mmol) in dichloromethane (0.4 mL) was added 
trifluoroacetic acid (0.1 mL). The reaction was stirred for 3 h at r.t. before being concentrated, diluted 
with sat. aq. NaHCO3 (2 mL), extracted into dichloromethane (3 x 10 mL), dried over Na2SO4, filtered, 
and concentrated in vacuo to give the title compound as a yellow oil (21.3 mg, 89%) used without 
further purification. 
IR (neat film, νmax, cm-1): 2913 (m), 1743 (m), 1650 (m), 1611 (m), 1542 (m), 1511 (s), 1450 (m), 1247 
(s), 1123 (s), 1066 (s); 1H NMR (400 MHz, CDCl3) δ: 7.34 – 7.18 (m, 10 H, Ar-H), 6.75 (d, J = 8.7 Hz, 2 H, 
H3), 6.65 (d, J = 8.7 Hz, 2 H, H2), 6.00 (d, J = 7.4 Hz, 1 H, NH), 4.81 – 4.77 (m, 1 H, H6), 4.62 (t, J = 7.5 
Hz, 1 H, H10), 4.11 (t, J = 4.6 Hz, 2 H, O-CH2), 3.87 (t, J = 4.6 Hz, 2 H, O-CH2), 3.76 – 3.66 (m, 11 H, OMe 
and 4x O-CH2), 3.54 (t, J = 4.8 Hz, 2 H, O-CH2), 3.00 – 2.80 (m, 6 H, N-CH2, H5 and H9), 2.26 (br s, 2 H, 
NH2); 13C NMR (101 MHz, CDCl3) δ: 171.8 (C7), 170.4 (C8), 157.7 (C1), 143.8, 143.6, 130.3 (C3), 128.6 
(2C), 128.0, 127.9, 127.7, 126.6 (C4), 126.5, 114.5 (C2), 72.8, 70.8, 70.6 (2C), 70.3, 69.7, 67.4 (7x O-
CH2), 53.1 (C6), 52.2 (OMe), 47.1 (C10), 42.9 (C9), 41.6 (N-CH2), 37.0 (C5); HRMS (ESI): m/z calcd for 
C33H43N2O7 [M+H]+: 579.3065; found: 579.3070; [α]D25 2.0° (c = 0.1, MeOH). 
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Methyl (S)-3-(4-((1-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-
thioxoimidazolidin-1-yl)-2-fluorophenyl)-1-oxo-5,8,11-trioxa-2-azatridecan-13-yl)oxy)phenyl)-2-
(3,3-diphenylpropanamido)propanoate (PROTAC-18) 
 
To a stirring solution of 2 (14 mg, 0.031 mmol) in DMF (0.3 mL), were added HATU (14 mg, 0.037 
mmol) and DIPEA (6.5 µL, 0.037 mmol). The reaction was stirred at r.t. for ca. 15 mins before 146 (20 
mg, 0.034 mmol) was added. The reaction was stirred for a further 5 h before being diluted with EtOAc 
(5 mL) and H2O (3 mL), extracted into EtOAc (2 x 5 mL), washed with brine (5 mL), dried over Na2SO4, 
filtered, and concentrated in vacuo. The residue was then purified by silica gel chromatography (2% 
MeOH/DCM) to give the title compound as a yellow oil (22.3 mg, 65%). 
Rf: 0.35 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 2920 (w), 1751 (m), 1653 (m), 1619 (m), 1532 (m), 
1508 (m), 1498 (m), 1438 (s), 1411 (m), 1311 (s), 1248 (m), 1219 (s), 1177 (m), 1136 (s), 1056 (m); 1H 
NMR (400 MHz, CDCl3) δ: 8.23 (t, J = 8.3 Hz, 1 H, H17), 8.01 – 7.97 (m, 2 H, H23 and H26), 7.84 (dd, J = 
8.2, 1.8 Hz, 1 H, H22), 7.33 – 7.14 (m, 13 H, 10x Ar-H, H14, H16, NH overlapping CHCl3), 6.73 (d, J = 8.7 
Hz, 2 H, H3), 6.65 (d, J = 8.7 Hz, 2 H, H2), 5.91 (d, J = 7.8 Hz, 1 H, NH), 4.80 – 4.75 (m, 1 H, H6), 4.61 (t, 
J = 7.8 Hz, 1 H, H10), 4.08 (t, J = 4.5 Hz, 2 H, O-CH2), 3.84 (t, J = 4.7 Hz, 2 H, O-CH2), 3.74 – 3.66 (m, 15 
H, OMe and 6x CH2), 3.00 – 2.88 (m, 3 H, H5 and H9), 2.85 – 2.81 (m, 1 H, H9), 1.61 (s, 6 H, 2x CH3); 13C 
NMR (101 MHz, CDCl3) δ: 179.8 (C=S), 174.5 (C19), 171.8 (C7), 170.4 (C8), 162.2 (d, J = 3.2 Hz, C11), 
160.4 (d, J = 250 Hz, C13), 157.7 (C1), 143.8, 143.6, 138.9 (d, J = 10 Hz, C12), 136.8 (C24), 135.3 (C23), 
133.9 (C25), 133.2 (d, J = 3.6 Hz, C17), 132.1 (C22), 130.2, 128.6 (2C), 128.0, 127.9, 127.6, 127.1 (d, J = 
5.6 Hz, C26), 126.6, 126.5, 126.1 (d, J = 2.9 Hz, C16), 123.1 (d, J = 12.5 Hz, C15), 119.1 (q, J = 273 Hz, 
CF3), 118.0 (d, J = 25.6 Hz, C14), 114.7 (C2), 114.5 (-C≡N), 110.4 (d, J = 4.4 Hz, C21), 70.8, 70.6, 70.4, 
69.7, 69.5, 67.3, 66.6 (7x O-CH2), 53.1 (C6), 52.2 (OMe), 47.1 (C10), 42.9 (C9), 40.0 (N-CH2), 37.0 (C5), 
23.8 (2x CH3); 19F NMR (376 MHz, CDCl3) δ: -62.0, -110.3; HRMS (ESI): m/z calcd for C53H53F4N5O9SNa 
[M+Na]+: 1034.3392; found: 1034.3415; [α]D25 9.0° (c = 0.1, MeOH). 
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(S)-3-(4-((1-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-
yl)-2-fluorophenyl)-1-oxo-5,8,11-trioxa-2-azatridecan-13-yl)oxy)phenyl)-2-(3,3-
diphenylpropanamido)propanoic acid (PROTAC-19) 
 
To a stirring solution of PROTAC-18 (18 mg, 0.0178 mmol) in acetic acid (0.5 mL) was added HCl (1 M, 
0.5 mL). The reaction was heated to 100 °C for 3 h before being cooled and concentrated to give the 
title compound as a yellow oil (12 mg, 67%) used without further purification. 
IR (neat film, νmax, cm-1): 3325 (w, NH), 2927 (m, CH), 2853 (w, CH), 1755 (m, C=O), 1724 (m, C=O), 
1708 (m, C=O), 1654 (m), 1619 (m), 1538 (m), 1514 (m), 1498 (m), 1440 (s), 1411 (s), 1311 (s), 1250 
(m), 1219 (s), 1178 (s), 1139 (s), 1056 (m); 1H NMR (400 MHz, CDCl3) δ: 8.19 (t, J = 8.3 Hz, 1 H, H17), 
7.98 (d, J = 8.2 Hz, H23), 7.94 (d, J = 1.9 Hz, H26), 7.81 (dd, J = 8.3, 1.9 Hz, H22), 7.32 – 7.13 (m, 13 H, 
10x Ar-H, H14, H16, NH overlapping CHCl3), 6.72 – 6.62 (m, 4 H, H2 and H3), 6.01 (d, J = 7.1 Hz, 1 H, 
NH), 4.75 – 4.71 (m, 1 H, H6), 4.63 – 4.60 (m, 1 H, H10), 4.06 (t, J = 4.5 Hz, 2 H, O-CH2), 3.82 – 3.80 (m, 
2 H, O-CH2), 3.72 – 3.53 (m, 12 H, 6x CH2), 3.01 – 2.89 (m, 3 H, H5 and H9), 2.85 – 2.81 (m, 1 H, H9), 
1.60 (s, 6 H, 2x CH3); 13C NMR (101 MHz, CDCl3) δ: 179.8 (C=S), 174.4 (C19), 172.3 (C7), 170.9 (C8), 
162.6 (d, J = 3.2 Hz, C11), 160.4 (d, J = 250 Hz, C13), 157.8 (C1), 143.7, 143.5, 139.2 (d, J = 10.6 Hz, 
C12), 136.8 (C24), 135.3 (C23), 133.7 (q, J = 34 Hz, C25), 133.3 (d, J = 2.9 Hz, C17), 132.1 (C22), 130.4 
(C3), 128.7, 128.6, 128.0 (2C), 127.6, 127.0 (q, J = 4.8 Hz, C26), 126.7, 126.6, 126.2 (d, J = 3.3 Hz, C16), 
122.5 (d, J = 11.3 Hz, C15), 121.8 (q, J = 273 Hz, CF3), 118.0 (d, J = 26.1 Hz, C14), 114.7 (C2), 114.5 (-
C≡N), 110.5 (d, J = 2.3 Hz, C21), 70.9, 70.7, 70.6, 70.3, 69.7, 69.2, 67.5 (7x O-CH2), 66.6 (C20), 53.3 (C6), 
47.2 (C10), 43.0 (C9), 40.2 (N-CH2), 36.6 (C5), 23.8 (2x CH3); 19F NMR (376 MHz, CDCl3) δ: -62.9, -111.0; 
HRMS (ESI): m/z calcd for C52H50F4N5O9S [M-H]-: 996.3271; found: 996.3300; [α]D20 32.5° (c = 0.08, 
MeOH). 
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Methyl (S)-3-(4-(2-(tert-butoxy)-2-oxoethoxy)phenyl)-2-(3,3-diphenylpropanamido)propanoate 
(147) 
 
To a stirring solution of 86 (315 mg, 0.78 mmol) in DMF (2 mL), were added potassium carbonate (216 
mg, 1.56 mmol), and tert-butyl bromoacetate (162 µL, 1.09 mmol). The reaction was heated to 80 °C 
for 6 h before being cooled, diluted with H2O (2 mL), extracted into EtOAc (3 x 10 mL), washed with 
brine (5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The residue was then purified by 
silica gel chromatography (1:1 Hex:EtOAc) to give the title compound as a yellow oil (320 mg, 79%). 
Rf: 0.31 (7:3 Hex:EtOAc); IR (neat film, νmax, cm-1): 2980 (w), 1746 (m), 1711 (m), 1661 (m), 1510 (m), 
1438 (m), 1367 (m), 1308 (m), 1216 (s), 1152 (s), 1080 (m); 1H NMR (400 MHz, CDCl3) δ: 7.34 – 7.21 
(m, 10 H, Ar-H overlapped CDCl3), 6.73 (d, J = 8.7 Hz, 2 H, H3), 6.66 (d, J = 8.7 Hz, 2 H, H2), 5.83 (d, J = 
7.5 Hz, 1 H, NH), 4.81 – 4.77 (m, 1 H, H6), 4.64 – 4.60 (m, 1 H, H10), 4.49 (s, 2 H, H11), 3.66 (s, 3 H, 
OMe), 2.97 – 2.84 (m, 4 H, H5 and H9), 1.51 (s, 9 H, 3x CH3); 13C NMR (101 MHz, CDCl3) δ: 171.7 (C7), 
170.3 (C8), 168.0 (C12), 157.0 (C1), 143.8, 143.6, 130.3 (C3), 128.6 (2C), 128.5, 128.0, 127.6, 126.7 
(C4), 126.5, 114.6 (C2), 82.4 (qC), 65.7 (C11), 53.1 (C6), 52.2 (OMe), 47.1 (C10), 43.0 (C9), 36.9 (C5), 
28.1 (3x CH3); HRMS (ESI): m/z calcd for C31H35NO6Na [M+Na]+: 540.2356; found: 540.2356; [α]D20 4.1° 
(c = 0.54, MeOH). 
 
(S)-2-(4-(2-(3,3-diphenylpropanamido)-3-methoxy-3-oxopropyl)phenoxy)acetic acid (148) 
 
To a stirring solution of 147 (128 mg, 0.25 mmol) in dichloromethane (0.8 mL) was added 
trifluoroacetic acid (0.2 mL). The reaction was stirred for 3 h at r.t. before being concentrated in vacuo 
to give the title compound as a yellow oil (110 mg, 96%) used without further purification. 
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Rf: 0.50 (7:3 EtOAc:Hex); IR (neat film, νmax, cm-1): 3355 (m), 2948 (w), 1735 (s), 1647 (m), 1611 (m), 
1542 (m), 1510 (s), 1438 (m), 1375 (w), 1213 (s), 1179 (s), 1121 (w), 1079 (m), 1019 (s); 1H NMR (400 
MHz, CDCl3) δ: 7.30 – 7.19 (m, 10 H, Ar-H overlapping CDCl3), 6.77 (d, J = 8.7 Hz, 2 H, H3), 6.68 (d, J = 
8.7 Hz, 2 H, H2), 6.21 (d, J = 7.9 Hz, 1 H, NH), 4.83 – 4.78 (m, 1 H, H6), 4.65 (s, 2 H, H11), 4.56 (t, J = 8.2 
Hz, 1 H, H10), 3.69 (s, 3 H, OMe), 3.06 – 2.81 (m, 4 H, H5 and H9); 13C NMR (101 MHz, CDCl3) δ: 172.4, 
172.1, 171.7 (3x C=O), 156.5 (C1), 143.2, 143.0, 130.5 (C3), 128.8, 128.7 (2C), 127.9, 127.6, 126.8 (C4), 
126.7, 114.7 (C2), 64.8 (C11), 53.3 (C6), 52.5 (OMe), 47.3 (C10), 42.8 (C9), 36.9 (C5); HRMS (ESI): m/z 
calcd for C31H35NO6Na [M-H]-: 460.1765; found: 460.1760; [α]D20 10.9° (c = 0.32, MeOH). 
 
Methyl (S)-3-(4-((2,2-dimethyl-4,18-dioxo-3,8,11,14-tetraoxa-5,17-diazanonadecan-19-
yl)oxy)phenyl)-2-(3,3-diphenylpropanamido)propanoate (149) 
 
To a stirring solution of 148 (25 mg, 0.054 mmol) in DMF (0.4 mL), were added HATU (23 mg, 0.059 
mmol) and DIPEA (10.4 µL, 0.059 mmol). The reaction was stirred at r.t. for ca. 15 mins before 92 (17 
mg, 0.059 mmol) was added. The reaction was stirred for a further 4 h before being diluted with EtOAc 
(5 mL) and H2O (3 mL), extracted into EtOAc (2 x 5 mL), washed with brine (5 mL), dried over Na2SO4, 
filtered, and concentrated in vacuo. The residue was then purified by silica gel chromatography (1 to 
5% MeOH/DCM) to give the title compound as a yellow oil (21 mg, 53%). 
Rf: 0.26 (6% MeOH/DCM); IR (neat film, νmax, cm-1): 3310 (w), 2926 (w), 2865 (w), 1742 (m), 1706 (m), 
1656 (s), 1536 (s), 1510 (s), 1450 (m), 1366 (m), 1274 (m), 1246 (s), 1175 (s), 1122 (s); 1H NMR (400 
MHz, CDCl3) δ: 7.34 – 7.20 (m, 10 H, Ar-H overlapping CDCl3), 7.02 (br s, 1 H, NH), 6.74 (d, J = 8.7 Hz, 2 
H, H3), 6.68 (d, J = 8.7 Hz, 2 H, H2), 5.92 (d, J = 6.7 Hz, 1 H, NH), 5.05 (br s, 1 H, NH), 4.81 – 4.77 (m, 1 
H, H6), 4.62 (t, J = 7.6 Hz, 1 H, H10), 4.46 (s, 2 H, H11), 3.68 – 3.51 (m, 17 H, 7x CH2 and OMe), 3.30 (q, 
J = 5.5 Hz, 2 H, N-CH2), 3.01 – 2.82 (m, 4 H, H5 and H9), 1.46 (s, 9 H, 3x CH3); 13C NMR (101 MHz, CDCl3) 
δ: 171.7, 170.4, 168.2 (3x C=O), 156.3 (C1), 156.0 (Boc-C=O), 143.8, 143.6, 130.5 (C3), 129.3, 128.6 
(2C), 128.0, 127.6, 126.6 (C4), 126.5, 114.7 (C2), 79.2 (qC), 70.5, 70.3, 70.2 (2C), 69.8 (overlapping O-
CH2), 67.4 (C11), 53.1 (C6), 52.3 (OMe), 47.1 (C10), 42.9 (C9), 40.3, 38.8 (2x N-CH2), 36.9 (C5), 28.4 (3x 
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CH3); HRMS (ESI): m/z calcd for C40H53N3O10Na [M+Na]+: 758.3623; found: 758.3608; [α]D20 10.0° (c = 
0.06, MeOH). 
 
Methyl (S)-3-(4-((14-amino-2-oxo-6,9,12-trioxa-3-azatetradecyl)oxy)phenyl)-2-(3,3-
diphenylpropanamido)propanoate (150) 
 
To a stirring solution of 149 (19 mg, 0.026 mmol) in dichloromethane (0.4 mL) was added 
trifluoroacetic acid (0.1 mL). The reaction was stirred for 3 h at r.t. before being concentrated, diluted 
with sat. aq. NaHCO3 (2 mL), extracted into dichloromethane (3 x 10 mL), dried over Na2SO4, filtered, 
and concentrated in vacuo to give the title compound as a yellow oil (16 mg, >98%) used without 
further purification. 
IR (neat film, νmax, cm-1): 3345 (m), 2920 (m), 1740 (m), 1650 (s), 1611 (m), 1542 (m), 1510 (s), 1446 
(m), 1350 (m), 1242 (m), 1101 (m); 1H NMR (400 MHz, CDCl3) δ: 7.34 – 7.18 (m, 10 H, Ar-H overlapping 
CDCl3), 6.74 (d, J = 8.7 Hz, 2 H, H3), 6.67 (d, J = 8.7 Hz, 2 H, H2), 6.09 (d, J = 7.6 Hz, 1 H, NH), 4.82 – 4.77 
(m, 1 H, H6), 4.62 (t, J = 8.0 Hz, 1 H, H10), 4.46 (s, 2 H, H11), 3.68 – 3.50 (m, 19 H, 8x CH2 and OMe), 
3.01 – 2.91 (m, 3 H, H5 and H9), 2.88 – 2.83 (m, 1 H, H9), 1.87 (br s, 2 H, NH2); 13C NMR (101 MHz, 
CDCl3) δ: 171.7, 170.4, 168.3 (3x C=O), 156.3 (C1), 143.8, 143.6, 130.5 (C3), 129.3, 128.6 (2C), 128.0, 
127.6, 126.6 (C4), 126.5, 114.7 (C2), 70.6, 70.5, 70.3, 70.2, 69.8 (overlapping O-CH2), 67.4 (C11), 53.1 
(C6), 52.3 (OMe), 47.1 (C10), 42.9 (C9), 38.8, 38.6 (2x N-CH2), 36.9 (C5); HRMS (ESI): m/z calcd for 
C35H46N3O8 [M+H]+: 636.3280; found: 636.3294; [α]D20 18.9° (c = 0.09, MeOH). 
 
 
 
 
258 
 
Methyl (S)-3-(4-((1-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-
thioxoimidazolidin-1-yl)-2-fluorophenyl)-1,15-dioxo-5,8,11-trioxa-2,14-diazahexadecan-16-
yl)oxy)phenyl)-2-(3,3-diphenylpropanamido)propanoate (PROTAC-20) 
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To a stirring solution of 2 (10 mg, 0.023 mmol) in DMF (0.2 mL), were added HATU (10 mg, 0.027 
mmol) and DIPEA (4.8 µL, 0.027 mmol). The reaction was stirred at r.t. for ca. 15 mins before 150 (16 
mg, 0.025 mmol) was added. The reaction was stirred for a further 8 h before being diluted with EtOAc 
(5 mL) and H2O (3 mL), extracted into EtOAc (2 x 5 mL), washed with brine (5 mL), dried over Na2SO4, 
filtered, and concentrated in vacuo. The residue was then purified by silica gel chromatography (2% 
MeOH/DCM) to give the title compound as a yellow oil (14 mg, 58%). 
Rf: 0.32 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 3300 (w), 2920 (w), 2865 (w), 1751 (m), 1657 (s), 
1620 (m), 1537 (m), 1507 (s), 1439 (s), 1413 (s), 1311 (s), 1218 (s), 1177 (s), 1136 (s), 1056 (m); 1H NMR 
(400 MHz, CDCl3) δ: 8.22 (t, J = 8.3 Hz, 1 H, H19), 7.98 (d, J = 8.3 Hz, 1 H, H25), 7.95 (d, J = 1.9 Hz, 1 H, 
H28), 7.82 (dd, J = 8.3, 1.9 Hz, 1 H, H22), 7.31 – 7.14 (m, 13 H, 10x Ar-H, H16, H18, NH overlapping 
CHCl3), 6.99 (t, J = 5.5 Hz, 1 H, NH), 6.71 (d, J = 8.7 Hz, 2 H, H3), 6.66 (d, J = 8.7 Hz, 2 H, H2), 5.92 (d, J = 
6.7 Hz, 1 H, NH), 4.78 – 4.75 (m, 1 H, H6), 4.60 (t, J = 7.9 Hz, H10), 4.42 (s, 2 H, H11), 3.68 – 3.57 (m, 17 
H, 7x CH2 and OMe), 3.54 (t, J = 5.3 Hz, 2 H, N-CH2), 2.98 – 2.82 (m, 4 H, H5 and H9), 1.60 (s, 6 H, 2x 
CH3); 13C NMR (101 MHz, CDCl3) δ: 179.8 (C20), 174.4 (C21), 171.7 (C7), 170.4 (C8), 168.2 (C12), 162.1 
(d, J = 3.0 Hz, C13), 160.3 (d, J = 250 Hz, C15), 156.2 (C1), 143.8, 143.5, 139.0 (d, J = 10.7 Hz, C14), 136.8 
(C24), 135.3 (C25), 133.7 (q, J = 33.5 Hz, C27), 133.3 (d, J = 3.5 Hz, C19), 132.1 (C24), 130.5 (C3), 129.3, 
128.6 (2C), 128.0, 127.6, 127.1 (q, J = 4.8 Hz, C28), 126.6 (C4), 126.5, 126.1 (d, J = 3.1 Hz, C18), 122.9 
(d, J = 12 Hz, C17), 121.8 (q, J = 275 Hz, CF3), 118.0 (d, J = 26.0 Hz, C16), 114.7 (2C, C2 and -C≡N), 110.4 
(q, J = 2.1 Hz, C23), 70.5, 70.4, 70.3, 69.7, 69.5, 67.4 (O-CH2), 66.6 (C22), 64.1 (C11), 53.1 (C6), 52.3 
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(OMe), 47.1 (C10), 42.9 (C9), 39.9, 38.8 (2x N-CH2), 36.9 (C5), 23.8 (2x CH3); 19F NMR (376 MHz, CDCl3) 
δ: -62.9, -111.3; HRMS (ESI): m/z calcd for C55H56F4N6O10SNa [M+Na]+: 1091.3607; found: 1091.3649; 
[α]D20 8.3° (c = 0.06, MeOH). 
 
1H-indol-3-yl acetate (156) 
 
Following a modified version of a reported procedure,312  to a stirring solution of indole  (0.358 g, 3.06 
mmol) and sodium hydroxide (0.123 g, 3.06 mmol) in methanol (30 mL) were added iodine (0.777 g, 
3.06 mmol) and a solution of potassium iodide (0.507 g, 3.06 mmol) in H2O (6 mL). The reaction was 
stirred in the dark at r.t. for 3 h before H2O (20 mL) was added and the precipitate was filtered, washed 
with H2O (10 mL), and dried in vacuo. The crude solid was then dissolved in acetic acid (16 mL) and 
silver acetate (0.714 g, 4.28 mmol) was added. The reaction was heated to 90 °C for 1 h before being 
cooled, filtered and concentrated in vacuo. The residue was then purified by silica gel chromatography 
(9:1 to 4:1 PE/EtOAc) to give the title compound as an amorphous white solid (0.180 g, 34%). 
Rf: 0.40 (8:2 PE/EtOAc); IR (neat film, νmax, cm-1): 3341 (s, NH), 3120 (w, CH), 1744 (s, C=O), 1626 (w), 
1581 (w), 1550 (w), 1490 (w), 1459 (m), 1428 (m), 1370 (m), 1349 (m), 1312 (m), 1244 (m), 1210 (s), 
1125 (m), 1098 (m), 1071 (m), 1009 (m); 1H NMR (400 MHz, CDCl3) δ : 7.85 (br s, 1 H, NH), 7.56 (d, J = 
7.9 Hz, 1 H), 7.36 (d, J = 2.8 Hz, 1 H), 7.33 (d, J = 8.1 Hz, 1 H), 7.24 – 7.20 (m, 1 H), 7.16 – 7.12 (m, 1 H), 
2.37 (s, 3 H, CH3); 13C NMR (101 MHz, CDCl3) δ : 168.7 (C=O), 133.1, 130.6, 122.8, 120.0, 119.9, 117.5, 
113.3, 111.3, 21.0 (CH3). 
Data are in accordance with those reported previously in literature.310 
 
(E)-2-(4-methoxybenzylidene)indolin-3-one (159) 
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Following a reported procedure.311 To a stirring solution of 4-ethynylanisole (110 mg, 0.50 mmol), 6-
iodoaniline (66.1 mg, 0.5 mmol), Pd(PPh3)4 (29 mg, 0.025 mmol) and triethylamine (0.418 mL, 3 mmol) 
in toluene (1 mL); a pre-stirred mixture (30 °C, 1.5 h) of acetic anhydride (94.5 µL, 1 mmol) and formic 
acid (38 µL, 1 mmol) was added dropwise. The reaction mixture was stirred at r.t. for 2 h then heated 
to 70 °C for 15 h before being cooled, filtered and concentrated in vacuo. The residue was then purified 
by silica gel chromatography (19:1 to 4:1 PE/EtOAc) to give the title compound as an amorphous 
orange solid (55 mg, 44%). 
Rf: 0.25 (9:1 PE 40-60/EtOAc); IR (neat film, νmax, cm-1): 3428 (w, NH), 2931 (w, CH), 1603 (m, C=O), 
1509 (m), 1499 (m), 1455 (m), 1431 (m), 1351 (m), 1286 (m), 1245 (s), 1178 (s), 1113 (m), 1025 (s); 1H 
NMR (400 MHz, CDCl3) δ : 8.27 (br s, 1 H, NH), 7.62 – 7.58 (m, 3 H), 7.38 (dd, J = 7.9, 0.9 Hz, 1 H), 7.17 
(dt, J = 7.0, 1.1 Hz, 1 H), 7.11 (dt, J = 7.8, 1.0 Hz, 1 H), 7.00 – 6.97 (m, 2 H), 6.72 (dd, J = 2.1, 0.9 Hz, 1 
H), 3.86 (s, 3 H, OMe); 13C NMR (101 MHz, CDCl3) δ : 159.4, 138.0, 136.6, 129.4, 126.5, 125.2, 121.9, 
120.3, 120.2, 114.5, 110.7, 98.8, 55.4 (OMe). 
Data are in accordance with those reported previously in literature.311 
 
2-(4-bromobenzylidene)indolin-3-one (152) 
 
156 (0.172 g, 0.982 mmol) was dissolved in sodium hydroxide (1.5 M, aq, 5.4 mL, 8.05 mmol) and 
heated to 100 °C for 15 mins. The reaction mixture was then cooled to 0 °C and a solution of 4-
bromobenzaldehyde (0.182 g, 0.982 mmol) in methanol (0.98 mL) was slowly added. The reaction was 
stirred at 0 °C for a further 30 mins then warmed to r.t. and stirred for 48 h, before being acidified 
with 1 M HCl, extracted into EtOAc (3 x 20 mL), dried over Na2SO4, filtered, and concentrated to give 
the title compound as a very dark yellow amorphous solid (0.271 g, 92%) which required no further 
purification.  
Rf: 0.17 (5% EtOAc/PE 40-60); IR (neat film, νmax, cm-1): 3267 (w, NH), 2928 (w, CH), 2857 (w, CH), 1698 
(s, C=O), 1618 (s), 1485 (s), 1467 (s), 1375 (m), 1314 (m), 1248 (m), 1212 (m), 1133 (m), 1073 (w), 1008 
(m); 1H NMR (400 MHz, d6-DMSO) δ : 9.85 (s, 1 H, NH), 7.70 – 7.65 (m, 4 H), 7.60 (d, J = 7.4 Hz, 1 H), 
7.57 – 7.53 (m, 1 H), 7.14 (d, J = 8.1 Hz, 1 H), 6.94 (t, J = 7.4 Hz, 1 H), 6.60 (s, 1 H); 13C NMR (101 MHz, 
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d6-DMSO) δ : 186.8 (C=O), 154.6, 137.0, 135.2, 133.9, 132.3, 132.1, 124.6, 121.9, 120.4, 120.4, 113.0, 
109.7. 
Data are in accordance with those reported previously in literature.311 
 
2-((tert-butoxycarbonyl)amino)ethyl methanesulfonate (164) 
 
To a stirring solution of 2-(N-tert-butoxycarbonylamino)ethanol (0.26 mL, 1.55 mmol) in 
dichloromethane (2 mL) cooled to 0 °C, were added DIPEA (0.324 mL, 1.86 mmol) and methanesulfonyl 
chloride (0.13 mL, 1.71 mmol). The reaction was warmed to r.t. and stirred for 3 h before being diluted 
with H2O (10 mL), extracted  into dichloromethane (3 x 15 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo to give the title compound (0.370 g, >98%) as a colourless oil which required 
no further purification. 
1H NMR (400 MHz, CDCl3) δ : 4.91 (br s, 1 H, NH), 4.28 (t, J = 5.6 Hz, 2 H, CH2-O), 3.47 (q, J = 5.6 Hz, 2 
H, CH2-N), 3.03 (s, 3 H, CH3), 1.44 (s, 9 H, 3 x CH3); 13C NMR (101 MHz, CDCl3) δ : 155.7 (C=O), 80.0 (Cq), 
68.9 (CH2-O), 40.0 (CH2-N), 37.4 (CH3), 28.3 (3 x CH3). 
Data are in accordance with those reported previously in literature355.  
 
2-[bis(tert-butoxycarbonyl)amino]ethyl bromide (172) 
 
To a stirring solution of di-tert-butyl-iminodicarboxylate (0.545 g, 2.5 mmol) in a mixture of 
tetrahydrofuran (15 mL) and DMF (5 mL) was added sodium hydride (0.105 g, 2.63 mmol). The reaction 
was heated to 65 °C for 2.5 h before 1,2-dibromoethane (0.97 mL, 11.3 mmol) was added, the reaction 
was then stirred at 65 °C for a further 3 h. The reaction was then cooled to 0 °C, ether (25 mL) and H2O 
(20 mL) were added. The organic was washed with H2O (2 x 20 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The residue was then purified by silica gel chromatography (2% to 10% 
Ether/PE 40-60) to give the title compound as a colourless oil (0.243 g, 30%). 
Rf: 0.88 (7:3 PE/EtOAc); IR (neat film, νmax, cm-1): 1770 (m, C=O), 1760 (m, C=O), 1523 (m), 1460 (w), 
1391 (w), 1365 (w), 1222 (w), 1142 (s), 1097 (s); 1H NMR (400 MHz, CDCl3) δ : 3.95 (t, J = 7.4 Hz, 2 H, 
CH2-N), 3.45 (t, J = 7.4 Hz, 2 H, CH2-Br), 1.50 (s, 18 H, 6 x CH3); 13C NMR (101 MHz, CDCl3) δ : 152.1 
(C=O), 82.9 (qC), 47.3 (C-N), 29.0 (C-Br), 28.0 (CH3); HRMS (ESI): Mass not found. 
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tert-Butyl (2-(1H-indol-1-yl)ethyl)carbamate (174) 
 
To a stirring solution of indole (0.20 g, 1.71 mmol) in DMF (6 mL) cooled to 0 °C was added NaH (60% 
w/w, 75 mg, 1.88 mmol). The reaction was stirred for 30 mins before being warmed to r.t. and a 
solution of 167 (0.509 g, 1.88 mmol) in DMF (2 mL) was added dropwise. The reaction mixture was 
stirred for a further 18 h at r.t. before being heated to 80 °C for 1 h. The mixture was then cooled, 
quenched with NH4Cl (aq. sat. 10 mL), extracted into EtOAc (3x 20 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. The residue was then purified by silica gel chromatography (9:1 PE/EtOAc) to 
give the title compound as a yellow oil (125 mg, 27%). 
Rf: 0.20 (9:1 PE/EtOAc); IR (neat film, νmax, cm-1): 3341 (w, NH), 2976 (w, CH), 2931 (w, CH), 1705 (s, 
C=O), 1512 (s), 1464 (m), 1394 (m), 1365 (m), 1270 (m), 1249 (m), 1169 (s); 1H NMR (400 MHz, CDCl3) 
δ : 7.63 (dt, J = 7.9, 1.0 Hz, 1 H, H5), 7.36 (d, J = 8.2 Hz, 1 H, H2), 7.23 – 7.19 (m, 1 H, H3), 7.13 – 7.08 
(m, 2 H, H8 and H4), 6.52 (dd, J = 3.1, 0.6 Hz 1 H, H7), 4.53 (br s, 1 H, NH), 4.28 (t, J = 5.7 Hz, 2 H, H9), 
3.50 (q, J = 6.0 Hz, 2 H, H10), 1.44 (s, 9 H, 3x CH3); 13C NMR (101 MHz, CDCl3) δ : 155.9 (C=O), 136.0 
(C1), 128.6 (C6), 127.9 (C8), 121.7 (C3), 121.0 (C5), 119.5 (C4), 109.3 (C2), 101.6 (C7), 79.7 (qC), 45.9 
(C9), 40.9 (C10), 28.3 (CH3); HRMS (ESI): m/z calcd for C15H20N2O2Na [M+Na]+: 283.1417; found: 
283.1418. 
 
4-Bromo-2,6-difluoroaniline (181) 
 
To a stirring solution of 2,6-difluoroaniline (1.29 g, 10 mmol) in acetonitrile (20 mL) was added N-
bromosuccinimide (1.78 g, 10 mmol). The reaction was stirred at r.t. for 18 h then diluted with hexane 
(25 mL) and water (25 mL). The aqueous was extracted with hexane (3 x 25 mL), and the combined 
organics were dried over MgSO4, filtered, and concentrated in vacuo. The residue was then purified 
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by silica gel chromatography (8:2 PE/DCM) to give the title compound as an off-white amorphous 
powder (1.22 g, 59%). 
Rf: 0.27 (8:2 PE/DCM); 1H NMR (400 MHz, CDCl3) δ : 6.99 (dd, J = 6.3, 1.2 Hz, 2 H, C-H), 3.73 (br s, 2 H, 
NH2); 13C NMR (101 MHz, CDCl3) δ : 151.9 (dd, J = 244, 8.9 Hz, C-F), 123.7 (t, J = 16.2 Hz, -C-NH2), 115.1 
– 114.7 (m, C-H), 107.2 (t, J = 11.7 Hz, -C-Br); 19F NMR (376 MHz, CDCl3) δ : - 130.70. 
Data are in accordance with those reported previously in literature.356 
 
5-Bromo-1,3-difluoro-2-nitrosobenzene (178) 
 
To a stirring solution of 181 (0.146 g, 0.70 mmol) in chloroform (1 mL) was added a solution of OxoneTM 
(0.432 g, 1.4 mmol) in water (2.8 mL). The reaction mixture was stirred vigorously at r.t. for 18 h before 
being extracted into chloroform (3 x 10 mL), washed with 1 M HCl (2bx 5 mL), NaHSO4 (sat. aq. 2 x 5 
mL), water (2 x 5 mL), and brine (5 mL). The organics were then dried over Na2SO4, filtered, and 
concentrated in vacuo to give the title compound as an off-white amorphous powder (135 mg, 87%) 
used without further purification.  
IR (neat film, νmax, cm-1): 3060 (w, CH), 2919 (w, CH), 1601 (s, NO), 1483 (m), 1432 (s), 1293 (m), 1276 
(s), 1193 (m), 1075 (m), 1060 (s); 1H NMR (400 MHz, CDCl3) δ : 7.34 (d, J = 8.2 Hz, 2 H); 13C NMR (101 
MHz, CDCl3) δ : 153.3 (dd, J = 273, 5 Hz, C-F), 145.5 (t, J = 8.3 Hz, C-NO), 130.6 (t, J = 12.3 Hz, C-Br), 
117.0 (dd, J = 23, 4 Hz, C-H). 
Data are in accordance with those reported previously in literature.357 
 
Ethyl 4-amino-3,5-difluorobenzoate (183) 
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To a stirring solution of 179 (70 mg, 0.40 mmol) in ethanol (1.5 mL) was added conc. H2SO4 (50 µL). 
The reaction was heated to reflux for 18 h before being cooled to rt, neutralised with NaHCO3, 
extracted into dichloromethane (3 x 20 mL), dried over MgSO4, filtered, and concentrated to give the 
title compound as an off-white amorphous powder (66 mg, 81%). 
Rf: 0.59 (7:3 PE 40-60/EtOAc); 1H NMR (400 MHz, CDCl3) δ : 7.57 – 7.49 (m, 2H, ArC-H), 4.33 (q, J = 7.2 
Hz, 2H, CH2), 4.12 (s, 2H, NH2), 1.37 (t, J = 7.2 Hz, 3H, CH3); 13C NMR (101 MHz, CDCl3) δ : 165.1 (C=O), 
150.7 (dd, J = 240, 8.2 Hz, C-F), 128.8 (t, J = 16.4 Hz, -C-NH2), 118.6 (t, J = 8.2 Hz, -C-COOEt), 112.8 – 
112.4 (m, C-H), 61.0 (CH2), 14.3 (CH3); 19F NMR (376 MHz, CDCl3) δ : -133.9. 
Data are in accordance with those reported previously in literature.285 
 
Ethyl (E)-4-((4-bromo-2,6-difluorophenyl)diazenyl)-3,5-difluorobenzoate (182) 
 
To a stirring solution of 178 (64 mg, 0.288 mmol) in a mixture of toluene (1 mL), acetic acid (1 mL) and 
TFA (0.2 mL) was added 183 (58 mg, 0.288 mmol). The reaction was stirred in the dark at r.t. for 5 days 
before concentrating in vacuo. The residue was then purified by silica gel chromatography (1 to 5% 
EtOAc/PE 40-60) to give the title compound as a red amorphous powder as a mixture of two isomers 
(32 mg, 27%, isomer ratio 1:0.25). 
Rf: 0.15 (3% EtOAc/PE 40-60); IR (neat film, νmax, cm-1): 3084 (w, CH), 2984 (w, CH), 1716 (s, C=O), 1597 
(m), 1574 (s), 1484 (m), 1465 (m), 1432 (s), 1370 (m), 1336 (s), 1304 (m), 1233 (s), 1193 (s), 1173 (m), 
1083 (m), 1053 (s), 1013 (s); 1H NMR (400 MHz, CDCl3) δ : 7.73 (d, J = 8.9 Hz, 2 H, major isomer), 7.56 
(d, J = 8.0 Hz, minor isomer), 7.30 (d, J = 8.3 Hz, 2 H, major isomer), 7.09 – 7.06 (m, minor isomer), 4.43 
(q, J = 7.1 Hz, 2 H, CH2, major isomer), 4.38 (q, J = 7.1 Hz, minor isomer), 1.43 (t, J = 7.1 Hz, 3 H, CH3, 
major isomer), 1.38 (t, J = 7.1 Hz, minor isomer); 13C NMR (101 MHz, CDCl3) δ : 163.8 (t, J = 3.0 Hz, C=O, 
major), 163.6 (t, J = 3.0 Hz, C=O, minor), 155.7 (dd, J = 265, 5 Hz, C-F, major), 154.9 (dd, J = 260, 3.6 
Hz, C-F, major), 151.6 (dd, J = 260, 5.5 Hz, C-F, minor), 151.2 (dd, J = 255, 5 Hz, C-F, minor), 134.8 (t, J 
= 16 Hz, minor), 134.4 (t, J = 10 Hz, major), 133.3 (t, J = 10 Hz. major), 132.4 (t, J = 9 Hz, minor), 130.9 
(t, J = 17 Hz, minor), 130.6 (t, J = 9.6 Hz, major), 125.1 (t, J = 12 Hz, major), 122.6 (t, J = 11.1 Hz, minor), 
116.9 – 116.7 (m, major), 116.4 – 116.1 (m, minor), 114.0 – 113.8 (m, major), 113.6 – 113.4 (m, minor), 
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62.1 (CH2), 14.2 (CH3); 19F NMR (376 MHz, CDCl3) δ : -117.4 (t, J = 5.6 Hz, minor), -118.1 (t, J = 5.6 Hz, 
minor), -118.1 (s, major), -120.0 (s, major). 
Data are in accordance with those reported previously in literature358. 
 
Ethyl (E)-4-((4-acetamido-2,6-difluorophenyl)diazenyl)-3,5-difluorobenzoate (188) 
 
To a stirring solution of 182 (29 mg, 0.072 mmol) in degassed 1,4-dioxane (0.9 mL) were added 
acetamide (12.7 mg, 0.215 mmol), XantPhos (8.3 mg, 0.014 mmol), Cs2CO3 (58.2 mg, 0.18 mmol) and 
finally Pd2(dba)3 (6.5 mg, 0.0072 mmol). The reaction mixture was heated to 90 °C for 1 h before being 
cooled, diluted with EtOAc (5 mL) and brine (5 mL), extracted into EtOAc (3 x 5 mL), dried over Na2SO4, 
filtered and concentrated in vacuo. The residue was then purified by silica gel chromatography (7:3 PE 
40-60/EtOAc) to give the title compound as a red amorphous powder as a mixture of two isomers (30 
mg, >98%, isomer ratio 1:0.3). 
Rf: 0.15 (7:3 PE 40-60/EtOAc); IR (neat film, νmax, cm-1): 3557 (w, NH), 3063 (w, CH), 3007 (w, CH), 1709 
(m, C=O), 1692 (m, C=O), 1603 (s), 1576 (m), 1541 (s), 1480 (m), 1427 (s), 1370 (s), 1336 (s), 1280 (m), 
1250 (s), 1202 (m), 1152 (s), 1095 (m), 1055 (s), 1016 (s); 1H NMR (400 MHz, CDCl3) δ : 7.71 (d, J = 8.8 
Hz, 2 H, H2, major), 7.56 – 7.53 (m, minor), 7.36 (d, J = 11.2 Hz, 2 H, H7, major), 7.15 (d, J = 9.7 Hz, 
minor), 4.42 (q, J = 7.1 Hz, 2 H, CH2, major), 4.37 (q, J = 7.1 Hz, minor), 2.24 (s, 3 H, Acetyl-CH3, major), 
2.16 (s, minor), 1.42 (t, J = 7.1 Hz, 3 H, CH3, major), 1.38 (t, J = 7.1 Hz, minor); 13C NMR (101 MHz, CDCl3) 
δ : 168.6 (N-C=O, major), 168.4 (N-C=O, minor), 164.0 (t, J = 3 Hz, O-C=O, major), 163.7 (t, J = 3 Hz, O-
C=O, minor), 156.9 (dd, J = 250, 6 Hz, C6, major), 154.8 (dd, J = 250, 6 Hz, C3, major), 152.2 (dd, J = 
250, 6 Hz, C-F, minor), 151.3 (dd, J = 250, 6 Hz, C-F, minor), 142.0 (t, J = 13.8 Hz, C8, major), 140.1 (t, J 
= 12.7 Hz, minor), 135.1 (t, J = 15.5 Hz, minor), 134.8 (t, J = 11 Hz, C4, major), 132.4 (t, J =  7.8 Hz, C1, 
major), 131.9 (t, J = 8.5 Hz, minor), 127.7 (t, J = 9 Hz, C5, major), 113.9 – 113.7 (m, C-H, C2, major), 
113.6 – 113.4 (m, minor), 103.1 (dd, J = 25.7, 2.9 Hz, C-H, C7, major), 102.9 – 102.7 (m, minor), 62.0 
(CH2), 24.9 (ester-CH3, major), 24.7 (Ac-CH3), 14.2 (ester-CH3, minor); 19F NMR (376 MHz, CDCl3) δ : -
116.8 (s, major), -117.2 (t, J = 5 Hz, minor), -118.2 (t, J = 5 Hz, minor), - 120.7 (s, major); HRMS (ESI): 
m/z calcd for C17H14F4N3O3 [M+H]+: 384.0966; found: 384.0965. 
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(E)-4-((4-(ethoxycarbonyl)-2,6-difluorophenyl)diazenyl)-3,5-difluorobenzoic acid (191) 
 
To a stirring solution of 179 (0.124 g, 0.72 mmol) in a mixture of dichloromethane (1.7 mL) and acetone 
(0.33 mL) was added a solution of OxoneTM (0.881 g, 1.43 mmol) in H2O (0.7 mL). The reaction was 
stirred vigorously for 18 h before being extracted into EtOAc (3 x 20 mL), washed with brine (5 mL), 
dried over Na2SO4, filtered and concentrated to give the crude product which was used immediately. 
To a stirring solution of crude 192 (70 mg, 0.374 mmol) in a mixture of toluene (1 mL), acetic acid (1 
mL) and TFA (0.2 mL) was added 183 (60 mg, 0.299 mmol). The reaction was stirred in the dark at r.t. 
for 5 days before concentrating in vacuo. The residue was then purified by silica gel chromatography 
(2:1:97 MeOH/AcOH/DCM) to give the title compound as a red amorphous powder as a mixture of 
two isomers (32 mg, 27%, isomer ratio 1:0.25). 
Rf:  0.55 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 2922 (br w, OH), 2827 (w, CH), 1692 (s, C=O), 1623 
(s, C=O), 1587 (s), 1537 (m), 1452 (m), 1417 (s), 1338 (s), 1277 (s), 1237 (s), 1146 (m), 1085 (w), 1051 
(m), 1019 (w); Only major isomer reported; 1H NMR (400 MHz, CDCl3) δ : 7.80 (dd, J = 17.6, 8.9 Hz, 2H, 
H1), 7.63 – 7.58 (m, 2H, H2), 4.46 (q, J = 7.2 Hz, 2H, CH2), 1.46 (t, J = 7.2 Hz, 3H, CH3); 13C NMR (101 
MHz, CDCl3) δ : 170.3, 163.7 (t, J = 3 Hz), 155.1 (dd, J = 250, 6 Hz, CF), 155.0 (dd, J = 250, 6 Hz, CF), 
146.7, 134.1 (t, J = 15.5 Hz), 130.6 (t, J =  13 Hz), 130.0 (t, J = 16 Hz), 114.6 – 113.9 (m, C2), 113.5 – 
112.6 (m, C1), 62.3 (CH2), 14.2 (CH3); 19F NMR (376 MHz, CDCl3) δ : -120.3 (d, J = 5 Hz), -133.7; HRMS 
(ESI): m/z calcd for C16H8F4N2O4 [M-H]-: 369.0504; Found: 369.0501. 
  
tert-Butyl (2-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-
yl)-2-fluorobenzamido)ethyl)carbamate (194) 
 
To a stirring solution of 2 (18 mg, 0.040 mmol) in DMF (0.3 mL) were added HATU (23 mg, 0.060 mmol) 
and DIPEA (10.4 µL, 0.060 mmol). The reaction mixture was stirred at r.t. for 15 mins before 193 (10 
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mg, 0.060 mmol) was added. The mixture was then stirred for a further 16 h before diluting in water 
(5 mL) and extracting into EtOAc (3 x 10 mL). The combined organics were then washed with 10% LiCl 
(2 x 5 mL), and brine (2 x 5 mL), before being dried over Na2SO4, filtered and concentrated in vacuo. 
The residue was purified through silica gel column chromatography (6:4 to 7:3 EtOAc/PE 40-60) to give 
the title compound as a colourless oil (22 mg, 92%). 
Rf: 0.36 (7:3 EtOAc/PE 40-60); IR (neat film, νmax, cm-1): 2925 (w, CH), 1759 (m, C=O), 1708 (m, C=O), 
1659 (m), 1621 (m), 1530 (m), 1500 (m), 1439 (s), 1409 (s), 1369 (m), 1312 (s), 1284 (m), 1219 (m), 
1177 (s), 1137 (s), 1054 (w); 1H NMR (400 MHz, CDCl3) δ : 8.26 (t, J = 8.5 Hz, 1 H, H6), 8.01 (d, J = 8.4 
Hz, 1 H, H11), 7.97 (d, J = 1.6 Hz, 1 H, H14), 7.85 (dd, J = 8.4, 1.6 Hz, 1 H, H10), 7.31 (br s, 1 H, NH), 7.26 
(dd, J = 8.4, 1.8 Hz, 1 H, H5), 7.17 (dd, J = 11.3, 1.6 Hz, 1 H, H3), 4.99 (br s, 1 H, NH), 3.65 – 3.62 (m, 2 
H, CH2), 3.44 – 3.40 (m, 2 H, CH2), 1.63 (s, 6 H, 2 x CH3), 1.45 (s, 9 H, 3 x CH3);13C NMR (101 MHz, CDCl3) 
δ : 179.7 (C=S), 174.5 (cyclic C=O), 161.9 (d, J = 274 Hz, C13), 159.7 (C15), 156.8 (Boc C=O), 139.1 (d, J 
= 10.5 Hz, C12), 136.8 (C1), 135.3 (C6), 133.7 (q, J = 33 Hz, C2), 133.2 (C11), 132.2 (C5), 127.1 (q, J = 5.2 
Hz, C3), 126.1 (C10), 122.6 (q, J = 250 Hz, CF3), 121.1 (C9), 118.0 (d, J = 26 Hz, C14), 114.7 (-C≡N), 110.4 
(q, J = 2.1 Hz, C4), 79.9 (Boc-qC), 66.6 (C7), 41.4 (CH2), 40.0 (CH2), 28.3 (Boc CH3), 23.9 (C8); 19F NMR 
(376 MHz, CDCl3) δ : -62.0, -109.9; HRMS (ESI): m/z calcd for [M+Na]+: 616.1612; found: 616.1630. 
 
N-(2-aminoethyl)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-
thioxoimidazolidin-1-yl)-2-fluorobenzamide (177) 
 
To a stirring solution of 194 (22 mg, 0.037 mmol) in dichloromethane (1 mL) was added trifluoroacetic 
acid (0.25 mL). The reaction was stirred for 3 h at r.t. before being concentrated, diluted with sat. aq. 
NaHCO3 (2 mL), extracted into dichloromethane (3 x 10 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo to give the title compound as a yellow oil (18 mg, >98%) used without further 
purification. 
IR (neat film, νmax, cm-1): 2921 (w, CH), 2851 (w, CH), 1756 (m, C=O), 1727 (w), 1655 (m), 1619 (m), 
1533 (m), 1498 (m), 1433 (s), 1411 (s), 1308 (s), 1284 (s), 1218 (s), 1176 (s), 1132 (s), 1055 (m); 1H NMR 
(400 MHz, CDCl3) δ : 8.23 (t, J = 8.5 Hz, 1 H, H6), 7.97 (d, J = 8.5 Hz, 1 H, H11), 7.93 (s, 1 H, H14), 7.80 
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(dd, J = 8.1, 1.5 Hz, 1 H, H10), 7.24 – 7.17 (m, 2 H, NH and H5), 7.13 (dd, J = 11.4, 1.5 Hz, H3), 3.55 (q, 
J = 5.5 Hz, 2 H, CH2), 3.00 – 2.96 (m, 2 H, CH2), 1.72 (br s, 2 H, NH2), 1.59 (s, 6 H, 2 x CH3); 13C NMR (101 
MHz, CDCl3) δ : 179.7 (C=S), 174.4 (cyclic C=O), 162.3 (d, J = 2.7 Hz, C15), 160.4 (d, J = 250 Hz, C13), 
139.0 (d, J = 10.5 Hz, C12), 136.8 (C1), 135.3 (C6), 133.7 (q, J = 34 Hz, C2), 133.3 (d, J = 3.3 Hz, C11), 
132.1 (C5), 127.1 (q, J = 4.3 Hz, C3), 126.1 (d, J = 3.2 Hz, C10), 123.0 (q, J = 250 Hz, CF3), 120.5 (C9), 
118.0 (d, J = 26 Hz, C14), 114.7 (-C≡N), 110.4 (q, J = 2.1 Hz, C4), 66.6 (C7), 42.5 (CH2), 41.0 (CH2), 23.9 
(C8); 19F NMR (376 MHz, CDCl3) δ : -62.0, -110.4; HRMS (ESI): m/z calcd for C22H20F4N5O2S [M+H]+: 
494.1268; found: 494.1288. 
 
Ethyl 4-((E)-(2,6-difluoro-4-((1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl) 
pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl)phenyl)diazenyl)-3,5-difluorobenzoate 
(195) 
 
To a stirring solution of 191 (8 mg, 0.022 mmol) in DMF (0.1 mL) were added HATU (9.9 mg, 0.026 
mmol) and DIPEA (9.4 µL, 0.054 mmol). The reaction mixture was stirred at r.t. for 15 mins before 154 
(13.2 mg, 0.026 mmol) was added. The mixture was then stirred for a further 16 h before diluting in 
water (5 mL) and extracting into EtOAc (3 x 10 mL). The combined organics were then washed with 
brine (2 x 5 mL), before being dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
purified through silica gel column chromatography (DCM to 4% MeOH/DCM) to give the title 
compound as an orange oil (11 mg, 65%). 
Rf: 0.29 (4% MeOH/DCM); IR (neat film, νmax, cm-1): 3395 (w, NH), 2961 (w, CH), 2865 (w, CH), 1703 (s, 
C=O), 1668 (m), 1627 (s), 1574 (m), 1532 (m), 1431 (s), 1365 (s), 1334 (m), 1232 (s), 1089 (m), 1048 
(m), 1016 (m); 1H NMR (400 MHz, CDCl3) δ : Mixture of cis and trans isomers, 8.69 (s, 1 H), 7.75 – 7.73 
(m, 1 H), 7.55 – 7.47 (m, 2 H), 7.39 – 7.33 (m, 4 H), 7.15 – 7.07 (m, 1 H), 6.89 (d, J = 9.0 Hz, 0.7 H), 6.75 
(d, J = 9.0 Hz, 0.3 H), 4.76 – 4.67 (m, 2 H), 4.62 – 4.57 (m, 2 H), 4.45 – 4.33 (m, 3 H), 4.08 – 4.01 (m, 1 
H), 3.74 – 3.71 (m, 1H), 2.59 – 2.54 (m, 1 H), 2.52 – 2.51 (m, 3 H), 2.15 – 2.10 (m, 1H), 1.43 (t, J = 7.2 
Hz, 2 H), 1.36 (t, J = 7.2 Hz, 1 H), 1.02 (s, 6 H), 0.98 (s, 3H); 13C NMR (101 MHz, CDCl3) δ : Only major 
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isomer reported; 171.2, 170.4, 164.3, 163.7, 155.2 (dd, J = 260, 4 Hz, C-F), 155.0 (dd, J = 260, 4 Hz, C-
F), 150.4, 148.5, 137.9, 137.0, 134.1, 133.7, 133.4, 131.5, 131.1, 129.6, 128.1, 114.0 – 113.8 (m, 1C), 
111.9 – 111.7 (m, 1C), 70.2, 62.2, 58.7, 58.2, 56.8, 43.3, 36.0, 35.8, 26.5, 16.0, 14.2; 19F NMR (376 MHz, 
CDCl3) δ : -118.3, -119.4; HRMS (ESI): m/z calcd for C38H38F4N6O6SNa [M+Na]+: 805.2402; Found 
805.2407. 
 
(2S,4R)-1-((S)-2-(4-((E)-(4-((2-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-
thioxoimidazolidin-1-yl)-2-fluorobenzamido)ethyl)carbamoyl)-2,6-difluorophenyl)diazenyl)-3,5-
difluorobenzamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (azoPROTAC1) 
 
To a stirring solution of 195 (4.2 mg, 0.0055 mmol) in a mixture of THF and H2O (2:1, 1 mL) was added 
lithium hydroxide (0.5 mg, 0.011 mmol). The reaction was stirred at r.t. for 3 h before acidifying to pH 
3 with 1 M HCl and extracting into EtOAc (3 x 10 mL). The combined organics were washed with brine 
(5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was directly 
dissolved in DMF (0.1 mL) and cooled to 0 °C, before HATU (2.51 mg, 0.0066 mmol) and DIPEA (1.1 µL, 
0.0066 mmol) were added. The reaction mixture was stirred for 15 mins before 177 (3.3 mg, 0.0066 
mmol) was added. The mixture was then warmed to r.t. and stirred for a further 16 h before diluting 
in water (5 mL) and extracting into EtOAc (3 x 10 mL). The combined organics were then washed with 
brine (2 x 5 mL), before being dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
purified through silica gel column chromatography (1 to 5% MeOH/DCM) to give the title compound 
as an orange oil (5.2 mg, 78%). 
Rf: 0.39 (6% MeOH/DCM); IR (neat film, νmax, cm-1): 3360 (w, NH), 2926 (w, CH), 2857 (w, CH), 1757 
(w), 1655 (s), 1633 (s), 1571 (m), 1537 (m), 1498 (m), 1430 (s), 1312 (s), 1221 (m), 1179 (m), 1141 (m), 
1052 (m); 1H NMR (700 MHz, CDCl3) δ : 8.71 (s, 1 H, H7), 8.32 (t, J = 8.4 Hz, 1 H, H1), 8.02 (d, J = 8.2 Hz, 
1 H, H6), 7.97 (d, J = 2.0 Hz, 1 H, H4), 7.85 (dd, J = 8.3, 2.0 Hz, 1 H, H5), 7.69 (t, J = 4.6 Hz, 1 H, NH), 7.59 
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(d, J = 9.1 Hz, 2 H), 7.49 (d, J = 8.7 Hz, 2 H), 7.43 – 7.35 (m, 5 H), 7.31 (dd, J = 8.5, 2.1 Hz, 1 H), 7.23 – 
7.19 (m, 1 H), 7.15 (t, J = 5.6 Hz, 1 H, NH), 6.83 (d, J = 8.9 Hz, 1 H), 4.78 – 4.75 (m, 1 H), 4.70 – 4.59 (m, 
3 H), 4.39 (dd, J = 15.1, 5.3 Hz, 1 H), 4.10 (d, J = 11.1 Hz, 1 H), 3.88 – 3.84 (m, 1 H), 3.78 – 3.74 (m, 3 H), 
3.69 – 3.68 (m, 1 H), 3.04 (br s, 1 H), 2.65 – 2.61 (m, 1 H), 2.55 (s, 3 H, CH3), 1.89 – 1.87 (m, 1 H), 1.64 
(s, 6 H, 2x CH3), 1.04 (s, 9 H, 3x CH3); 13C NMR (176 MHz, CDCl3) δ : 179.8 (C=S), 174.4 (cyclic C=O), 
171.3, 170.4, 164.5, 164.4, 161.8, 160.6 (d, J = 250 Hz, C-F), 155.4 (dd, J = 260, 4 Hz, C-F), 155.2 (dd, J 
= 260, 4 Hz, C-F), 150.4, 148.5, 139.8 (d, J = 10.5 Hz), 137.9, 137.6, 136.7, 135.4, 133.9, 133.7, 133.4, 
133.2, 133.1, 132.1, 131.5, 131.2, 129.6, 128.2, 127.1, 126.5, 121.8 (q, J = 250 Hz, CF3), 121.7, 118.2 
(d, J = 26 Hz, C14), 114.7 (-C≡N), 111.8 – 111.7 (m, 1C), 111.5 – 111.3 (m, 1C), 110.5, 68.0, 66.7, 58.6, 
58.2, 56.8, 43.4, 42.5, 40.1, 35.9, 35.7, 26.5, 23.9, 16.1; 19F NMR (376 MHz, CDCl3) δ : -62.0, -109.7, -
117.3 (d, J = 134 Hz), -118.4 (d, J = 38 Hz); Mixture of cis and trans, only major isomer reported; HRMS 
(ESI): m/z calcd for C58H51F8N11O7S2Na [M+Na]+: 1252.3179; found: 1252.3190. 
 
tert-Butyl (2-(4-bromophenoxy)ethyl)carbamate (198) 
 
Following a literature procedure,359 to a stirring solution of 4-bromophenol (1.00 g, 5.8 mmol) in DMF 
(15 mL) were added potassium carbonate (6.99 g, 50.6 mmol) and 2-(boc-amino)ethyl bromide (1.08 
g, 4.82 mmol). The reaction mixture was stirred at 65 °C for 24 h before being cooled to r.t., diluted 
with H2O (50 mL) and extracted into EtOAc (3x 100 mL). The organics were washed with brine (50 mL), 
dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified through silica gel 
column chromatography (5% EtOAc/PE 40-60) to give the title compound as a colourless oil (1.50 g, 
98%). 
Rf: 0.10 (5% EtOAc/PE 40-60); IR (neat film, νmax, cm-1): 3346 (w, NH), 2974 (w, CH), 2884 (w, CH), 1686 
(m), 1588 (w), 1515 (m), 1488 (s), 1392 (w), 1366 (m), 1282 (m), 1241 (s), 1170 (s), 1111 (w), 1067 (m), 
1003 (w); 1H NMR (400 MHz, CDCl3) δ : 7.37 (d, J = 9.1 Hz, 2 H),  6.77 (d, J = 9.1 Hz, 2 H), 4.97 (br s, 1 
H), 3.98 (t, J = 5.2 Hz, 2 H), 3.52 (q, J = 5.2 Hz, 2 H), 1.45 (s, 9 H); 13C NMR (101 MHz, CDCl3) δ : 157.7, 
155.1, 132.3, 117.2, 116.2, 79.7, 67.4, 40.0, 28.4. 
Data are in accordance with those reported previously in literature.359 
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2-((4-(2-((tert-butoxycarbonyl)amino)ethoxy)phenyl)amino)-2-methylpropanoic acid (199) 
 
To a stirring solution of 198 (0.516 g, 1.63 mmol) in a mixture of DMF (7.2 mL) and H2O (1.8 mL) were 
added aminoisobutyric acid (0.202 g, 1.96 mmol), potassium carbonate (0.901 g, 6.52 mmol), copper 
(I) iodide (47 mg, 0.245 mmol), and 2-acetylcyclohexanone (42 µL, 0.33 mmol). The reaction mixture 
was heated to 90 °C for 18 h, then cooled, diluted with H2O (20 mL), and washed with EtOAc (3 x 20 
mL). The aqueous was then acidified with citric acid to pH 3, then extracted with EtOAc (3 x 20 mL), 
washed with brine (25 mL), dried over MgSO4, filtered, and concentrated in vacuo. The residue was 
purified through silica gel column chromatography (1 to 6% MeOH/DCM) to give the title compound 
as a white amorphous solid (0.123 g, 22%). 
Rf: 0.20 (6% MeOH/DCM); IR (neat film, νmax, cm-1): 2971 (w, CH), 1687 (s), 1615 (s), 1557 (m), 1515 
(s), 1462 (m), 1431 (m), 1401 (m), 1366 (s), 1306 (m), 1261 (s), 1173 (s), 1111 (w), 1056 (w); 1H NMR 
(400 MHz, MeOD) δ : 7.13 (d, J = 8.3 Hz, 2 H, Ar-H), 6.95 (d, J = 8.3 Hz, 2 H, Ar-H), 3.99 (t, J = 5.3 Hz, 2 
H, H8), 3.41 (t, J = 5.3 Hz, 2 H, H9), 1.44 (s, 9 H, Boc-CH3), 1.41 (s, 6 H, H3); 13C NMR (101 MHz, MeOD) 
δ : 176.1 (C1), 157.2, 157.1 (C7 and Boc C=O), 130.2 (C4), 123.7, 114.9 (C5 and C6), 78.8 (Boc-qC), 67.0 
(C8), 63.7 (C2), 39.5 (C9), 27.3 (Boc-CH3), 22.9 (C3); HRMS (ESI): m/z calcd for C17H25N2O5 [M-H]-: 
337.1763; Found: 337.1762. 
 
Methyl 2-((4-(2-((tert-butoxycarbonyl)amino)ethoxy)phenyl)amino)-2-methylpropanoate (200) 
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To a stirring solution of 199 (84 mg, 0.25 mmol) in DMF (1.5 mL) were added potassium carbonate 
(51.4 mg, 138.2 mmol) and iodomethane (23 µL, 0.372 mmol). The reaction mixture was heated to 
45 °C for 4 h before cooling and concentrating in vacuo. The residue was purified through silica gel 
column chromatography (9:1 to 8:2 PE 40-60/EtOAc) to give the title compound as a colourless oil (52 
mg, 59%). 
Rf: 0.60 (1:1 PE 40-60/EtOAc); IR (neat film, νmax, cm-1): 3387 (w, NH), 2977 (w, CH), 2936 (w, CH), 1697 
(m, C=O), 1508 (s), 1465 (m), 1383 (m), 1365 (m), 1272 (m), 1238 (s), 1165 (s), 1143 (s), 1067 (w); 1H 
NMR (400 MHz, CDCl3) δ : 6.73 (d, J = 8.9 Hz, 2 H, Ar-H), 6.62 (d, J = 8.9 Hz, 2 H, Ar-H), 4.98 (br s, 1 H, 
NH), 3.94 (t, J = 5.0 Hz, 2 H, H8), 3.69 (s, 3 H, OMe), 3.48 (q, J = 5.0 Hz, 2 H, H9), 1.49 (s, 6 H, H3), 1.44 
(s, 9 H, Boc-CH3); 13C NMR (101 MHz, CDCl3) δ : 176.8 (C1), 155.9 (Boc-C=O), 152.7 (C7), 139.3 (C4), 
119.5, 115.1 (C5 and C6), 79.4 (Boc-qC), 67.6 (C8), 58.4 (C2), 52.3 (OMe), 40.2 (C9), 28.4 (Boc-CH3), 
26.3 (C3); HRMS (ESI): m/z calcd for C18H28N2O5Na [M+Na]+: 375.1896; Found: 375.1883. 
 
tert-Butyl (2-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-
yl)phenoxy)ethyl)carbamate (201) 
 
To a stirring solution of 200 (40 mg, 0.114 mmol) in DMF (0.5 mL) was added 5 (39 mg, 0.17 mmol). 
The reaction mixture was heated to 90 °C for 7 h, before being cooled, diluted with H2O (5 mL) and 
extracted with EtOAc (3 x 15 mL). The organics were washed with brine (10 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The residue was purified through silica gel column 
chromatography (15% Acetone/Hexane) to give the title compound as a colourless oil (60 mg, 96%). 
Rf: 0.14 (15% Acetone/Hexane); IR (neat film, νmax, cm-1): 3380 (w, NH), 2979 (w, CH), 2873 (w, CH), 
1755 (m, C=O), 1707 (s, C=O), 1612 (w), 1504 (s), 1440 (s), 1389 (m), 1365 (m), 1310 (s), 1286 (s), 1246 
(s), 1195 (s), 1169 (s), 1137 (s), 1055 (m), 1003 (w); 1H NMR (400 MHz, CDCl3) δ : 7.98 – 7.96 (m, 2 H, 
H12, H15), 7.84 (dd, J = 8.2, 2.2 Hz, 1 H, H16), 7.21 (d, J = 9.2 Hz, 2 H, H5), 7.03 (d, J = 9.2 Hz, 2 H, H4), 
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4.98 (br s, 1 H, NH), 4.07 (t, J = 5.1 Hz, 2 H, H2), 3.56 (q, J = 5.1 Hz, 2 H, H1), 1.57 (s, 6 H, H10), 1.46 (s, 
9 H, Boc-CH3); 13C NMR (101 MHz, CDCl3) δ : 180.2 (C7), 175.0 (C8), 159.3 (C3), 155.8 (Boc-C=O), 137.2 
(C14), 135.2 (C15), 133.6 (q, J = 34 Hz, C13), 132.2 (C16), 130.7 (C6), 127.7 (C5), 127.1 (q, J = 4.7 Hz, 
C12), 121.9 (q, J = 273 Hz, CF3), 115.5 (C4), 114.8 (-C≡N), 110.2 (q, J = 2.1 Hz, C11), 79.7 (Boc-qC), 67.5 
(C2), 66.3 (C9), 40.0 (C1), 28.4 (Boc-CH3), 23.6 (C10); 19F NMR (376 MHz, CDCl3) δ: -61.9; HRMS (ESI): 
m/z calcd for C26H27N4O4F3SNa [M+Na]+: 571.1603; Found: 571.1604. 
 
4-(3-(4-(2-aminoethoxy)phenyl)-4,4-dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-
(trifluoromethyl)benzonitrile (202) 
 
To a stirring solution of 201 (50 mg, 0.09 mmol) in dichloromethane (0.8 mL) was added TFA (0.2 mL). 
The reaction mixture was stirred at r.t. for 4 h before being quenched with NaHCO3 (sat. aq.). The 
mixture was then extracted into dichloromethane (3 x 10 mL), washed with brine (5 mL), dried over 
Na2SO4, filtered and concentrated in vacuo to give the title compound as a white amorphous solid (45 
mg, 98%) which was used without further purification. 
IR (neat film, νmax, cm-1): 2928 (w, CH), 1753 (m, C=O), 1709 (m), 1666 (w), 1611 (w), 1504 (m), 1431 
(s), 1364 (m), 1309 (s), 1282 (s), 1246 (s), 1222 (m), 1192 (s), 1169 (s), 1132 (s), 1054 (m), 1002 (w); 1H 
NMR (400 MHz, MeOD) δ : 7.98 (m, 2 H, H12, H15), 7.84 (dd, J = 8.4, 1.9 Hz, 1 H, H16), 7.20 (d, J = 8.9 
Hz, 2 H, H5), 7.04 (d, J = 8.9 Hz, 2 H, H4), 4.04 (t, J = 5.2 Hz, 2 H, H2), 3.13 (br s, 2 H, H1), 1.57 (s, 6 H, 
H10); 13C NMR (101 MHz, MeOD) δ : 180.1 (C7), 175.1 (C8), 159.7 (C3), 137.2 (C14), 135.2 (C15), 133.5 
(q, J = 34 Hz, C13), 132.2 (C16), 130.6 (C6), 127.4 (C5), 127.1 (q, J = 4.7 Hz, C12), 121.9 (q, J = 273 Hz, 
CF3), 115.6 (C4), 114.8 (-C≡N), 110.1 (q, J = 2.2 Hz, C11), 70.5 (C2), 66.3 (C9), 41.4 (C1), 23.6 (C10); 19F 
NMR (376 MHz, CDCl3) δ: -62.0; HRMS (ESI): m/z calcd for C21H19F3N4O2S [M+H]+: 449.1254; Found: 
449.1259. 
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(2S,4R)-1-((S)-2-(4-((E)-(4-((2-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-
thioxoimidazolidin-1-yl)phenoxy)ethyl)carbamoyl)-2,6-difluorophenyl)diazenyl)-3,5-
difluorobenzamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (azoPROTAC2) 
 
To a stirring solution of 195 (11.7 mg, 0.015 mmol) in a mixture of THF and H2O (2:1, 1 mL) was added 
lithium hydroxide (1.3 mg, 0.030 mmol). The reaction was stirred at r.t. for 3 h before acidifying to pH 
3 with 1 M HCl and extracting into EtOAc (3 x 10 mL). The combined organics were washed with brine 
(5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was directly 
dissolved in DMF (0.2 mL) and cooled to 0 °C, before HATU (7.5 mg, 0.0197 mmol) and DIPEA (3.4 µL, 
0.0197 mmol) were added. The reaction mixture was stirred for 15 mins before 202 (9.4 mg, 0.021 
mmol) was added. The mixture was then warmed to r.t. and stirred for a further 16 h before diluting 
in water (5 mL) and extracting into EtOAc (3 x 10 mL). The combined organics were then washed with 
brine (2 x 5 mL), before being dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
purified through silica gel column chromatography (1 to 4% MeOH/DCM) to give the title compound 
as an orange oil (8 mg, 47%). 
Rf: 0.40 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 3345 (w, NH), 2922 (w, CH), 1754 (w, C=O), 1720 
(w, C=O), 1653 (m, C=O), 1625 (m), 1575 (m), 1511 (m), 1428 (s), 1371 (m), 1312 (m), 1286 (m), 1246 
(m), 1193 (m), 1173 (m), 1138 (m), 1049 (m); Mixture of cis and trans, only major isomer reported; 1H 
NMR (500 MHz, CDCl3) δ : 8.68 (s, 1 H, H6), 8.00 – 7.95 (m, 2H), 7.85 - 7.82 (m, 1 H), 7.49 (dd, J = 21.0, 
9.0 Hz, 1 H), 7.40 – 7.31 (m, 6 H), 7.26 – 7.24 (m, 1 H), 7.23 – 7.18 (m, 2 H), 7.15 – 7.01 (m, 3 H), 6.75 
– 6.69 (m, 2 H), 4.75 – 4.53 (m, 4 H), 4.37 – 4.30 (m, 1 H), 4.16 (t, J = 5.3 Hz, 2 H), 4.00 (d, J = 11.4 Hz, 
1 H), 3.88 – 3.78 (m, 2 H), 3.72 – 3.64 (m, 1 H), 2.50 (s, 3 H, CH3), 2.49 – 2.44 (m, 1 H), 2.10 – 2.06 (m, 
1 H), 1.56 (s, 6 H, 2x CH3), 0.98 (s, 9 H, 3x CH3); 13C NMR (126 MHz, CDCl3) δ : 180.2 (C=S), 175.0 (cyclic 
C=O), 171.2, 170.5, 164.4, 164.3, 160.0, 151.4 (d, J = 260 Hz, C-F), 151.2 (d, J = 260 Hz, C-F), 150.4, 
148.5, 137.8, 137.1, 136.4, 135.7, 135.2, 134.1, 133.7, 133.6 (q, J = 26 Hz), 132.2, 131.5, 131.1, 130.8, 
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129.6, 128.1, 128.0, 127.1 (q, J = 4.9 Hz), 121.9 (q, J = 275 Hz, CF3), 115.6, 114.8 (-C≡N), 111.8 – 111.3 
(m, 2C), 110.2, 70.2, 66.6, 66.3, 58.7, 58.2, 56.8, 43.3, 39.7, 36.0, 35.7, 26.5, 23.6, 16.0; 19F NMR (376 
MHz, CDCl3) δ: -62.0, -117.1 (dt, J = 59, 5.6 Hz), -118.2; HRMS (ESI): m/z calcd for C57H52F7N10O7S2 
[M+H]+: 1185.3345; Found: 1185.3355. 
 
Ethyl (E)-4-((2,6-difluoro-4-hydroxyphenyl)diazenyl)benzoate (209) 
 
To a stirring solution of ethyl 4-aminobenzoate (0.50 g, 3.0 mmol) in a mixture of acetic acid (3 mL) 
and conc. H2SO4 (0.4 mL) cooled to 0 °C, was very slowly added a solution of sodium nitrite (0.29 g, 4.2 
mmol) in H2O (0.6 mL). The reaction was stirred at 0 °C for 30 mins before being very slowly added to 
a 0 °C solution of 3,5-difluorophenol (0.398 g, 3.06 mmol) and NaOH (2.52 g, 63 mmol) in H2O (2 mL). 
The solution was then stirred for 30 mins, then filtered, and the solid washed with cold H2O to yield 
the title compound as an amorphous dark brown solid (0.75 g, 82%).  
IR (neat film, νmax, cm-1): 3358 (w, NH), 3075 (w, CH), 1687 (s, C=O), 1623 (s), 1590 (m), 1527 (m), 1470 
(m), 1440 (m), 1353 (m), 1285 (s), 1229 (m), 1155 (s), 1108 (m), 1053 (m), 1011 (w); 1H NMR (400 MHz, 
d-DMSO) δ : 11.41 (s, 1 H, OH), 8.12 – 8.08 (m, 2 H, H2), 7.85 – 7.81 (m, 2 H, H3), 6.68 (d, J = 12 Hz, 2 
H, H7), 4.33 (q, J = 7.1 Hz, 2 H, CH2), 1.32 (t, J = 7.1 Hz, 3 H, CH3); 13C NMR (101 MHz, CDCl3) δ : 165.8 
(C=O), 162.7 (C8), 157.6 (dd, J = 260, 8 Hz, C6), 155.8 (C4), 131.9 (C1), 130.9 (C2), 122.6 (C5), 122.4 
(C3), 100.9 (dd, J = 23, 3 Hz, C7), 61.5 (CH2), 14.6 (CH3); 19F NMR (376 MHz, CDCl3) δ : -118.4; HRMS 
(ESI): m/z calcd for C15H13F2N2O3 [M+H]+: 307.0889; Found: 307.0888. 
 
Ethyl (E)-4-((4-(2-(tert-butoxy)-2-oxoethoxy)-2,6-difluorophenyl)diazenyl)benzoate (210) 
 
To a stirring solution of 209 (73 mg, 0.238 mmol) in DMF (1.5 mL) were added tert-butyl bromoacetate 
(42.2 µL, 0.286 mmol), potassium carbonate (66 mg, 0.477 mmol) and a catalytic amount of potassium 
iodide. The reaction was heated to 100 °C for 18 h before being cooled, diluted with water (3 mL), 
extracted into DCM (3 x 10 mL) then into EtOAc (3 x 10 mL), dried over Na2SO4, filtered, and 
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concentrated in vacuo. The residue was purified through silica gel column chromatography (9:1 PE 40-
60/EtOAc) to give the title compound as an amorphous orange solid (92 mg, 92%). 
Rf: 0.55 (8:2 PE 40-60/EtOAc); IR (neat film, νmax, cm-1): 2982 (w, CH), 1752 (m, C=O), 1718 (m, C=O), 
1625 (m), 1582 (w), 1445 (w), 1369 (m), 1275 (m), 1231 (m), 1146 (s), 1105 (m), 1059 (m); 1H NMR 
(400 MHz, CDCl3) δ : 8.18 (d, J = 8.6 Hz, 2 H, H2), 7.91 (d, J = 8.6 Hz, 2 H, H3), 6.60 (d, J = 10.7 Hz, 2 H, 
H7), 4.57 (s, 2 H, CH2), 4.41 (q, J = 7.1 Hz, 2 H, Et-CH2), 1.51 (s, 9 H, 3x CH3), 1.43 (t, J = 7.1 Hz, 3 H, Et-
CH3); 13C NMR (101 MHz, CDCl3) δ : 166.5 (tBu-O-C=O), 166.0 (Ar-C=O), 160.1 (d, J = 260 Hz, C6), 156.2 
(C8), 155.8 (C4), 132.4 (C1), 130.5 (C2), 122.5 (C5), 122.4 (C3), 99.6 (dd, J = 24.5, 2.8 Hz, C7), 83.3 (qC), 
66.0 (CH2), 61.3 (CH2-CH3), 28.0 (3x CH3), 14.3 (CH3); 19F NMR (376 MHz, CDCl3) δ : -116.6; HRMS (ESI): 
m/z calcd for C21H23F2N2O5 [M+H]+: 421.1570; Found: 421.1566. 
 
(E)-2-(4-((4-(ethoxycarbonyl)phenyl)diazenyl)-3,5-difluorophenoxy)acetic acid (211) 
 
To a stirring solution of 210 (30 mg, 0.071 mmol) in dichloromethane (1 mL) was added TFA (0.5 mL). 
The reaction was stirred at r.t. for 3 h before being concentrated in vacuo. The residue was purified 
through silica gel column chromatography (3 to 5% MeOH/DCM + 1% AcOH) to give the title 
compound as an amorphous orange solid (16 mg, 62%). 
Rf: 0.23 (5% MeOH/DCM + 1% AcOH); IR (neat film, νmax, cm-1): 1718 (s, C=O), 1700 (s, C=O), 1629 (s), 
1623 (s), 1540 (m), 1435 (m), 1363 (m), 1300 (m), 1278 (s), 1167 (m), 1101 (m), 1066 (m); Mixture of 
cis and trans isomers, only major reported; 1H NMR (400 MHz, d-DMSO) δ : 8.15 (d, J = 8.5 Hz, 2 H, 
H2), 7.90 (d, J = 8.5 Hz, 2 H, H3), 7.00 (d, J = 11.7 Hz, 2 H, H7), 4.83 (s, 2 H, CH2), 4.36 (q, J = 7.0 Hz, 2 
H, Et-CH2), 1.36 (t, J = 7.0 Hz, 3 H, Et-CH3); 13C NMR (101 MHz, d-DMSO) δ : 169.7 (acid C=O), 165.6 (Ar-
C=O), 162.0 (C8), 157.1 (dd, J = 260, 7.7 Hz, C6), 155.7 (C4), 132.3 (C1), 131.0 (C2), 130.7 (C5), 122.8 
(C3), 100.6 (dd, J = 23.8, 2.4 Hz, C7), 66.3 (CH2), 61.6 (Et-CH2), 14.6 (CH3); 19F NMR (376 MHz, CDCl3) δ 
: -117.4; HRMS (ESI): m/z calcd for C17H13F2N2O5 [M-H]-: 363.0798; Found: 363.0788. 
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Ethyl 4-((E)-(2,6-difluoro-4-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-
yl)benzyl)carbamoyl)pyrrolidine-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-
oxoethoxy)phenyl)diazenyl)benzoate (212) 
 
To a stirring solution of 211 (14 mg, 0.038 mmol) in DMF (0.5 mL) were added HATU (17.5 mg, 0.046 
mmol) and DIPEA (16.5 µL, 0.095 mmol). The reaction mixture was stirred at r.t. for 15 mins before 
154 (21.4 mg, 0.042 mmol) was added. The mixture was then stirred for a further 6 h before diluting 
in water (5 mL) and extracting into EtOAc (3 x 10 mL). The combined organics were then washed with 
brine (2 x 5 mL), before being dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
purified through silica gel column chromatography (DCM to 4% MeOH/DCM) to give the title 
compound as an orange oil (20 mg, 68%). 
Rf: 0.30 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 3374 (w, NH), 2957 (w, CH), 1716 (m, C=O), 1672 
(m, C=O), 1623 (s), 1581 (m), 1523 (m), 1480 (m), 1436 (m), 1407 (m), 1369 (m), 1350 (m), 1273 (s), 
1226 (m), 1152 (s), 1097 (m), 1058 (m), 1014 (m); Mixture of cis and trans isomers, only major 
reported; 1H NMR (400 MHz, CDCl3) δ : 8.67 (s, 1 H, H28), 8.17 (d, J = 8.5 Hz, 2 H, H2), 7.90 (d, J = 8.5 
Hz, 2 H, H3), 7.38 – 7.32 (m, 4 H, H22, H23), 7.24 – 7.20 (m, 1 H, NH), 6.92 (d, J = 8.7 Hz, 1 H, NH), 6.65 
(d, J = 10.5 Hz, 2 H, H7), 4.73 – 4.68 (m, 1 H), 4.61 – 4.52 (m, 4 H), 4.44 – 4.30 (m, 4 H), 4.02 – 3.95 (m, 
1 H), 3.69 – 3.65 (m, 1 H), 2.56 – 2.47 (m, 4 H), 2.14 – 2.10 (m, 1 H), 1.42 (t, J = 7.2 Hz, 3 H, Et-CH2), 
0.95 (s, 9 H, H13); 13C NMR (101 MHz, CDCl3) δ : 170.9, 170.5, 166.9, 166.0, 165.6, 157.4 (dd, J = 260, 
9 Hz, C-F), 155.6, 150.4, 148.5, 137.9, 132.6 (C1), 131.1 (C2), 130.5 (C5), 130.3, 129.5, 128.1, 122.5 
(C3), 118.4, 100.0 – 99.7 (m, C7), 70.2, 67.5, 61.3, 58.7, 57.1, 56.8, 43.3, 36.1, 35.4, 26.3 (C27), 16.0 
(C13), 14.3 (Et-CH3); 19F NMR (376 MHz, CDCl3) δ : -116.8; HRMS (ESI): m/z calcd for C40H44F2N5O7S 
[M+H]+: 776.2923; Found: 776.2879. 
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(2S,4R)-1-((S)-2-(2-(4-((E)-(4-((2-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-
thioxoimidazolidin-1-yl)phenoxy)ethyl)carbamoyl)phenyl)diazenyl)-3,5-
difluorophenoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-
yl)benzyl)pyrrolidine-2-carboxamide (azoPROTAC3) 
 
To a stirring solution of 212 (16 mg, 0.0206 mmol) in a mixture of THF and H2O (2:1, 1 mL) was added 
lithium hydroxide (1.7 mg, 0.0412 mmol). The reaction was stirred at r.t. for 3 h before acidifying to 
pH 3 with 1 M HCl and extracting into EtOAc (3 x 10 mL). The combined organics were washed with 
brine (5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was directly 
dissolved in DMF (0.2 mL) and cooled to 0 °C, before HATU (10.2 mg, 0.0268 mmol) and DIPEA (4.7 µL, 
0.0268 mmol) were added. The reaction mixture was stirred for 15 mins before 202 (12.0 mg, 0.0268 
mmol) was added. The mixture was then warmed to r.t. and stirred for a further 16 h before diluting 
in water (5 mL) and extracting into EtOAc (3 x 10 mL). The combined organics were then washed with 
brine (2 x 5 mL), before being dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
purified through silica gel column chromatography (1 to 5% MeOH/DCM) to give the title compound 
as a colourless oil (7 mg, 30%). 
Rf: 0.31 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 3348 (w, NH), 2922 (w, CH), 2855 (w, CH), 1759 
(m, C=O), 1708 (m, C=O), 1666 (m, C=O), 1626 (s), 1581 (m), 1538 (m), 1512 (s), 1436 (s), 1353 (m), 
1311 (s), 1247 (m), 1222 (m), 1194 (m), 1166 (s), 1142 (s), 1055 (m); Mixture of cis and trans isomers, 
only major reported; 1H NMR (500 MHz, CDCl3) δ : 8.68 (s, 1 H), 7.98 – 7.90 (m, 4 H), 7.84 (dt, J = 8.2, 
2.2 Hz, 1 H), 7.73 (d, J = 8.6 Hz, 1 H), 7.39 – 7.33 (m, 4 H), 7.25 – 7.17 (m, 3 H), 7.10 – 7.03 (m, 3H), 6.96 
(d, J = 8.4 Hz, 1 H), 6.70 – 6.61 (m, 2 H), 6.39 (d, J = 8.6 Hz, 1 H), 4.73 (t, J = 7.8 Hz, 1 H), 4.61 – 4.53 (m, 
4 H), 4.39 – 4.34 (m, 2 H), 4.25 (t, J = 5 Hz, 2 H), 4.04 (d, J = 11.6 Hz, 1 H), 3.97 – 3.93 (m, 2 H), 3.68 – 
3.64 (m, 1 H), 2.62 – 2.50 (m, 4 H), 2.18 – 2.13 (m, 1 H), 1.58 (s, 6 H, 2x CH3), 0.94 (s, 9 H, 3x CH3); 13C 
NMR (126 MHz, CDCl3) δ : 180.2, 175.0, 171.0, 170.3, 166.9, 166.8, 166.5, 159.2, 157.5 (dd, J = 260, 8 
Hz, C-F), 157.2, 155.0, 150.4, 148.5, 137.9, 137.1, 136.3, 135.2, 133.6 (q, J = 34 Hz), 131.3 (d, J = 50 Hz), 
131.1, 130.8, 129.6, 128.2, 128.0, 127.8, 127.1 (q, J = 5 Hz), 122.9, 121.8 (q, J = 275 Hz), 118.9, 115.6, 
114.8, 110.2 (m), 100.0 – 99.7 (m), 70.3, 67.6, 67.0, 66.3, 58.5, 57.1, 56.7, 43.3, 39.6, 35.8, 35.3, 26.3, 
23.6, 16.0; 19F NMR (376 MHz, CDCl3) δ : -62.0, -115.9; HRMS (ESI): m/z calcd for C58H57F5N10O8S2 
[M+2H]2+: 590.1856; Found: 590.1861. 
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4-acetoxybenzoic acid (214) 
 
Following a literature procedure,360 to a stirring solution of 4-hydroxybenzoic acid (1.00 g, 7.24 mmol) 
in pyridine (7 mL) was added acetic anhydride (0.75 mL, 7.97 mmol). The reaction mixture was heated 
to reflux for 2 h before being cooled to r.t. and poured over NaHCO3 (sat. aq. 30 mL). The solution was 
then acidified to pH 2 with conc. HCl and the precipitate was filtered, washed with H2O, and dried in 
vacuo to give the title compound as a white amorphous solid (1.25 g, 96%) used without further 
purification. 
Rf: 0.31 (1:1 PE/EtOAc); IR (neat film, νmax, cm-1): 2839 (br w, OH), 2674 (w, CH), 1753 (s, C=O), 1682 
(s, C=O), 1605 (m), 1508 (w), 1429 (m), 1373 (m), 1317 (m), 1290 (m), 1222 (s), 1204 (s), 1168 (s), 1129 
(m), 1104 (w), 1018 (m); 1H NMR (400 MHz, CDCl3) δ: 8.15 – 8.12 (m, 2 H), 7.23 – 7.19 (m, 2 H), 2.35 
(s, 3 H); 13C NMR (101 MHz, CDCl3) δ: 169.9, 168.8, 154.9, 131.8, 126.8, 121.7, 21.2. 
Data are in accordance with those reported previously in literature.360 
 
4-(6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene-3-carbonyl)phenyl acetate (216) 
 
To a stirring solution of 214 (0.347 g, 1.93 mmol) in dichloromethane (6 mL) cooled to 0 °C were 
dropwise added oxalyl chloride (0.49 mL, 5.78 mmol), followed by a few drops of DMF. The reaction 
mixture was warmed to r.t. and stirred for 1 h before concentrating in vacuo to give the acyl chloride 
as a white solid. This was then dissolved in dichloromethane (10 mL) and cooled to 0 °C, 6-methoxy-
2-(4-methoxyphenyl)-benzo[b]thiophene (0.417 g, 1.54 mmol) was added followed by AlCl3 (0.386 g, 
2.90 mmol) in three portions, over 5 mins. The reaction was warmed to r.t. and stirred for 1 h before 
being carefully quenched with ice-water, followed by 1 M HCl. The reaction was separated and the 
aqueous further extracted with dichloromethane (2 x 30 mL). The combined organics were dried over 
Na2SO4, filtered and concentrated in vacuo.  The residue was purified through silica gel column 
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chromatography (7:3 PE 40-60/DCM to DCM) to give the title compound as a yellow amorphous solid 
(0.29 g, 35%). 
Rf: 0.23 (3:1 DCM/PE 40-60); 1H NMR (400 MHz, CDCl3) δ: 7.81 – 7.78 (m, 2 H), 7.59 (d, J = 8.9 Hz, 1 H), 
7.33 – 7.29 (m, 3 H), 7.02 – 6.97 (m, 3 H), 6.77 – 6.74 (m, 2 H), 3.89 (s, 3 H), 3.75 (s, 3H), 2.27 (s, 3 H); 
13C NMR (101 MHz, CDCl3) δ: 193.1, 168.6, 159.9, 157.7, 154.3, 144.1, 140.0, 135.0, 133.7, 131.5, 
130.4, 130.0, 125.7, 124.1, 121.5, 114.9, 114.1, 104.5, 55.6, 55.3, 21.1. 
Data are in accordance with those reported previously in literature.317 
 
(4-hydroxyphenyl)(6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-yl)methanone (217) 
 
To a stirring solution of 216 (0.29 g, 0.67 mmol) in a mixture of EtOH (7 mL) and water (3 mL) was 
added sodium acetate (0.275 g, 3.35 mmol). The reaction mixture was heated to 90 °C and stirred for 
12 h before cooling and concentrating in vacuo. The residue was dissolved in EtOAc (15 mL) and water 
(10 mL), separated and the aqueous extracted with EtOAc (2 x 15 mL). The combined organics were 
dried over Na2SO4, filtered and concentrated in vacuo to give the title compound as a yellow oil (0.234 
g, 89%) used without further purification. 
Rf: 0.48 (5% MeOH/DCM); IR (neat film, νmax, cm-1): 3307 (br w, OH), 2952 (w, CH), 1630 (m), 1602 (s), 
1573 (m), 1535 (m), 1499 (m), 1474 (m), 1438 (m), 1351 (w), 1294 (m), 1252 (s), 1225 (m), 1178 (m), 
1162 (m), 1076 (w), 1030 (m); 1H NMR (400 MHz, CDCl3) δ: 7.74 – 7.70 (m, 2 H), 7.53 (d, J = 9.1 Hz, 1 
H), 7.35 – 7.31 (m, 3 H), 6.96 (dd, J = 9.1, 2.4 Hz, 1 H), 6.77 – 6.66 (m, 4 H), 5.73 (s, 1 H), 3.88 (s, 3 H), 
3.74 (s, 3 H); 13C NMR (101 MHz, CDCl3) δ: 193.3 (C=O), 160.3, 159.7, 157.6, 142.8, 140.0, 133.9, 132.7, 
130.5, 130.4, 130.3, 126.0, 124.0, 115.2, 114.8, 114.1, 104.5, 55.6, 55.3. 
Data are in accordance with those reported previously in literature317. 
 
 
 
 
281 
 
(4-(2-(ethylamino)ethoxy)phenyl)(6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophen-3-
yl)methanone (218) 
 
 
To a stirring solution of 217 (0.229 g, 0.59 mmol) in acetonitrile (10 mL) were added 1,2-
dibromoethane (0.102 mL, 1.18 mmol) and Cs2CO3 (0.287 mg, 0.88 mmol). The reaction mixture was 
heated to 80 °C and stirred for 14 h before being cooled, filtered, washed with acetonitrile (10 mL) 
and concentrated in vacuo. The residue was dissolved in DMF (6 mL) and ethylamine (2.95 mL, 2 M, 
THF) was added. The reaction mixture was heated to 80 °C for 14 h before being cooled, diluted with 
EtOAc (20 mL) and brine (15 mL). The layers were separated and the aqueous extracted with EtOAc (2 
x 15 mL). The combined organics were dried over Na2SO4, filtered and concentrated.  The residue was 
purified through silica gel column chromatography (DCM to 9:1 DCM/MeOH) to give the title 
compound as a yellow amorphous solid (0.29 g, 35%). 
Rf: 0.28 (1:9 MeOH/DCM); 1H NMR (400 MHz, CDCl3) δ: 7.75 (d, J = 8.9 Hz, 2 H), 7.52 (d, J = 9.1 Hz, 1 
H), 7.35 – 7.31 (m, 3 H), 6.95 (dd, J = 9.1, 2.4 Hz, 1 H), 6.77 – 6.73 (m, 4 H), 4.11 (t, J = 5.1 Hz, 2 H), 3.88 
(s, 3 H), 3.74 (s, 3 H), 3.06 (t, J = 5.1 Hz, 2 H), 2.81 (q, J = 7.2 Hz, 2 H), 1.19 (t, J = 7.2 Hz, 3 H); 13C NMR 
(101 MHz, CDCl3) δ: 193.2, 162.5, 159.7, 157.6, 142.5, 140.1, 133.9, 132.3, 130.7, 130.4, 130.3, 126.0, 
124.0, 114.8, 114.2, 114.1, 104.5, 66.2, 55.6, 55.2, 47.5, 43.8, 13.9. 
Data are in accordance with those reported previously in literature.317 
 
(4-(2-(ethylamino)ethoxy)phenyl)(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-
yl)methanone (219) 
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To a stirring solution of 218 (0.080 g, 0.173 mmol) in dichloromethane (3 mL) cooled to 0 °C was 
dropwise added boron tribromide (1 M in DCM, 0.69 mL, 0.693 mmol). The reaction mixture was 
warmed to rt. and stirred for 2 h before being quenched with MeOH (0.25 mL) and concentrated in 
vacuo. The residue was dissolved in NaHCO3 (sat. aq.) and extracted into EtOAc (3 x 20 mL), dried over 
Na2SO4, filtered and concentrated.  The residue was purified through silica gel column 
chromatography (9:1 to 8:1 DCM/MeOH) to give the title compound as a yellow amorphous solid 
(0.055 g, 73%). 
Rf: 0.14 (15% MeOH/DCM); IR (neat film, νmax, cm-1): 3186 (br m, OH), 2970 (w, CH), 2888 (w, CH), 1633 
(m), 1594 (s), 1569 (m), 1536 (m), 1502 (m), 1465 (m), 1419 (m), 1354 (m), 1306 (m), 1250 (s)< 1226 
(s), 1165 (s), 1133 (m), 1107 (m), 1078 (m), 1039 (s); 1H NMR (400 MHz, CDCl3) δ: 7.71 (d, J = 8.8 Hz, 2 
H), 7.42 (d, J = 8.9 Hz, 1 H), 7.26 (d, J = 2.3 Hz, 1 H), 7.19 – 7.15 (m, 2 H), 6.88 – 6.85 (m, 3 H), 6.63 – 
6.59 (m, 2 H), 4.16 (t, J = 5.1 Hz, 2 H), 3.15 (t, J = 5.1 Hz, 2 H), 2.88 (q, J = 7.3 Hz, 2 H), 1.21 (t, J = 7.3 
Hz, 3 H); 13C NMR (101 MHz, CDCl3) δ: 194.1 (C=O), 162.7, 157.9, 155.4, 142.7, 140.0, 132.8, 132.1, 
130.8, 130.0, 129.7, 124.6, 123.3, 115.1, 114.7, 113.9, 106.5, 65.2, 47.9, 43.1, 11.7. 
Data are in accordance with those reported previously in literature.317 
 
(2S,4R)-1-((S)-2-(4-((Z)-(4-(ethyl(2-(4-(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophene-3-
carbonyl)phenoxy)ethyl)carbamoyl)-2,6-difluorophenyl)diazenyl)-3,5-difluorobenzamido)-3,3-
dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
(azoPROTAC4) 
 
To a stirring solution of 195 (7 mg, 0.0089 mmol) in a mixture of THF and H2O (2:1, 1 mL) was added 
lithium hydroxide (0.7 mg, 0.0178 mmol). The reaction was stirred at r.t. for 3 h before acidifying to 
283 
 
pH 3 with 1 M HCl and extracting into EtOAc (3 x 10 mL). The combined organics were washed with 
brine (5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was directly 
dissolved in DMF (0.2 mL) and cooled to 0 °C, before HATU (4.4 mg, 0.0116 mmol) and DIPEA (2.0 µL, 
0.0116 mmol) were added. The reaction mixture was stirred for 15 mins before 219 (5.0 mg, 0.0116 
mmol) was added. The mixture was then warmed to r.t. and stirred for a further 16 h before diluting 
in water (5 mL) and extracting into EtOAc (3 x 10 mL). The combined organics were then washed with 
brine (2 x 5 mL), before being dried over Na2SO4, filtered and concentrated in vacuo. The residue was 
purified through silica gel column chromatography (5% MeOH/DCM) to give the title compound as a 
red amorphous solid (3.5 mg, 35%). 
Rf: 0.25 (5% MeOH/DCM); Mixture of cis and trans isomers, only major reported; 1H NMR (500 MHz, 
MeOD) δ : 7.82 – 7.38 (m, 10 H), 7.29 – 7.00 (m, 5 H), 6.91 – 6.80 (m, 3 H), 6.65 – 6.58 (m, 2 H), 4.65 – 
4.50 (m, 4 H), 4.42 – 4.23 (m, 2 H), 4.16 – 3.70 (m, 5 H), 3.56 – 3.42 (m, 2 H), 2.47 (s, 3 H), 2.27 – 2.03 
(m , 2 H), 1.19 – 1.06 (m, 12 H); 13C NMR (126 MHz, MeOD) δ : 194.2, 173.0, 170.5, 168.8, 165.1, 161.9, 
157.8, 155.4, 155.3 (dd, J = 260, 4 Hz, C-F), 154.9 (dd, J = 260, 4 Hz, C-F), 151.4, 150.1, 147.6, 142.8, 
140.0, 138.9, 132.9, 132.1, 131.9, 130.1, 130.0, 129.8, 129.2, 129.0, 128.9, 128.1, 127.8, 127.5, 124.6, 
123.4, 115.0, 114.7, 113.9, 111.9 – 111.7 (m, 1C), 106.4, 70.1, 69.7, 67.5, 59.5, 58.5, 56.8, 45.2, 42.3, 
37.6, 35.8, 25.6, 14.4, 13.0; 19F NMR (376 MHz, MeOD) δ : -74.0 (m), -121.2 (m); HRMS (ESI): m/z calcd 
for C61H56F4N7O9S2 [M+H]+: 1170.3512; Found: 1170.3513. 
 
4-Fluoroisobenzofuran-1,3-dione (225) 
  
Following a reported procedure;361 a stirring solution of 3-fluorophthalic acid (0.500 g, 2.7 mmol) in 
acetic anhydride (4 mL) was refluxed at 140 °C for 2 h. The reaction mixture was then concentrated in 
vacuo to give the title compound as an off-white amorphous solid (0.448 g, 90%). 
1H NMR (400 MHz, CDCl3) δ: 7.97 – 7.92 (m, 1H), 7.85 (d, J = 7.7 Hz, 1 H), 7.57 (t, J = 8.6 Hz, 1 H); 13C 
NMR (101 MHz, CDCl3) δ: 161.6 (d, J = 2.9 Hz, C=O), 158.8 (d, J = 2.2 Hz, C=O), 158.5 (d, J = 275 Hz, C-
F), 139.0 (d, J = 7.7 Hz), 133.3, 124.0 (d, J = 19 Hz), 122.0 (d, J = 4.2 Hz), 117.7 (d, J = 13.4 Hz); 19F NMR 
(376 MHz, CDCl3) δ : -108.4. 
Data are in accordance with those reported previously in literature.361 
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2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (223) 
 
Following a reported procedure;362 to a stirring solution of 225 (50 mg, 0.3 mmol) in acetic acid (1 mL) 
were added rac-α-aminoglutarimide hydrochloride (54.3 mg, 0.33 mmol) and potassium acetate (91.1 
mg, 0.95 mmol). The reaction mixture was heated to 90 °C and stirred for 15 h. The reaction was then 
cooled to r.t., diluted with H2O (5 mL), extracted into EtOAc (3 x 10 mL), washed with brine (5 mL), 
dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified through silica gel 
column chromatography (1% MeOH/DCM) to give the title compound as a white amorphous solid (80 
mg, 96%). 
Rf: 0.57 (5% MeOH/DCM); IR (neat film, νmax, cm-1):  3275 (w, NH), 3087 (w, CH), 2920 (w, CH), 1779 
(m, C=O), 1703 (s, C=O), 1623 (m), 1610 (m), 1479 (m), 1384 (s), 1350 (m), 1327 (m), 1300 (m), 1256 
(s), 1199 (s), 1115 (m), 1018 (m); 1H NMR (400 MHz, d-DMSO) δ: 11.13 (s, 1 H, NH), 7.96 – 7.91 (m, 1 
H), 7.77 (d, J = 7.4 Hz, 1 H), 7.72 (t, J = 9.1 Hz, 1 H), 5.14 (dd, J = 12.8, 5.5 Hz, 1 H), 2.92 -2.83 (m, 1 H), 
2.61 – 2.54 (m, 1 H), 2.52 – 2.44 (m, 1 H, overlapping DMSO), 2.07 – 2.03 (m, 1 H);  13C NMR (101 MHz, 
d-DMSO) δ: 173.2, 170.1, 166.6 (d, J = 3 Hz), 164.4, 157.3 (d, J = 260 Hz, C-F), 138.5 (d, J = 7.9 Hz), 
133.9 (d, J = 1.5 Hz), 123.5 (d, J = 19 Hz), 120.5 (d, J = 3.8 Hz), 117.5 (d, J = 12 Hz), 49.5, 31.3, 22.3; 19F 
NMR (376 MHz, CDCl3) δ : -114.7. 
Data are in accordance with those reported previously in literature.363 
 
tert-Butyl (2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)carbamate (227) 
 
Following a reported procedure;364 to a stirring solution of 223 (25 mg, 0.091 mmol) in DMF (0.5 mL) 
were added N-Boc-ethylenediamine (16 mg, 0.010 mmol) and DIPEA (31.5 µL, 0.181 mmol). The 
reaction mixture was heated to 90 °C and stirred for 15 h. The reaction was then cooled to r.t., diluted 
with H2O (5 mL), extracted into EtOAc (3 x 10 mL), washed with brine (5 mL), dried over Na2SO4, filtered 
and concentrated in vacuo. The residue was purified through silica gel column chromatography (30 to 
50% EtOAc/PE 40-60) to give the title compound as a yellow amorphous solid (22 mg, 58%). 
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Rf: 0.28 (1:1 PE 40-60/EtOAc); IR (neat film, νmax, cm-1): 3365 (w, NH), 3000 (w, CH), 1732 (m, C=O), 
1714 (s, C=O), 1697 (s, C=O), 1623 (m), 1511 (m), 1482 (w), 1408 (m), 1368 (m), 1320 (m), 1290 (m), 
1260 (m), 1209 (m), 1171 (m), 1131 (m), 1111 (m), 1080 (m), 1022 (m); 1H NMR (400 MHz, d6-DMSO) 
δ: 11.07 (s, 1 H, NH), 7.56 (t, J = 7.7 Hz, 1 H), 7.12 (d, J = 8.7 Hz, 1 H), 7.02 – 6.97 (m, 2 H), 6.69 (t, J = 
6.2 Hz, 1 H, NH), 5.03 (dd, J = 12.8, 5.6 Hz, 1 H), 3.40 – 3.33 (m, 2 H, overlapping H2O), 3.10 (q, J = 5.6 
Hz, 2 H), 2.91 – 2.82 (m, 1 H), 2.65 – 2.44 (m, 2 H, overlapping DMSO), 2.04 – 1.96 (m, 1 H), 1.34 (s, 9 
H, 3x CH3); 13C NMR (101 MHz, d6-DMSO) δ: 173.3, 170.5, 169.2, 167.8, 156.3, 146.8, 136.6, 132.7, 
117.5, 110.9, 109.7, 78.2, 49.0, 42.0, 40.1, 31.4, 28.6, 22.6. 
Data are in accordance with those reported previously in literature.364 
 
tert-Butyl (1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)azetidin-3-yl)carbamate (228) 
 
To a stirring solution of 223 (50 mg, 0.181 mmol) in DMF (1 mL) were added tert-butyl N-(azetidin-3-
yl)carbamate hydrochloride (41.6 mg, 0.199 mmol) and DIPEA (101 µL, 0.579 mmol). The reaction 
mixture was heated to 90 °C and stirred for 15 h. The reaction was then cooled to r.t., diluted with 
H2O (5 mL), extracted into EtOAc (3 x 10 mL), washed with brine (5 mL), dried over Na2SO4, filtered 
and concentrated in vacuo. The residue was purified through silica gel column chromatography (1:1 
EtOAc/PE 40-60) to give the title compound as a yellow amorphous solid (77 mg, >98%). 
Rf: 0.23 (1:1 PE 40-60/EtOAc); IR (neat film, νmax, cm-1): 2929 (w, CH), 1701 (s, C=O), 1618 (w), 1575 
(w), 1542 (w), 1489 (m), 1470 (m), 1396 (m), 1364 (m), 1323 (m), 1260 (m), 1197 (m), 1163 (m), 1121 
(m), 1065 (w), 1032 (w); 1H NMR (400 MHz, d6-DMSO) δ: 11.13 (s, 1 H), 7.58 – 7.54 (m, 2 H), 7.11 (d, 
J = 7.0 Hz, 1 H), 6.77 (d, J = 8.4 Hz, 1 H), 5.04 (dd, J = 12.8, 5.5 Hz, 1 H), 4.43 – 4.40 (m, 2 H), 4.36 – 4.32 
(m, 1 H), 3.95 – 3.92 (m, 2 H), 2.90 – 2.82 (m, 1 H), 2.59 – 2.52 (m, 2 H), 2.00 – 1.96 (m, 1 H), 1.38 (s, 9 
H); 13C NMR (101 MHz, d6-DMSO) δ: 173.3, 170.5, 167.6, 166.9, 155.4, 148.1, 135.4, 133.7, 120.6, 
112.3, 110.7, 78.7, 61.3, 49.1, 41.0, 31.4, 28.6, 22.5. 
Data are in accordance with those reported previously in literature.365 
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tert-Butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazine-1-carboxylate (229) 
 
To a stirring solution of 223 (25 mg, 0.091 mmol) in DMF (0.5 mL) were added 1-Boc-piperazine (16 
mg, 0.010 mmol) and DIPEA (31.5 µL, 0.181 mmol). The reaction mixture was heated to 90 °C and 
stirred for 15 h. The reaction was then cooled to r.t., diluted with H2O (5 mL), extracted into EtOAc (3 
x 10 mL), washed with brine (5 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue 
was purified through silica gel column chromatography (30 to 50% EtOAc/PE 40-60) to give the title 
compound as a yellow amorphous solid (34 mg, 84%). 
Rf: 0.24 (1:1 PE 40-60/EtOAc); IR (neat film, νmax, cm-1): 2915 (w, CH), 1699 (s, C=O), 1616 (w), 1540 
(w), 1403 (m), 1362 (m), 1329 (m), 1267 (m), 1243 (m), 1197 (m), 1174 (m), 1131 (m), 1041 (m), 1006 
(m); 1H NMR (400 MHz, d6-DMSO) δ: 11.08 (s, 1 H), 7.70 (t, J = 7.4 Hz, 1 H), 7.38 – 7.32 (m, 2 H), 5.11 
– 5.06 (m, 1 H), 3,49 (br s, 4 H), 3,23 (br s, 3 H), 2.91 – 2.80 (m, 1 H), 2.60 – 2.52 (m, 2 H), 2.02 – 1.99 
(m, 1 H), 1.41 (s, 9 H);  13C NMR (101 MHz, d6-DMSO) δ: 173.3, 170.4, 167.5, 166.8, 154.3, 150.0, 136.4, 
134.0, 124.4, 117.4, 115.7, 79.5, 50.8, 49.3, 43.4, 31.4, 28.5, 22.5. 
Data are in accordance with those reported previously in literature.366  
 
4-((2-aminoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (220) 
 
To a stirring solution of 227 (18 mg, 0.043 mmol) in dichloromethane (0.5 mL) was added 
trifluoroacetic acid (0.5 mL). The reaction was stirred for 3 h at r.t. before being concentrated, diluted 
with sat. aq. NaHCO3 (2 mL), extracted into dichloromethane (3 x 10 mL), dried over Na2SO4, filtered, 
and concentrated in vacuo to give the title compound as a yellow oil (14 mg, >98%) 
Rf: 0.35 (1:9:0.1 MeOH/DCM/NEt3); IR (neat film, νmax, cm-1): 3383 (w, NH), 2976 (w, CH), 2917 (w, CH), 
1720 (m, C=O), 1697 (s, C=O), 1626 (m), 1604 (m), 1513 (m), 1464 (m), 1405 (m), 1360 (m), 1325 (m), 
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1256 (m), 1198 (m), 1164 (m), 1110 (m), 1086 (m), 1042 (m), 1020 (m); 1H NMR (400 MHz, MeOD) δ: 
7.58 (t, J = 7.9 Hz, 1 H), 7.13 – 7.09 (m, 2 H), 5.06 (dd, J = 13, 5.8 Hz, 1 H), 3.54 (t, J = 6.5 Hz, 2 H), 3.34 
(s, 2 H), 3.02 (t, J = 6.5 Hz, 2 H), 2.91 – 2.66 (m, 3 H), 2.14 – 2.07 (m, 1 H); 13C NMR (101 MHz, MeOD) 
δ: 173.2, 170.3, 169.2, 167.8, 146.4, 135.6, 132.6, 116.5, 111.1, 110.6, 48.8, 42.0, 39.3, 30.8, 22.4. 
Data are in accordance with those reported previously in literature.364 
 
 
5.4. General Biological procedures 
5.4.1. Cell proliferation assay protocol 
LNCaP and PC3 cells were grown in Roswell Park Memorial Institute 1640 (RPMI-1640) medium with 
10% fetal calf serum (FCS) and 1% glutamax. The cells were seeded in a 96-well black-walled clear flat-
bottom polystyrene plate (2,000 cells/well) and incubated at 37 °C in a 5% CO2 atmosphere for 24 h. 
The two cell lines were treated with varying concentrations of PROTACs (from 10 mM stock solution 
in DMSO) in triplicate for five days in RPMI-1640 with 10% FCS and 1% glutamax, and a final DMSO 
concentration of 1%. The plates were monitored using an Essen Bioscience Incucyte live-cell analysis 
system which analysed the plates every 4 h to calculate pIC50 values based on confluence. 
 
5.4.2. CETSA protocol for AR degradation assay run with Dr Joseph Shaw 
This protocol was run as previously reported.174 LNCaP cells were grown in RPMI-1640 medium with 
L-glutamine and 10% FCS. PROTACs (from 10 mM stock solution in DMSO) in triplicate were dosed into 
384-well PCR plate using a hp Tecan D3000e digital dispenser. LNCaP cells were seeded to 3.5 x 107 
cells/mL and 5 µL was added to each well using a Multidrop Combi dispenser. The plate was incubated 
for either 1 h or 4.5 h, and then AR levels were quantified using AlphaScreen® technology as follows. 
2x SureFire Lysis Buffer (20 µL/well) was added and following 10 mins incubation, samples were briefly 
clarified. Samples were mixed and 3 µL of lysate was transferred to a 384-well ProxiPlate. A solution 
of 1x ImmunoAssay Buffer was prepared containing 0.08 µg/mL Dako Mouse anti-AR antibody, 0.15 
µg/mL Merck Millipore Rabbit anti-AR antibody, 120 µg/mL Anti-mouse IgG Alpha Donor beads and 
30 µg/mL Anti-rabbit IgG AlphaLISA Acceptor beads. 6 µL of this solution was added to the lysate in 
the ProxiPlate under subdued light. The plate was then sealed and incubated for 16 h in the dark 
before analysis using an EnVision plate reader. Data was plotted in GraphPad Prism 6 to fit a nonlinear 
regression and determine 50% effective concentrations (EC50) by Dr Joseph Shaw. 
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5.4.3. Expression and purification of MDM2 (6-125) with Rohan Eapen 
As previously reported.367 A gene encoding for MDM2 (6-125) was cloned into a pRSETa vector. The 
plasmid was transformed into the E. coli expression cell line, C41(DE3). Colonies were picked and 
grown in 2xYT medium (Formedium), supplemented with ampicillin (50 µg/ mL) at 37 °C, and shaken 
at 180 rpm in an orbital incubator until an OD600 = 0.6 was achieved. Cultures were then induced with 
0.5 mM IPTG, and the temperature was lowered to 25 °C for overnight incubation. Cells were pelleted 
and resuspended in lysis buffer (50 mM Tris-HCl, 500 mM NaCl, 20 mM Imidazole, 1 mM DTT, 0.1% 
(v/v) Tween 20, 1 SigmaFAST EDTA-free protease inhibitor (Sigma), pH 8.5). Lysozyme and DNase were 
added, and cells were lysed by sonication on ice (20 cycles, 10 seconds on, 10 seconds off). Lysate was 
centrifuged at 40000 x g for 1 h at 4 °C. Supernatant containing the His-tagged protein was diluted to 
100 mL with buffer A (20 mM Tris-HCl, 500 mM NaCl, 1 mM DTT, pH 8.5) and loaded onto a 5 mL 
HisTrap Excel column. The column was washed with 20 column volumes (CV) of buffer A + 20 mM 
Imidazole and then eluted in 5 CV of buffer B (20 mM Tris-HCl, 500 mM NaCl, 500 mM Imidazole, 1 
mM DTT, pH 8.5). Eluted proteins were desalted using a Centripure P25 column (Generon) into 
phosphate buffered saline (PBS) + 1 mM DTT, pH 7.4. 100 units of thrombin (Sigma, T4648) were added 
to the desalted protein and allowed to cleave overnight at 4 °C. Protein was then diluted with buffer 
C (20 mM Bis-Tris, 1mM DTT, pH 6.5) to approximately 30 mM NaCl in the protein sample. Protein was 
then loaded onto a MonoS column and eluted with a linear gradient over 20 CV using buffer D (20 mM 
Bis-Tris, 1 M NaCl, 1mM DTT, pH 6.5). Eluted protein fractions were pooled and analysed for purity by 
SDS PAGE and the correct mass was confirmed by mass spectrometry. 
 
5.4.4. Competition fluorescence polarisation procedure 
Competition fluorescence polarisation was carried out using MDM2 and a 5-TAMRA-labelled tracer 
peptide in a similar fashion as previously described.175 The dissociation constant of the tracer peptide 
was previously described by Lau et al.175. Stock solutions of small molecule/peptide inhibitors in DMSO 
(50/10 mM) were diluted in assay buffer (1 × PBS + 0.01% (v/v) Tween 20 + 3% (v/v) DMSO) to a top 
concentration of 3 mM for small molecules and 10 µM for peptides, then 2/3-fold serial dilutions were 
made to give a 20-point titration. A stock solution of FP tracer (1 mM) was diluted in assay buffer to a 
concentration of 200 nM (final assay concentration of 50 nM). MDM2 was diluted in assay buffer to a 
concentration of 380 nM (final assay concentration of 95 nM). Dilutions of small molecule/peptide 
inhibitors (20 µL), FP tracer (10 µL) and MDM2 (10 µL) were added to a 384-well plate (OptiPlate™ -
384 F, Perkin Elmer) and incubated at r.t. for 1 hour. Titrations were conducted in triplicate. 
Fluorescence polarisation was measured using a BMG ClarioStar plate reader using an excitation filter 
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at 540 nm and emission filter at 590 nm, with a 20 nm bandwidth. Graphs were plotted using 
GraphPad Prism 7.0 and analysed using the following equation:  
𝑟 = 𝑟଴ + (𝑟 ௕ + 𝑟଴) ×
2ඥ(𝑑ଶ − 3𝑒 cos(𝜃 3)⁄ − 9
3𝐾ௗଵ + 2ඥ(𝑑ଶ − 3𝑒) cos(𝜃 3)⁄ − 𝑑
 
 
𝑑 = 𝐾ௗଵ + 𝐾ௗଶ + [𝐿]௦௧ + [𝐿]௧ − [𝑃]௧  
 
𝑒 = 𝐾ௗଵ([𝐿]௧ − [𝑃]௧) + 𝐾ௗଶ([𝐿]௦௧ − [𝑃]௧) + 𝐾ௗଵ𝐾ௗଶ 
 
𝜃 = cosିଵ(
−2𝑑ଷ + 9𝑑𝑒 − 27𝑓
2ඥ(𝑑ଶ − 3𝑒)ଷ
) 
 
𝑓 = −𝐾ௗଵ𝐾ௗଶ[𝑃]௧ 
Where, r is anisotropy measured, r0 is anisotropy of free peptide, rb is anisotropy of MDM2:5-TAMRA 
peptide complex, Kd1 is apparent dissociation constant of 5-TAMRA peptide to MDM2, Kd2 is 
dissociation constant of non-labelled ligand to MDM2, [P]t is MDM2 concentration, [L]t is non-labelled 
ligand concentration and [L]st is 5-TAMRA peptide concentration. 
 
5.4.5. CETSA protocol for target engagement run by Dr Joseph Shaw 
This protocol was run as previously reported.174 Using the same LNCaP cell-line, dosing procedure, and 
endpoint as previously described for the CETSA AR degradation assay with the following modifications. 
For the antagonist binding mode: following the PROTAC dosing, a 2x DHT dose response (1 nM total 
concentration) was prepared in media and 5 µL was added to each well. Following the assay time-
course, both agonist and antagonist binding modes were heat shocked at 46 °C for 3 mins, followed 
by a 3 mins cool at 25 °C using a Veriti SimpliAmp (ThermoFisher) prior to addition of SureFire Lysis 
Buffer and subsequent AlphaScreen® endpoint read-out and analysis previously described. 
 
5.4.6. Differential Scanning Fluorimetry (DSF) with Rohan Eapen 
For computationally predicted MDM2 binders: stock solutions of small molecules in DMSO (50 mM) 
were diluted to concentrations of 5 mM, 1 mM and 200 µM in assay buffer (1 × PBS + 0.01% (v/v) 
Tween 20 + 10% (v/v) DMSO). For literature MDM2 binders: stock solutions of small molecules in 
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DMSO (20 mM) were diluted to concentrations of 800 µM, 400 µM and 200 µM in assay buffer (1 × 
PBS + 0.01% (v/v) Tween 20 + 10% (v/v) DMSO). 
A combined solution of MDM2 and SYPRO-Orange (Thermo Fisher) was prepared by diluting stock 
MDM2 and SYPRO-Orange in assay buffer to a concentration of 40 µM and 10x respectively (final assay 
concentration of 20 µM and 5x). Stocks of small molecules (10 µL), and SYPRO-Orange/MDM2 (10 µL) 
were diluted into a 96-well plate. Each sample was run in triplicate. Thermal melt curves were attained 
using a Bio-Rad CFX Connect, measuring fluorescence intensity at 568 nm over a temperature range 
of 25 – 95 °C at a step ramp rate of 0.5 °C per 30 seconds. Fluorescence intensity curves were plotted 
and analysed using GraphPad Prism 7.0 software to determine the melting temperature (Tm) of each 
thermal ramp using the following equation. 
𝑌 = 𝐴 +
𝐵 − 𝐴
1 + 𝑒ቀ
ିு
ோ ቁ×ቀ
ଵ
௫ି
ଵ
௧ቁାቀ
஼
ோ×୪୬ቀ
௫
௧ቁା
௧
௫ିଵቁ
 
Where, Y is the observed fluorescence intensity of SYPRO Orange, A is the fluorescence intensity of 
SYPRO-Orange in the presence of non-native protein, B is the fluorescence intensity of SYPRO-Orange 
in the presence of native protein, H is the enthalpy of protein unfolding, C is the heat capacity of 
protein unfolding, R is the gas constant (8.314 J.mol-1) and t is the melting temperature (Tm). Data are 
plotted as the average ΔTm of MDM2 with each small molecule compound, at their respective 
concentrations compared to apo MDM2 (5% (v/v) DMSO).  
 
5.4.7. AR degradation by AlphaScreen® of MDM2 PROTACs run by Dr Andreas Hock 
Using a very similar method to the CETSA AlphaScreen® AR degradation protocol previously described. 
LNCaP cells were grown in RPMI-1640 medium with L-glutamine and 10% FCS. PROTACs (from 10 mM 
stock solution in DMSO) in triplicate were dosed into 384-well PCR plates using a hp Tecan D3000e 
digital dispenser. LNCaP cells were seeded to 7,500 cells/well using a Multidrop Combi dispenser. The 
plates were incubated for 16 h and the endogenous AR levels were quantified using AlphaScreen® 
technology and fitted using GraphPad Prism 6 as previously described, to give qAC50 values 
corresponding to 50% AR degradation. 
 
5.4.8. AR degradation imaging assay run by Dr Andreas Hock 
LNCaP cells were grown in RPMI-1640 medium containing 10% FCS and 1% glutamine. Cells were 
plated on Perkin-Elmer 384-well Cell Carrier Ultra plates at 12,000 cells per well (40 µL). PROTACs 
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(from 10 mM stock solution in DMSO) were dosed using Echo 555 dispenser, and the plates incubated 
for 16 h before fixing with 4% paraformaldehyde (final concentration) for 30 mins and stained for AR 
and FKBP5 as follows. The plates were washed 3 x with PBS using a Biotek washer before incubating 
with anti-AR N terminal (mouse) antibody (1:1000), diluted in modified blocking buffer for 2 h at r.t. 
The plates were then washed with PBS and incubated with anti-mouse secondary antibody- 488 
(1:500) and DRAQ5 (1:2000) diluted in modified blocking buffer for 45 mins at r.t. Finally, the plates 
were washed with 3 x PBS and sealed with black plate seals. The plates were imaged on the CellInsight 
and analysed using Columbus and Genedata software by Dr Andreas Hock. 
 
5.4.9. Photoswitchable PROTAC AR degradation protocol run with Dr Andreas Hock 
Using the same protocol as described previously with minor modifications. LNCaP cells were grown in 
RPMI-1640 medium containing 10% FCS and 1% glutamine. Cells were plated on Perkin-Elmer 384-
well Cell Carrier Ultra plates at 12,000 cells per well (40 µL).  
For azoPROTAC1: PROTAC (10 mM stock solution in DMSO) was dosed at top concentration of 30 µM 
generating a 7-point dose response curve. After dosing, the plate was then irradiated with either 415 
nm or 530 nm Thorlab mounted LEDs for 10 mins and the plate incubated for 24 h prior to fixing, 
staining and analysing on the CellInsight as described previously. 
For azoPROTAC1 and azoPROTAC2: PROTAC (10 mM stock solution in DMSO) was irradiated with 530 
nm LEDs for 30 mins prior to being dosed on the assay plate at a top concentration of 30 µM, to 
generate a 14-point two-fold dilution dose-response curve. The 530 nm irradiated plates were directly 
placed in a dark incubator after dosing, whilst the remaining plates were irradiated for 10 mins with 
415 nm LEDs. The plates were then incubated for 6 h, before being fixed and stained as described 
previously. 
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